Set	Rank	Size	NES	ES	p-val	FDR
WP_UREA_CYCLE_AND_METABOLISM_OF_AMINO_GROUPS	1	20	2.017	0.713	6.061E-05	4.024E-02
MOREIRA_RESPONSE_TO_TSA_UP	2	26	1.977	0.731	1.251E-04	4.024E-02
VANTVEER_BREAST_CANCER_BRCA1_UP	3	27	1.943	0.632	2.155E-04	4.024E-02
KIM_MYC_AMPLIFICATION_TARGETS_UP	4	165	1.938	0.616	2.348E-04	4.024E-02
MARZEC_IL2_SIGNALING_UP	5	106	1.932	0.509	2.587E-04	4.024E-02
REACTOME_ATTENUATION_PHASE	6	28	1.929	0.667	2.740E-04	4.024E-02
SOGA_COLORECTAL_CANCER_MYC_UP	7	77	1.926	0.805	2.864E-04	4.024E-02
BROWN_MYELOID_CELL_DEVELOPMENT_DN	8	111	1.925	0.536	2.954E-04	4.024E-02
WP_PYRIMIDINE_METABOLISM_AND_RELATED_DISEASES	9	15	1.916	0.676	3.406E-04	4.125E-02
WP_PURINE_METABOLISM_AND_RELATED_DISORDERS	10	20	1.903	0.733	4.068E-04	4.162E-02
REACTOME_HSF1_DEPENDENT_TRANSACTIVATION	11	35	1.901	0.628	4.200E-04	4.162E-02
MANALO_HYPOXIA_DN	12	231	1.872	0.636	6.748E-04	5.905E-02
SANSOM_APC_TARGETS_REQUIRE_MYC	13	174	1.869	0.554	7.043E-04	5.905E-02
WP_PPARALPHA_PATHWAY	14	25	1.865	0.555	7.606E-04	5.922E-02
HALLMARK_MYC_TARGETS_V2	15	47	1.845	0.888	0.001	0.069
WP_TRIACYLGLYCERIDE_SYNTHESIS	16	21	1.842	0.543	0.001	0.069
KEGG_PURINE_METABOLISM	17	142	1.841	0.469	0.001	0.069
BILD_MYC_ONCOGENIC_SIGNATURE	18	158	1.83	0.521	0.001	0.077
REACTOME_HSF1_ACTIVATION	19	31	1.819	0.626	0.001	0.085
COLDREN_GEFITINIB_RESISTANCE_UP	20	61	1.804	0.654	0.002	0.100
SCHUHMACHER_MYC_TARGETS_UP	21	70	1.791	0.826	0.002	0.114
ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_UP	22	68	1.788	0.689	0.002	0.114
GAJATE_RESPONSE_TO_TRABECTEDIN_DN	23	15	1.777	0.755	0.003	0.127
ELVIDGE_HYPOXIA_BY_DMOG_DN	24	48	1.772	0.503	0.003	0.129
GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_DN	25	21	1.769	0.555	0.003	0.129
REACTOME_RRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL	26	36	1.765	0.85	0.003	0.129
BIOCARTA_ARF_PATHWAY	27	17	1.761	0.682	0.003	0.129
WP_ONECARBON_METABOLISM	28	28	1.76	0.484	0.003	0.129
IVANOVA_HEMATOPOIESIS_INTERMEDIATE_PROGENITOR	29	95	1.745	0.622	0.004	0.146
DUTERTRE_ESTRADIOL_RESPONSE_6HR_UP	30	199	1.743	0.455	0.004	0.146
JAIN_NFKB_SIGNALING	31	65	1.743	0.608	0.004	0.146
SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY	32	29	1.739	0.775	0.004	0.148
REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT	33	48	1.731	0.728	0.005	0.159
KIM_MYCN_AMPLIFICATION_TARGETS_UP	34	85	1.724	0.427	0.005	0.169
REACTOME_SYNTHESIS_OF_PA	35	30	1.718	0.441	0.006	0.174
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN	36	44	1.717	0.812	0.006	0.174
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_11	37	73	1.712	0.62	0.006	0.174
REACTOME_METABOLISM_OF_FOLATE_AND_PTERINES	38	15	1.712	0.606	0.006	0.174
WP_METHIONINE_DE_NOVO_AND_SALVAGE_PATHWAY	39	20	1.707	0.621	0.006	0.179
REACTOME_TRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL	40	24	1.705	0.805	0.007	0.179
ZHANG_RESPONSE_TO_CANTHARIDIN_DN	41	56	1.702	0.687	0.007	0.181
REACTOME_GENE_SILENCING_BY_RNA	42	65	1.701	0.591	0.007	0.181
SHEPARD_CRASH_AND_BURN_MUTANT_UP	43	163	1.697	0.515	0.007	0.185
REACTOME_TRNA_PROCESSING	44	76	1.689	0.704	0.008	0.199
KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM	45	30	1.683	0.529	0.009	0.208
CARRILLOREIXACH_HEPATOBLASTOMA_VS_NORMAL_HYPERMETHYLATED_AND_DN	46	16	1.674	0.521	0.010	0.224
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP	47	42	1.671	0.776	0.010	0.224
REACTOME_MITOCHONDRIAL_TRANSLATION	48	92	1.67	0.787	0.010	0.224
KEGG_PENTOSE_PHOSPHATE_PATHWAY	49	26	1.665	0.641	0.011	0.232
REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION	50	39	1.663	0.707	0.011	0.232
REACTOME_METABOLISM_OF_WATER_SOLUBLE_VITAMINS_AND_COFACTORS	51	108	1.659	0.381	0.011	0.232
KEGG_CYSTEINE_AND_METHIONINE_METABOLISM	52	31	1.659	0.511	0.011	0.232
WP_GLYCOSYLATION_AND_RELATED_CONGENITAL_DEFECTS	53	19	1.658	0.751	0.011	0.232
REACTOME_AZATHIOPRINE_ADME	54	23	1.654	0.506	0.012	0.239
WP_UREA_CYCLE_AND_ASSOCIATED_PATHWAYS	55	23	1.647	0.579	0.013	0.250
SMIRNOV_RESPONSE_TO_IR_6HR_DN	56	101	1.645	0.369	0.013	0.250
COLLER_MYC_TARGETS_UP	57	21	1.644	0.84	0.013	0.250
REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_INITIATION_FROM_TYPE_3_PROMOTER	58	27	1.642	0.711	0.013	0.250
HESS_TARGETS_OF_HOXA9_AND_MEIS1_UP	59	61	1.641	0.573	0.014	0.250
TIAN_TNF_SIGNALING_NOT_VIA_NFKB	60	21	1.637	0.531	0.014	0.256
GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN	61	129	1.634	0.45	0.015	0.261
DANG_MYC_TARGETS_UP	62	112	1.63	0.647	0.015	0.268
MOOTHA_GLYCOLYSIS	63	20	1.626	0.588	0.016	0.268
NELSON_RESPONSE_TO_ANDROGEN_DN	64	17	1.626	0.54	0.016	0.268
MULLIGAN_NTF3_SIGNALING_VIA_INSR_AND_IGF1R_UP	65	19	1.626	0.713	0.016	0.268
REACTOME_DEFECTS_IN_VITAMIN_AND_COFACTOR_METABOLISM	66	19	1.624	0.536	0.016	0.268
ELVIDGE_HIF1A_TARGETS_UP	67	54	1.623	0.589	0.016	0.268
KEGG_ONE_CARBON_POOL_BY_FOLATE	68	17	1.621	0.566	0.017	0.269
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_UP	69	36	1.619	0.628	0.017	0.269
REACTOME_RNA_POLYMERASE_I_PROMOTER_ESCAPE	70	27	1.618	0.695	0.017	0.269
REACTOME_RNA_POLYMERASE_I_TRANSCRIPTION_TERMINATION	71	26	1.615	0.693	0.018	0.272
REACTOME_METABOLISM_OF_NUCLEOTIDES	72	81	1.613	0.456	0.018	0.275
XU_CREBBP_TARGETS_UP	73	17	1.611	0.588	0.019	0.277
LEE_METASTASIS_AND_RNA_PROCESSING_UP	74	15	1.609	0.78	0.019	0.278
REACTOME_PIWI_INTERACTING_RNA_PIRNA_BIOGENESIS	75	26	1.606	0.578	0.020	0.282
IRITANI_MAD1_TARGETS_DN	76	36	1.605	0.74	0.020	0.282
KEGG_BETA_ALANINE_METABOLISM	77	22	1.596	0.532	0.022	0.298
WU_HBX_TARGETS_3_UP	78	17	1.596	0.561	0.022	0.298
KEGG_RNA_POLYMERASE	79	27	1.595	0.711	0.022	0.298
REACTOME_RRNA_PROCESSING	80	168	1.594	0.697	0.022	0.298
REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_INITIATION_FROM_TYPE_1_PROMOTER	81	26	1.585	0.716	0.024	0.320
PID_MYC_ACTIV_PATHWAY	82	75	1.584	0.583	0.024	0.320
SANSOM_APC_MYC_TARGETS	83	194	1.582	0.465	0.025	0.323
WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_DN	84	277	1.58	0.418	0.025	0.324
IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR	85	334	1.573	0.436	0.027	0.344
GROSS_HYPOXIA_VIA_HIF1A_UP	86	62	1.567	0.557	0.028	0.347
WELCSH_BRCA1_TARGETS_DN	87	113	1.567	0.587	0.028	0.347
COLLIS_PRKDC_SUBSTRATES	88	15	1.566	0.662	0.029	0.347
REACTOME_TRNA_AMINOACYLATION	89	15	1.565	0.744	0.029	0.347
BHAT_ESR1_TARGETS_VIA_AKT1_UP	90	228	1.565	0.409	0.029	0.347
WELCH_GATA1_TARGETS	91	24	1.563	0.517	0.029	0.347
MOOTHA_GLUCONEOGENESIS	92	31	1.561	0.506	0.030	0.347
NOJIMA_SFRP2_TARGETS_UP	93	28	1.56	0.463	0.030	0.347
REACTOME_SNRNP_ASSEMBLY	94	44	1.559	0.694	0.030	0.347
WP_PYRIMIDINE_METABOLISM	95	73	1.559	0.523	0.030	0.347
HELLER_HDAC_TARGETS_DN	96	248	1.558	0.383	0.031	0.347
CAIRO_PML_TARGETS_BOUND_BY_MYC_UP	97	21	1.558	0.639	0.031	0.347
REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_TERMINATION	98	22	1.549	0.753	0.033	0.357
REACTOME_RNA_POLYMERASE_III_CHAIN_ELONGATION	99	17	1.548	0.751	0.034	0.357
TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA	100	88	1.547	0.347	0.034	0.357
WP_REGULATION_OF_APOPTOSIS_BY_PARATHYROID_HORMONERELATED_PROTEIN	101	21	1.546	0.489	0.034	0.357
CAIRO_HEPATOBLASTOMA_CLASSES_UP	102	495	1.546	0.56	0.034	0.357
HELLER_SILENCED_BY_METHYLATION_DN	103	95	1.545	0.435	0.035	0.357
REACTOME_DISEASES_ASSOCIATED_WITH_N_GLYCOSYLATION_OF_PROTEINS	104	16	1.544	0.761	0.035	0.357
WP_IMATINIB_AND_CHRONIC_MYELOID_LEUKEMIA	105	18	1.544	0.452	0.035	0.357
REACTOME_GAMMA_CARBOXYLATION_HYPUSINE_FORMATION_AND_ARYLSULFATASE_ACTIVATION	106	36	1.543	0.482	0.035	0.357
CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_UP	107	41	1.543	0.605	0.035	0.357
SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM	108	122	1.542	0.687	0.035	0.357
BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP	109	179	1.54	0.381	0.036	0.359
REACTOME_TRANSLATION	110	244	1.536	0.68	0.037	0.364
REACTOME_N_GLYCAN_ANTENNAE_ELONGATION	111	15	1.535	0.555	0.038	0.364
REACTOME_TRNA_PROCESSING_IN_THE_NUCLEUS	112	49	1.535	0.644	0.038	0.364
REACTOME_REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE	113	72	1.535	0.543	0.038	0.364
MUELLER_PLURINET	114	257	1.53	0.467	0.039	0.371
BURTON_ADIPOGENESIS_5	115	95	1.53	0.545	0.039	0.371
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION	116	84	1.528	0.416	0.040	0.373
KEGG_ARGININE_AND_PROLINE_METABOLISM	117	50	1.524	0.438	0.041	0.384
REACTOME_PROTEIN_LOCALIZATION	118	138	1.522	0.486	0.042	0.387
REACTOME_BIOSYNTHESIS_OF_THE_N_GLYCAN_PRECURSOR_DOLICHOL_LIPID_LINKED_OLIGOSACCHARIDE_LLO_AND_TRANSFER_TO_A_NASCENT_PROTEIN	119	68	1.514	0.418	0.045	0.411
MATTIOLI_MGUS_VS_PCL	120	85	1.509	0.496	0.046	0.418
CEBALLOS_TARGETS_OF_TP53_AND_MYC_UP	121	18	1.508	0.569	0.047	0.418
WP_TP53_NETWORK	122	18	1.508	0.59	0.047	0.418
WALLACE_PROSTATE_CANCER_UP	123	18	1.505	0.579	0.048	0.421
BENPORATH_ES_1	124	310	1.505	0.382	0.048	0.421
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP	125	169	1.505	0.444	0.048	0.421
LA_MEN1_TARGETS	126	21	1.502	0.474	0.049	0.425
DAIRKEE_CANCER_PRONE_RESPONSE_BPA	127	45	1.501	0.561	0.050	0.425
KEGG_SPLICEOSOME	128	94	1.496	0.63	0.052	0.440
KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM	129	32	1.489	0.48	0.054	0.460
MARSON_FOXP3_CORE_DIRECT_TARGETS	130	15	1.486	0.542	0.056	0.466
REACTOME_CELLULAR_RESPONSE_TO_HEAT_STRESS	131	88	1.485	0.507	0.056	0.466
REACTOME_HIV_TRANSCRIPTION_INITIATION	132	47	1.482	0.612	0.058	0.474
KEGG_N_GLYCAN_BIOSYNTHESIS	133	42	1.482	0.584	0.058	0.474
CERVERA_SDHB_TARGETS_1_DN	134	33	1.479	0.521	0.059	0.478
NIKOLSKY_BREAST_CANCER_19Q13.1_AMPLICON	135	18	1.478	0.553	0.059	0.478
SHIN_B_CELL_LYMPHOMA_CLUSTER_2	136	29	1.476	0.454	0.060	0.482
CUI_TCF21_TARGETS_DN	137	30	1.47	0.436	0.063	0.503
KEGG_PYRIMIDINE_METABOLISM	138	86	1.466	0.473	0.065	0.514
CHIANG_LIVER_CANCER_SUBCLASS_POLYSOMY7_DN	139	19	1.463	0.514	0.066	0.517
HALLMARK_MYC_TARGETS_V1	140	168	1.462	0.682	0.066	0.517
DAUER_STAT3_TARGETS_DN	141	45	1.46	0.446	0.068	0.523
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_14	142	110	1.458	0.563	0.068	0.525
REACTOME_TP53_REGULATES_TRANSCRIPTION_OF_GENES_INVOLVED_IN_CYTOCHROME_C_RELEASE	143	15	1.457	0.549	0.069	0.526
MOREAUX_B_LYMPHOCYTE_MATURATION_BY_TACI_DN	144	54	1.456	0.627	0.070	0.527
MALONEY_RESPONSE_TO_17AAG_UP	145	37	1.449	0.427	0.073	0.549
KONDO_COLON_CANCER_HCP_WITH_H3K27ME1	146	19	1.446	0.463	0.075	0.553
MARCINIAK_ER_STRESS_RESPONSE_VIA_CHOP	147	19	1.445	0.501	0.075	0.553
REACTOME_MEIOTIC_RECOMBINATION	148	25	1.444	0.515	0.076	0.553
BOYLAN_MULTIPLE_MYELOMA_C_UP	149	38	1.444	0.427	0.076	0.553
REACTOME_INTERACTIONS_OF_REV_WITH_HOST_CELLULAR_PROTEINS	150	32	1.44	0.649	0.078	0.567
KEGG_RNA_DEGRADATION	151	50	1.437	0.571	0.079	0.570
PRAMOONJAGO_SOX4_TARGETS_DN	152	42	1.437	0.508	0.079	0.570
HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_DN	153	236	1.436	0.363	0.080	0.570
PID_MYC_PATHWAY	154	23	1.435	0.608	0.081	0.572
REACTOME_MICRORNA_MIRNA_BIOGENESIS	155	18	1.432	0.669	0.082	0.579
KEGG_SELENOAMINO_ACID_METABOLISM	156	20	1.431	0.539	0.083	0.579
BILANGES_RAPAMYCIN_SENSITIVE_VIA_TSC1_AND_TSC2	157	57	1.428	0.589	0.084	0.584
MOOTHA_HUMAN_MITODB_6_2002	158	389	1.427	0.47	0.085	0.584
GARY_CD5_TARGETS_DN	159	358	1.427	0.518	0.085	0.584
WP_TRANSLATION_FACTORS	160	37	1.421	0.65	0.088	0.596
WANG_TARGETS_OF_MLL_CBP_FUSION_DN	161	37	1.421	0.554	0.088	0.596
REACTOME_TRANSCRIPTION_OF_E2F_TARGETS_UNDER_NEGATIVE_CONTROL_BY_DREAM_COMPLEX	162	16	1.421	0.542	0.089	0.596
REACTOME_FGFR2_MUTANT_RECEPTOR_ACTIVATION	163	33	1.419	0.483	0.090	0.599
MOOTHA_MITOCHONDRIA	164	399	1.417	0.467	0.091	0.599
KORKOLA_YOLK_SAC_TUMOR_UP	165	17	1.416	0.558	0.091	0.599
REACTOME_VITAMIN_B5_PANTOTHENATE_METABOLISM	166	17	1.415	0.433	0.092	0.599
REACTOME_NUCLEAR_IMPORT_OF_REV_PROTEIN	167	29	1.415	0.644	0.092	0.599
REACTOME_MRNA_CAPPING	168	29	1.413	0.61	0.093	0.605
UEDA_CENTRAL_CLOCK	169	76	1.411	0.438	0.095	0.610
REACTOME_TRANSCRIPTION_OF_THE_HIV_GENOME	170	62	1.408	0.555	0.096	0.618
REACTOME_METABOLISM_OF_PORPHYRINS	171	24	1.403	0.411	0.099	0.623
BIOCARTA_CARDIACEGF_PATHWAY	172	17	1.403	0.499	0.099	0.623
DANG_REGULATED_BY_MYC_UP	173	61	1.403	0.488	0.099	0.623
WENG_POR_TARGETS_GLOBAL_DN	174	20	1.403	0.456	0.099	0.623
CAIRO_HEPATOBLASTOMA_POOR_SURVIVAL	175	15	1.401	0.519	0.101	0.623
WP_PI3KAKTMTOR_VITAMIN_D3_SIGNALING	176	21	1.399	0.43	0.102	0.623
BONOME_OVARIAN_CANCER_POOR_SURVIVAL_DN	177	15	1.399	0.492	0.102	0.623
SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_UP	178	43	1.399	0.566	0.102	0.623
BURTON_ADIPOGENESIS_PEAK_AT_16HR	179	39	1.398	0.466	0.102	0.623
REACTOME_KSRP_KHSRP_BINDS_AND_DESTABILIZES_MRNA	180	16	1.397	0.596	0.103	0.623
BENPORATH_MYC_TARGETS_WITH_EBOX	181	209	1.396	0.413	0.104	0.624
REACTOME_POSTMITOTIC_NUCLEAR_PORE_COMPLEX_NPC_REFORMATION	182	24	1.395	0.702	0.104	0.625
MELLMAN_TUT1_TARGETS_UP	183	18	1.393	0.566	0.106	0.630
BIOCARTA_CHEMICAL_PATHWAY	184	17	1.392	0.536	0.107	0.631
REACTOME_FORMATION_OF_THE_EARLY_ELONGATION_COMPLEX	185	29	1.389	0.601	0.108	0.637
BASSO_B_LYMPHOCYTE_NETWORK	186	115	1.388	0.47	0.109	0.637
BOYLAN_MULTIPLE_MYELOMA_C_D_UP	187	111	1.385	0.366	0.111	0.644
REACTOME_RMTS_METHYLATE_HISTONE_ARGININES	188	28	1.384	0.55	0.112	0.644
BILANGES_SERUM_RESPONSE_TRANSLATION	189	28	1.384	0.571	0.112	0.644
WP_APOPTOSIS_MODULATION_BY_HSP70	190	18	1.379	0.496	0.114	0.655
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_LARGE_VS_TINY_UP	191	31	1.379	0.442	0.115	0.655
REACTOME_EXPORT_OF_VIRAL_RIBONUCLEOPROTEINS_FROM_NUCLEUS	192	28	1.378	0.624	0.116	0.655
CHEN_ETV5_TARGETS_TESTIS	193	19	1.377	0.484	0.116	0.655
LU_TUMOR_VASCULATURE_UP	194	25	1.376	0.396	0.117	0.655
WP_EUKARYOTIC_TRANSCRIPTION_INITIATION	195	41	1.374	0.588	0.118	0.660
REACTOME_METABOLISM_OF_VITAMINS_AND_COFACTORS	196	169	1.373	0.307	0.119	0.660
LU_TUMOR_ENDOTHELIAL_MARKERS_UP	197	18	1.37	0.408	0.121	0.668
WP_HISTONE_MODIFICATIONS	198	30	1.368	0.466	0.122	0.673
MCGOWAN_RSP6_TARGETS_UP	199	17	1.366	0.463	0.124	0.676
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_DN	200	22	1.366	0.39	0.124	0.676
ZHAN_MULTIPLE_MYELOMA_CD2_DN	201	39	1.364	0.43	0.125	0.677
SANSOM_APC_TARGETS	202	157	1.361	0.325	0.127	0.683
REACTOME_TRANSCRIPTIONAL_REGULATION_BY_SMALL_RNAS	203	40	1.361	0.597	0.127	0.683
REACTOME_COMPLEX_I_BIOGENESIS	204	42	1.36	0.645	0.128	0.683
LI_DCP2_BOUND_MRNA	205	74	1.357	0.551	0.130	0.683
WONG_EMBRYONIC_STEM_CELL_CORE	206	289	1.357	0.504	0.130	0.683
HALLMARK_UNFOLDED_PROTEIN_RESPONSE	207	97	1.357	0.516	0.130	0.683
REACTOME_TRANSCRIPTIONAL_REGULATION_BY_THE_AP_2_TFAP2_FAMILY_OF_TRANSCRIPTION_FACTORS	208	32	1.357	0.428	0.130	0.683
LIU_PROSTATE_CANCER_UP	209	77	1.353	0.408	0.133	0.691
WP_METABOLIC_REPROGRAMMING_IN_COLON_CANCER	210	40	1.352	0.549	0.134	0.691
DEN_INTERACT_WITH_LCA5	211	23	1.352	0.604	0.134	0.691
REACTOME_VIRAL_MESSENGER_RNA_SYNTHESIS	212	39	1.349	0.591	0.136	0.700
WP_MITOCHONDRIAL_GENE_EXPRESSION	213	16	1.346	0.452	0.138	0.706
REACTOME_TRANSPORT_OF_VITAMINS_NUCLEOSIDES_AND_RELATED_MOLECULES	214	41	1.345	0.417	0.139	0.709
WP_INTERACTIONS_OF_NATURAL_KILLER_CELLS_IN_PANCREATIC_CANCER	215	24	1.343	0.456	0.140	0.710
WONG_MITOCHONDRIA_GENE_MODULE	216	194	1.342	0.508	0.141	0.712
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX	217	25	1.332	0.462	0.148	0.745
GRADE_COLON_AND_RECTAL_CANCER_UP	218	229	1.33	0.487	0.150	0.749
REACTOME_REGULATION_OF_GLUCOKINASE_BY_GLUCOKINASE_REGULATORY_PROTEIN	219	27	1.329	0.56	0.151	0.750
KARLSSON_TGFB1_TARGETS_UP	220	97	1.328	0.517	0.152	0.750
MATZUK_CENTRAL_FOR_FEMALE_FERTILITY	221	29	1.328	0.397	0.152	0.750
LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_UP	222	145	1.324	0.349	0.155	0.754
POMEROY_MEDULLOBLASTOMA_PROGNOSIS_DN	223	41	1.324	0.533	0.155	0.754
KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE	224	25	1.324	0.424	0.155	0.754
REACTOME_HIV_TRANSCRIPTION_ELONGATION	225	35	1.321	0.557	0.157	0.759
REACTOME_BBSOME_MEDIATED_CARGO_TARGETING_TO_CILIUM	226	20	1.32	0.528	0.158	0.759
MALTA_CURATED_STEMNESS_MARKERS	227	20	1.32	0.421	0.158	0.759
NUNODA_RESPONSE_TO_DASATINIB_IMATINIB_UP	228	28	1.319	0.463	0.159	0.759
GRABARCZYK_BCL11B_TARGETS_DN	229	51	1.318	0.333	0.159	0.759
CUI_TCF21_TARGETS_2_UP	230	340	1.315	0.3	0.162	0.760
PURBEY_TARGETS_OF_CTBP1_AND_SATB1_DN	231	137	1.315	0.325	0.162	0.760
YEGNASUBRAMANIAN_PROSTATE_CANCER	232	111	1.315	0.299	0.162	0.760
MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP	233	320	1.314	0.405	0.162	0.760
REACTOME_TRANSCRIPTIONAL_REGULATION_OF_GRANULOPOIESIS	234	29	1.313	0.403	0.164	0.760
NUTT_GBM_VS_AO_GLIOMA_DN	235	38	1.312	0.424	0.164	0.760
REACTOME_SULFUR_AMINO_ACID_METABOLISM	236	22	1.311	0.425	0.165	0.760
ELVIDGE_HYPOXIA_DN	237	123	1.311	0.464	0.165	0.760
REACTOME_ZINC_TRANSPORTERS	238	17	1.31	0.523	0.166	0.762
REACTOME_ABORTIVE_ELONGATION_OF_HIV_1_TRANSCRIPT_IN_THE_ABSENCE_OF_TAT	239	19	1.306	0.593	0.169	0.767
WP_GLYCEROLIPIDS_AND_GLYCEROPHOSPHOLIPIDS	240	21	1.305	0.47	0.170	0.767
STARK_HYPPOCAMPUS_22Q11_DELETION_DN	241	16	1.304	0.512	0.171	0.767
REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA	242	180	1.304	0.526	0.171	0.767
VANLOO_SP3_TARGETS_DN	243	73	1.304	0.354	0.171	0.767
SMIRNOV_RESPONSE_TO_IR_2HR_DN	244	50	1.303	0.34	0.172	0.767
REACTOME_ATF4_ACTIVATES_GENES_IN_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS	245	25	1.302	0.555	0.173	0.767
CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_DN	246	41	1.3	0.337	0.174	0.772
KEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM	247	31	1.299	0.388	0.176	0.775
MOREAUX_MULTIPLE_MYELOMA_BY_TACI_DN	248	132	1.296	0.516	0.178	0.775
HALLMARK_DNA_REPAIR	249	135	1.294	0.444	0.179	0.775
REACTOME_RNA_POLYMERASE_II_PRE_TRANSCRIPTION_EVENTS	250	73	1.294	0.498	0.179	0.775
DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_UP	251	288	1.294	0.292	0.180	0.775
REACTOME_SUMOYLATION_OF_SUMOYLATION_PROTEINS	252	30	1.293	0.549	0.180	0.775
REACTOME_GLYCOLYSIS	253	65	1.293	0.44	0.180	0.775
WP_MITOCHONDRIAL_COMPLEX_I_ASSEMBLY_MODEL_OXPHOS_SYSTEM	254	40	1.293	0.621	0.181	0.775
ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN	255	272	1.29	0.296	0.183	0.776
FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN	256	46	1.289	0.416	0.183	0.776
REACTOME_RNA_POLYMERASE_I_TRANSCRIPTION_INITIATION	257	41	1.289	0.507	0.184	0.776
HOFMANN_CELL_LYMPHOMA_UP	258	42	1.288	0.411	0.185	0.776
CHEN_HOXA5_TARGETS_9HR_DN	259	33	1.287	0.477	0.185	0.776
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_10	260	55	1.287	0.529	0.185	0.776
TAVOR_CEBPA_TARGETS_DN	261	30	1.284	0.407	0.188	0.784
HOLLERN_ADENOMYOEPITHELIAL_BREAST_TUMOR	262	17	1.283	0.41	0.189	0.784
MARIADASON_RESPONSE_TO_CURCUMIN_SULINDAC_5	263	21	1.283	0.481	0.189	0.784
MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_UP	264	85	1.282	0.413	0.190	0.785
SONG_TARGETS_OF_IE86_CMV_PROTEIN	265	50	1.279	0.441	0.192	0.789
REACTOME_SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY	266	47	1.279	0.617	0.192	0.789
OISHI_CHOLANGIOMA_STEM_CELL_LIKE_UP	267	294	1.275	0.388	0.195	0.798
REACTOME_FATTY_ACYL_COA_BIOSYNTHESIS	268	30	1.272	0.416	0.198	0.807
BROWNE_HCMV_INFECTION_24HR_UP	269	129	1.269	0.295	0.201	0.810
SA_G1_AND_S_PHASES	270	15	1.269	0.504	0.201	0.810
ABRAHAM_ALPC_VS_MULTIPLE_MYELOMA_DN	271	20	1.269	0.571	0.201	0.810
KEGG_GALACTOSE_METABOLISM	272	25	1.265	0.432	0.205	0.815
KEGG_BASAL_TRANSCRIPTION_FACTORS	273	33	1.265	0.495	0.205	0.815
BIOCARTA_CTCF_PATHWAY	274	23	1.264	0.468	0.205	0.815
ABRAMSON_INTERACT_WITH_AIRE	275	36	1.263	0.576	0.206	0.815
REACTOME_B_WICH_COMPLEX_POSITIVELY_REGULATES_RRNA_EXPRESSION	276	25	1.263	0.536	0.206	0.815
REACTOME_MRNA_SPLICING	277	138	1.262	0.516	0.208	0.817
CHNG_MULTIPLE_MYELOMA_HYPERPLOID_UP	278	45	1.257	0.601	0.212	0.828
REACTOME_HIV_ELONGATION_ARREST_AND_RECOVERY	279	25	1.257	0.54	0.212	0.828
REACTOME_EUKARYOTIC_TRANSLATION_INITIATION	280	105	1.252	0.591	0.216	0.842
PEART_HDAC_PROLIFERATION_CLUSTER_DN	281	66	1.25	0.378	0.219	0.846
BOYLAN_MULTIPLE_MYELOMA_C_CLUSTER_UP	282	29	1.246	0.397	0.221	0.846
GENTILE_UV_RESPONSE_CLUSTER_D9	283	18	1.244	0.481	0.224	0.846
GENTILE_UV_LOW_DOSE_UP	284	24	1.243	0.498	0.224	0.846
KEGG_LYSINE_DEGRADATION	285	39	1.243	0.389	0.225	0.846
REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX	286	29	1.242	0.414	0.225	0.846
REACTOME_SUMOYLATION_OF_UBIQUITINYLATION_PROTEINS	287	34	1.24	0.486	0.227	0.846
REACTOME_PERK_REGULATES_GENE_EXPRESSION	288	30	1.24	0.517	0.228	0.846
BURTON_ADIPOGENESIS_4	289	38	1.237	0.44	0.230	0.846
REACTOME_TELOMERE_MAINTENANCE	290	52	1.234	0.434	0.233	0.846
REACTOME_INFLUENZA_INFECTION	291	149	1.233	0.525	0.234	0.846
REACTOME_FORMATION_OF_TC_NER_PRE_INCISION_COMPLEX	292	50	1.233	0.516	0.234	0.846
JIANG_TIP30_TARGETS_DN	293	23	1.232	0.481	0.234	0.846
WP_SARSCOV2_MITOCHONDRIAL_CHRONIC_OXIDATIVE_STRESS_AND_ENDOTHELIAL_DYSFUNCTION	294	20	1.232	0.356	0.235	0.846
GAZDA_DIAMOND_BLACKFAN_ANEMIA_MYELOID_DN	295	35	1.231	0.427	0.236	0.846
VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_UP	296	56	1.231	0.477	0.236	0.846
YAUCH_HEDGEHOG_SIGNALING_PARACRINE_UP	297	119	1.23	0.307	0.236	0.846
BAKKER_FOXO3_TARGETS_DN	298	137	1.23	0.303	0.237	0.846
REACTOME_DISEASES_OF_METABOLISM	299	214	1.229	0.302	0.238	0.846
REACTOME_SELENOAMINO_ACID_METABOLISM	300	104	1.228	0.555	0.239	0.846
JAZAG_TGFB1_SIGNALING_VIA_SMAD4_UP	301	90	1.227	0.314	0.239	0.846
STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN	302	386	1.226	0.406	0.240	0.846
CHANDRAN_METASTASIS_TOP50_UP	303	27	1.226	0.489	0.240	0.846
JAATINEN_HEMATOPOIETIC_STEM_CELL_UP	304	252	1.225	0.309	0.241	0.846
REACTOME_PYRUVATE_METABOLISM	305	28	1.225	0.4	0.241	0.846
SANSOM_WNT_PATHWAY_REQUIRE_MYC	306	60	1.224	0.328	0.242	0.846
REACTOME_INTERACTIONS_OF_VPR_WITH_HOST_CELLULAR_PROTEINS	307	32	1.224	0.538	0.242	0.846
TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C	308	320	1.223	0.345	0.243	0.846
REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY	309	46	1.222	0.516	0.244	0.846
REACTOME_TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM	310	61	1.222	0.511	0.245	0.846
HOWLIN_CITED1_TARGETS_2_DN	311	15	1.221	0.402	0.245	0.846
BIOCARTA_MITOCHONDRIA_PATHWAY	312	17	1.221	0.428	0.245	0.846
BHATTACHARYA_EMBRYONIC_STEM_CELL	313	73	1.219	0.421	0.247	0.846
NIKOLSKY_BREAST_CANCER_12Q13_Q21_AMPLICON	314	37	1.218	0.385	0.248	0.846
REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION_TERMINATION	315	49	1.217	0.491	0.249	0.846
REACTOME_COOPERATION_OF_PDCL_PHLP1_AND_TRIC_CCT_IN_G_PROTEIN_BETA_FOLDING	316	38	1.217	0.39	0.249	0.846
REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES	317	333	1.214	0.369	0.252	0.846
BOYAULT_LIVER_CANCER_SUBCLASS_G1_DN	318	35	1.213	0.42	0.252	0.846
CHEOK_RESPONSE_TO_MERCAPTOPURINE_AND_HD_MTX_DN	319	21	1.213	0.412	0.253	0.846
HALLMARK_UV_RESPONSE_UP	320	146	1.213	0.32	0.253	0.846
WP_G1_TO_S_CELL_CYCLE_CONTROL	321	54	1.212	0.384	0.254	0.846
REACTOME_TRANSPORT_OF_THE_SLBP_DEPENDANT_MATURE_MRNA	322	30	1.212	0.555	0.254	0.846
REACTOME_PKMTS_METHYLATE_HISTONE_LYSINES	323	32	1.211	0.438	0.255	0.846
MARSON_FOXP3_TARGETS_DN	324	45	1.21	0.324	0.256	0.846
REACTOME_RNA_POLYMERASE_I_TRANSCRIPTION	325	44	1.205	0.471	0.261	0.846
WP_GLYCEROPHOSPHOLIPID_BIOSYNTHETIC_PATHWAY	326	26	1.204	0.358	0.262	0.846
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_CIS	327	47	1.203	0.423	0.263	0.846
WP_OXIDATIVE_PHOSPHORYLATION	328	37	1.203	0.561	0.263	0.846
MATZUK_OVULATION	329	15	1.203	0.409	0.263	0.846
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_5	330	27	1.202	0.393	0.263	0.846
KEGG_PYRUVATE_METABOLISM	331	39	1.202	0.37	0.264	0.846
BREDEMEYER_RAG_SIGNALING_VIA_ATM_NOT_VIA_NFKB_DN	332	34	1.202	0.341	0.264	0.846
REACTOME_EUKARYOTIC_TRANSLATION_ELONGATION	333	93	1.2	0.584	0.265	0.846
WP_GASTRIC_CANCER_NETWORK_2	334	25	1.199	0.405	0.266	0.846
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_UP	335	189	1.199	0.322	0.267	0.846
REACTOME_MRNA_SPLICING_MINOR_PATHWAY	336	40	1.198	0.537	0.267	0.846
CHENG_IMPRINTED_BY_ESTRADIOL	337	89	1.198	0.311	0.267	0.846
SLEBOS_HEAD_AND_NECK_CANCER_WITH_HPV_UP	338	58	1.197	0.359	0.269	0.846
REACTOME_THE_CITRIC_ACID_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT	339	131	1.197	0.446	0.269	0.846
REACTOME_G0_AND_EARLY_G1	340	23	1.197	0.419	0.269	0.846
WP_BASE_EXCISION_REPAIR	341	31	1.197	0.413	0.269	0.846
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE	342	109	1.195	0.568	0.270	0.846
WP_PREIMPLANTATION_EMBRYO	343	46	1.193	0.313	0.272	0.846
REACTOME_TP53_REGULATES_TRANSCRIPTION_OF_CELL_DEATH_GENES	344	36	1.192	0.376	0.273	0.846
JAZAG_TGFB1_SIGNALING_DN	345	29	1.191	0.328	0.275	0.846
WP_GLYCOLYSIS_AND_GLUCONEOGENESIS	346	41	1.188	0.384	0.277	0.846
REACTOME_GLUCOSE_METABOLISM	347	84	1.188	0.376	0.278	0.846
MATSUDA_NATURAL_KILLER_DIFFERENTIATION	348	414	1.188	0.243	0.278	0.846
NIKOLSKY_BREAST_CANCER_8Q23_Q24_AMPLICON	349	116	1.187	0.287	0.278	0.846
BACOLOD_RESISTANCE_TO_ALKYLATING_AGENTS_DN	350	42	1.187	0.382	0.278	0.846
VILLANUEVA_LIVER_CANCER_KRT19_DN	351	54	1.186	0.323	0.280	0.846
KEGG_GLYCOLYSIS_GLUCONEOGENESIS	352	59	1.185	0.351	0.281	0.846
CADWELL_ATG16L1_TARGETS_DN	353	51	1.184	0.333	0.281	0.846
REACTOME_REGULATION_OF_PYRUVATE_DEHYDROGENASE_PDH_COMPLEX	354	15	1.181	0.418	0.284	0.846
MADAN_DPPA4_TARGETS	355	43	1.18	0.366	0.285	0.846
REACTOME_RESOLUTION_OF_ABASIC_SITES_AP_SITES	356	37	1.179	0.395	0.286	0.846
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING_AND_HEAT_PRODUCTION_BY_UNCOUPLING_PROTEINS	357	83	1.179	0.497	0.287	0.846
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_LARGE_VS_TINY_DN	358	31	1.178	0.364	0.287	0.846
REACTOME_ASSOCIATION_OF_TRIC_CCT_WITH_TARGET_PROTEINS_DURING_BIOSYNTHESIS	359	35	1.176	0.446	0.289	0.846
RICKMAN_METASTASIS_UP	360	249	1.176	0.364	0.290	0.846
REACTOME_N_GLYCAN_ANTENNAE_ELONGATION_IN_THE_MEDIAL_TRANS_GOLGI	361	26	1.174	0.373	0.292	0.846
REACTOME_TRANSFERRIN_ENDOCYTOSIS_AND_RECYCLING	362	29	1.173	0.367	0.292	0.846
SANSOM_APC_TARGETS_UP	363	110	1.173	0.325	0.293	0.846
MANN_RESPONSE_TO_AMIFOSTINE_UP	364	19	1.171	0.501	0.294	0.846
ZHAN_MULTIPLE_MYELOMA_SUBGROUPS	365	30	1.171	0.506	0.295	0.846
EPPERT_PROGENITOR	366	109	1.171	0.407	0.295	0.846
ALFANO_MYC_TARGETS	367	204	1.17	0.324	0.296	0.846
SAKAI_TUMOR_INFILTRATING_MONOCYTES_DN	368	73	1.17	0.41	0.296	0.846
WP_LEUCINE_ISOLEUCINE_AND_VALINE_METABOLISM	369	21	1.169	0.481	0.296	0.846
WANG_IMMORTALIZED_BY_HOXA9_AND_MEIS1_DN	370	22	1.169	0.376	0.296	0.846
WP_MAPK_PATHWAY_IN_CONGENITAL_THYROID_CANCER	371	15	1.169	0.437	0.296	0.846
BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_UP	372	26	1.167	0.344	0.298	0.846
GAVIN_IL2_RESPONSIVE_FOXP3_TARGETS_UP	373	17	1.167	0.349	0.299	0.846
REACTOME_CHROMOSOME_MAINTENANCE	374	70	1.165	0.381	0.301	0.846
BLANCO_MELO_INFLUENZA_A_INFECTION_A594_CELLS_UP	375	34	1.163	0.37	0.303	0.846
FONTAINE_FOLLICULAR_THYROID_ADENOMA_DN	376	63	1.162	0.301	0.304	0.846
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S	377	45	1.161	0.549	0.305	0.846
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_17	378	155	1.16	0.455	0.306	0.846
IBRAHIM_NRF1_UP	379	342	1.16	0.429	0.306	0.846
HANN_RESISTANCE_TO_BCL2_INHIBITOR_DN	380	45	1.159	0.323	0.307	0.846
RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_UP	381	25	1.159	0.418	0.307	0.846
REACTOME_FORMATION_OF_RNA_POL_II_ELONGATION_COMPLEX	382	50	1.159	0.461	0.307	0.846
HUMMEL_BURKITTS_LYMPHOMA_UP	383	34	1.158	0.344	0.308	0.846
BROWNE_HCMV_INFECTION_8HR_UP	384	95	1.158	0.301	0.308	0.846
REACTOME_NONSENSE_MEDIATED_DECAY_NMD	385	111	1.156	0.531	0.309	0.846
CHEMELLO_SOLEUS_VS_EDL_MYOFIBERS_UP	386	18	1.156	0.38	0.310	0.846
FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_DN	387	79	1.155	0.37	0.311	0.846
KEGG_RIBOSOME	388	86	1.155	0.576	0.311	0.846
ZHAN_MULTIPLE_MYELOMA_MS_DN	389	33	1.154	0.366	0.312	0.846
CHEOK_RESPONSE_TO_MERCAPTOPURINE_AND_LD_MTX_DN	390	16	1.154	0.366	0.312	0.846
KEGG_MISMATCH_REPAIR	391	23	1.153	0.442	0.312	0.846
TOMLINS_PROSTATE_CANCER_UP	392	35	1.152	0.436	0.314	0.846
TSUNODA_CISPLATIN_RESISTANCE_DN	393	44	1.151	0.357	0.315	0.846
REACTOME_BUTYRATE_RESPONSE_FACTOR_1_BRF1_BINDS_AND_DESTABILIZES_MRNA	394	16	1.151	0.528	0.315	0.846
WP_NANOMATERIAL_INDUCED_APOPTOSIS	395	19	1.151	0.407	0.315	0.846
REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS	396	29	1.15	0.403	0.316	0.846
NAGY_TFTC_COMPONENTS_HUMAN	397	15	1.15	0.47	0.316	0.846
REACTOME_PROCESSING_OF_CAPPED_INTRONLESS_PRE_MRNA	398	27	1.149	0.468	0.317	0.846
LAU_APOPTOSIS_CDKN2A_UP	399	55	1.149	0.409	0.317	0.846
REACTOME_SIGNALING_BY_FGFR2_IIIA_TM	400	19	1.149	0.524	0.317	0.846
BOYAULT_LIVER_CANCER_SUBCLASS_G12_UP	401	34	1.145	0.462	0.322	0.846
PID_HIV_NEF_PATHWAY	402	35	1.144	0.33	0.322	0.846
REACTOME_DISEASES_OF_CARBOHYDRATE_METABOLISM	403	32	1.144	0.338	0.323	0.846
SANA_RESPONSE_TO_IFNG_DN	404	78	1.144	0.409	0.323	0.846
WOOD_EBV_EBNA1_TARGETS_UP	405	103	1.144	0.375	0.323	0.846
REACTOME_DRUG_ADME	406	79	1.143	0.288	0.324	0.846
SHARMA_PILOCYTIC_ASTROCYTOMA_LOCATION_UP	407	23	1.142	0.333	0.324	0.846
CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP	408	139	1.142	0.269	0.324	0.846
GAVIN_FOXP3_TARGETS_CLUSTER_T7	409	83	1.142	0.377	0.325	0.846
KEGG_DNA_REPLICATION	410	34	1.14	0.387	0.326	0.846
REACTOME_TELOMERE_EXTENSION_BY_TELOMERASE	411	17	1.139	0.474	0.327	0.846
LEE_TARGETS_OF_PTCH1_AND_SUFU_UP	412	46	1.139	0.318	0.328	0.846
MATTIOLI_MULTIPLE_MYELOMA_SUBGROUPS	413	15	1.138	0.377	0.329	0.846
WP_OVARIAN_INFERTILITY	414	32	1.137	0.309	0.330	0.846
REACTOME_HIV_LIFE_CYCLE	415	132	1.137	0.42	0.330	0.846
PID_ATM_PATHWAY	416	29	1.136	0.402	0.331	0.846
WAGNER_APO2_SENSITIVITY	417	24	1.135	0.39	0.331	0.846
ZHAN_VARIABLE_EARLY_DIFFERENTIATION_GENES_DN	418	27	1.135	0.478	0.332	0.846
LUI_THYROID_CANCER_CLUSTER_3	419	21	1.135	0.558	0.332	0.846
HOFMANN_CELL_LYMPHOMA_DN	420	39	1.134	0.303	0.333	0.846
MULLIGHAN_MLL_SIGNATURE_1_DN	421	202	1.133	0.241	0.333	0.846
GROSS_HIF1A_TARGETS_DN	422	20	1.133	0.409	0.334	0.846
VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_DN	423	34	1.132	0.404	0.335	0.846
KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM	424	42	1.131	0.361	0.336	0.846
HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_24HR	425	40	1.129	0.344	0.338	0.846
REACTOME_METAL_ION_SLC_TRANSPORTERS	426	26	1.129	0.386	0.339	0.846
REACTOME_EXTENSION_OF_TELOMERES	427	38	1.128	0.391	0.339	0.846
REACTOME_RNA_POLYMERASE_II_TRANSCRIBES_SNRNA_GENES	428	59	1.126	0.449	0.342	0.846
GAUSSMANN_MLL_AF4_FUSION_TARGETS_D_UP	429	32	1.125	0.344	0.342	0.846
GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_DN	430	55	1.125	0.426	0.343	0.846
RIZKI_TUMOR_INVASIVENESS_2D_UP	431	60	1.123	0.313	0.344	0.846
KIM_ALL_DISORDERS_DURATION_CORR_DN	432	127	1.122	0.392	0.345	0.846
REACTOME_TRISTETRAPROLIN_TTP_ZFP36_BINDS_AND_DESTABILIZES_MRNA	433	16	1.122	0.504	0.345	0.846
REACTOME_MITOCHONDRIAL_FATTY_ACID_BETA_OXIDATION	434	30	1.121	0.4	0.346	0.846
REACTOME_HSP90_CHAPERONE_CYCLE_FOR_STEROID_HORMONE_RECEPTORS_SHR_IN_THE_PRESENCE_OF_LIGAND	435	45	1.121	0.372	0.347	0.846
REACTOME_GLYOXYLATE_METABOLISM_AND_GLYCINE_DEGRADATION	436	29	1.121	0.336	0.347	0.846
MODY_HIPPOCAMPUS_PRENATAL	437	37	1.117	0.487	0.351	0.846
VIETOR_IFRD1_TARGETS	438	20	1.116	0.417	0.352	0.846
REACTOME_SYNTHESIS_OF_SUBSTRATES_IN_N_GLYCAN_BIOSYTHESIS	439	56	1.112	0.3	0.356	0.846
MCCLUNG_CREB1_TARGETS_DN	440	48	1.112	0.307	0.357	0.846
REACTOME_DNA_DAMAGE_RECOGNITION_IN_GG_NER	441	33	1.112	0.483	0.357	0.846
LE_NEURONAL_DIFFERENTIATION_DN	442	19	1.111	0.359	0.357	0.846
ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_DN	443	42	1.111	0.366	0.357	0.846
REACTOME_REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS	444	164	1.11	0.463	0.358	0.846
MOOTHA_PGC	445	365	1.109	0.342	0.359	0.846
REACTOME_BRANCHED_CHAIN_AMINO_ACID_CATABOLISM	446	20	1.109	0.462	0.359	0.846
DAIRKEE_CANCER_PRONE_RESPONSE_BPA_E2	447	102	1.109	0.333	0.359	0.846
FERNANDEZ_BOUND_BY_MYC	448	173	1.109	0.312	0.360	0.846
REACTOME_RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY	449	100	1.109	0.521	0.360	0.846
PID_DNA_PK_PATHWAY	450	15	1.108	0.459	0.360	0.846
REACTOME_TRANSPORT_OF_MATURE_MRNAS_DERIVED_FROM_INTRONLESS_TRANSCRIPTS	451	37	1.108	0.491	0.360	0.846
NIKOLSKY_BREAST_CANCER_1Q21_AMPLICON	452	33	1.108	0.334	0.361	0.846
JINESH_BLEBBISHIELD_VS_LIVE_CONTROL_UP	453	273	1.108	0.255	0.361	0.846
GRADE_COLON_VS_RECTAL_CANCER_UP	454	25	1.107	0.35	0.362	0.846
WP_INTEGRATED_CANCER_PATHWAY	455	42	1.107	0.373	0.362	0.846
MCMURRAY_TP53_HRAS_COOPERATION_RESPONSE_UP	456	22	1.106	0.328	0.362	0.846
TIEN_INTESTINE_PROBIOTICS_6HR_UP	457	46	1.106	0.47	0.363	0.846
REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_MULTIPLE_NUCLEOTIDE_PATCH_REPLACEMENT_PATHWAY	458	24	1.105	0.426	0.364	0.846
REACTOME_NONHOMOLOGOUS_END_JOINING_NHEJ	459	26	1.104	0.412	0.365	0.846
VANOEVELEN_MYOGENESIS_SIN3A_TARGETS	460	173	1.104	0.339	0.365	0.846
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT	461	78	1.103	0.495	0.366	0.846
REACTOME_NS1_MEDIATED_EFFECTS_ON_HOST_PATHWAYS	462	35	1.103	0.473	0.366	0.846
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1	463	414	1.102	0.305	0.367	0.846
CARRILLOREIXACH_MRS3_VS_LOWER_RISK_HEPATOBLASTOMA_UP	464	36	1.102	0.326	0.367	0.846
WP_LIPID_METABOLISM_IN_SENESCENT_CELLS	465	20	1.102	0.405	0.367	0.846
WP_TRYPTOPHAN_METABOLISM	466	28	1.101	0.325	0.368	0.846
REACTOME_HIV_INFECTION	467	211	1.099	0.39	0.371	0.846
BERNARD_PPAPDC1B_TARGETS_DN	468	47	1.099	0.268	0.371	0.846
YORDY_RECIPROCAL_REGULATION_BY_ETS1_AND_SP100_DN	469	57	1.095	0.273	0.375	0.846
WP_ENDOTHELIN_PATHWAYS	470	30	1.095	0.313	0.375	0.846
LUI_THYROID_CANCER_PAX8_PPARG_DN	471	37	1.095	0.449	0.375	0.846
REACTOME_DISEASES_OF_DNA_REPAIR	472	42	1.095	0.374	0.375	0.846
REACTOME_TP53_REGULATES_TRANSCRIPTION_OF_DNA_REPAIR_GENES	473	50	1.094	0.414	0.376	0.846
WP_HAIR_FOLLICLE_DEVELOPMENT_ORGANOGENESIS_PART_2_OF_3	474	30	1.094	0.334	0.376	0.846
REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS	475	121	1.093	0.4	0.377	0.846
REACTOME_FGFR2_ALTERNATIVE_SPLICING	476	20	1.091	0.511	0.379	0.846
HALLMARK_OXIDATIVE_PHOSPHORYLATION	477	173	1.091	0.457	0.379	0.846
JAERVINEN_AMPLIFIED_IN_LARYNGEAL_CANCER	478	31	1.091	0.372	0.379	0.846
ZAMORA_NOS2_TARGETS_UP	479	50	1.089	0.404	0.381	0.846
RHODES_CANCER_META_SIGNATURE	480	55	1.089	0.467	0.382	0.846
DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP	481	117	1.088	0.295	0.382	0.846
MALONEY_RESPONSE_TO_17AAG_DN	482	63	1.087	0.464	0.383	0.846
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN	483	47	1.086	0.299	0.384	0.846
KEGG_GLYCEROPHOSPHOLIPID_METABOLISM	484	60	1.085	0.274	0.386	0.846
REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS	485	20	1.084	0.386	0.387	0.846
HONMA_DOCETAXEL_RESISTANCE	486	28	1.083	0.437	0.388	0.846
REACTOME_NEGATIVE_EPIGENETIC_REGULATION_OF_RRNA_EXPRESSION	487	44	1.083	0.385	0.388	0.846
BIOCARTA_P53HYPOXIA_PATHWAY	488	21	1.082	0.444	0.389	0.846
ROVERSI_GLIOMA_LOH_REGIONS	489	40	1.082	0.314	0.389	0.846
WP_WNTBETACATENIN_SIGNALING_PATHWAY_IN_LEUKEMIA	490	26	1.082	0.317	0.389	0.846
MOOTHA_VOXPHOS	491	67	1.081	0.471	0.390	0.846
REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_METHYLATION	492	16	1.081	0.493	0.390	0.846
WP_AMINO_ACID_METABOLISM	493	83	1.081	0.299	0.390	0.846
WP_CYTOSOLIC_DNASENSING_PATHWAY	494	67	1.081	0.259	0.390	0.846
KEGG_PANTOTHENATE_AND_COA_BIOSYNTHESIS	495	16	1.081	0.321	0.390	0.846
REACTOME_DNA_REPLICATION_PRE_INITIATION	496	89	1.08	0.434	0.391	0.846
KEGG_BASE_EXCISION_REPAIR	497	33	1.08	0.362	0.392	0.846
WP_CYTOPLASMIC_RIBOSOMAL_PROTEINS	498	88	1.08	0.518	0.392	0.846
ZHU_CMV_24_HR_UP	499	73	1.079	0.38	0.392	0.846
NAM_FXYD5_TARGETS_DN	500	16	1.078	0.495	0.393	0.846
TOOKER_GEMCITABINE_RESISTANCE_UP	501	69	1.077	0.372	0.395	0.846
BLANCO_MELO_COVID19_SARS_COV_2_INFECTION_CALU3_CELLS_DN	502	17	1.076	0.471	0.395	0.846
CHOW_RASSF1_TARGETS_DN	503	24	1.076	0.384	0.396	0.846
BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN	504	107	1.075	0.287	0.396	0.846
KEGG_BUTANOATE_METABOLISM	505	31	1.074	0.343	0.398	0.846
HEIDENBLAD_AMPLICON_8Q24_UP	506	31	1.074	0.37	0.398	0.846
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_SMALL_VS_HUGE_DN	507	27	1.073	0.319	0.399	0.846
CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN	508	159	1.073	0.427	0.399	0.846
RIZKI_TUMOR_INVASIVENESS_3D_DN	509	229	1.072	0.24	0.400	0.846
REACTOME_AUF1_HNRNP_D0_BINDS_AND_DESTABILIZES_MRNA	510	52	1.072	0.483	0.400	0.846
KEGG_PROTEIN_EXPORT	511	19	1.071	0.532	0.401	0.846
REACTOME_DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT_THE_CENTROMERE	512	19	1.07	0.357	0.402	0.846
BOYLAN_MULTIPLE_MYELOMA_D_UP	513	71	1.069	0.297	0.404	0.846
TAYLOR_METHYLATED_IN_ACUTE_LYMPHOBLASTIC_LEUKEMIA	514	58	1.068	0.317	0.405	0.846
CONRAD_STEM_CELL	515	37	1.068	0.281	0.405	0.846
WP_FOXA2_PATHWAY	516	19	1.067	0.353	0.405	0.846
ASTIER_INTEGRIN_SIGNALING	517	50	1.067	0.276	0.406	0.846
REACTOME_METABOLISM_OF_CARBOHYDRATES	518	264	1.066	0.264	0.406	0.846
KEGG_PROPANOATE_METABOLISM	519	30	1.066	0.376	0.407	0.846
CAFFAREL_RESPONSE_TO_THC_DN	520	23	1.064	0.43	0.409	0.846
ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN	521	289	1.063	0.311	0.410	0.846
PID_LKB1_PATHWAY	522	37	1.062	0.364	0.411	0.846
WP_MIRNA_REGULATION_OF_DNA_DAMAGE_RESPONSE	523	65	1.062	0.336	0.412	0.846
REACTOME_SUMOYLATION_OF_RNA_BINDING_PROTEINS	524	39	1.058	0.43	0.416	0.846
RHEIN_ALL_GLUCOCORTICOID_THERAPY_DN	525	319	1.055	0.406	0.419	0.846
REACTOME_POSITIVE_EPIGENETIC_REGULATION_OF_RRNA_EXPRESSION	526	40	1.055	0.428	0.419	0.846
LUI_TARGETS_OF_PAX8_PPARG_FUSION	527	26	1.054	0.496	0.420	0.846
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_8	528	41	1.054	0.326	0.420	0.846
WP_PROTEOGLYCAN_BIOSYNTHESIS	529	15	1.054	0.449	0.421	0.846
ANDERSEN_CHOLANGIOCARCINOMA_CLASS1	530	49	1.053	0.28	0.421	0.846
BROWNE_HCMV_INFECTION_18HR_UP	531	148	1.053	0.288	0.422	0.846
WP_PROSTAGLANDIN_AND_LEUKOTRIENE_METABOLISM_IN_SENESCENCE	532	30	1.053	0.298	0.422	0.846
KEGG_GLYOXYLATE_AND_DICARBOXYLATE_METABOLISM	533	15	1.052	0.362	0.422	0.846
BIOCARTA_TID_PATHWAY	534	19	1.052	0.329	0.423	0.846
MAEKAWA_ATF2_TARGETS	535	21	1.051	0.322	0.424	0.846
GRADE_COLON_VS_RECTAL_CANCER_DN	536	41	1.051	0.298	0.424	0.846
KANNAN_TP53_TARGETS_DN	537	21	1.05	0.374	0.425	0.846
HALLMARK_WNT_BETA_CATENIN_SIGNALING	538	40	1.049	0.313	0.426	0.846
BILANGES_SERUM_SENSITIVE_VIA_TSC1	539	19	1.048	0.344	0.427	0.846
KEGG_PROTEASOME	540	42	1.047	0.475	0.428	0.846
REACTOME_DNA_STRAND_ELONGATION	541	29	1.046	0.371	0.429	0.846
JIANG_AGING_CEREBRAL_CORTEX_UP	542	29	1.046	0.358	0.430	0.846
WP_DNA_DAMAGE_RESPONSE	543	62	1.046	0.334	0.430	0.846
RASHI_RESPONSE_TO_IONIZING_RADIATION_1	544	32	1.044	0.35	0.431	0.846
BOCHKIS_FOXA2_TARGETS	545	363	1.044	0.231	0.431	0.846
BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_UP	546	20	1.044	0.378	0.432	0.846
WP_ELECTRON_TRANSPORT_CHAIN_OXPHOS_SYSTEM_IN_MITOCHONDRIA	547	71	1.044	0.447	0.432	0.846
REACTOME_COOPERATION_OF_PREFOLDIN_AND_TRIC_CCT_IN_ACTIN_AND_TUBULIN_FOLDING	548	23	1.043	0.413	0.433	0.846
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_4NM_UP	549	19	1.043	0.295	0.433	0.846
REACTOME_RESOLUTION_OF_D_LOOP_STRUCTURES_THROUGH_SYNTHESIS_DEPENDENT_STRAND_ANNEALING_SDSA	550	20	1.041	0.374	0.435	0.846
MARKS_HDAC_TARGETS_UP	551	21	1.039	0.333	0.437	0.846
REACTOME_PCNA_DEPENDENT_LONG_PATCH_BASE_EXCISION_REPAIR	552	21	1.038	0.4	0.438	0.846
REACTOME_TRANSCRIPTION_COUPLED_NUCLEOTIDE_EXCISION_REPAIR_TC_NER	553	75	1.037	0.379	0.439	0.846
BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_C	554	69	1.037	0.241	0.440	0.846
KEGG_HOMOLOGOUS_RECOMBINATION	555	24	1.037	0.304	0.440	0.846
KYNG_RESPONSE_TO_H2O2_VIA_ERCC6	556	16	1.036	0.424	0.441	0.846
WP_MRNA_PROCESSING	557	91	1.035	0.431	0.441	0.846
REACTOME_KERATAN_SULFATE_BIOSYNTHESIS	558	26	1.034	0.329	0.443	0.846
BIOCARTA_CDMAC_PATHWAY	559	15	1.033	0.419	0.444	0.846
BILANGES_SERUM_AND_RAPAMYCIN_SENSITIVE_GENES	560	59	1.033	0.478	0.444	0.846
WP_NUCLEOTIDE_EXCISION_REPAIR_IN_XERODERMA_PIGMENTOSUM	561	54	1.033	0.346	0.444	0.846
BIOCARTA_PROTEASOME_PATHWAY	562	18	1.033	0.522	0.445	0.846
DUAN_PRDM5_TARGETS	563	66	1.031	0.263	0.446	0.846
WAKASUGI_HAVE_ZNF143_BINDING_SITES	564	51	1.031	0.337	0.446	0.846
GOLDRATH_IMMUNE_MEMORY	565	61	1.031	0.247	0.447	0.846
REACTOME_BASE_EXCISION_REPAIR	566	44	1.03	0.349	0.447	0.846
BILANGES_SERUM_SENSITIVE_GENES	567	69	1.03	0.288	0.447	0.846
CAFFAREL_RESPONSE_TO_THC_UP	568	26	1.029	0.472	0.449	0.846
VARELA_ZMPSTE24_TARGETS_UP	569	35	1.028	0.378	0.450	0.846
REACTOME_MISMATCH_REPAIR	570	15	1.026	0.438	0.451	0.846
MAYBURD_RESPONSE_TO_L663536_DN	571	44	1.026	0.408	0.452	0.846
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN	572	141	1.025	0.247	0.453	0.846
REACTOME_PHOSPHORYLATION_OF_THE_APC_C	573	17	1.025	0.5	0.453	0.846
DESERT_PERIVENOUS_HEPATOCELLULAR_CARCINOMA_SUBCLASS_UP	574	133	1.025	0.262	0.453	0.846
TONG_INTERACT_WITH_PTTG1	575	40	1.024	0.358	0.454	0.846
GALE_APL_WITH_FLT3_MUTATED_UP	576	42	1.024	0.38	0.455	0.846
REACTOME_FATTY_ACID_METABOLISM	577	151	1.023	0.238	0.455	0.846
VECCHI_GASTRIC_CANCER_EARLY_UP	578	345	1.023	0.288	0.455	0.846
MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_UP	579	137	1.023	0.296	0.455	0.846
REACTOME_FORMATION_OF_TUBULIN_FOLDING_INTERMEDIATES_BY_CCT_TRIC	580	16	1.023	0.423	0.456	0.846
BIOCARTA_TEL_PATHWAY	581	17	1.02	0.427	0.459	0.846
REACTOME_INTERCONVERSION_OF_NUCLEOTIDE_DI_AND_TRIPHOSPHATES	582	22	1.019	0.378	0.460	0.846
SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_DN	583	22	1.018	0.384	0.461	0.846
WP_FLUOROPYRIMIDINE_ACTIVITY	584	32	1.018	0.301	0.461	0.846
MARSON_BOUND_BY_E2F4_UNSTIMULATED	585	494	1.017	0.293	0.462	0.846
REACTOME_DUAL_INCISION_IN_TC_NER	586	62	1.016	0.376	0.463	0.846
REACTOME_GLYCEROPHOSPHOLIPID_BIOSYNTHESIS	587	101	1.016	0.26	0.463	0.846
REACTOME_STABILIZATION_OF_P53	588	55	1.016	0.455	0.464	0.846
HOSHIDA_LIVER_CANCER_SURVIVAL_DN	589	100	1.015	0.22	0.464	0.846
HALLMARK_ADIPOGENESIS	590	176	1.015	0.307	0.465	0.846
BIOCARTA_WNT_PATHWAY	591	22	1.015	0.372	0.465	0.846
REACTOME_MTORC1_MEDIATED_SIGNALLING	592	15	1.015	0.489	0.465	0.846
REACTOME_HCMV_LATE_EVENTS	593	44	1.014	0.414	0.465	0.846
HOLLEMAN_ASPARAGINASE_RESISTANCE_B_ALL_UP	594	20	1.014	0.462	0.465	0.846
BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP	595	150	1.014	0.416	0.466	0.846
JINESH_BLEBBISHIELD_TRANSFORMED_STEM_CELL_SPHERES_DN	596	217	1.014	0.244	0.466	0.846
REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPORTERS	597	19	1.013	0.382	0.467	0.846
MATZUK_IMPLANTATION_AND_UTERINE	598	18	1.012	0.343	0.468	0.846
WP_PARKINUBIQUITIN_PROTEASOMAL_SYSTEM_PATHWAY	599	55	1.012	0.388	0.469	0.846
REACTOME_DISEASES_OF_MITOTIC_CELL_CYCLE	600	36	1.012	0.389	0.469	0.846
MORI_SMALL_PRE_BII_LYMPHOCYTE_DN	601	66	1.011	0.331	0.469	0.846
SARTIPY_BLUNTED_BY_INSULIN_RESISTANCE_UP	602	16	1.011	0.375	0.470	0.846
MOHANKUMAR_HOXA1_TARGETS_UP	603	330	1.01	0.297	0.470	0.846
HOLLEMAN_PREDNISOLONE_RESISTANCE_ALL_UP	604	16	1.01	0.427	0.471	0.846
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_UP	605	84	1.01	0.259	0.471	0.846
REACTOME_SWITCHING_OF_ORIGINS_TO_A_POST_REPLICATIVE_STATE	606	81	1.008	0.426	0.473	0.846
WP_AMPACTIVATED_PROTEIN_KINASE_SIGNALING	607	62	1.008	0.275	0.473	0.846
ZHU_CMV_ALL_UP	608	95	1.007	0.308	0.474	0.846
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4	609	245	1.006	0.196	0.475	0.846
REACTOME_DNA_REPAIR	610	243	1.006	0.317	0.475	0.846
FEVR_CTNNB1_TARGETS_DN	611	448	1.006	0.306	0.475	0.846
ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_UP	612	59	1.006	0.273	0.475	0.846
SCHLOSSER_SERUM_RESPONSE_AUGMENTED_BY_MYC	613	89	1.005	0.331	0.476	0.847
LU_EZH2_TARGETS_UP	614	207	1.002	0.305	0.479	0.851
REACTOME_REPRODUCTION	615	72	1.001	0.246	0.481	0.852
PUJANA_BREAST_CANCER_LIT_INT_NETWORK	616	93	1.001	0.353	0.481	0.852
LIN_MELANOMA_COPY_NUMBER_UP	617	55	1.0	0.302	0.482	0.852
RAMALHO_STEMNESS_UP	618	160	0.999	0.373	0.483	0.852
KAUFFMANN_DNA_REPAIR_GENES	619	211	0.997	0.296	0.486	0.852
WP_HEREDITARY_LEIOMYOMATOSIS_AND_RENAL_CELL_CARCINOMA_PATHWAY	620	19	0.996	0.417	0.487	0.852
REACTOME_CONVERSION_FROM_APC_C_CDC20_TO_APC_C_CDH1_IN_LATE_ANAPHASE	621	18	0.995	0.455	0.488	0.852
HALLMARK_GLYCOLYSIS	622	185	0.995	0.289	0.488	0.852
RASHI_RESPONSE_TO_IONIZING_RADIATION_5	623	114	0.995	0.263	0.488	0.852
DARWICHE_PAPILLOMA_RISK_LOW_DN	624	127	0.995	0.239	0.489	0.852
SHEPARD_BMYB_MORPHOLINO_UP	625	182	0.994	0.275	0.489	0.852
REACTOME_NUCLEAR_PORE_COMPLEX_NPC_DISASSEMBLY	626	30	0.994	0.445	0.490	0.852
REACTOME_ABERRANT_REGULATION_OF_MITOTIC_EXIT_IN_CANCER_DUE_TO_RB1_DEFECTS	627	18	0.993	0.465	0.491	0.852
YU_BAP1_TARGETS	628	25	0.992	0.313	0.491	0.852
REACTOME_DISEASES_OF_GLYCOSYLATION	629	120	0.991	0.276	0.492	0.852
REACTOME_INSERTION_OF_TAIL_ANCHORED_PROTEINS_INTO_THE_ENDOPLASMIC_RETICULUM_MEMBRANE	630	18	0.991	0.378	0.493	0.852
HEDENFALK_BREAST_CANCER_BRACX_UP	631	17	0.99	0.382	0.494	0.852
REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION	632	80	0.99	0.33	0.494	0.852
REACTOME_CELLULAR_RESPONSE_TO_STARVATION	633	134	0.988	0.403	0.497	0.854
NAKAJIMA_EOSINOPHIL	634	21	0.987	0.351	0.497	0.854
REACTOME_SUMOYLATION_OF_DNA_DAMAGE_RESPONSE_AND_REPAIR_PROTEINS	635	69	0.986	0.361	0.498	0.854
DARWICHE_PAPILLOMA_RISK_HIGH_UP	636	120	0.985	0.271	0.499	0.854
BILD_E2F3_ONCOGENIC_SIGNATURE	637	193	0.985	0.242	0.500	0.854
KEGG_OTHER_GLYCAN_DEGRADATION	638	15	0.984	0.424	0.501	0.854
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE	639	52	0.983	0.333	0.502	0.854
JIANG_AGING_HYPOTHALAMUS_UP	640	43	0.983	0.392	0.503	0.854
BERENJENO_TRANSFORMED_BY_RHOA_UP	641	453	0.983	0.323	0.503	0.854
WP_7Q1123_COPY_NUMBER_VARIATION_SYNDROME	642	84	0.981	0.276	0.504	0.854
REACTOME_NUCLEOTIDE_EXCISION_REPAIR	643	102	0.981	0.369	0.504	0.854
BIOCARTA_VIP_PATHWAY	644	26	0.979	0.326	0.506	0.855
HALLMARK_E2F_TARGETS	645	170	0.977	0.348	0.509	0.855
REACTOME_DNA_REPLICATION	646	114	0.977	0.367	0.509	0.855
REACTOME_SYNTHESIS_SECRETION_AND_DEACYLATION_OF_GHRELIN	647	16	0.977	0.368	0.509	0.855
WP_TUMOR_SUPPRESSOR_ACTIVITY_OF_SMARCB1	648	29	0.976	0.316	0.511	0.855
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS	649	83	0.974	0.405	0.513	0.855
BOYAULT_LIVER_CANCER_SUBCLASS_G6_UP	650	52	0.973	0.256	0.513	0.855
KEGG_PARKINSONS_DISEASE	651	94	0.973	0.368	0.514	0.855
LEE_CALORIE_RESTRICTION_NEOCORTEX_DN	652	61	0.973	0.271	0.514	0.855
BENPORATH_ES_CORE_NINE_CORRELATED	653	96	0.972	0.295	0.515	0.855
WEST_ADRENOCORTICAL_TUMOR_MARKERS_DN	654	19	0.972	0.31	0.515	0.855
ACEVEDO_LIVER_CANCER_WITH_H3K9ME3_DN	655	64	0.972	0.245	0.515	0.855
REACTOME_AMINO_ACID_TRANSPORT_ACROSS_THE_PLASMA_MEMBRANE	656	32	0.971	0.322	0.516	0.855
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_DN	657	22	0.969	0.36	0.518	0.855
WP_UNFOLDED_PROTEIN_RESPONSE	658	23	0.969	0.371	0.519	0.855
BRUINS_UVC_RESPONSE_MIDDLE	659	76	0.968	0.295	0.520	0.855
REACTOME_SYNTHESIS_OF_DNA	660	107	0.966	0.365	0.522	0.855
POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_UP	661	57	0.966	0.276	0.522	0.855
REACTOME_ACYL_CHAIN_REMODELLING_OF_PG	662	16	0.966	0.329	0.522	0.855
FIGUEROA_AML_METHYLATION_CLUSTER_5_DN	663	40	0.965	0.29	0.523	0.855
REACTOME_RESOLUTION_OF_D_LOOP_STRUCTURES	664	23	0.965	0.32	0.523	0.855
REACTOME_SIGNALING_BY_FGFR2_IN_DISEASE	665	43	0.964	0.301	0.524	0.855
OSADA_ASCL1_TARGETS_UP	666	42	0.961	0.269	0.527	0.855
CAFFAREL_RESPONSE_TO_THC_24HR_5_UP	667	26	0.96	0.444	0.529	0.855
PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_DN	668	47	0.96	0.426	0.530	0.855
TCGA_GLIOBLASTOMA_COPY_NUMBER_DN	669	27	0.959	0.324	0.530	0.855
REACTOME_CHROMATIN_MODIFYING_ENZYMES	670	144	0.959	0.302	0.531	0.855
WP_CLEAR_CELL_RENAL_CELL_CARCINOMA_PATHWAYS	671	74	0.957	0.276	0.532	0.855
BARIS_THYROID_CANCER_UP	672	23	0.957	0.388	0.533	0.855
REACTOME_S_PHASE	673	143	0.956	0.354	0.533	0.855
WP_DNA_IRDOUBLE_STRAND_BREAKS_AND_CELLULAR_RESPONSE_VIA_ATM	674	51	0.956	0.303	0.534	0.855
STEIN_ESRRA_TARGETS_UP	675	311	0.954	0.289	0.536	0.855
KEGG_HISTIDINE_METABOLISM	676	26	0.952	0.286	0.538	0.855
KIM_GASTRIC_CANCER_CHEMOSENSITIVITY	677	76	0.951	0.283	0.539	0.855
NADLER_HYPERGLYCEMIA_AT_OBESITY	678	54	0.949	0.266	0.542	0.855
BURTON_ADIPOGENESIS_6	679	164	0.949	0.275	0.542	0.855
REACTOME_INHIBITION_OF_THE_PROTEOLYTIC_ACTIVITY_OF_APC_C_REQUIRED_FOR_THE_ONSET_OF_ANAPHASE_BY_MITOTIC_SPINDLE_CHECKPOINT_COMPONENTS	680	19	0.948	0.457	0.543	0.855
KRIEG_KDM3A_TARGETS_NOT_HYPOXIA	681	153	0.948	0.29	0.543	0.855
LOCKWOOD_AMPLIFIED_IN_LUNG_CANCER	682	174	0.947	0.324	0.544	0.855
WP_IL7_SIGNALING_PATHWAY	683	25	0.947	0.338	0.544	0.855
BIOCARTA_GLEEVEC_PATHWAY	684	23	0.947	0.373	0.545	0.855
WP_DOPAMINERGIC_NEUROGENESIS	685	30	0.946	0.374	0.545	0.855
REACTOME_INHIBITION_OF_DNA_RECOMBINATION_AT_TELOMERE	686	20	0.946	0.424	0.546	0.855
NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON	687	100	0.945	0.249	0.546	0.855
GOLDRATH_HOMEOSTATIC_PROLIFERATION	688	112	0.945	0.334	0.546	0.855
ODONNELL_TARGETS_OF_MYC_AND_TFRC_DN	689	35	0.945	0.31	0.547	0.855
KEGG_MATURITY_ONSET_DIABETES_OF_THE_YOUNG	690	19	0.945	0.361	0.547	0.855
HE_PTEN_TARGETS_UP	691	18	0.943	0.419	0.549	0.855
OZEN_MIR125B1_TARGETS	692	20	0.942	0.344	0.550	0.855
HOFFMANN_IMMATURE_TO_MATURE_B_LYMPHOCYTE_DN	693	43	0.942	0.27	0.550	0.855
REACTOME_NUCLEOTIDE_SALVAGE	694	20	0.939	0.322	0.554	0.855
LAMB_CCND1_TARGETS	695	18	0.939	0.39	0.554	0.855
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION	696	42	0.937	0.308	0.556	0.855
BIOCARTA_P53_PATHWAY	697	16	0.935	0.352	0.558	0.855
ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_DN	698	49	0.935	0.348	0.559	0.855
REACTOME_MEIOSIS	699	53	0.935	0.291	0.559	0.855
MORI_PLASMA_CELL_UP	700	39	0.934	0.347	0.559	0.855
RUAN_RESPONSE_TO_TROGLITAZONE_UP	701	23	0.934	0.328	0.560	0.855
TARTE_PLASMA_CELL_VS_PLASMABLAST_DN	702	263	0.934	0.336	0.560	0.855
BROWNE_HCMV_INFECTION_48HR_UP	703	162	0.933	0.21	0.560	0.855
GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN	704	246	0.932	0.291	0.562	0.855
KEGG_ASCORBATE_AND_ALDARATE_METABOLISM	705	17	0.932	0.318	0.563	0.855
STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_UP	706	25	0.931	0.312	0.563	0.855
REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES	707	47	0.93	0.4	0.564	0.855
SHIPP_DLBCL_CURED_VS_FATAL_DN	708	38	0.93	0.287	0.565	0.855
REACTOME_CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY	709	80	0.929	0.381	0.566	0.855
KOINUMA_COLON_CANCER_MSI_UP	710	15	0.928	0.347	0.566	0.855
MCBRYAN_PUBERTAL_BREAST_4_5WK_DN	711	171	0.928	0.222	0.567	0.855
LEE_LIVER_CANCER_MYC_E2F1_DN	712	59	0.926	0.233	0.569	0.855
REACTOME_KERATAN_SULFATE_KERATIN_METABOLISM	713	32	0.926	0.297	0.569	0.855
WP_DNA_REPAIR_PATHWAYS_FULL_NETWORK	714	110	0.925	0.293	0.570	0.855
REACTOME_MATURATION_OF_SARSCOV2_SPIKE_PROTEIN	715	35	0.924	0.332	0.571	0.855
SHAFFER_IRF4_TARGETS_IN_MYELOMA_VS_MATURE_B_LYMPHOCYTE	716	91	0.924	0.32	0.572	0.855
ZHAN_MULTIPLE_MYELOMA_UP	717	45	0.924	0.301	0.572	0.855
TERAO_AOX4_TARGETS_SKIN_UP	718	27	0.923	0.339	0.573	0.855
REACTOME_CHAPERONE_MEDIATED_AUTOPHAGY	719	20	0.923	0.326	0.573	0.855
STAEGE_EWING_FAMILY_TUMOR	720	24	0.922	0.282	0.574	0.855
KEGG_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI_ANCHOR_BIOSYNTHESIS	721	24	0.922	0.367	0.574	0.855
SMID_BREAST_CANCER_LUMINAL_B_UP	722	143	0.921	0.212	0.576	0.855
REACTOME_TP53_REGULATES_TRANSCRIPTION_OF_ADDITIONAL_CELL_CYCLE_GENES_WHOSE_EXACT_ROLE_IN_THE_P53_PATHWAY_REMAIN_UNCERTAIN	723	18	0.92	0.382	0.576	0.855
REACTOME_TRIGLYCERIDE_METABOLISM	724	32	0.92	0.262	0.577	0.855
WP_3Q29_COPY_NUMBER_VARIATION_SYNDROME	725	50	0.919	0.303	0.577	0.855
FONTAINE_THYROID_TUMOR_UNCERTAIN_MALIGNANCY_DN	726	24	0.918	0.274	0.579	0.855
PAL_PRMT5_TARGETS_UP	727	169	0.918	0.335	0.579	0.855
KEGG_NUCLEOTIDE_EXCISION_REPAIR	728	44	0.918	0.322	0.579	0.855
WEBER_METHYLATED_HCP_IN_SPERM_DN	729	25	0.917	0.356	0.581	0.855
WIERENGA_PML_INTERACTOME	730	32	0.915	0.351	0.583	0.855
CHOI_ATL_CHRONIC_VS_ACUTE_DN	731	16	0.914	0.433	0.584	0.855
LI_CYTIDINE_ANALOG_PATHWAY	732	15	0.914	0.308	0.584	0.855
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_DN	733	48	0.913	0.232	0.585	0.855
TCGA_GLIOBLASTOMA_COPY_NUMBER_UP	734	58	0.913	0.261	0.585	0.855
MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER	735	39	0.913	0.297	0.585	0.855
HU_GENOTOXIC_DAMAGE_24HR	736	28	0.912	0.349	0.586	0.855
OUILLETTE_CLL_13Q14_DELETION_DN	737	47	0.912	0.238	0.586	0.855
TAKADA_GASTRIC_CANCER_COPY_NUMBER_DN	738	23	0.911	0.268	0.587	0.855
RUAN_RESPONSE_TO_TNF_DN	739	75	0.911	0.245	0.587	0.855
REACTOME_METABOLIC_DISORDERS_OF_BIOLOGICAL_OXIDATION_ENZYMES	740	29	0.911	0.266	0.588	0.855
WEBER_METHYLATED_ICP_IN_FIBROBLAST	741	16	0.91	0.397	0.588	0.855
WP_NUCLEOTIDE_EXCISION_REPAIR	742	43	0.909	0.326	0.589	0.855
LIN_MELANOMA_COPY_NUMBER_DN	743	35	0.909	0.374	0.590	0.855
DARWICHE_SKIN_TUMOR_PROMOTER_UP	744	115	0.908	0.244	0.590	0.855
CERIBELLI_GENES_INACTIVE_AND_BOUND_BY_NFY	745	25	0.908	0.284	0.592	0.855
REACTOME_SARS_COV_2_HOST_INTERACTIONS	746	178	0.907	0.283	0.592	0.855
BAELDE_DIABETIC_NEPHROPATHY_UP	747	80	0.907	0.255	0.592	0.855
GOLUB_ALL_VS_AML_DN	748	21	0.906	0.332	0.593	0.855
REACTOME_GLOBAL_GENOME_NUCLEOTIDE_EXCISION_REPAIR_GG_NER	749	79	0.905	0.337	0.594	0.855
AUNG_GASTRIC_CANCER	750	45	0.905	0.24	0.594	0.855
DURCHDEWALD_SKIN_CARCINOGENESIS_UP	751	71	0.905	0.232	0.595	0.855
REACTOME_G1_S_DNA_DAMAGE_CHECKPOINTS	752	65	0.904	0.381	0.596	0.855
KEGG_TYROSINE_METABOLISM	753	39	0.902	0.268	0.598	0.855
HUANG_DASATINIB_RESISTANCE_DN	754	58	0.902	0.247	0.599	0.855
REACTOME_SUMOYLATION_OF_CHROMATIN_ORGANIZATION_PROTEINS	755	52	0.901	0.343	0.600	0.855
KAAB_HEART_ATRIUM_VS_VENTRICLE_DN	756	225	0.9	0.246	0.600	0.855
YANG_BREAST_CANCER_ESR1_BULK_DN	757	19	0.9	0.34	0.600	0.855
WP_PRADERWILLI_AND_ANGELMAN_SYNDROME	758	60	0.899	0.227	0.602	0.855
CORRE_MULTIPLE_MYELOMA_DN	759	51	0.899	0.222	0.602	0.855
MARTIN_VIRAL_GPCR_SIGNALING_DN	760	42	0.898	0.235	0.603	0.855
REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_PHOSPHORYLATION	761	86	0.898	0.302	0.603	0.855
REACTOME_METABOLISM_OF_COFACTORS	762	19	0.897	0.3	0.604	0.855
HALLMARK_MTORC1_SIGNALING	763	181	0.895	0.323	0.606	0.855
NIKOLSKY_BREAST_CANCER_16Q24_AMPLICON	764	37	0.895	0.275	0.607	0.855
PID_BARD1_PATHWAY	765	28	0.894	0.345	0.607	0.855
HUNSBERGER_EXERCISE_REGULATED_GENES	766	29	0.894	0.265	0.608	0.855
ZHOU_TNF_SIGNALING_30MIN	767	41	0.893	0.345	0.608	0.855
WP_DNA_REPLICATION	768	34	0.893	0.304	0.609	0.855
REACTOME_PI_3K_CASCADE_FGFR2	769	23	0.891	0.291	0.612	0.855
REACTOME_METABOLISM_OF_POLYAMINES	770	56	0.89	0.385	0.612	0.855
TIEN_INTESTINE_PROBIOTICS_2HR_UP	771	28	0.89	0.352	0.612	0.855
PID_E2F_PATHWAY	772	66	0.89	0.272	0.613	0.855
ROVERSI_GLIOMA_COPY_NUMBER_UP	773	84	0.889	0.224	0.613	0.855
LIU_SOX4_TARGETS_DN	774	252	0.887	0.293	0.616	0.855
UDAYAKUMAR_MED1_TARGETS_UP	775	109	0.887	0.336	0.616	0.855
PARK_HSC_AND_MULTIPOTENT_PROGENITORS	776	37	0.887	0.314	0.616	0.855
KEGG_PRIMARY_IMMUNODEFICIENCY	777	35	0.887	0.288	0.617	0.855
REACTOME_NUCLEAR_EVENTS_MEDIATED_BY_NFE2L2	778	77	0.887	0.362	0.617	0.855
KUUSELO_PANCREATIC_CANCER_19Q13_AMPLIFICATION	779	22	0.886	0.29	0.617	0.855
LIN_NPAS4_TARGETS_UP	780	125	0.885	0.229	0.618	0.855
REACTOME_THE_CANONICAL_RETINOID_CYCLE_IN_RODS_TWILIGHT_VISION	781	21	0.885	0.307	0.619	0.855
STEGER_ADIPOGENESIS_UP	782	21	0.885	0.304	0.619	0.855
REACTOME_SCF_SKP2_MEDIATED_DEGRADATION_OF_P27_P21	783	58	0.884	0.396	0.620	0.855
FERRANDO_LYL1_NEIGHBORS	784	15	0.884	0.325	0.620	0.855
PUJANA_BRCA_CENTERED_NETWORK	785	104	0.883	0.336	0.621	0.855
WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA	786	55	0.883	0.289	0.621	0.855
KYNG_RESPONSE_TO_H2O2	787	60	0.882	0.282	0.622	0.855
WP_DNA_MISMATCH_REPAIR	788	23	0.882	0.34	0.623	0.855
REACTOME_DETOXIFICATION_OF_REACTIVE_OXYGEN_SPECIES	789	34	0.881	0.277	0.623	0.855
WP_HOSTPATHOGEN_INTERACTION_OF_HUMAN_CORONAVIRUSES_APOPTOSIS	790	21	0.881	0.267	0.623	0.855
GRATIAS_RETINOBLASTOMA_16Q24	791	15	0.881	0.367	0.623	0.855
YOKOE_CANCER_TESTIS_ANTIGENS	792	29	0.881	0.277	0.624	0.855
RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP	793	491	0.88	0.337	0.624	0.855
HASLINGER_B_CLL_WITH_17P13_DELETION	794	20	0.88	0.339	0.624	0.855
KEGG_O_GLYCAN_BIOSYNTHESIS	795	26	0.88	0.284	0.625	0.855
WP_NEURODEGENERATION_WITH_BRAIN_IRON_ACCUMULATION_NBIA_SUBTYPES_PATHWAY	796	34	0.88	0.307	0.625	0.855
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_CIS	797	101	0.878	0.273	0.627	0.856
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13	798	137	0.877	0.333	0.628	0.856
REACTOME_ABERRANT_REGULATION_OF_MITOTIC_G1_S_TRANSITION_IN_CANCER_DUE_TO_RB1_DEFECTS	799	17	0.877	0.322	0.628	0.856
REACTOME_HOMOLOGOUS_DNA_PAIRING_AND_STRAND_EXCHANGE	800	34	0.877	0.317	0.628	0.856
ALCALA_APOPTOSIS	801	78	0.875	0.268	0.631	0.856
REACTOME_RHOBTB2_GTPASE_CYCLE	802	19	0.874	0.398	0.631	0.856
REACTOME_SLC_TRANSPORTER_DISORDERS	803	92	0.874	0.222	0.632	0.856
REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1	804	52	0.873	0.382	0.633	0.856
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_DN	805	47	0.872	0.233	0.634	0.856
ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_UP	806	43	0.872	0.242	0.634	0.856
GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_UP	807	20	0.872	0.335	0.634	0.856
STEIN_ESRRA_TARGETS	808	425	0.872	0.261	0.635	0.856
REACTOME_ORC1_REMOVAL_FROM_CHROMATIN	809	62	0.87	0.378	0.636	0.856
REACTOME_REGULATION_OF_TP53_ACTIVITY	810	139	0.87	0.277	0.636	0.856
BIOCARTA_PPARA_PATHWAY	811	49	0.869	0.277	0.637	0.856
KEGG_OXIDATIVE_PHOSPHORYLATION	812	96	0.868	0.322	0.639	0.858
BENPORATH_ES_2	813	27	0.867	0.251	0.640	0.858
REACTOME_PROTEIN_FOLDING	814	83	0.867	0.25	0.640	0.858
REACTOME_GLYCOSAMINOGLYCAN_METABOLISM	815	107	0.864	0.232	0.644	0.859
TERAO_AOX4_TARGETS_HG_UP	816	23	0.864	0.318	0.644	0.859
WP_SLEEP_REGULATION	817	37	0.864	0.281	0.644	0.859
RUAN_RESPONSE_TO_TROGLITAZONE_DN	818	16	0.862	0.291	0.646	0.860
REACTOME_HEDGEHOG_LIGAND_BIOGENESIS	819	62	0.861	0.33	0.647	0.861
MEISSNER_BRAIN_ICP_WITH_H3K4ME3	820	20	0.856	0.273	0.653	0.868
MIKKELSEN_ES_HCP_WITH_H3K27ME3	821	35	0.856	0.343	0.654	0.868
CHESLER_BRAIN_QTL_CIS	822	60	0.854	0.253	0.656	0.868
KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION	823	72	0.853	0.237	0.657	0.868
FORTSCHEGGER_PHF8_TARGETS_UP	824	205	0.853	0.235	0.657	0.868
REACTOME_TRANSCRIPTIONAL_REGULATION_BY_TP53	825	301	0.852	0.276	0.658	0.868
BIOCARTA_VEGF_PATHWAY	826	25	0.852	0.306	0.658	0.868
REACTOME_GLUCONEOGENESIS	827	33	0.851	0.287	0.659	0.869
BIOCARTA_IGF1MTOR_PATHWAY	828	18	0.844	0.357	0.668	0.873
REACTOME_PHOSPHOLIPASE_C_MEDIATED_CASCADE_FGFR2	829	18	0.843	0.321	0.668	0.873
PID_CERAMIDE_PATHWAY	830	43	0.843	0.292	0.668	0.873
PROVENZANI_METASTASIS_UP	831	156	0.843	0.269	0.669	0.873
REACTOME_PLATELET_CALCIUM_HOMEOSTASIS	832	25	0.842	0.284	0.670	0.873
FINAK_BREAST_CANCER_SDPP_SIGNATURE	833	22	0.841	0.359	0.671	0.873
REACTOME_CLASS_I_PEROXISOMAL_MEMBRANE_PROTEIN_IMPORT	834	19	0.841	0.324	0.672	0.873
KEGG_GLYCOSAMINOGLYCAN_DEGRADATION	835	21	0.84	0.29	0.672	0.873
IBRAHIM_NRF2_UP	836	425	0.839	0.302	0.674	0.873
TANG_SENESCENCE_TP53_TARGETS_UP	837	31	0.839	0.225	0.674	0.873
REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	838	42	0.839	0.271	0.674	0.873
REACTOME_NUCLEAR_EVENTS_STIMULATED_BY_ALK_SIGNALING_IN_CANCER	839	18	0.838	0.329	0.675	0.873
KLEIN_PRIMARY_EFFUSION_LYMPHOMA_UP	840	47	0.837	0.242	0.676	0.873
RAHMAN_TP53_TARGETS_PHOSPHORYLATED	841	18	0.837	0.418	0.676	0.873
ELLWOOD_MYC_TARGETS_DN	842	32	0.837	0.289	0.676	0.873
WANG_CLASSIC_ADIPOGENIC_TARGETS_OF_PPARG	843	25	0.837	0.285	0.676	0.873
REACTOME_BASE_EXCISION_REPAIR_AP_SITE_FORMATION	844	17	0.836	0.332	0.677	0.873
AGUIRRE_PANCREATIC_CANCER_COPY_NUMBER_UP	845	241	0.836	0.251	0.677	0.873
WP_SPHINGOLIPID_METABOLISM_IN_SENESCENCE	846	19	0.835	0.312	0.679	0.874
ALONSO_METASTASIS_UP	847	159	0.834	0.301	0.679	0.874
REACTOME_NEUROTRANSMITTER_RELEASE_CYCLE	848	49	0.834	0.246	0.680	0.874
ZHENG_IL22_SIGNALING_DN	849	35	0.832	0.226	0.682	0.876
APPIERTO_RESPONSE_TO_FENRETINIDE_UP	850	35	0.83	0.269	0.684	0.877
FIGUEROA_AML_METHYLATION_CLUSTER_2_UP	851	45	0.83	0.206	0.685	0.877
SAMOLS_TARGETS_OF_KHSV_MIRNAS_DN	852	48	0.829	0.252	0.686	0.877
WP_DIFFERENTIATION_OF_WHITE_AND_BROWN_ADIPOCYTE	853	24	0.829	0.273	0.686	0.877
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_RED_DN	854	23	0.828	0.284	0.687	0.877
REACTOME_UNFOLDED_PROTEIN_RESPONSE_UPR	855	86	0.826	0.277	0.689	0.878
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_PINK_DN	856	26	0.826	0.253	0.690	0.878
TUOMISTO_TUMOR_SUPPRESSION_BY_COL13A1_DN	857	16	0.825	0.301	0.690	0.878
REACTOME_PEROXISOMAL_PROTEIN_IMPORT	858	58	0.825	0.248	0.691	0.878
WP_MIRNA_REGULATION_OF_P53_PATHWAY_IN_PROSTATE_CANCER	859	22	0.822	0.315	0.694	0.878
WP_WNT_SIGNALING_PATHWAY	860	48	0.822	0.246	0.694	0.878
REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM	861	51	0.821	0.245	0.696	0.878
REACTOME_LAGGING_STRAND_SYNTHESIS	862	18	0.821	0.305	0.696	0.878
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_7	863	60	0.821	0.308	0.696	0.878
WP_METABOLIC_REPROGRAMMING_IN_PANCREATIC_CANCER	864	41	0.821	0.324	0.696	0.878
WARTERS_RESPONSE_TO_IR_SKIN	865	58	0.82	0.252	0.697	0.878
REACTOME_UCH_PROTEINASES	866	77	0.817	0.344	0.700	0.880
ZHANG_BREAST_CANCER_PROGENITORS_UP	867	345	0.817	0.295	0.700	0.880
REACTOME_DECTIN_2_FAMILY	868	22	0.816	0.303	0.701	0.880
REACTOME_REGULATION_OF_PTEN_STABILITY_AND_ACTIVITY	869	65	0.815	0.349	0.703	0.881
SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE	870	69	0.814	0.304	0.704	0.881
BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_DN	871	152	0.814	0.265	0.704	0.881
JISON_SICKLE_CELL_DISEASE_DN	872	147	0.813	0.27	0.705	0.881
WP_FAMILIAL_HYPERLIPIDEMIA_TYPE_4	873	19	0.811	0.295	0.707	0.882
REACTOME_DNA_DOUBLE_STRAND_BREAK_REPAIR	874	111	0.81	0.237	0.708	0.882
SHIN_B_CELL_LYMPHOMA_CLUSTER_5	875	18	0.81	0.267	0.708	0.882
WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK	876	109	0.81	0.235	0.709	0.882
SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6	877	369	0.807	0.245	0.712	0.885
REACTOME_MITOTIC_G1_PHASE_AND_G1_S_TRANSITION	878	135	0.806	0.291	0.713	0.885
REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1	879	70	0.806	0.353	0.714	0.885
BROWNE_HCMV_INFECTION_14HR_UP	880	130	0.802	0.244	0.718	0.885
REACTOME_CARGO_TRAFFICKING_TO_THE_PERICILIARY_MEMBRANE	881	45	0.802	0.267	0.718	0.885
KEGG_ARACHIDONIC_ACID_METABOLISM	882	51	0.801	0.237	0.719	0.885
WP_CORI_CYCLE	883	17	0.801	0.312	0.719	0.885
SIMBULAN_PARP1_TARGETS_DN	884	16	0.801	0.305	0.719	0.885
REACTOME_NUCLEAR_ENVELOPE_BREAKDOWN	885	44	0.8	0.327	0.720	0.885
REACTOME_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION	886	78	0.8	0.276	0.720	0.885
BROWNE_HCMV_INFECTION_16HR_UP	887	193	0.8	0.23	0.720	0.885
REACTOME_G2_M_CHECKPOINTS	888	112	0.799	0.292	0.721	0.885
WP_PARKINSONS_DISEASE_PATHWAY	889	33	0.799	0.235	0.722	0.885
REACTOME_SYNTHESIS_OF_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI	890	18	0.797	0.336	0.723	0.885
PID_FANCONI_PATHWAY	891	38	0.796	0.269	0.724	0.885
LEI_HOXC8_TARGETS_DN	892	17	0.796	0.269	0.725	0.885
RICKMAN_HEAD_AND_NECK_CANCER_A	893	84	0.796	0.209	0.725	0.885
VERNELL_RETINOBLASTOMA_PATHWAY_UP	894	60	0.794	0.25	0.728	0.886
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_CYCLIN_B	895	21	0.793	0.367	0.728	0.886
KAAB_FAILED_HEART_VENTRICLE_DN	896	38	0.792	0.287	0.730	0.886
REACTOME_TRP_CHANNELS	897	28	0.791	0.266	0.731	0.886
SEIDEN_MET_SIGNALING	898	17	0.79	0.372	0.732	0.886
WP_PROTEASOME_DEGRADATION	899	57	0.789	0.344	0.733	0.886
REACTOME_DEGRADATION_OF_DVL	900	55	0.789	0.345	0.733	0.886
REACTOME_SARS_COV_2_INFECTION	901	258	0.789	0.234	0.733	0.886
SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP	902	416	0.789	0.251	0.734	0.886
ZHAN_MULTIPLE_MYELOMA_SPIKED	903	21	0.788	0.261	0.734	0.886
GUILLAUMOND_KLF10_TARGETS_DN	904	25	0.786	0.233	0.736	0.888
REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM	905	38	0.785	0.244	0.738	0.889
KEGG_FATTY_ACID_METABOLISM	906	39	0.784	0.23	0.739	0.889
KIM_TIAL1_TARGETS	907	26	0.783	0.298	0.740	0.889
FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_UP	908	48	0.783	0.304	0.740	0.889
REACTOME_KEAP1_NFE2L2_PATHWAY	909	96	0.782	0.317	0.741	0.889
REACTOME_SARS_COV_INFECTIONS	910	348	0.779	0.22	0.745	0.891
NIKOLSKY_BREAST_CANCER_16P13_AMPLICON	911	91	0.778	0.251	0.745	0.891
LOPEZ_TRANSLATION_VIA_FN1_SIGNALING	912	33	0.778	0.302	0.746	0.891
REACTOME_SURFACTANT_METABOLISM	913	24	0.777	0.273	0.747	0.891
TIEN_INTESTINE_PROBIOTICS_24HR_UP	914	466	0.776	0.292	0.748	0.891
ZHAN_LATE_DIFFERENTIATION_GENES_UP	915	31	0.776	0.258	0.748	0.891
REACTOME_PEROXISOMAL_LIPID_METABOLISM	916	27	0.776	0.232	0.748	0.891
WHITFIELD_CELL_CYCLE_G1_S	917	102	0.774	0.242	0.750	0.892
GRUETZMANN_PANCREATIC_CANCER_DN	918	182	0.771	0.194	0.754	0.893
CHOI_ATL_STAGE_PREDICTOR	919	32	0.769	0.312	0.756	0.893
DACOSTA_UV_RESPONSE_VIA_ERCC3_UP	920	279	0.769	0.233	0.756	0.893
REACTOME_INTRINSIC_PATHWAY_OF_FIBRIN_CLOT_FORMATION	921	23	0.768	0.275	0.757	0.893
SMIRNOV_RESPONSE_TO_IR_2HR_UP	922	43	0.768	0.282	0.758	0.893
REACTOME_SIGNALING_BY_NOTCH1_PEST_DOMAIN_MUTANTS_IN_CANCER	923	50	0.768	0.242	0.758	0.893
KEGG_ETHER_LIPID_METABOLISM	924	25	0.767	0.24	0.758	0.893
CAFFAREL_RESPONSE_TO_THC_24HR_5_DN	925	41	0.767	0.283	0.758	0.893
REACTOME_ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES	926	72	0.767	0.266	0.759	0.893
KAYO_CALORIE_RESTRICTION_MUSCLE_DN	927	76	0.766	0.218	0.760	0.893
REACTOME_DEFECTIVE_CFTR_CAUSES_CYSTIC_FIBROSIS	928	56	0.765	0.327	0.761	0.893
WP_DNA_IRDAMAGE_AND_CELLULAR_RESPONSE_VIA_ATR	929	72	0.764	0.245	0.762	0.893
REACTOME_DEGRADATION_OF_AXIN	930	53	0.762	0.334	0.764	0.893
YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP	931	47	0.762	0.302	0.764	0.893
REACTOME_DISORDERS_OF_TRANSMEMBRANE_TRANSPORTERS	932	165	0.762	0.209	0.764	0.893
TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_UP	933	75	0.762	0.265	0.764	0.893
WP_CELL_CYCLE	934	110	0.761	0.265	0.766	0.893
REACTOME_DNA_DOUBLE_STRAND_BREAK_RESPONSE	935	34	0.759	0.268	0.767	0.893
WHITFIELD_CELL_CYCLE_M_G1	936	102	0.758	0.283	0.769	0.893
REACTOME_DEADENYLATION_OF_MRNA	937	19	0.758	0.37	0.769	0.893
WP_TRANSLATION_INHIBITORS_IN_CHRONICALLY_ACTIVATED_PDGFRA_CELLS	938	44	0.757	0.26	0.769	0.893
FLORIO_HUMAN_NEOCORTEX	939	15	0.757	0.309	0.769	0.893
PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_DN	940	23	0.756	0.257	0.771	0.893
REACTOME_NEGATIVE_REGULATION_OF_NOTCH4_SIGNALING	941	52	0.755	0.345	0.772	0.893
NIKOLSKY_BREAST_CANCER_7P22_AMPLICON	942	23	0.755	0.257	0.772	0.893
REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_ACETYLATION	943	24	0.755	0.292	0.772	0.893
WEBER_METHYLATED_LCP_IN_SPERM_UP	944	15	0.753	0.351	0.774	0.893
REACTOME_APC_CDC20_MEDIATED_DEGRADATION_OF_NEK2A	945	24	0.753	0.346	0.775	0.893
REACTOME_TRANSPORT_OF_BILE_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AMINE_COMPOUNDS	946	83	0.747	0.219	0.781	0.894
NOUZOVA_TRETINOIN_AND_H4_ACETYLATION	947	100	0.747	0.256	0.781	0.894
KEGG_CELL_CYCLE	948	114	0.745	0.262	0.783	0.894
GOLUB_ALL_VS_AML_UP	949	24	0.745	0.313	0.783	0.894
PUJANA_BREAST_CANCER_WITH_BRCA1_MUTATED_UP	950	47	0.744	0.267	0.784	0.894
SETLUR_PROSTATE_CANCER_TMPRSS2_ERG_FUSION_UP	951	60	0.744	0.222	0.784	0.894
HAHTOLA_MYCOSIS_FUNGOIDES_CD4_DN	952	95	0.744	0.298	0.784	0.894
REACTOME_ABC_FAMILY_PROTEINS_MEDIATED_TRANSPORT	953	98	0.743	0.228	0.785	0.894
REACTOME_HDR_THROUGH_HOMOLOGOUS_RECOMBINATION_HRR	954	54	0.743	0.235	0.785	0.894
KRIGE_AMINO_ACID_DEPRIVATION	955	23	0.742	0.327	0.786	0.894
HAHTOLA_MYCOSIS_FUNGOIDES_DN	956	15	0.742	0.271	0.786	0.894
REACTOME_ACTIVATION_OF_BAD_AND_TRANSLOCATION_TO_MITOCHONDRIA	957	15	0.742	0.325	0.786	0.894
REACTOME_RESPONSE_OF_EIF2AK1_HRI_TO_HEME_DEFICIENCY	958	15	0.742	0.369	0.786	0.894
CHUNG_BLISTER_CYTOTOXICITY_UP	959	112	0.742	0.24	0.786	0.894
WP_DISORDERS_OF_BILE_ACID_SYNTHESIS_AND_BILIARY_TRANSPORT	960	20	0.741	0.254	0.787	0.894
REACTOME_HATS_ACETYLATE_HISTONES	961	51	0.74	0.269	0.788	0.894
REACTOME_TELOMERE_C_STRAND_LAGGING_STRAND_SYNTHESIS	962	27	0.739	0.266	0.789	0.894
JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_UP	963	42	0.736	0.286	0.792	0.897
WENG_POR_TARGETS_LIVER_DN	964	19	0.735	0.236	0.794	0.897
BIOCARTA_ATRBRCA_PATHWAY	965	21	0.734	0.255	0.795	0.898
REN_BOUND_BY_E2F	966	50	0.734	0.265	0.795	0.898
WP_RETINOBLASTOMA_GENE_IN_CANCER	967	82	0.733	0.265	0.796	0.898
PUJANA_XPRSS_INT_NETWORK	968	145	0.732	0.264	0.797	0.898
HALLMARK_PEROXISOME	969	97	0.729	0.198	0.800	0.898
REACTOME_IRON_UPTAKE_AND_TRANSPORT	970	51	0.729	0.228	0.800	0.898
LINDGREN_BLADDER_CANCER_WITH_LOH_IN_CHR9Q	971	90	0.729	0.248	0.800	0.898
FLECHNER_PBL_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP	972	132	0.728	0.256	0.802	0.898
REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE	973	22	0.727	0.322	0.802	0.898
LEE_CALORIE_RESTRICTION_MUSCLE_UP	974	35	0.725	0.237	0.804	0.899
DER_IFN_GAMMA_RESPONSE_UP	975	67	0.725	0.238	0.804	0.899
REACTOME_DUAL_INCISION_IN_GG_NER	976	41	0.725	0.267	0.805	0.899
RAMPON_ENRICHED_LEARNING_ENVIRONMENT_LATE_UP	977	21	0.723	0.258	0.807	0.899
BLANCO_MELO_COVID19_SARS_COV_2_INFECTION_A594_ACE2_EXPRESSING_CELLS_DN	978	85	0.721	0.191	0.809	0.899
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_DN	979	21	0.719	0.312	0.811	0.899
REACTOME_RHOBTB_GTPASE_CYCLE	980	30	0.719	0.292	0.811	0.899
REACTOME_NUCLEAR_ENVELOPE_NE_REASSEMBLY	981	57	0.719	0.27	0.811	0.899
REACTOME_ABC_TRANSPORTER_DISORDERS	982	73	0.718	0.248	0.811	0.899
REACTOME_RETROGRADE_TRANSPORT_AT_THE_TRANS_GOLGI_NETWORK	983	40	0.717	0.263	0.812	0.899
BORCZUK_MALIGNANT_MESOTHELIOMA_UP	984	254	0.717	0.291	0.813	0.899
WANG_METASTASIS_OF_BREAST_CANCER_ESR1_UP	985	17	0.717	0.294	0.813	0.899
PUJANA_BRCA2_PCC_NETWORK	986	368	0.717	0.221	0.813	0.899
VERNOCHET_ADIPOGENESIS	987	18	0.715	0.249	0.815	0.900
OSMAN_BLADDER_CANCER_DN	988	303	0.714	0.224	0.816	0.900
REACTOME_SIGNALING_BY_ROBO_RECEPTORS	989	208	0.712	0.267	0.818	0.901
REACTOME_MAPK6_MAPK4_SIGNALING	990	81	0.712	0.27	0.818	0.901
WP_CILIARY_LANDSCAPE	991	181	0.709	0.237	0.822	0.904
REACTOME_ACTIVATION_OF_BH3_ONLY_PROTEINS	992	29	0.705	0.242	0.825	0.906
ODONNELL_METASTASIS_DN	993	24	0.704	0.216	0.826	0.907
WP_CLASSICAL_PATHWAY_OF_STEROIDOGENESIS_WITH_GLUCOCORTICOID_AND_MINERALOCORTICOID_METABOLISM	994	16	0.701	0.288	0.829	0.909
REACTOME_HOMOLOGY_DIRECTED_REPAIR	995	85	0.698	0.214	0.833	0.911
BONOME_OVARIAN_CANCER_POOR_SURVIVAL_UP	996	25	0.698	0.245	0.833	0.911
KEGG_HUNTINGTONS_DISEASE	997	153	0.697	0.227	0.834	0.911
REACTOME_METABOLISM_OF_STEROID_HORMONES	998	29	0.694	0.214	0.836	0.913
APPIERTO_RESPONSE_TO_FENRETINIDE_DN	999	36	0.694	0.25	0.837	0.913
HALLMARK_PANCREAS_BETA_CELLS	1000	36	0.692	0.202	0.839	0.913
WP_PURINERGIC_SIGNALING	1001	30	0.691	0.229	0.839	0.913
REACTOME_DEGRADATION_OF_GLI1_BY_THE_PROTEASOME	1002	57	0.691	0.287	0.839	0.913
LUI_THYROID_CANCER_CLUSTER_4	1003	15	0.69	0.285	0.840	0.913
REACTOME_TRANSCRIPTIONAL_REGULATION_BY_VENTX	1004	34	0.685	0.252	0.845	0.917
CHEN_NEUROBLASTOMA_COPY_NUMBER_GAINS	1005	43	0.682	0.204	0.848	0.920
SILIGAN_BOUND_BY_EWS_FLT1_FUSION	1006	42	0.68	0.186	0.850	0.921
FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP	1007	57	0.679	0.265	0.851	0.921
BOYAULT_LIVER_CANCER_SUBCLASS_G123_UP	1008	42	0.678	0.3	0.852	0.921
WP_OXYSTEROLS_DERIVED_FROM_CHOLESTEROL	1009	43	0.676	0.206	0.854	0.921
WP_STRIATED_MUSCLE_CONTRACTION_PATHWAY	1010	38	0.676	0.218	0.854	0.921
WANG_TUMOR_INVASIVENESS_UP	1011	329	0.671	0.234	0.858	0.921
BENPORATH_PROLIFERATION	1012	117	0.671	0.242	0.859	0.921
ONKEN_UVEAL_MELANOMA_DN	1013	451	0.67	0.222	0.860	0.921
REACTOME_SUMOYLATION_OF_DNA_REPLICATION_PROTEINS	1014	41	0.67	0.265	0.860	0.921
REACTOME_MTOR_SIGNALLING	1015	30	0.669	0.275	0.860	0.921
MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN	1016	230	0.669	0.264	0.860	0.921
REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE	1017	39	0.669	0.21	0.860	0.921
REACTOME_CELLULAR_RESPONSE_TO_CHEMICAL_STRESS	1018	174	0.668	0.23	0.862	0.921
MOOTHA_FFA_OXYDATION	1019	20	0.667	0.243	0.862	0.921
KEGG_LINOLEIC_ACID_METABOLISM	1020	27	0.666	0.274	0.863	0.921
WHITEHURST_PACLITAXEL_SENSITIVITY	1021	31	0.666	0.207	0.863	0.921
VETTER_TARGETS_OF_PRKCA_AND_ETS1_UP	1022	15	0.665	0.271	0.864	0.921
REACTOME_REGULATION_OF_RUNX2_EXPRESSION_AND_ACTIVITY	1023	69	0.664	0.258	0.865	0.922
REACTOME_APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS	1024	82	0.663	0.282	0.866	0.922
FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN	1025	41	0.66	0.27	0.868	0.923
BOUDOUKHA_BOUND_BY_IGF2BP2	1026	87	0.66	0.234	0.869	0.923
REACTOME_VOLTAGE_GATED_POTASSIUM_CHANNELS	1027	43	0.656	0.26	0.872	0.924
ANDERSEN_LIVER_CANCER_KRT19_UP	1028	30	0.656	0.268	0.872	0.924
WINTER_HYPOXIA_DN	1029	40	0.656	0.215	0.872	0.924
REACTOME_DECTIN_1_MEDIATED_NONCANONICAL_NF_KB_SIGNALING	1030	58	0.649	0.268	0.878	0.929
WP_FATTY_ACID_TRANSPORTERS	1031	17	0.647	0.22	0.880	0.929
PETRETTO_HEART_MASS_QTL_CIS_DN	1032	19	0.647	0.215	0.880	0.929
REACTOME_NEDDYLATION	1033	212	0.643	0.206	0.883	0.932
WP_MITOCHONDRIAL_COMPLEX_IV_ASSEMBLY	1034	21	0.639	0.275	0.887	0.935
REACTOME_PROCESSING_OF_INTRONLESS_PRE_MRNAS	1035	18	0.638	0.293	0.887	0.935
PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_UP	1036	59	0.634	0.257	0.890	0.937
REACTOME_FORMATION_OF_INCISION_COMPLEX_IN_GG_NER	1037	43	0.63	0.266	0.893	0.939
MIKKELSEN_ES_HCP_WITH_H3_UNMETHYLATED	1038	51	0.629	0.209	0.895	0.939
REACTOME_DEGRADATION_OF_BETA_CATENIN_BY_THE_DESTRUCTION_COMPLEX	1039	80	0.628	0.258	0.895	0.939
WP_SEROTONIN_AND_ANXIETY	1040	16	0.627	0.22	0.896	0.939
WONG_PROTEASOME_GENE_MODULE	1041	46	0.626	0.282	0.897	0.939
HOLLEMAN_PREDNISOLONE_RESISTANCE_B_ALL_UP	1042	17	0.625	0.28	0.898	0.939
BLANCO_MELO_COVID19_SARS_COV_2_INFECTION_A594_CELLS_DN	1043	62	0.621	0.206	0.900	0.941
SESTO_RESPONSE_TO_UV_C0	1044	98	0.619	0.242	0.902	0.942
REACTOME_INTRA_GOLGI_TRAFFIC	1045	33	0.616	0.227	0.904	0.943
REACTOME_G2_M_DNA_DAMAGE_CHECKPOINT	1046	48	0.615	0.219	0.905	0.943
REACTOME_DISEASES_ASSOCIATED_WITH_GLYCOSAMINOGLYCAN_METABOLISM	1047	36	0.614	0.194	0.906	0.943
REACTOME_PROCESSING_OF_DNA_DOUBLE_STRAND_BREAK_ENDS	1048	52	0.613	0.215	0.907	0.943
WP_OXIDATION_BY_CYTOCHROME_P450	1049	56	0.61	0.173	0.909	0.944
MIKKELSEN_IPS_WITH_HCP_H3K27ME3	1050	91	0.607	0.208	0.911	0.946
MCCABE_HOXC6_TARGETS_CANCER_DN	1051	17	0.603	0.254	0.914	0.947
REACTOME_UB_SPECIFIC_PROCESSING_PROTEASES	1052	150	0.601	0.217	0.915	0.947
SALVADOR_MARTIN_PEDIATRIC_TBD_ANTI_TNF_THERAPY_NONRESPONDER_PRE_TREATMENT_UP	1053	18	0.601	0.245	0.915	0.947
REACTOME_GAP_FILLING_DNA_REPAIR_SYNTHESIS_AND_LIGATION_IN_GG_NER	1054	25	0.6	0.217	0.916	0.947
HSIAO_HOUSEKEEPING_GENES	1055	352	0.599	0.237	0.917	0.947
TAKAO_RESPONSE_TO_UVB_RADIATION_UP	1056	74	0.598	0.231	0.917	0.947
HAHTOLA_SEZARY_SYNDROM_DN	1057	39	0.595	0.204	0.919	0.947
REACTOME_CLASS_C_3_METABOTROPIC_GLUTAMATE_PHEROMONE_RECEPTORS	1058	30	0.594	0.235	0.920	0.947
REACTOME_THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT	1059	64	0.594	0.247	0.920	0.947
REACTOME_ERCC6_CSB_AND_EHMT2_G9A_POSITIVELY_REGULATE_RRNA_EXPRESSION	1060	16	0.592	0.253	0.922	0.948
REACTOME_RUNX1_REGULATES_TRANSCRIPTION_OF_GENES_INVOLVED_IN_DIFFERENTIATION_OF_HSCS	1061	67	0.589	0.24	0.923	0.949
RICKMAN_HEAD_AND_NECK_CANCER_B	1062	41	0.586	0.185	0.925	0.950
PID_ATR_PATHWAY	1063	37	0.581	0.208	0.929	0.952
WP_MAJOR_RECEPTORS_TARGETED_BY_EPINEPHRINE_AND_NOREPINEPHRINE	1064	15	0.578	0.221	0.930	0.952
HOLLEMAN_VINCRISTINE_RESISTANCE_ALL_DN	1065	19	0.578	0.252	0.931	0.952
OUELLET_OVARIAN_CANCER_INVASIVE_VS_LMP_UP	1066	100	0.576	0.245	0.932	0.953
REACTOME_REGULATION_OF_RUNX3_EXPRESSION_AND_ACTIVITY	1067	54	0.574	0.258	0.933	0.953
MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED	1068	178	0.563	0.178	0.940	0.959
MACAEVA_PBMC_RESPONSE_TO_IR	1069	78	0.551	0.171	0.946	0.965
REACTOME_CELLULAR_RESPONSE_TO_HYPOXIA	1070	69	0.549	0.222	0.947	0.965
WANG_RESPONSE_TO_FORSKOLIN_UP	1071	21	0.541	0.203	0.951	0.968
WP_PEPTIDE_GPCRS	1072	68	0.54	0.202	0.952	0.968
DING_LUNG_CANCER_EXPRESSION_BY_COPY_NUMBER	1073	88	0.536	0.222	0.954	0.969
MEINHOLD_OVARIAN_CANCER_LOW_GRADE_DN	1074	18	0.525	0.254	0.959	0.970
REACTOME_PTEN_REGULATION	1075	119	0.524	0.194	0.959	0.970
REACTOME_FCERI_MEDIATED_NF_KB_ACTIVATION	1076	80	0.523	0.191	0.960	0.970
CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_UP	1077	26	0.522	0.177	0.960	0.970
HU_ANGIOGENESIS_DN	1078	27	0.521	0.246	0.961	0.970
FIGUEROA_AML_METHYLATION_CLUSTER_6_DN	1079	24	0.521	0.193	0.961	0.970
WP_KYNURENINE_PATHWAY_AND_LINKS_TO_CELL_SENESCENCE	1080	20	0.502	0.158	0.968	0.976
APPEL_IMATINIB_RESPONSE	1081	31	0.501	0.179	0.968	0.976
REACTOME_PINK1_PRKN_MEDIATED_MITOPHAGY	1082	17	0.5	0.233	0.969	0.976
GUTIERREZ_MULTIPLE_MYELOMA_UP	1083	26	0.491	0.233	0.972	0.978
MEISSNER_NPC_HCP_WITH_H3K27ME3	1084	66	0.48	0.171	0.976	0.981
VILIMAS_NOTCH1_TARGETS_DN	1085	25	0.477	0.192	0.976	0.981
WP_MONOAMINE_GPCRS	1086	33	0.471	0.204	0.978	0.982
TIMOFEEVA_GROWTH_STRESS_VIA_STAT1_DN	1087	15	0.455	0.209	0.982	0.985
KEGG_AUTOIMMUNE_THYROID_DISEASE	1088	49	0.44	0.159	0.986	0.988
REACTOME_AMINE_LIGAND_BINDING_RECEPTORS	1089	41	0.408	0.174	0.991	0.992
FARMER_BREAST_CANCER_CLUSTER_1	1090	41	0.354	0.143	0.997	0.997
KONDO_PROSTATE_CANCER_WITH_H3K27ME3	1091	135	-0.324	-0.116	0.998	0.998
KEGG_ALLOGRAFT_REJECTION	1092	34	-0.369	-0.141	0.996	0.996
REACTOME_TRANSLESION_SYNTHESIS_BY_POLK	1093	16	-0.373	-0.161	0.995	0.996
MIKKELSEN_IPS_HCP_WITH_H3_UNMETHYLATED	1094	66	-0.383	-0.136	0.994	0.995
REACTOME_OLFACTORY_SIGNALING_PATHWAY	1095	97	-0.384	-0.148	0.994	0.995
WP_GPCRS_CLASS_A_RHODOPSINLIKE	1096	228	-0.39	-0.138	0.994	0.995
REACTOME_REGULATION_OF_FZD_BY_UBIQUITINATION	1097	20	-0.39	-0.126	0.993	0.995
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION	1098	252	-0.401	-0.142	0.992	0.994
REACTOME_CREATION_OF_C4_AND_C2_ACTIVATORS	1099	20	-0.445	-0.197	0.984	0.987
REACTOME_CGMP_EFFECTS	1100	15	-0.462	-0.224	0.980	0.983
WP_FATTY_ACID_OMEGAOXIDATION	1101	15	-0.464	-0.194	0.980	0.982
BOSCO_TH1_CYTOTOXIC_MODULE	1102	98	-0.464	-0.156	0.980	0.982
REACTOME_ASYMMETRIC_LOCALIZATION_OF_PCP_PROTEINS	1103	62	-0.468	-0.194	0.979	0.982
MIKKELSEN_MCV6_HCP_WITH_H3K27ME3	1104	349	-0.471	-0.16	0.978	0.981
REACTOME_DEFENSINS	1105	29	-0.472	-0.189	0.977	0.981
REACTOME_NITRIC_OXIDE_STIMULATES_GUANYLATE_CYCLASE	1106	18	-0.476	-0.224	0.976	0.980
MIKKELSEN_MEF_HCP_WITH_H3K27ME3	1107	464	-0.478	-0.167	0.975	0.980
REACTOME_FERTILIZATION	1108	19	-0.495	-0.194	0.970	0.974
VANDESLUIS_COMMD1_TARGETS_GROUP_4_DN	1109	15	-0.496	-0.202	0.970	0.974
KUROZUMI_RESPONSE_TO_ONCOCYTIC_VIRUS_AND_CYCLIC_RGD	1110	18	-0.5	-0.217	0.968	0.973
BIOCARTA_AMAN_PATHWAY	1111	15	-0.502	-0.196	0.967	0.973
REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_BETA_CELLS	1112	16	-0.502	-0.164	0.967	0.973
REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC	1113	25	-0.523	-0.234	0.959	0.965
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL	1114	129	-0.523	-0.173	0.959	0.965
CURSONS_NATURAL_KILLER_CELLS	1115	20	-0.529	-0.239	0.956	0.962
WU_ALZHEIMER_DISEASE_DN	1116	15	-0.531	-0.194	0.955	0.962
BOQUEST_STEM_CELL_CULTURED_VS_FRESH_DN	1117	28	-0.535	-0.209	0.953	0.960
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS	1118	52	-0.543	-0.187	0.949	0.956
PID_CONE_PATHWAY	1119	22	-0.545	-0.229	0.948	0.955
WP_FARNESOID_X_RECEPTOR_PATHWAY	1120	18	-0.548	-0.203	0.946	0.954
REACTOME_FGFR1_LIGAND_BINDING_AND_ACTIVATION	1121	15	-0.559	-0.229	0.940	0.948
KEGG_RETINOL_METABOLISM	1122	50	-0.559	-0.181	0.940	0.948
REACTOME_POTASSIUM_CHANNELS	1123	102	-0.559	-0.188	0.940	0.948
REACTOME_CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS	1124	281	-0.565	-0.193	0.937	0.945
REACTOME_GPCR_LIGAND_BINDING	1125	396	-0.566	-0.184	0.936	0.945
REACTOME_SIGNALING_BY_NOTCH4	1126	76	-0.57	-0.224	0.934	0.943
WP_SELECTIVE_EXPRESSION_OF_CHEMOKINE_RECEPTORS_DURING_TCELL_POLARIZATION	1127	29	-0.571	-0.213	0.933	0.943
SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN	1128	36	-0.571	-0.202	0.933	0.943
REACTOME_PD_1_SIGNALING	1129	20	-0.573	-0.215	0.932	0.942
WP_PHOTODYNAMIC_THERAPYINDUCED_UNFOLDED_PROTEIN_RESPONSE	1130	24	-0.578	-0.245	0.929	0.939
WP_GLYCOSAMINOGLYCAN_DEGRADATION	1131	17	-0.579	-0.214	0.928	0.939
KIM_LIVER_CANCER_POOR_SURVIVAL_DN	1132	42	-0.58	-0.19	0.928	0.939
REACTOME_TRIGLYCERIDE_CATABOLISM	1133	20	-0.582	-0.199	0.926	0.937
MIKKELSEN_IPS_ICP_WITH_H3K27ME3	1134	45	-0.583	-0.209	0.926	0.937
BIOCARTA_MTOR_PATHWAY	1135	19	-0.587	-0.27	0.923	0.934
REACTOME_PHOSPHOLIPASE_C_MEDIATED_CASCADE_FGFR4	1136	15	-0.588	-0.229	0.922	0.934
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_DN	1137	29	-0.589	-0.261	0.921	0.933
REACTOME_E3_UBIQUITIN_LIGASES_UBIQUITINATE_TARGET_PROTEINS	1138	39	-0.591	-0.251	0.920	0.933
GENTILE_RESPONSE_CLUSTER_D3	1139	49	-0.592	-0.252	0.920	0.932
REACTOME_TCR_SIGNALING	1140	110	-0.594	-0.182	0.919	0.931
REACTOME_RUNX1_INTERACTS_WITH_CO_FACTORS_WHOSE_PRECISE_EFFECT_ON_RUNX1_TARGETS_IS_NOT_KNOWN	1141	36	-0.595	-0.219	0.918	0.931
SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_DN	1142	15	-0.599	-0.224	0.915	0.928
REACTOME_TERMINATION_OF_TRANSLESION_DNA_SYNTHESIS	1143	29	-0.6	-0.22	0.914	0.928
WEBER_METHYLATED_HCP_IN_FIBROBLAST_DN	1144	34	-0.601	-0.192	0.913	0.927
SU_PANCREAS	1145	41	-0.607	-0.198	0.909	0.923
NABA_PROTEOGLYCANS	1146	29	-0.612	-0.237	0.905	0.920
REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR	1147	77	-0.618	-0.248	0.901	0.915
KAUFFMANN_MELANOMA_RELAPSE_UP	1148	56	-0.62	-0.199	0.899	0.914
REACTOME_RECOGNITION_OF_DNA_DAMAGE_BY_PCNA_CONTAINING_REPLICATION_COMPLEX	1149	30	-0.621	-0.237	0.899	0.914
KEGG_ASTHMA	1150	27	-0.623	-0.273	0.897	0.912
REACTOME_TP53_REGULATES_METABOLIC_GENES	1151	65	-0.625	-0.248	0.895	0.910
WALLACE_PROSTATE_CANCER_RACE_UP	1152	253	-0.626	-0.165	0.895	0.910
KIM_BIPOLAR_DISORDER_OLIGODENDROCYTE_DENSITY_CORR_DN	1153	82	-0.626	-0.205	0.894	0.910
REACTOME_MITOPHAGY	1154	24	-0.626	-0.275	0.894	0.910
SEIDEN_ONCOGENESIS_BY_MET	1155	71	-0.628	-0.28	0.893	0.910
LEE_LIVER_CANCER_SURVIVAL_DN	1156	149	-0.628	-0.247	0.893	0.909
KIM_LRRC3B_TARGETS	1157	29	-0.63	-0.22	0.891	0.908
SMITH_TERT_TARGETS_UP	1158	129	-0.631	-0.247	0.890	0.907
PID_P53_REGULATION_PATHWAY	1159	53	-0.636	-0.267	0.887	0.904
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN	1160	77	-0.636	-0.208	0.886	0.904
BIOCARTA_CARM_ER_PATHWAY	1161	24	-0.637	-0.215	0.885	0.903
WP_TCA_CYCLE_AKA_KREBS_OR_CITRIC_ACID_CYCLE	1162	18	-0.639	-0.292	0.884	0.902
REACTOME_CELL_CYCLE_CHECKPOINTS	1163	214	-0.64	-0.227	0.883	0.901
REACTOME_HDR_THROUGH_SINGLE_STRAND_ANNEALING_SSA	1164	31	-0.641	-0.22	0.882	0.901
BIOCARTA_CK1_PATHWAY	1165	16	-0.642	-0.206	0.881	0.900
KEGG_PEROXISOME	1166	72	-0.642	-0.179	0.881	0.900
HOLLEMAN_ASPARAGINASE_RESISTANCE_ALL_DN	1167	20	-0.642	-0.287	0.881	0.900
REACTOME_DEUBIQUITINATION	1168	210	-0.643	-0.219	0.881	0.900
AGUIRRE_PANCREATIC_CANCER_COPY_NUMBER_DN	1169	187	-0.643	-0.203	0.880	0.900
MIKKELSEN_MEF_ICP_WITH_H3K27ME3	1170	157	-0.643	-0.225	0.880	0.900
BIOCARTA_NKT_PATHWAY	1171	26	-0.644	-0.24	0.880	0.900
BRACHAT_RESPONSE_TO_CAMPTOTHECIN_DN	1172	34	-0.647	-0.242	0.877	0.897
RICKMAN_HEAD_AND_NECK_CANCER_D	1173	28	-0.648	-0.228	0.876	0.896
REACTOME_ASSEMBLY_OF_ACTIVE_LPL_AND_LIPC_LIPASE_COMPLEXES	1174	15	-0.648	-0.254	0.876	0.896
SERVITJA_ISLET_HNF1A_TARGETS_DN	1175	97	-0.648	-0.187	0.876	0.896
REACTOME_REGULATION_OF_RAS_BY_GAPS	1176	64	-0.65	-0.269	0.875	0.896
HSIAO_LIVER_SPECIFIC_GENES	1177	236	-0.65	-0.177	0.874	0.896
FRASOR_RESPONSE_TO_ESTRADIOL_UP	1178	34	-0.651	-0.175	0.874	0.896
KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION	1179	45	-0.653	-0.228	0.871	0.893
REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION	1180	102	-0.654	-0.216	0.871	0.893
REACTOME_GLYCOSPHINGOLIPID_METABOLISM	1181	36	-0.654	-0.214	0.871	0.893
OUILLETTE_CLL_13Q14_DELETION_UP	1182	60	-0.654	-0.172	0.870	0.893
REACTOME_G1_S_SPECIFIC_TRANSCRIPTION	1183	23	-0.655	-0.226	0.870	0.892
LEE_TARGETS_OF_PTCH1_AND_SUFU_DN	1184	78	-0.655	-0.166	0.869	0.892
WP_DEGRADATION_PATHWAY_OF_SPHINGOLIPIDS_INCLUDING_DISEASES	1185	15	-0.655	-0.287	0.869	0.892
ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_UP	1186	137	-0.657	-0.207	0.868	0.892
REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS	1187	172	-0.657	-0.219	0.868	0.892
REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE	1188	59	-0.658	-0.195	0.867	0.892
KEGG_PRIMARY_BILE_ACID_BIOSYNTHESIS	1189	16	-0.659	-0.259	0.866	0.891
DIRMEIER_LMP1_RESPONSE_LATE_DN	1190	28	-0.66	-0.252	0.865	0.890
WANG_RESPONSE_TO_ANDROGEN_UP	1191	26	-0.66	-0.263	0.865	0.890
KEGG_LYSOSOME	1192	116	-0.661	-0.209	0.864	0.889
FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_UP	1193	18	-0.664	-0.239	0.861	0.887
HALLMARK_FATTY_ACID_METABOLISM	1194	149	-0.665	-0.192	0.861	0.886
SU_LIVER	1195	57	-0.669	-0.22	0.857	0.882
KIM_ALL_DISORDERS_CALB1_CORR_UP	1196	462	-0.671	-0.206	0.855	0.881
BIOCARTA_EICOSANOID_PATHWAY	1197	21	-0.671	-0.24	0.855	0.881
KANG_FLUOROURACIL_RESISTANCE_UP	1198	18	-0.672	-0.28	0.854	0.881
REACTOME_PROTEIN_UBIQUITINATION	1199	55	-0.672	-0.284	0.854	0.880
REACTOME_TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT	1200	164	-0.673	-0.212	0.853	0.880
MOOTHA_TCA	1201	15	-0.675	-0.314	0.851	0.878
REACTOME_ENDOSOMAL_SORTING_COMPLEX_REQUIRED_FOR_TRANSPORT_ESCRT	1202	27	-0.675	-0.28	0.851	0.878
REACTOME_MITOTIC_PROPHASE	1203	69	-0.677	-0.26	0.849	0.877
PIEPOLI_LGI1_TARGETS_UP	1204	16	-0.677	-0.224	0.849	0.877
BLANCO_MELO_COVID19_SARS_COV_2_INFECTION_A594_ACE2_EXPRESSING_CELLS_RUXOLITINIB_DN	1205	68	-0.678	-0.204	0.849	0.877
WP_GENES_RELATED_TO_PRIMARY_CILIUM_DEVELOPMENT_BASED_ON_CRISPR	1206	61	-0.679	-0.22	0.847	0.875
REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3	1207	88	-0.68	-0.26	0.847	0.875
EHLERS_ANEUPLOIDY_UP	1208	29	-0.68	-0.259	0.846	0.875
KEGG_OLFACTORY_TRANSDUCTION	1209	115	-0.682	-0.234	0.844	0.873
REACTOME_BETA_DEFENSINS	1210	21	-0.684	-0.278	0.842	0.871
CHESLER_BRAIN_HIGHEST_EXPRESSION	1211	36	-0.687	-0.229	0.839	0.869
REACTOME_INCRETIN_SYNTHESIS_SECRETION_AND_INACTIVATION	1212	20	-0.687	-0.233	0.839	0.869
MACLACHLAN_BRCA1_TARGETS_UP	1213	20	-0.688	-0.297	0.839	0.868
BLUM_RESPONSE_TO_SALIRASIB_UP	1214	211	-0.688	-0.262	0.838	0.868
REACTOME_AMINO_ACIDS_REGULATE_MTORC1	1215	34	-0.689	-0.241	0.838	0.868
SCHRAETS_MLL_TARGETS_UP	1216	30	-0.689	-0.242	0.838	0.868
WP_NONALCOHOLIC_FATTY_LIVER_DISEASE	1217	145	-0.692	-0.226	0.834	0.865
REACTOME_FGFR2_LIGAND_BINDING_AND_ACTIVATION	1218	18	-0.693	-0.263	0.834	0.864
FAELT_B_CLL_WITH_VH3_21_DN	1219	46	-0.695	-0.281	0.831	0.862
BIOCARTA_VDR_PATHWAY	1220	22	-0.695	-0.295	0.831	0.862
CHNG_MULTIPLE_MYELOMA_HYPERPLOID_DN	1221	30	-0.698	-0.304	0.829	0.860
WP_PHOSPHODIESTERASES_IN_NEURONAL_FUNCTION	1222	48	-0.7	-0.247	0.827	0.858
GOTTWEIN_TARGETS_OF_KSHV_MIR_K12_11	1223	50	-0.701	-0.252	0.825	0.857
CADWELL_ATG16L1_TARGETS_UP	1224	86	-0.704	-0.212	0.823	0.855
HOEGERKORP_CD44_TARGETS_TEMPORAL_DN	1225	23	-0.704	-0.213	0.823	0.855
BIOCARTA_G1_PATHWAY	1226	27	-0.704	-0.291	0.822	0.855
REACTOME_TRANSLATION_OF_SARSCOV2_STRUCTURAL_PROTEINS	1227	55	-0.705	-0.253	0.821	0.854
BLANCO_MELO_HUMAN_PARAINFLUENZA_VIRUS_3_INFECTION_A594_CELLS_DN	1228	82	-0.706	-0.26	0.821	0.853
MARCHINI_TRABECTEDIN_RESISTANCE_DN	1229	43	-0.707	-0.248	0.820	0.852
MMS_MOUSE_LYMPH_HIGH_4HRS_UP	1230	32	-0.708	-0.279	0.818	0.851
SEKI_INFLAMMATORY_RESPONSE_LPS_DN	1231	21	-0.712	-0.246	0.814	0.847
REACTOME_RHOBTB1_GTPASE_CYCLE	1232	20	-0.714	-0.302	0.812	0.846
MISIAK_ANAPLASTIC_THYROID_CARCINOMA_DN	1233	17	-0.715	-0.241	0.811	0.845
MIKKELSEN_MEF_LCP_WITH_H3K27ME3	1234	52	-0.715	-0.275	0.811	0.844
REACTOME_PLASMA_LIPOPROTEIN_ASSEMBLY	1235	18	-0.716	-0.245	0.810	0.844
RASHI_RESPONSE_TO_IONIZING_RADIATION_4	1236	38	-0.717	-0.196	0.809	0.843
MILI_PSEUDOPODIA_HAPTOTAXIS_UP	1237	396	-0.718	-0.27	0.808	0.843
RIZ_ERYTHROID_DIFFERENTIATION_HBZ	1238	34	-0.718	-0.222	0.808	0.842
MIKKELSEN_NPC_HCP_WITH_H3K27ME3	1239	285	-0.719	-0.233	0.806	0.841
HAHTOLA_MYCOSIS_FUNGOIDES_SKIN_UP	1240	148	-0.72	-0.238	0.805	0.840
LIAN_NEUTROPHIL_GRANULE_CONSTITUENTS	1241	22	-0.72	-0.252	0.805	0.840
LEE_LIVER_CANCER_DENA_DN	1242	72	-0.721	-0.187	0.805	0.840
DESERT_EXTRACELLULAR_MATRIX_HEPATOCELLULAR_CARCINOMA_SUBCLASS_UP	1243	20	-0.721	-0.254	0.804	0.840
WP_METAPATHWAY_BIOTRANSFORMATION_PHASE_I_AND_II	1244	157	-0.722	-0.192	0.804	0.840
MEISSNER_NPC_HCP_WITH_H3K4ME2_AND_H3K27ME3	1245	285	-0.724	-0.231	0.802	0.838
KEGG_REGULATION_OF_AUTOPHAGY	1246	33	-0.724	-0.201	0.801	0.837
KEGG_ALPHA_LINOLENIC_ACID_METABOLISM	1247	17	-0.725	-0.256	0.801	0.837
REACTOME_TRANSLESION_SYNTHESIS_BY_Y_FAMILY_DNA_POLYMERASES_BYPASSES_LESIONS_ON_DNA_TEMPLATE	1248	34	-0.725	-0.276	0.800	0.837
REACTOME_METABOLISM_OF_AMINE_DERIVED_HORMONES	1249	18	-0.726	-0.297	0.800	0.837
LEE_LIVER_CANCER_MYC_TGFA_DN	1250	58	-0.726	-0.201	0.799	0.837
WP_GENES_ASSOCIATED_WITH_THE_DEVELOPMENT_OF_RHEUMATOID_ARTHRITIS	1251	18	-0.726	-0.301	0.799	0.836
FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN	1252	45	-0.728	-0.268	0.797	0.835
RICKMAN_HEAD_AND_NECK_CANCER_F	1253	51	-0.728	-0.222	0.797	0.835
REACTOME_HCMV_INFECTION	1254	78	-0.728	-0.264	0.797	0.835
BIOCARTA_DC_PATHWAY	1255	17	-0.731	-0.337	0.794	0.832
REACTOME_INWARDLY_RECTIFYING_K_CHANNELS	1256	35	-0.731	-0.239	0.794	0.832
HASLINGER_B_CLL_WITH_CHROMOSOME_12_TRISOMY	1257	19	-0.733	-0.312	0.792	0.831
REACTOME_TP53_REGULATES_TRANSCRIPTION_OF_GENES_INVOLVED_IN_G2_CELL_CYCLE_ARREST	1258	16	-0.733	-0.288	0.792	0.831
REACTOME_MITOTIC_METAPHASE_AND_ANAPHASE	1259	192	-0.733	-0.27	0.792	0.831
REACTOME_HEDGEHOG_ON_STATE	1260	81	-0.733	-0.251	0.792	0.831
KONDO_PROSTATE_CANCER_HCP_WITH_H3K27ME3	1261	72	-0.734	-0.183	0.791	0.831
REACTOME_STRIATED_MUSCLE_CONTRACTION	1262	36	-0.734	-0.224	0.791	0.831
REACTOME_TP53_REGULATES_TRANSCRIPTION_OF_CELL_CYCLE_GENES	1263	44	-0.736	-0.251	0.789	0.829
REACTOME_PI_3K_CASCADE_FGFR4	1264	20	-0.737	-0.235	0.787	0.827
WP_BIOGENIC_AMINE_SYNTHESIS	1265	15	-0.738	-0.31	0.787	0.827
REACTOME_REGULATION_OF_TP53_EXPRESSION_AND_DEGRADATION	1266	33	-0.739	-0.276	0.786	0.826
MEISSNER_BRAIN_HCP_WITH_H3K4ME2_AND_H3K27ME3	1267	47	-0.739	-0.246	0.785	0.826
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION	1268	272	-0.74	-0.233	0.784	0.825
KEGG_TASTE_TRANSDUCTION	1269	43	-0.742	-0.241	0.782	0.823
WP_NEPHROGENESIS	1270	16	-0.743	-0.293	0.781	0.822
PID_HIF1A_PATHWAY	1271	15	-0.743	-0.283	0.781	0.822
REACTOME_SYNTHESIS_OF_VERY_LONG_CHAIN_FATTY_ACYL_COAS	1272	17	-0.743	-0.25	0.781	0.822
KAAB_FAILED_HEART_ATRIUM_DN	1273	125	-0.744	-0.272	0.780	0.822
BIDUS_METASTASIS_UP	1274	165	-0.745	-0.28	0.779	0.821
DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_UP	1275	67	-0.745	-0.243	0.778	0.820
BOGNI_TREATMENT_RELATED_MYELOID_LEUKEMIA_UP	1276	25	-0.746	-0.267	0.778	0.820
SABATES_COLORECTAL_ADENOMA_DN	1277	253	-0.747	-0.225	0.777	0.819
HATADA_METHYLATED_IN_LUNG_CANCER_UP	1278	305	-0.748	-0.184	0.775	0.818
HOLLMANN_APOPTOSIS_VIA_CD40_DN	1279	218	-0.749	-0.23	0.775	0.818
GLASS_IGF2BP1_CLIP_TARGETS_KNOCKDOWN_DN	1280	87	-0.749	-0.263	0.774	0.817
KYNG_RESPONSE_TO_H2O2_VIA_ERCC6_UP	1281	29	-0.751	-0.284	0.771	0.815
HOLLEMAN_ASPARAGINASE_RESISTANCE_ALL_UP	1282	19	-0.751	-0.258	0.771	0.815
REACTOME_INTRINSIC_PATHWAY_FOR_APOPTOSIS	1283	50	-0.752	-0.253	0.771	0.814
KEGG_CARDIAC_MUSCLE_CONTRACTION	1284	70	-0.753	-0.213	0.770	0.814
CHENG_RESPONSE_TO_NICKEL_ACETATE	1285	39	-0.753	-0.255	0.770	0.814
REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR	1286	111	-0.753	-0.248	0.770	0.814
RIZKI_TUMOR_INVASIVENESS_2D_DN	1287	55	-0.753	-0.23	0.769	0.814
MCGARVEY_SILENCED_BY_METHYLATION_IN_COLON_CANCER	1288	41	-0.755	-0.229	0.767	0.812
FOURNIER_ACINAR_DEVELOPMENT_LATE_2	1289	244	-0.756	-0.29	0.767	0.812
WP_AUTOPHAGY	1290	21	-0.756	-0.319	0.766	0.811
HEIDENBLAD_AMPLIFIED_IN_PANCREATIC_CANCER	1291	41	-0.756	-0.266	0.766	0.811
KAUFFMANN_DNA_REPLICATION_GENES	1292	128	-0.757	-0.227	0.765	0.811
PECE_MAMMARY_STEM_CELL_UP	1293	116	-0.758	-0.313	0.764	0.810
REACTOME_POLYMERASE_SWITCHING_ON_THE_C_STRAND_OF_THE_TELOMERE	1294	20	-0.761	-0.285	0.760	0.806
REACTOME_CYTOSOLIC_SENSORS_OF_PATHOGEN_ASSOCIATED_DNA	1295	58	-0.762	-0.275	0.760	0.806
LIU_NASOPHARYNGEAL_CARCINOMA	1296	64	-0.762	-0.226	0.759	0.806
MEBARKI_HCC_PROGENITOR_WNT_DN_BLOCKED_BY_FZD8CRD	1297	46	-0.764	-0.263	0.757	0.803
REACTOME_PCP_CE_PATHWAY	1298	89	-0.765	-0.287	0.757	0.803
REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_C_STRAND_OF_THE_TELOMERE	1299	18	-0.765	-0.305	0.757	0.803
YAGI_AML_RELAPSE_PROGNOSIS	1300	31	-0.767	-0.303	0.754	0.801
REACTOME_TNFR2_NON_CANONICAL_NF_KB_PATHWAY	1301	95	-0.768	-0.226	0.752	0.799
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_DN	1302	144	-0.769	-0.245	0.751	0.799
REACTOME_REGULATION_OF_SIGNALING_BY_CBL	1303	22	-0.77	-0.302	0.751	0.798
JIANG_AGING_CEREBRAL_CORTEX_DN	1304	42	-0.77	-0.27	0.750	0.798
REACTOME_PKA_ACTIVATION_IN_GLUCAGON_SIGNALLING	1305	17	-0.771	-0.227	0.749	0.797
REACTOME_CLASS_B_2_SECRETIN_FAMILY_RECEPTORS	1306	86	-0.772	-0.237	0.748	0.796
HILLION_HMGA1_TARGETS	1307	79	-0.772	-0.215	0.748	0.796
WP_EFFECT_OF_PROGERIN_ON_GENES_INVOLVED_IN_HUTCHINSONGILFORD_PROGERIA_SYNDROME	1308	20	-0.772	-0.317	0.748	0.796
IIZUKA_LIVER_CANCER_PROGRESSION_G2_G3_UP	1309	23	-0.772	-0.24	0.748	0.796
FINETTI_BREAST_CANCER_KINOME_GREEN	1310	15	-0.774	-0.316	0.746	0.795
REACTOME_SCAVENGING_OF_HEME_FROM_PLASMA	1311	18	-0.774	-0.355	0.746	0.795
REACTOME_DNA_DAMAGE_BYPASS	1312	43	-0.777	-0.294	0.743	0.791
WATANABE_COLON_CANCER_MSI_VS_MSS_DN	1313	58	-0.778	-0.219	0.742	0.791
REACTOME_COMMON_PATHWAY_OF_FIBRIN_CLOT_FORMATION	1314	22	-0.778	-0.257	0.741	0.790
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_TOP20_UP	1315	19	-0.778	-0.239	0.741	0.790
BIOCARTA_EIF4_PATHWAY	1316	22	-0.78	-0.333	0.739	0.789
OUELLET_CULTURED_OVARIAN_CANCER_INVASIVE_VS_LMP_UP	1317	64	-0.781	-0.315	0.738	0.788
KEGG_NICOTINATE_AND_NICOTINAMIDE_METABOLISM	1318	20	-0.782	-0.253	0.737	0.787
BLANCO_MELO_RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_A594_CELLS_DN	1319	95	-0.782	-0.269	0.737	0.787
LINSLEY_MIR16_TARGETS	1320	167	-0.784	-0.253	0.735	0.785
KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_GANGLIO_SERIES	1321	15	-0.785	-0.287	0.734	0.784
THILLAINADESAN_ZNF217_TARGETS_UP	1322	33	-0.785	-0.293	0.733	0.784
REACTOME_PHASE_I_FUNCTIONALIZATION_OF_COMPOUNDS	1323	94	-0.786	-0.205	0.732	0.783
WP_METABOLISM_OF_SPINGOLIPIDS_IN_ER_AND_GOLGI_APPARATUS	1324	16	-0.787	-0.271	0.731	0.782
FUJII_YBX1_TARGETS_DN	1325	176	-0.788	-0.237	0.730	0.781
BUFFA_HYPOXIA_METAGENE	1326	39	-0.789	-0.336	0.728	0.780
REACTOME_BLOOD_GROUP_SYSTEMS_BIOSYNTHESIS	1327	21	-0.789	-0.323	0.728	0.780
REACTOME_LYSOSOME_VESICLE_BIOGENESIS	1328	32	-0.789	-0.273	0.728	0.780
ZHONG_SECRETOME_OF_LUNG_CANCER_AND_FIBROBLAST	1329	123	-0.789	-0.261	0.728	0.780
REACTOME_INTERLEUKIN_1_SIGNALING	1330	103	-0.789	-0.29	0.728	0.780
REACTOME_N_GLYCAN_TRIMMING_IN_THE_ER_AND_CALNEXIN_CALRETICULIN_CYCLE	1331	28	-0.792	-0.346	0.726	0.778
REACTOME_CONSTITUTIVE_SIGNALING_BY_AKT1_E17K_IN_CANCER	1332	20	-0.793	-0.316	0.723	0.776
BIOCARTA_ERAD_PATHWAY	1333	16	-0.794	-0.338	0.723	0.776
HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_UP	1334	60	-0.794	-0.217	0.723	0.775
MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_UP	1335	20	-0.795	-0.255	0.722	0.775
VALK_AML_CLUSTER_5	1336	26	-0.795	-0.279	0.722	0.775
JAZAG_TGFB1_SIGNALING_UP	1337	92	-0.795	-0.21	0.722	0.775
KIM_WT1_TARGETS_DN	1338	381	-0.796	-0.271	0.720	0.774
REACTOME_ENDOGENOUS_STEROLS	1339	25	-0.796	-0.247	0.720	0.774
WANG_SMARCE1_TARGETS_DN	1340	311	-0.797	-0.251	0.720	0.774
KEGG_TYPE_I_DIABETES_MELLITUS	1341	40	-0.797	-0.276	0.719	0.773
BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_UP	1342	27	-0.798	-0.247	0.719	0.773
WILLERT_WNT_SIGNALING	1343	20	-0.798	-0.32	0.718	0.772
REACTOME_TRANSLESION_SYNTHESIS_BY_POLH	1344	17	-0.799	-0.339	0.717	0.772
REACTOME_ROLE_OF_PHOSPHOLIPIDS_IN_PHAGOCYTOSIS	1345	29	-0.8	-0.254	0.716	0.771
LI_AMPLIFIED_IN_LUNG_CANCER	1346	173	-0.8	-0.271	0.715	0.770
LEE_AGING_MUSCLE_UP	1347	35	-0.801	-0.262	0.715	0.770
BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_48HR_UP	1348	18	-0.802	-0.256	0.714	0.769
BIOCARTA_G2_PATHWAY	1349	23	-0.802	-0.314	0.713	0.768
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_DN	1350	36	-0.803	-0.26	0.712	0.768
DER_IFN_ALPHA_RESPONSE_UP	1351	70	-0.803	-0.257	0.712	0.768
BIOCARTA_CELLCYCLE_PATHWAY	1352	22	-0.803	-0.309	0.712	0.768
WP_CONGENITAL_GENERALIZED_LIPODYSTROPHY	1353	16	-0.804	-0.326	0.711	0.767
MIKKELSEN_ES_ICP_WITH_H3K27ME3	1354	33	-0.805	-0.33	0.710	0.766
REACTOME_OXIDATIVE_STRESS_INDUCED_SENESCENCE	1355	60	-0.806	-0.259	0.709	0.765
IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_DN	1356	23	-0.806	-0.379	0.708	0.765
MEISSNER_BRAIN_HCP_WITH_H3K27ME3	1357	222	-0.808	-0.255	0.707	0.763
ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_UP	1358	28	-0.808	-0.266	0.706	0.763
JOHNSTONE_PARVB_TARGETS_2_DN	1359	261	-0.808	-0.295	0.706	0.763
GALE_APL_WITH_FLT3_MUTATED_DN	1360	15	-0.809	-0.342	0.705	0.762
KEGG_ALZHEIMERS_DISEASE	1361	138	-0.809	-0.248	0.705	0.762
WP_FACTORS_AND_PATHWAYS_AFFECTING_INSULINLIKE_GROWTH_FACTOR_IGF1AKT_SIGNALING	1362	31	-0.809	-0.269	0.705	0.762
MORI_MATURE_B_LYMPHOCYTE_DN	1363	68	-0.81	-0.262	0.704	0.762
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_DN	1364	161	-0.81	-0.215	0.703	0.761
REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX1	1365	162	-0.811	-0.247	0.703	0.761
HOSHIDA_LIVER_CANCER_SUBCLASS_S2	1366	105	-0.811	-0.277	0.703	0.761
REACTOME_GOLGI_ASSOCIATED_VESICLE_BIOGENESIS	1367	51	-0.812	-0.294	0.702	0.761
YUAN_ZNF143_PARTNERS	1368	18	-0.814	-0.352	0.700	0.758
LIN_APC_TARGETS	1369	56	-0.814	-0.287	0.699	0.758
ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_DN	1370	18	-0.814	-0.238	0.699	0.758
REACTOME_HCMV_EARLY_EVENTS	1371	59	-0.816	-0.295	0.697	0.756
WINNEPENNINCKX_MELANOMA_METASTASIS_UP	1372	125	-0.816	-0.294	0.696	0.756
WP_EXERCISEINDUCED_CIRCADIAN_REGULATION	1373	45	-0.817	-0.317	0.695	0.755
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_DN	1374	115	-0.817	-0.219	0.695	0.755
WP_16P112_DISTAL_DELETION_SYNDROME	1375	30	-0.818	-0.254	0.695	0.755
MAGRANGEAS_MULTIPLE_MYELOMA_IGG_VS_IGA_UP	1376	16	-0.818	-0.333	0.694	0.755
XU_GH1_AUTOCRINE_TARGETS_UP	1377	140	-0.818	-0.18	0.694	0.755
SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_UP	1378	71	-0.818	-0.289	0.694	0.755
NAKAMURA_ADIPOGENESIS_LATE_DN	1379	33	-0.819	-0.305	0.693	0.754
REACTOME_RHOH_GTPASE_CYCLE	1380	30	-0.821	-0.291	0.691	0.752
WP_HIPPOCAMPAL_SYNAPTOGENESIS_AND_NEUROGENESIS	1381	24	-0.822	-0.244	0.689	0.750
NGUYEN_NOTCH1_TARGETS_DN	1382	75	-0.822	-0.304	0.689	0.750
REACTOME_SYNTHESIS_SECRETION_AND_INACTIVATION_OF_GLUCAGON_LIKE_PEPTIDE_1_GLP_1	1383	17	-0.824	-0.268	0.688	0.749
WP_DRUG_INDUCTION_OF_BILE_ACID_PATHWAY	1384	15	-0.824	-0.333	0.687	0.749
WANG_RECURRENT_LIVER_CANCER_DN	1385	16	-0.825	-0.314	0.686	0.748
SARTIPY_NORMAL_AT_INSULIN_RESISTANCE_DN	1386	15	-0.826	-0.277	0.685	0.747
KYNG_RESPONSE_TO_H2O2_VIA_ERCC6_DN	1387	41	-0.827	-0.305	0.684	0.746
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN	1388	482	-0.827	-0.239	0.684	0.746
MINGUEZ_LIVER_CANCER_VASCULAR_INVASION_DN	1389	21	-0.829	-0.255	0.681	0.743
REACTOME_APOPTOTIC_FACTOR_MEDIATED_RESPONSE	1390	16	-0.829	-0.328	0.681	0.743
MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_DN	1391	60	-0.83	-0.237	0.680	0.743
SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC_DN	1392	19	-0.83	-0.27	0.680	0.742
LEE_LIVER_CANCER_SURVIVAL_UP	1393	159	-0.831	-0.229	0.680	0.742
PODAR_RESPONSE_TO_ADAPHOSTIN_DN	1394	15	-0.831	-0.313	0.678	0.741
REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS	1395	42	-0.832	-0.3	0.678	0.741
REACTOME_AQUAPORIN_MEDIATED_TRANSPORT	1396	51	-0.832	-0.235	0.678	0.741
TOMIDA_METASTASIS_UP	1397	20	-0.832	-0.323	0.678	0.741
HALLMARK_SPERMATOGENESIS	1398	122	-0.833	-0.191	0.677	0.740
EPPERT_LSC_R	1399	31	-0.833	-0.294	0.676	0.740
BIOCARTA_PML_PATHWAY	1400	17	-0.834	-0.286	0.675	0.739
LOPES_METHYLATED_IN_COLON_CANCER_UP	1401	26	-0.835	-0.301	0.674	0.738
BLANCO_MELO_MERS_COV_INFECTION_MCR5_CELLS_DN	1402	28	-0.835	-0.278	0.674	0.738
SMID_BREAST_CANCER_LUMINAL_A_UP	1403	78	-0.836	-0.255	0.673	0.738
WARTERS_IR_RESPONSE_5GY	1404	37	-0.837	-0.245	0.672	0.737
REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT	1405	30	-0.837	-0.22	0.672	0.737
ZHAN_MULTIPLE_MYELOMA_HP_UP	1406	36	-0.837	-0.233	0.672	0.737
WANG_LMO4_TARGETS_DN	1407	273	-0.838	-0.269	0.671	0.736
REACTOME_DOPAMINE_NEUROTRANSMITTER_RELEASE_CYCLE	1408	22	-0.838	-0.274	0.671	0.736
DOANE_BREAST_CANCER_CLASSES_UP	1409	61	-0.838	-0.221	0.671	0.736
MILI_PSEUDOPODIA	1410	34	-0.838	-0.336	0.671	0.736
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_DN	1411	71	-0.839	-0.249	0.669	0.735
KEGG_BIOSYNTHESIS_OF_UNSATURATED_FATTY_ACIDS	1412	18	-0.843	-0.313	0.665	0.731
WILENSKY_RESPONSE_TO_DARAPLADIB	1413	28	-0.843	-0.308	0.665	0.730
REACTOME_CALNEXIN_CALRETICULIN_CYCLE	1414	23	-0.843	-0.373	0.664	0.730
JOHANSSON_BRAIN_CANCER_EARLY_VS_LATE_DN	1415	41	-0.843	-0.273	0.664	0.730
REACTOME_M_PHASE	1416	284	-0.844	-0.293	0.663	0.730
SPIRA_SMOKERS_LUNG_CANCER_UP	1417	35	-0.844	-0.294	0.663	0.730
JIANG_HYPOXIA_VIA_VHL	1418	16	-0.847	-0.356	0.660	0.726
SHEN_SMARCA2_TARGETS_UP	1419	336	-0.848	-0.371	0.659	0.725
SHEN_SMARCA2_TARGETS_DN	1420	264	-0.848	-0.307	0.659	0.725
REACTOME_CELL_CYCLE_MITOTIC	1421	411	-0.848	-0.277	0.658	0.725
WP_16P112_PROXIMAL_DELETION_SYNDROME	1422	60	-0.849	-0.276	0.658	0.725
REACTOME_BUDDING_AND_MATURATION_OF_HIV_VIRION	1423	24	-0.849	-0.368	0.658	0.725
SCHLINGEMANN_SKIN_CARCINOGENESIS_TPA_UP	1424	32	-0.85	-0.299	0.656	0.723
REACTOME_CARGO_CONCENTRATION_IN_THE_ER	1425	32	-0.85	-0.293	0.656	0.723
JIANG_AGING_HYPOTHALAMUS_DN	1426	33	-0.851	-0.324	0.655	0.722
REACTOME_SYNTHESIS_OF_ACTIVE_UBIQUITIN_ROLES_OF_E1_AND_E2_ENZYMES	1427	26	-0.852	-0.393	0.654	0.722
WALLACE_PROSTATE_CANCER_RACE_DN	1428	66	-0.852	-0.257	0.654	0.722
REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIRED_FOR_GAG_SYNTHESIS	1429	22	-0.853	-0.286	0.653	0.722
REACTOME_ER_QUALITY_CONTROL_COMPARTMENT_ERQC	1430	18	-0.853	-0.388	0.653	0.722
REACTOME_ASPIRIN_ADME	1431	29	-0.853	-0.321	0.653	0.722
KANG_GLIS3_TARGETS	1432	34	-0.853	-0.292	0.652	0.721
REACTOME_TRANSCRIPTIONAL_REGULATION_BY_E2F6	1433	34	-0.854	-0.303	0.652	0.721
REACTOME_HEDGEHOG_OFF_STATE	1434	99	-0.854	-0.277	0.651	0.721
MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP	1435	179	-0.854	-0.24	0.651	0.721
REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS	1436	78	-0.856	-0.224	0.650	0.719
STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_DN	1437	38	-0.856	-0.279	0.650	0.719
TSENG_IRS1_TARGETS_UP	1438	93	-0.856	-0.24	0.649	0.719
CHANGOLKAR_H2AFY_TARGETS_DN	1439	32	-0.857	-0.234	0.648	0.718
KAMMINGA_EZH2_TARGETS	1440	39	-0.858	-0.355	0.647	0.717
REN_ALVEOLAR_RHABDOMYOSARCOMA_UP	1441	90	-0.858	-0.243	0.647	0.717
REACTOME_ASPARAGINE_N_LINKED_GLYCOSYLATION	1442	264	-0.859	-0.258	0.645	0.715
REACTOME_SIGNALING_BY_FGFR_IN_DISEASE	1443	58	-0.86	-0.259	0.645	0.715
WP_STATIN_INHIBITION_OF_CHOLESTEROL_PRODUCTION	1444	28	-0.861	-0.278	0.644	0.714
LANDIS_ERBB2_BREAST_PRENEOPLASTIC_DN	1445	53	-0.861	-0.272	0.644	0.714
SETLUR_PROSTATE_CANCER_TMPRSS2_ERG_FUSION_DN	1446	20	-0.861	-0.312	0.643	0.714
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_12	1447	72	-0.861	-0.278	0.643	0.714
GRYDER_PAX3FOXO1_TOP_ENHANCERS	1448	363	-0.861	-0.263	0.643	0.714
REACTOME_FCGR_ACTIVATION	1449	18	-0.862	-0.307	0.643	0.714
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION	1450	339	-0.863	-0.258	0.641	0.713
REACTOME_SYNTHESIS_OF_PC	1451	26	-0.863	-0.285	0.641	0.712
REACTOME_PI_3K_CASCADE_FGFR1	1452	21	-0.863	-0.282	0.641	0.712
REACTOME_BIOSYNTHESIS_OF_SPECIALIZED_PRORESOLVING_MEDIATORS_SPMS	1453	18	-0.863	-0.291	0.641	0.712
KEGG_CITRATE_CYCLE_TCA_CYCLE	1454	30	-0.864	-0.345	0.640	0.712
PID_TELOMERASE_PATHWAY	1455	64	-0.864	-0.298	0.639	0.712
PID_MTOR_4PATHWAY	1456	61	-0.867	-0.339	0.636	0.708
OHGUCHI_LIVER_HNF4A_TARGETS_DN	1457	136	-0.867	-0.256	0.636	0.708
MCMURRAY_TP53_HRAS_COOPERATION_RESPONSE_DN	1458	62	-0.867	-0.21	0.636	0.708
GALLUZZI_PERMEABILIZE_MITOCHONDRIA	1459	39	-0.867	-0.314	0.636	0.708
WP_ENDOPLASMIC_RETICULUM_STRESS_RESPONSE_IN_CORONAVIRUS_INFECTION	1460	45	-0.867	-0.26	0.636	0.708
REACTOME_SEPARATION_OF_SISTER_CHROMATIDS	1461	153	-0.868	-0.324	0.635	0.708
YAMASHITA_LIVER_CANCER_STEM_CELL_DN	1462	75	-0.869	-0.235	0.634	0.708
HECKER_IFNB1_TARGETS	1463	85	-0.869	-0.247	0.634	0.707
SYED_ESTRADIOL_RESPONSE	1464	17	-0.869	-0.322	0.634	0.707
REACTOME_ACYL_CHAIN_REMODELLING_OF_PC	1465	21	-0.869	-0.314	0.633	0.707
WP_NUCLEAR_RECEPTORS	1466	38	-0.87	-0.265	0.633	0.707
BIOCARTA_SHH_PATHWAY	1467	16	-0.87	-0.301	0.633	0.707
WP_EXTRAFOLLICULAR_B_CELL_ACTIVATION_BY_SARSCOV2	1468	65	-0.87	-0.286	0.633	0.707
JIANG_HYPOXIA_CANCER	1469	48	-0.871	-0.315	0.631	0.706
MAHADEVAN_IMATINIB_RESISTANCE_DN	1470	17	-0.872	-0.356	0.630	0.705
ZHAN_MULTIPLE_MYELOMA_DN	1471	40	-0.872	-0.261	0.630	0.705
ANDERSEN_LIVER_CANCER_KRT19_DN	1472	71	-0.872	-0.259	0.630	0.705
ZHAN_V2_LATE_DIFFERENTIATION_GENES	1473	38	-0.872	-0.311	0.630	0.705
CAIRO_HEPATOBLASTOMA_UP	1474	177	-0.872	-0.303	0.630	0.705
GENTILE_UV_RESPONSE_CLUSTER_D5	1475	28	-0.872	-0.342	0.630	0.705
BOYAULT_LIVER_CANCER_SUBCLASS_G3_DN	1476	47	-0.873	-0.251	0.629	0.705
REACTOME_INSULIN_RECEPTOR_RECYCLING	1477	24	-0.873	-0.276	0.629	0.705
DESERT_STEM_CELL_HEPATOCELLULAR_CARCINOMA_SUBCLASS_UP	1478	204	-0.874	-0.288	0.628	0.704
NAKAMURA_ADIPOGENESIS_EARLY_DN	1479	34	-0.875	-0.315	0.627	0.703
REACTOME_CYTOPROTECTION_BY_HMOX1	1480	53	-0.875	-0.301	0.627	0.703
ROESSLER_LIVER_CANCER_METASTASIS_DN	1481	41	-0.875	-0.291	0.627	0.703
WP_VITAMIN_A_AND_CAROTENOID_METABOLISM	1482	39	-0.875	-0.252	0.626	0.703
PARK_HSC_VS_MULTIPOTENT_PROGENITORS_UP	1483	16	-0.876	-0.363	0.626	0.703
REACTOME_HDACS_DEACETYLATE_HISTONES	1484	31	-0.876	-0.318	0.625	0.703
VANDESLUIS_NORMAL_EMBRYOS_DN	1485	20	-0.876	-0.28	0.625	0.703
HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	1486	44	-0.876	-0.329	0.625	0.703
REACTOME_CLEC7A_DECTIN_1_SIGNALING	1487	93	-0.876	-0.317	0.625	0.703
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_UP	1488	80	-0.877	-0.275	0.624	0.702
WP_MICROGLIA_PATHOGEN_PHAGOCYTOSIS_PATHWAY	1489	39	-0.877	-0.265	0.624	0.702
HOLLEMAN_VINCRISTINE_RESISTANCE_B_ALL_DN	1490	15	-0.877	-0.408	0.624	0.702
ENK_UV_RESPONSE_KERATINOCYTE_DN	1491	418	-0.877	-0.333	0.624	0.702
HOEBEKE_LYMPHOID_STEM_CELL_DN	1492	82	-0.877	-0.299	0.624	0.702
REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX2	1493	114	-0.878	-0.302	0.623	0.702
TAKAO_RESPONSE_TO_UVB_RADIATION_DN	1494	85	-0.879	-0.325	0.622	0.701
SUMI_HNF4A_TARGETS	1495	23	-0.879	-0.335	0.621	0.701
REACTOME_SUMOYLATION	1496	161	-0.879	-0.258	0.621	0.700
BUCKANOVICH_T_LYMPHOCYTE_HOMING_ON_TUMOR_DN	1497	19	-0.88	-0.269	0.620	0.700
REACTOME_SMAD2_SMAD3_SMAD4_HETEROTRIMER_REGULATES_TRANSCRIPTION	1498	35	-0.881	-0.344	0.620	0.699
WOO_LIVER_CANCER_RECURRENCE_DN	1499	73	-0.881	-0.228	0.619	0.699
REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT	1500	235	-0.881	-0.235	0.619	0.699
MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_DN	1501	23	-0.881	-0.328	0.619	0.699
RODWELL_AGING_KIDNEY_NO_BLOOD_DN	1502	119	-0.882	-0.24	0.618	0.698
CAMPS_COLON_CANCER_COPY_NUMBER_UP	1503	72	-0.883	-0.224	0.617	0.698
BIOCARTA_STATHMIN_PATHWAY	1504	19	-0.883	-0.261	0.617	0.697
RHODES_UNDIFFERENTIATED_CANCER	1505	62	-0.884	-0.352	0.616	0.697
BRACHAT_RESPONSE_TO_METHOTREXATE_DN	1506	23	-0.884	-0.313	0.616	0.697
WP_GPCRS_OTHER	1507	72	-0.885	-0.296	0.615	0.696
TIEN_INTESTINE_PROBIOTICS_24HR_DN	1508	184	-0.885	-0.321	0.615	0.696
NADLER_OBESITY_DN	1509	48	-0.885	-0.262	0.614	0.696
PID_WNT_SIGNALING_PATHWAY	1510	27	-0.885	-0.28	0.614	0.696
BOYAULT_LIVER_CANCER_SUBCLASS_G23_UP	1511	42	-0.886	-0.34	0.614	0.695
FERRANDO_HOX11_NEIGHBORS	1512	23	-0.886	-0.265	0.613	0.695
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR	1513	68	-0.887	-0.302	0.612	0.694
WP_MTHFR_DEFICIENCY	1514	22	-0.887	-0.258	0.612	0.694
REACTOME_POTENTIAL_THERAPEUTICS_FOR_SARS	1515	101	-0.889	-0.246	0.610	0.692
REACTOME_XENOBIOTICS	1516	22	-0.889	-0.345	0.610	0.692
REACTOME_MITOCHONDRIAL_BIOGENESIS	1517	63	-0.889	-0.268	0.610	0.692
PUIFFE_INVASION_INHIBITED_BY_ASCITES_UP	1518	67	-0.889	-0.292	0.609	0.692
KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM	1519	31	-0.889	-0.25	0.609	0.692
LEE_RECENT_THYMIC_EMIGRANT	1520	183	-0.89	-0.259	0.608	0.691
IWANAGA_E2F1_TARGETS_INDUCED_BY_SERUM	1521	18	-0.892	-0.339	0.606	0.689
PACHER_TARGETS_OF_IGF1_AND_IGF2_UP	1522	32	-0.892	-0.313	0.606	0.689
PID_TCR_CALCIUM_PATHWAY	1523	24	-0.893	-0.244	0.605	0.689
JIANG_VHL_TARGETS	1524	68	-0.893	-0.315	0.605	0.688
LIN_TUMOR_ESCAPE_FROM_IMMUNE_ATTACK	1525	15	-0.894	-0.301	0.604	0.688
LI_WILMS_TUMOR	1526	24	-0.894	-0.306	0.604	0.688
ZHAN_MULTIPLE_MYELOMA_CD1_UP	1527	43	-0.895	-0.282	0.603	0.687
WP_DYRK1A	1528	52	-0.895	-0.274	0.603	0.687
REACTOME_SENESCENCE_ASSOCIATED_SECRETORY_PHENOTYPE_SASP	1529	49	-0.895	-0.341	0.603	0.687
REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT	1530	27	-0.895	-0.378	0.602	0.686
GYORFFY_DOXORUBICIN_RESISTANCE	1531	30	-0.896	-0.255	0.601	0.686
ROSS_AML_OF_FAB_M7_TYPE	1532	64	-0.896	-0.257	0.601	0.686
REACTOME_COBALAMIN_CBL_VITAMIN_B12_TRANSPORT_AND_METABOLISM	1533	19	-0.896	-0.28	0.601	0.686
HAHTOLA_CTCL_PATHOGENESIS	1534	15	-0.896	-0.372	0.601	0.686
EINAV_INTERFERON_SIGNATURE_IN_CANCER	1535	24	-0.897	-0.306	0.601	0.686
OKAWA_NEUROBLASTOMA_1P36_31_DELETION	1536	21	-0.897	-0.327	0.600	0.685
PID_RB_1PATHWAY	1537	65	-0.898	-0.284	0.599	0.684
HORIUCHI_WTAP_TARGETS_DN	1538	258	-0.898	-0.294	0.599	0.684
REACTOME_GABA_RECEPTOR_ACTIVATION	1539	60	-0.898	-0.252	0.599	0.684
MARKEY_RB1_ACUTE_LOF_UP	1540	199	-0.899	-0.299	0.598	0.684
REACTOME_HS_GAG_BIOSYNTHESIS	1541	30	-0.899	-0.285	0.598	0.684
MISIAK_ANAPLASTIC_THYROID_CARCINOMA_UP	1542	41	-0.899	-0.263	0.597	0.684
REACTOME_SENSORY_PERCEPTION_OF_TASTE	1543	37	-0.899	-0.319	0.597	0.684
REACTOME_APOPTOSIS	1544	163	-0.9	-0.303	0.596	0.683
KIM_WT1_TARGETS_12HR_DN	1545	176	-0.901	-0.297	0.596	0.683
HOLLMANN_APOPTOSIS_VIA_CD40_UP	1546	169	-0.901	-0.251	0.596	0.682
STONER_ESOPHAGEAL_CARCINOGENESIS_UP	1547	29	-0.901	-0.348	0.595	0.682
WEI_MIR34A_TARGETS	1548	121	-0.902	-0.269	0.595	0.682
MA_MYELOID_DIFFERENTIATION_UP	1549	37	-0.902	-0.311	0.594	0.682
KAAB_FAILED_HEART_ATRIUM_UP	1550	29	-0.902	-0.266	0.594	0.681
KAYO_AGING_MUSCLE_DN	1551	108	-0.903	-0.289	0.593	0.681
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP	1552	104	-0.904	-0.31	0.592	0.680
BIOCARTA_BARRESTIN_SRC_PATHWAY	1553	16	-0.904	-0.302	0.591	0.679
HEDENFALK_BREAST_CANCER_BRACX_DN	1554	17	-0.905	-0.374	0.591	0.678
KEGG_ABC_TRANSPORTERS	1555	44	-0.905	-0.258	0.590	0.678
HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_4HR	1556	31	-0.905	-0.289	0.590	0.678
MORI_SMALL_PRE_BII_LYMPHOCYTE_UP	1557	69	-0.906	-0.23	0.590	0.678
KEGG_STEROID_HORMONE_BIOSYNTHESIS	1558	46	-0.907	-0.294	0.589	0.677
XU_GH1_EXOGENOUS_TARGETS_DN	1559	88	-0.907	-0.209	0.589	0.677
XU_GH1_EXOGENOUS_TARGETS_UP	1560	44	-0.908	-0.328	0.587	0.676
REACTOME_CYCLIN_D_ASSOCIATED_EVENTS_IN_G1	1561	46	-0.908	-0.316	0.587	0.676
REACTOME_COPII_MEDIATED_VESICLE_TRANSPORT	1562	59	-0.908	-0.338	0.587	0.676
WALLACE_JAK2_TARGETS_UP	1563	18	-0.908	-0.34	0.587	0.676
CHICAS_RB1_TARGETS_LOW_SERUM	1564	70	-0.909	-0.294	0.586	0.676
WANG_NFKB_TARGETS	1565	23	-0.909	-0.331	0.586	0.676
REACTOME_ACTIVATION_OF_ANTERIOR_HOX_GENES_IN_HINDBRAIN_DEVELOPMENT_DURING_EARLY_EMBRYOGENESIS	1566	56	-0.909	-0.258	0.586	0.675
LI_LUNG_CANCER	1567	41	-0.91	-0.315	0.585	0.675
PID_CD8_TCR_DOWNSTREAM_PATHWAY	1568	64	-0.91	-0.246	0.584	0.674
PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN	1569	35	-0.911	-0.279	0.584	0.674
PID_AR_TF_PATHWAY	1570	46	-0.911	-0.251	0.584	0.674
WP_ALLOGRAFT_REJECTION	1571	81	-0.913	-0.284	0.581	0.671
GUO_HEX_TARGETS_DN	1572	56	-0.915	-0.25	0.579	0.669
REACTOME_SIGNALING_BY_NOTCH	1573	161	-0.915	-0.295	0.578	0.669
WP_NICOTINE_EFFECT_ON_DOPAMINERGIC_NEURONS	1574	21	-0.917	-0.313	0.576	0.666
DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP	1575	275	-0.918	-0.221	0.575	0.665
LEE_LIVER_CANCER_MYC_UP	1576	49	-0.918	-0.3	0.575	0.665
WP_GDNFRET_SIGNALING_AXIS	1577	21	-0.919	-0.29	0.574	0.665
REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS	1578	53	-0.921	-0.264	0.572	0.662
MARIADASON_REGULATED_BY_HISTONE_ACETYLATION_DN	1579	33	-0.921	-0.315	0.571	0.661
STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN	1580	51	-0.922	-0.235	0.570	0.661
LINDGREN_BLADDER_CANCER_CLUSTER_1_UP	1581	97	-0.922	-0.324	0.570	0.661
REACTOME_PLATELET_HOMEOSTASIS	1582	79	-0.923	-0.245	0.570	0.660
REACTOME_FRS_MEDIATED_FGFR2_SIGNALING	1583	25	-0.923	-0.287	0.569	0.659
MEBARKI_HCC_PROGENITOR_WNT_DN_CTNNB1_DEPENDENT	1584	23	-0.923	-0.362	0.569	0.659
GAVIN_FOXP3_TARGETS_CLUSTER_T4	1585	74	-0.924	-0.276	0.568	0.659
WANG_CLIM2_TARGETS_DN	1586	143	-0.924	-0.315	0.568	0.659
INGA_TP53_TARGETS	1587	16	-0.924	-0.386	0.568	0.659
MITSIADES_RESPONSE_TO_APLIDIN_DN	1588	208	-0.924	-0.333	0.567	0.659
NAKAMURA_CANCER_MICROENVIRONMENT_DN	1589	36	-0.925	-0.368	0.567	0.659
ZAMORA_NOS2_TARGETS_DN	1590	76	-0.925	-0.288	0.567	0.659
BIOCARTA_CSK_PATHWAY	1591	20	-0.925	-0.318	0.567	0.659
WP_TARGET_OF_RAPAMYCIN_SIGNALING	1592	32	-0.925	-0.365	0.567	0.659
GERHOLD_ADIPOGENESIS_UP	1593	46	-0.926	-0.272	0.566	0.659
MANNE_COVID19_COMBINED_COHORT_VS_HEALTHY_DONOR_PLATELETS_UP	1594	133	-0.926	-0.263	0.566	0.658
LINDGREN_BLADDER_CANCER_CLUSTER_3_UP	1595	261	-0.929	-0.292	0.562	0.655
REACTOME_PHASE_4_RESTING_MEMBRANE_POTENTIAL	1596	18	-0.929	-0.357	0.562	0.655
REACTOME_CA_DEPENDENT_EVENTS	1597	36	-0.93	-0.245	0.561	0.653
KEGG_MTOR_SIGNALING_PATHWAY	1598	45	-0.93	-0.319	0.561	0.653
HUANG_GATA2_TARGETS_DN	1599	60	-0.931	-0.305	0.560	0.653
REACTOME_COMPLEMENT_CASCADE	1600	60	-0.931	-0.322	0.560	0.653
MATZUK_SPERMATOGONIA	1601	24	-0.931	-0.3	0.560	0.653
ZHONG_SECRETOME_OF_LUNG_CANCER_AND_MACROPHAGE	1602	70	-0.931	-0.316	0.560	0.653
REACTOME_TRANS_GOLGI_NETWORK_VESICLE_BUDDING	1603	65	-0.932	-0.33	0.558	0.652
MEBARKI_HCC_PROGENITOR_WNT_DN_CTNNB1_DEPENDENT_BLOCKED_BY_FZD8CRD	1604	15	-0.934	-0.413	0.556	0.650
PID_ERA_GENOMIC_PATHWAY	1605	61	-0.934	-0.275	0.556	0.649
PID_HEDGEHOG_2PATHWAY	1606	21	-0.934	-0.279	0.556	0.649
MANNE_COVID19_ICU_VS_HEALTHY_DONOR_PLATELETS_DN	1607	115	-0.935	-0.23	0.555	0.649
REACTOME_ARACHIDONIC_ACID_METABOLISM	1608	50	-0.935	-0.256	0.555	0.649
DUNNE_TARGETS_OF_AML1_MTG8_FUSION_UP	1609	49	-0.935	-0.27	0.555	0.649
SMID_BREAST_CANCER_NORMAL_LIKE_UP	1610	414	-0.937	-0.252	0.553	0.647
REACTOME_NEUREXINS_AND_NEUROLIGINS	1611	52	-0.937	-0.281	0.553	0.647
PYEON_HPV_POSITIVE_TUMORS_UP	1612	65	-0.937	-0.299	0.553	0.647
LANG_MYB_FAMILY_TARGETS	1613	28	-0.938	-0.336	0.551	0.645
BENITEZ_GBM_PROTEASOME_INHIBITION_RESPONSE	1614	40	-0.938	-0.367	0.551	0.645
REACTOME_MITOTIC_G2_G2_M_PHASES	1615	159	-0.939	-0.32	0.551	0.645
WP_7OXOC_AND_7BETAHC_PATHWAYS	1616	25	-0.939	-0.293	0.550	0.645
REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS	1617	46	-0.939	-0.265	0.550	0.645
HALLMARK_PROTEIN_SECRETION	1618	88	-0.941	-0.38	0.548	0.642
REACTOME_REGULATION_OF_PTEN_GENE_TRANSCRIPTION	1619	49	-0.941	-0.324	0.547	0.642
WP_INTERACTIONS_BETWEEN_LOXL4_AND_OXIDATIVE_STRESS_PATHWAY	1620	18	-0.942	-0.342	0.546	0.641
KYNG_WERNER_SYNDROM_AND_NORMAL_AGING_DN	1621	153	-0.942	-0.268	0.546	0.641
RUAN_RESPONSE_TO_TNF_TROGLITAZONE_UP	1622	17	-0.943	-0.334	0.546	0.641
REACTOME_ADORA2B_MEDIATED_ANTI_INFLAMMATORY_CYTOKINES_PRODUCTION	1623	127	-0.943	-0.275	0.546	0.641
WEST_ADRENOCORTICAL_TUMOR_UP	1624	250	-0.943	-0.334	0.545	0.641
WP_GABA_RECEPTOR_SIGNALING	1625	31	-0.944	-0.287	0.545	0.641
WHITE_NEUROBLASTOMA_WITH_1P36.3_DELETION	1626	19	-0.944	-0.354	0.544	0.640
YANG_BREAST_CANCER_ESR1_LASER_UP	1627	25	-0.944	-0.298	0.544	0.640
REACTOME_RESPONSE_OF_MTB_TO_PHAGOCYTOSIS	1628	20	-0.945	-0.379	0.543	0.639
KLEIN_TARGETS_OF_BCR_ABL1_FUSION	1629	45	-0.945	-0.29	0.543	0.639
AMIT_EGF_RESPONSE_40_MCF10A	1630	15	-0.946	-0.386	0.542	0.639
MARTINEZ_RB1_TARGETS_DN	1631	462	-0.946	-0.234	0.542	0.639
MILI_PSEUDOPODIA_CHEMOTAXIS_UP	1632	58	-0.946	-0.353	0.542	0.639
MEISSNER_NPC_ICP_WITH_H3_UNMETHYLATED	1633	16	-0.947	-0.375	0.541	0.638
PARK_HSC_MARKERS	1634	40	-0.947	-0.333	0.541	0.638
HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN	1635	33	-0.947	-0.279	0.540	0.637
WANG_ADIPOGENIC_GENES_REPRESSED_BY_SIRT1	1636	26	-0.948	-0.3	0.539	0.637
REACTOME_PLATELET_SENSITIZATION_BY_LDL	1637	17	-0.948	-0.352	0.539	0.636
HOLLERN_MICROACINAR_BREAST_TUMOR_UP	1638	39	-0.949	-0.263	0.539	0.636
REACTOME_METABOLISM_OF_ANGIOTENSINOGEN_TO_ANGIOTENSINS	1639	17	-0.949	-0.353	0.539	0.636
LY_AGING_OLD_DN	1640	50	-0.95	-0.379	0.537	0.635
CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN	1641	90	-0.95	-0.332	0.537	0.634
ZHOU_TNF_SIGNALING_4HR	1642	43	-0.951	-0.346	0.536	0.634
MODY_HIPPOCAMPUS_POSTNATAL	1643	54	-0.951	-0.268	0.536	0.634
KEGG_P53_SIGNALING_PATHWAY	1644	63	-0.952	-0.325	0.535	0.633
REACTOME_SENSORY_PERCEPTION	1645	282	-0.952	-0.28	0.535	0.633
BARRIER_COLON_CANCER_RECURRENCE_DN	1646	16	-0.954	-0.385	0.532	0.630
BIOCARTA_MTA3_PATHWAY	1647	15	-0.954	-0.349	0.532	0.630
AIYAR_COBRA1_TARGETS_DN	1648	25	-0.955	-0.35	0.531	0.630
MODY_HIPPOCAMPUS_NEONATAL	1649	28	-0.957	-0.305	0.528	0.626
FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_UP	1650	129	-0.958	-0.29	0.528	0.626
CHANGOLKAR_H2AFY_TARGETS_UP	1651	40	-0.958	-0.303	0.527	0.625
REACTOME_PLASMA_LIPOPROTEIN_REMODELING	1652	29	-0.958	-0.327	0.527	0.625
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP	1653	323	-0.959	-0.243	0.527	0.625
TOOKER_GEMCITABINE_RESISTANCE_DN	1654	108	-0.959	-0.373	0.527	0.625
WANG_RECURRENT_LIVER_CANCER_UP	1655	17	-0.959	-0.413	0.526	0.625
VANTVEER_BREAST_CANCER_METASTASIS_UP	1656	37	-0.959	-0.269	0.526	0.625
LIU_COMMON_CANCER_GENES	1657	50	-0.959	-0.344	0.526	0.625
REACTOME_LATE_ENDOSOMAL_MICROAUTOPHAGY	1658	29	-0.96	-0.344	0.525	0.624
REACTOME_GABA_SYNTHESIS_RELEASE_REUPTAKE_AND_DEGRADATION	1659	19	-0.96	-0.341	0.525	0.624
REACTOME_SIALIC_ACID_METABOLISM	1660	32	-0.96	-0.262	0.525	0.624
WP_TRANSSULFURATION_ONECARBON_METABOLISM_AND_RELATED_PATHWAYS	1661	63	-0.961	-0.224	0.524	0.623
HWANG_PROSTATE_CANCER_MARKERS	1662	25	-0.962	-0.347	0.523	0.623
WP_ATM_SIGNALING_IN_DEVELOPMENT_AND_DISEASE	1663	38	-0.962	-0.335	0.523	0.622
CHIBA_RESPONSE_TO_TSA	1664	37	-0.962	-0.352	0.523	0.622
WP_MITOCHONDRIAL_LONG_CHAIN_FATTY_ACID_BETAOXIDATION	1665	15	-0.963	-0.368	0.522	0.622
ZWANG_EGF_INTERVAL_UP	1666	65	-0.963	-0.251	0.522	0.622
BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_D	1667	215	-0.963	-0.207	0.521	0.621
ABE_INNER_EAR	1668	39	-0.963	-0.334	0.521	0.621
HEIDENBLAD_AMPLICON_12P11_12_UP	1669	31	-0.964	-0.28	0.521	0.621
HUI_MAPK14_TARGETS_UP	1670	19	-0.964	-0.303	0.521	0.621
MATZUK_SPERMATOCYTE	1671	64	-0.965	-0.229	0.520	0.621
WP_PPAR_SIGNALING_PATHWAY	1672	66	-0.965	-0.24	0.519	0.620
BRUINS_UVC_RESPONSE_EARLY_LATE	1673	237	-0.966	-0.261	0.519	0.620
FRIDMAN_IMMORTALIZATION_DN	1674	30	-0.966	-0.382	0.518	0.619
SHAFFER_IRF4_MULTIPLE_MYELOMA_PROGRAM	1675	34	-0.966	-0.346	0.518	0.619
YOSHIMURA_MAPK8_TARGETS_DN	1676	331	-0.967	-0.288	0.518	0.619
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP	1677	116	-0.967	-0.343	0.518	0.619
MANNE_COVID19_ICU_VS_HEALTHY_DONOR_PLATELETS_UP	1678	99	-0.968	-0.268	0.517	0.618
DER_IFN_BETA_RESPONSE_UP	1679	95	-0.968	-0.32	0.516	0.618
BLANCO_MELO_COVID19_SARS_COV_2_POS_PATIENT_LUNG_TISSUE_UP	1680	135	-0.968	-0.329	0.516	0.617
LEIN_MEDULLA_MARKERS	1681	70	-0.968	-0.242	0.516	0.617
REACTOME_SUMOYLATION_OF_TRANSCRIPTION_FACTORS	1682	20	-0.969	-0.362	0.515	0.617
RIZ_ERYTHROID_DIFFERENTIATION_6HR	1683	33	-0.969	-0.278	0.514	0.617
LI_ADIPOGENESIS_BY_ACTIVATED_PPARG	1684	18	-0.97	-0.326	0.513	0.615
MIKKELSEN_MCV6_ICP_WITH_H3K27ME3	1685	61	-0.971	-0.346	0.512	0.614
DORN_ADENOVIRUS_INFECTION_12HR_DN	1686	27	-0.971	-0.376	0.512	0.614
WP_IL5_SIGNALING_PATHWAY	1687	39	-0.972	-0.307	0.512	0.614
CASTELLANO_NRAS_TARGETS_UP	1688	64	-0.972	-0.288	0.512	0.614
BOYLAN_MULTIPLE_MYELOMA_PCA3_DN	1689	56	-0.972	-0.24	0.511	0.614
MASSARWEH_RESPONSE_TO_ESTRADIOL	1690	52	-0.972	-0.306	0.511	0.614
NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON	1691	123	-0.973	-0.263	0.510	0.613
HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_DN	1692	60	-0.974	-0.256	0.509	0.611
GENTILE_UV_RESPONSE_CLUSTER_D7	1693	30	-0.975	-0.425	0.508	0.611
YAGI_AML_WITH_T_9_11_TRANSLOCATION	1694	114	-0.975	-0.266	0.508	0.611
IVANOVSKA_MIR106B_TARGETS	1695	73	-0.976	-0.314	0.507	0.610
SERVITJA_LIVER_HNF1A_TARGETS_DN	1696	149	-0.976	-0.27	0.506	0.610
KEGG_STARCH_AND_SUCROSE_METABOLISM	1697	40	-0.977	-0.256	0.506	0.609
GENTLES_LEUKEMIC_STEM_CELL_DN	1698	15	-0.977	-0.351	0.506	0.609
REACTOME_GLUCAGON_TYPE_LIGAND_RECEPTORS	1699	33	-0.978	-0.333	0.505	0.608
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN	1700	194	-0.978	-0.294	0.504	0.608
KOHOUTEK_CCNT2_TARGETS	1701	43	-0.979	-0.255	0.503	0.607
RIZ_ERYTHROID_DIFFERENTIATION	1702	75	-0.979	-0.292	0.503	0.607
LEE_LIVER_CANCER_ACOX1_DN	1703	62	-0.979	-0.255	0.503	0.606
REACTOME_SARS_COV_1_INFECTION	1704	49	-0.98	-0.339	0.503	0.606
MEBARKI_HCC_PROGENITOR_FZD8CRD_DN	1705	333	-0.981	-0.293	0.501	0.605
MEISSNER_BRAIN_HCP_WITH_H3_UNMETHYLATED	1706	30	-0.981	-0.322	0.501	0.605
SWEET_LUNG_CANCER_KRAS_UP	1707	411	-0.982	-0.274	0.500	0.604
REACTOME_G_ALPHA_S_SIGNALLING_EVENTS	1708	147	-0.982	-0.297	0.500	0.604
PETRETTO_HEART_MASS_QTL_CIS_UP	1709	25	-0.982	-0.321	0.500	0.604
REACTOME_INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC	1710	164	-0.983	-0.313	0.499	0.604
NAKAMURA_ADIPOGENESIS_LATE_UP	1711	85	-0.983	-0.283	0.499	0.604
BROWNE_HCMV_INFECTION_4HR_DN	1712	215	-0.983	-0.246	0.499	0.604
RAMASWAMY_METASTASIS_UP	1713	51	-0.983	-0.323	0.498	0.603
RICKMAN_HEAD_AND_NECK_CANCER_E	1714	74	-0.983	-0.323	0.498	0.603
WP_TYPE_I_COLLAGEN_SYNTHESIS_IN_THE_CONTEXT_OF_OSTEOGENESIS_IMPERFECTA	1715	29	-0.983	-0.335	0.498	0.603
REACTOME_SUMOYLATION_OF_DNA_METHYLATION_PROTEINS	1716	16	-0.983	-0.353	0.498	0.603
RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_DN	1717	27	-0.984	-0.334	0.497	0.603
REACTOME_BETA_CATENIN_INDEPENDENT_WNT_SIGNALING	1718	139	-0.984	-0.303	0.497	0.603
JEPSEN_SMRT_TARGETS	1719	31	-0.985	-0.298	0.496	0.602
GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_DN	1720	85	-0.985	-0.29	0.496	0.602
WP_P38_MAPK_SIGNALING_PATHWAY	1721	34	-0.986	-0.342	0.495	0.601
RODWELL_AGING_KIDNEY_DN	1722	115	-0.986	-0.245	0.495	0.601
DELPUECH_FOXO3_TARGETS_DN	1723	32	-0.986	-0.413	0.495	0.601
TURASHVILI_BREAST_CARCINOMA_DUCTAL_VS_LOBULAR_UP	1724	18	-0.986	-0.382	0.495	0.601
BERENJENO_TRANSFORMED_BY_RHOA_REVERSIBLY_DN	1725	27	-0.987	-0.372	0.494	0.601
DAIRKEE_CANCER_PRONE_RESPONSE_E2	1726	27	-0.987	-0.297	0.494	0.601
MIKKELSEN_MCV6_LCP_WITH_H3K27ME3	1727	19	-0.987	-0.422	0.494	0.601
HAN_JNK_SINGALING_DN	1728	35	-0.987	-0.27	0.494	0.601
REACTOME_PI_3K_CASCADE_FGFR3	1729	18	-0.988	-0.33	0.493	0.601
CHIARETTI_T_ALL_REFRACTORY_TO_THERAPY	1730	24	-0.988	-0.316	0.493	0.600
IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP	1731	140	-0.989	-0.229	0.491	0.598
WP_ALSTROM_SYNDROME	1732	24	-0.99	-0.341	0.491	0.598
DELACROIX_RAR_BOUND_ES	1733	355	-0.99	-0.231	0.491	0.598
REACTOME_ANTIMICROBIAL_PEPTIDES	1734	64	-0.99	-0.339	0.491	0.598
REACTOME_SIGNALING_BY_RETINOIC_ACID	1735	41	-0.99	-0.255	0.490	0.598
HALLMARK_G2M_CHECKPOINT	1736	171	-0.991	-0.338	0.490	0.598
REACTOME_SIGNALING_BY_ALK	1737	27	-0.991	-0.328	0.490	0.598
SIMBULAN_PARP1_TARGETS_UP	1738	29	-0.991	-0.385	0.490	0.598
ODONNELL_METASTASIS_UP	1739	62	-0.991	-0.294	0.490	0.598
GROSS_ELK3_TARGETS_UP	1740	25	-0.991	-0.324	0.490	0.598
HATADA_METHYLATED_IN_LUNG_CANCER_DN	1741	24	-0.992	-0.36	0.488	0.597
IVANOVA_HEMATOPOIESIS_STEM_CELL_AND_PROGENITOR	1742	425	-0.993	-0.213	0.488	0.596
EPPERT_CE_HSC_LSC	1743	35	-0.993	-0.274	0.488	0.596
WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_UP	1744	93	-0.993	-0.342	0.487	0.596
WINTER_HYPOXIA_UP	1745	79	-0.993	-0.383	0.487	0.596
WP_22Q112_COPY_NUMBER_VARIATION_SYNDROME	1746	96	-0.993	-0.287	0.487	0.596
BIOCARTA_CHREBP_PATHWAY	1747	19	-0.993	-0.32	0.487	0.596
SWEET_KRAS_ONCOGENIC_SIGNATURE	1748	79	-0.993	-0.324	0.487	0.596
RUIZ_TNC_TARGETS_DN	1749	122	-0.994	-0.325	0.486	0.596
NUTT_GBM_VS_AO_GLIOMA_UP	1750	45	-0.994	-0.352	0.486	0.596
PID_RHODOPSIN_PATHWAY	1751	23	-0.994	-0.376	0.486	0.596
KEGG_PROXIMAL_TUBULE_BICARBONATE_RECLAMATION	1752	23	-0.994	-0.29	0.486	0.596
REACTOME_METABOLISM_OF_FAT_SOLUBLE_VITAMINS	1753	44	-0.994	-0.289	0.486	0.596
REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES	1754	49	-0.994	-0.356	0.486	0.596
REACTOME_NEURONAL_SYSTEM	1755	387	-0.994	-0.265	0.486	0.596
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2	1756	262	-0.995	-0.195	0.485	0.595
REACTOME_CASPASE_ACTIVATION_VIA_DEATH_RECEPTORS_IN_THE_PRESENCE_OF_LIGAND	1757	16	-0.996	-0.349	0.484	0.595
KEGG_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS	1758	49	-0.996	-0.278	0.484	0.595
SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN	1759	360	-0.996	-0.314	0.483	0.594
SESTO_RESPONSE_TO_UV_C5	1760	44	-0.996	-0.436	0.483	0.594
FAELT_B_CLL_WITH_VH3_21_UP	1761	37	-0.996	-0.35	0.483	0.594
WP_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS	1762	36	-0.996	-0.31	0.483	0.594
TIEN_INTESTINE_PROBIOTICS_6HR_DN	1763	138	-0.997	-0.375	0.482	0.594
PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN	1764	118	-0.998	-0.355	0.482	0.594
CAIRO_LIVER_DEVELOPMENT_UP	1765	140	-0.999	-0.28	0.480	0.591
REACTOME_PROSTACYCLIN_SIGNALLING_THROUGH_PROSTACYCLIN_RECEPTOR	1766	19	-1.0	-0.356	0.480	0.591
REACTOME_VASOPRESSIN_REGULATES_RENAL_WATER_HOMEOSTASIS_VIA_AQUAPORINS	1767	43	-1.0	-0.282	0.479	0.591
KEGG_TRYPTOPHAN_METABOLISM	1768	36	-1.001	-0.274	0.478	0.589
BOGNI_TREATMENT_RELATED_MYELOID_LEUKEMIA_DN	1769	29	-1.002	-0.344	0.477	0.589
REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY	1770	50	-1.002	-0.291	0.477	0.589
REACTOME_PARACETAMOL_ADME	1771	24	-1.002	-0.318	0.477	0.589
MISSIAGLIA_REGULATED_BY_METHYLATION_DN	1772	101	-1.002	-0.345	0.476	0.589
REACTOME_FC_EPSILON_RECEPTOR_FCERI_SIGNALING	1773	130	-1.003	-0.324	0.476	0.588
ZHAN_MULTIPLE_MYELOMA_HP_DN	1774	38	-1.003	-0.314	0.476	0.588
REACTOME_TNFS_BIND_THEIR_PHYSIOLOGICAL_RECEPTORS	1775	27	-1.004	-0.38	0.474	0.586
HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN	1776	63	-1.004	-0.247	0.474	0.586
REACTOME_BIOLOGICAL_OXIDATIONS	1777	182	-1.005	-0.226	0.473	0.586
KLEIN_PRIMARY_EFFUSION_LYMPHOMA_DN	1778	49	-1.006	-0.255	0.473	0.585
WP_LNCRNA_IN_CANONICAL_WNT_SIGNALING_AND_COLORECTAL_CANCER	1779	88	-1.006	-0.256	0.472	0.585
HAMAI_APOPTOSIS_VIA_TRAIL_DN	1780	171	-1.006	-0.284	0.472	0.585
WP_JOUBERT_SYNDROME	1781	55	-1.007	-0.286	0.472	0.585
WP_NOCGMPPKG_MEDIATED_NEUROPROTECTION	1782	42	-1.007	-0.301	0.472	0.585
SMITH_LIVER_CANCER	1783	42	-1.007	-0.346	0.471	0.584
REACTOME_RA_BIOSYNTHESIS_PATHWAY	1784	20	-1.008	-0.299	0.471	0.584
REACTOME_G_ALPHA_I_SIGNALLING_EVENTS	1785	273	-1.009	-0.268	0.469	0.582
BIOCARTA_ATM_PATHWAY	1786	19	-1.01	-0.431	0.468	0.581
WP_LIPID_METABOLISM_PATHWAY	1787	27	-1.01	-0.337	0.468	0.581
ENK_UV_RESPONSE_KERATINOCYTE_UP	1788	482	-1.01	-0.314	0.468	0.581
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_DN	1789	15	-1.012	-0.33	0.466	0.579
VILLANUEVA_LIVER_CANCER_KRT19_UP	1790	137	-1.012	-0.309	0.465	0.578
GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_UP	1791	165	-1.013	-0.322	0.465	0.578
BROWNE_HCMV_INFECTION_20HR_UP	1792	200	-1.013	-0.252	0.464	0.578
PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_UP	1793	243	-1.014	-0.308	0.464	0.577
REACTOME_PEPTIDE_HORMONE_METABOLISM	1794	79	-1.014	-0.255	0.464	0.577
WANG_LMO4_TARGETS_UP	1795	279	-1.014	-0.326	0.463	0.577
HANN_RESISTANCE_TO_BCL2_INHIBITOR_UP	1796	32	-1.014	-0.363	0.463	0.577
QI_PLASMACYTOMA_DN	1797	87	-1.014	-0.31	0.463	0.577
MULLIGHAN_MLL_SIGNATURE_2_DN	1798	237	-1.015	-0.257	0.462	0.576
REACTOME_NEGATIVE_REGULATION_OF_NMDA_RECEPTOR_MEDIATED_NEURONAL_TRANSMISSION	1799	21	-1.016	-0.359	0.461	0.575
REACTOME_CD28_DEPENDENT_PI3K_AKT_SIGNALING	1800	20	-1.016	-0.331	0.461	0.575
CARD_MIR302A_TARGETS	1801	70	-1.016	-0.288	0.461	0.575
REACTOME_INLB_MEDIATED_ENTRY_OF_LISTERIA_MONOCYTOGENES_INTO_HOST_CELL	1802	15	-1.016	-0.417	0.461	0.575
BROWNE_HCMV_INFECTION_12HR_UP	1803	91	-1.016	-0.261	0.461	0.575
REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_7ALPHA_HYDROXYCHOLESTEROL	1804	24	-1.017	-0.357	0.460	0.575
REACTOME_TRANSPORT_OF_INORGANIC_CATIONS_ANIONS_AND_AMINO_ACIDS_OLIGOPEPTIDES	1805	101	-1.017	-0.286	0.460	0.575
REACTOME_SYNTHESIS_OF_LEUKOTRIENES_LT_AND_EOXINS_EX	1806	17	-1.018	-0.399	0.459	0.574
FLORIO_NEOCORTEX_BASAL_RADIAL_GLIA_UP	1807	259	-1.018	-0.286	0.459	0.574
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN	1808	79	-1.018	-0.34	0.459	0.574
NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_UP	1809	226	-1.018	-0.348	0.459	0.574
LEE_LIVER_CANCER_CIPROFIBRATE_DN	1810	63	-1.018	-0.288	0.459	0.574
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP	1811	483	-1.018	-0.364	0.459	0.574
WHITEFORD_PEDIATRIC_CANCER_MARKERS	1812	101	-1.018	-0.333	0.459	0.574
SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A5	1813	51	-1.019	-0.301	0.458	0.573
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_DN	1814	15	-1.02	-0.391	0.457	0.573
WP_NCRNAS_INVOLVED_IN_WNT_SIGNALING_IN_HEPATOCELLULAR_CARCINOMA	1815	82	-1.02	-0.261	0.457	0.573
KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT	1816	34	-1.02	-0.361	0.456	0.572
MARTORIATI_MDM4_TARGETS_FETAL_LIVER_DN	1817	436	-1.02	-0.3	0.456	0.572
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS	1818	121	-1.021	-0.369	0.456	0.572
WEIGEL_OXIDATIVE_STRESS_BY_HNE_AND_H2O2	1819	35	-1.021	-0.344	0.456	0.572
GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP	1820	152	-1.021	-0.244	0.456	0.572
CEBALLOS_TARGETS_OF_TP53_AND_MYC_DN	1821	29	-1.021	-0.359	0.455	0.572
BURTON_ADIPOGENESIS_PEAK_AT_24HR	1822	36	-1.021	-0.332	0.455	0.572
HOWLIN_PUBERTAL_MAMMARY_GLAND	1823	60	-1.021	-0.248	0.455	0.572
REACTOME_AUTOPHAGY	1824	112	-1.021	-0.344	0.455	0.572
OSMAN_BLADDER_CANCER_UP	1825	329	-1.022	-0.351	0.455	0.572
BIOCARTA_LIS1_PATHWAY	1826	17	-1.022	-0.337	0.454	0.572
REACTOME_CELLULAR_SENESCENCE	1827	120	-1.022	-0.34	0.454	0.571
KEGG_THYROID_CANCER	1828	29	-1.023	-0.359	0.453	0.571
RAMASWAMY_METASTASIS_DN	1829	54	-1.024	-0.254	0.452	0.570
BENPORATH_OCT4_TARGETS	1830	240	-1.025	-0.277	0.451	0.569
LI_CISPLATIN_RESISTANCE_UP	1831	20	-1.025	-0.35	0.451	0.569
LIU_LIVER_CANCER	1832	26	-1.025	-0.32	0.451	0.569
WANG_LSD1_TARGETS_DN	1833	36	-1.025	-0.279	0.451	0.569
BARRIER_COLON_CANCER_RECURRENCE_UP	1834	34	-1.025	-0.324	0.451	0.569
REACTOME_UNBLOCKING_OF_NMDA_RECEPTORS_GLUTAMATE_BINDING_AND_ACTIVATION	1835	21	-1.026	-0.373	0.450	0.569
REACTOME_O_LINKED_GLYCOSYLATION	1836	91	-1.026	-0.29	0.450	0.568
CHEN_LIVER_METABOLISM_QTL_CIS	1837	81	-1.026	-0.257	0.450	0.568
ONGUSAHA_TP53_TARGETS	1838	35	-1.027	-0.356	0.449	0.568
ACEVEDO_LIVER_CANCER_DN	1839	437	-1.027	-0.253	0.449	0.568
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_SMALL_VS_HUGE_UP	1840	32	-1.027	-0.357	0.449	0.567
REACTOME_TRANSPORT_TO_THE_GOLGI_AND_SUBSEQUENT_MODIFICATION	1841	163	-1.027	-0.317	0.449	0.567
LAIHO_COLORECTAL_CANCER_SERRATED_DN	1842	70	-1.028	-0.361	0.448	0.567
GNATENKO_PLATELET_SIGNATURE	1843	35	-1.028	-0.38	0.448	0.567
KEGG_SPHINGOLIPID_METABOLISM	1844	28	-1.028	-0.371	0.448	0.567
WP_PI3KAKTMTOR_SIGNALING_PATHWAY_AND_THERAPEUTIC_OPPORTUNITIES	1845	24	-1.028	-0.423	0.447	0.567
REACTOME_AFLATOXIN_ACTIVATION_AND_DETOXIFICATION	1846	16	-1.029	-0.358	0.447	0.566
REACTOME_TRANSCRIPTIONAL_ACTIVITY_OF_SMAD2_SMAD3_SMAD4_HETEROTRIMER	1847	49	-1.029	-0.408	0.446	0.566
BIOCARTA_CASPASE_PATHWAY	1848	21	-1.029	-0.322	0.446	0.566
LANDIS_ERBB2_BREAST_TUMORS_65_DN	1849	36	-1.03	-0.313	0.445	0.565
MARTINEZ_RESPONSE_TO_TRABECTEDIN_UP	1850	64	-1.03	-0.377	0.445	0.565
CORONEL_RFX7_DIRECT_TARGETS_UP	1851	36	-1.032	-0.356	0.443	0.563
WP_NAD_METABOLISM	1852	15	-1.032	-0.349	0.443	0.563
BIOCARTA_ERK_PATHWAY	1853	26	-1.033	-0.395	0.442	0.562
BLANCO_MELO_MERS_COV_INFECTION_MCR5_CELLS_UP	1854	197	-1.033	-0.256	0.442	0.562
SATO_SILENCED_EPIGENETICALLY_IN_PANCREATIC_CANCER	1855	39	-1.033	-0.29	0.442	0.562
WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_DN	1856	87	-1.033	-0.362	0.442	0.562
KEGG_DRUG_METABOLISM_OTHER_ENZYMES	1857	40	-1.034	-0.289	0.441	0.561
WP_CCL18_SIGNALING_PATHWAY	1858	30	-1.034	-0.346	0.440	0.561
KEGG_PHENYLALANINE_METABOLISM	1859	17	-1.035	-0.361	0.440	0.560
MARKEY_RB1_CHRONIC_LOF_UP	1860	105	-1.035	-0.262	0.440	0.560
KORKOLA_CORRELATED_WITH_POU5F1	1861	26	-1.036	-0.352	0.439	0.559
REACTOME_SARS_COV_2_ACTIVATES_MODULATES_INNATE_AND_ADAPTIVE_IMMUNE_RESPONSES	1862	107	-1.036	-0.286	0.439	0.559
FOSTER_KDM1A_TARGETS_UP	1863	203	-1.036	-0.259	0.438	0.559
REACTOME_NEF_MEDIATES_DOWN_MODULATION_OF_CELL_SURFACE_RECEPTORS_BY_RECRUITING_THEM_TO_CLATHRIN_ADAPTERS	1864	21	-1.036	-0.366	0.438	0.559
ROPERO_HDAC2_TARGETS	1865	89	-1.036	-0.262	0.438	0.559
REACTOME_GLUTAMATE_NEUROTRANSMITTER_RELEASE_CYCLE	1866	23	-1.037	-0.309	0.438	0.559
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP	1867	70	-1.038	-0.253	0.437	0.558
REACTOME_ACYL_CHAIN_REMODELLING_OF_PS	1868	19	-1.038	-0.337	0.437	0.558
VALK_AML_CLUSTER_6	1869	30	-1.038	-0.288	0.436	0.558
REACTOME_COPI_INDEPENDENT_GOLGI_TO_ER_RETROGRADE_TRAFFIC	1870	41	-1.039	-0.378	0.436	0.557
REACTOME_RORA_ACTIVATES_GENE_EXPRESSION	1871	15	-1.039	-0.402	0.436	0.557
LY_AGING_PREMATURE_DN	1872	27	-1.039	-0.399	0.435	0.556
HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_DN	1873	82	-1.04	-0.402	0.434	0.556
WP_COMPLEMENT_ACTIVATION	1874	21	-1.04	-0.412	0.434	0.556
VERHAAK_GLIOBLASTOMA_NEURAL	1875	112	-1.041	-0.243	0.433	0.555
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINED_IN_MONOCYTE_UP	1876	20	-1.041	-0.323	0.432	0.554
HASLINGER_B_CLL_WITH_11Q23_DELETION	1877	19	-1.042	-0.406	0.432	0.554
REACTOME_INTERLEUKIN_1_FAMILY_SIGNALING	1878	133	-1.042	-0.334	0.432	0.554
MUNSHI_MULTIPLE_MYELOMA_UP	1879	75	-1.043	-0.288	0.431	0.553
HALLMARK_KRAS_SIGNALING_DN	1880	180	-1.043	-0.324	0.430	0.552
WP_NONSMALL_CELL_LUNG_CANCER	1881	70	-1.043	-0.322	0.430	0.552
PID_AR_PATHWAY	1882	50	-1.043	-0.359	0.430	0.552
ZHANG_INTERFERON_RESPONSE	1883	22	-1.044	-0.338	0.430	0.552
VECCHI_GASTRIC_CANCER_EARLY_DN	1884	295	-1.044	-0.25	0.430	0.552
CHEOK_RESPONSE_TO_HD_MTX_DN	1885	19	-1.044	-0.445	0.429	0.552
OUYANG_PROSTATE_CANCER_PROGRESSION_DN	1886	20	-1.044	-0.428	0.429	0.552
CHANDRAN_METASTASIS_UP	1887	155	-1.044	-0.299	0.429	0.552
REACTOME_MITOTIC_SPINDLE_CHECKPOINT	1888	90	-1.045	-0.383	0.429	0.552
REACTOME_EARLY_SARS_COV_2_INFECTION_EVENTS	1889	34	-1.045	-0.321	0.429	0.552
GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN	1890	77	-1.045	-0.253	0.429	0.552
MEISSNER_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3	1891	120	-1.045	-0.309	0.429	0.552
REACTOME_SEROTONIN_NEUROTRANSMITTER_RELEASE_CYCLE	1892	17	-1.046	-0.363	0.428	0.551
REACTOME_CARDIAC_CONDUCTION	1893	123	-1.047	-0.316	0.427	0.550
PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_UP	1894	246	-1.047	-0.247	0.427	0.550
DARWICHE_PAPILLOMA_PROGRESSION_RISK	1895	60	-1.047	-0.258	0.426	0.550
NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON	1896	268	-1.047	-0.24	0.426	0.550
HOLLEMAN_VINCRISTINE_RESISTANCE_B_ALL_UP	1897	35	-1.048	-0.371	0.425	0.549
HAHTOLA_CTCL_CUTANEOUS	1898	23	-1.048	-0.376	0.425	0.549
WP_FERROPTOSIS	1899	60	-1.049	-0.318	0.424	0.548
KEGG_GLUTATHIONE_METABOLISM	1900	45	-1.049	-0.344	0.424	0.548
CHIARETTI_T_ALL_RELAPSE_PROGNOSIS	1901	15	-1.049	-0.41	0.424	0.548
PID_HNF3A_PATHWAY	1902	43	-1.049	-0.281	0.424	0.548
DARWICHE_PAPILLOMA_RISK_HIGH_DN	1903	139	-1.049	-0.248	0.424	0.548
STANELLE_E2F1_TARGETS	1904	26	-1.05	-0.314	0.423	0.547
WP_MAMMALIAN_DISORDER_OF_SEXUAL_DEVELOPMENT	1905	24	-1.05	-0.358	0.423	0.547
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_DN	1906	85	-1.051	-0.283	0.422	0.547
BIOCARTA_P38MAPK_PATHWAY	1907	36	-1.051	-0.366	0.422	0.546
KOYAMA_SEMA3B_TARGETS_DN	1908	277	-1.052	-0.264	0.421	0.546
MACLACHLAN_BRCA1_TARGETS_DN	1909	16	-1.052	-0.413	0.421	0.546
PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP	1910	143	-1.052	-0.334	0.421	0.545
BECKER_TAMOXIFEN_RESISTANCE_UP	1911	51	-1.053	-0.335	0.420	0.544
AMUNDSON_RESPONSE_TO_ARSENITE	1912	183	-1.054	-0.335	0.419	0.544
SESTO_RESPONSE_TO_UV_C3	1913	18	-1.054	-0.481	0.419	0.544
WANG_CISPLATIN_RESPONSE_AND_XPC_UP	1914	159	-1.054	-0.252	0.419	0.544
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR	1915	101	-1.054	-0.358	0.418	0.544
RIZ_ERYTHROID_DIFFERENTIATION_HEMGN	1916	25	-1.055	-0.335	0.418	0.543
FAELT_B_CLL_WITH_VH_REARRANGEMENTS_UP	1917	40	-1.055	-0.354	0.417	0.542
BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_48HR_UP	1918	19	-1.056	-0.351	0.417	0.542
CHEN_ETV5_TARGETS_SERTOLI	1919	23	-1.056	-0.381	0.417	0.542
GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_DN	1920	28	-1.056	-0.284	0.416	0.542
REACTOME_DNA_DAMAGE_TELOMERE_STRESS_INDUCED_SENESCENCE	1921	26	-1.057	-0.418	0.415	0.541
WP_CELL_DIFFERENTIATION_EXPANDED_INDEX	1922	19	-1.058	-0.368	0.415	0.540
NIKOLSKY_OVERCONNECTED_IN_BREAST_CANCER	1923	19	-1.058	-0.304	0.414	0.540
YIH_RESPONSE_TO_ARSENITE_C4	1924	16	-1.058	-0.419	0.414	0.540
WP_TCA_CYCLE_AND_DEFICIENCY_OF_PYRUVATE_DEHYDROGENASE_COMPLEX_PDHC	1925	16	-1.058	-0.465	0.414	0.540
REACTOME_GLUTATHIONE_CONJUGATION	1926	30	-1.058	-0.368	0.414	0.540
IVANOVA_HEMATOPOIESIS_STEM_CELL_SHORT_TERM	1927	15	-1.058	-0.332	0.414	0.540
MATZUK_MEIOTIC_AND_DNA_REPAIR	1928	36	-1.058	-0.277	0.414	0.540
HOFFMANN_IMMATURE_TO_MATURE_B_LYMPHOCYTE_UP	1929	36	-1.058	-0.314	0.414	0.540
VALK_AML_CLUSTER_13	1930	23	-1.059	-0.338	0.413	0.540
REACTOME_PROGRAMMED_CELL_DEATH	1931	190	-1.06	-0.354	0.412	0.539
REACTOME_DIGESTION	1932	20	-1.06	-0.406	0.412	0.539
REACTOME_FANCONI_ANEMIA_PATHWAY	1933	28	-1.06	-0.307	0.412	0.539
BLUM_RESPONSE_TO_SALIRASIB_DN	1934	299	-1.06	-0.333	0.412	0.539
KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND_NEOLACTO_SERIES	1935	25	-1.061	-0.369	0.411	0.538
BIOCARTA_IL2RB_PATHWAY	1936	37	-1.061	-0.307	0.411	0.538
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_UP	1937	45	-1.061	-0.29	0.411	0.538
IKEDA_MIR30_TARGETS_DN	1938	20	-1.062	-0.353	0.410	0.538
YAGI_AML_SURVIVAL	1939	104	-1.062	-0.303	0.410	0.537
LEE_AGING_NEOCORTEX_DN	1940	61	-1.063	-0.29	0.409	0.536
BLANCO_MELO_INFLUENZA_A_INFECTION_A594_CELLS_DN	1941	79	-1.063	-0.325	0.408	0.536
GABRIELY_MIR21_TARGETS	1942	236	-1.064	-0.386	0.408	0.535
BROWNE_HCMV_INFECTION_1HR_DN	1943	182	-1.064	-0.236	0.407	0.535
GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP	1944	80	-1.065	-0.246	0.406	0.533
PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_DN	1945	114	-1.067	-0.3	0.405	0.532
REACTOME_ANTI_INFLAMMATORY_RESPONSE_FAVOURING_LEISHMANIA_PARASITE_INFECTION	1946	165	-1.067	-0.303	0.405	0.532
QI_HYPOXIA_TARGETS_OF_HIF1A_AND_FOXA2	1947	29	-1.067	-0.372	0.405	0.532
KEGG_CHRONIC_MYELOID_LEUKEMIA	1948	72	-1.067	-0.376	0.404	0.531
REACTOME_C_TYPE_LECTIN_RECEPTORS_CLRS	1949	129	-1.067	-0.322	0.404	0.531
REACTOME_GLUCAGON_SIGNALING_IN_METABOLIC_REGULATION	1950	33	-1.068	-0.309	0.404	0.531
BURTON_ADIPOGENESIS_PEAK_AT_8HR	1951	38	-1.068	-0.397	0.403	0.531
RASHI_RESPONSE_TO_IONIZING_RADIATION_6	1952	71	-1.069	-0.272	0.402	0.529
BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_UP	1953	160	-1.07	-0.276	0.401	0.528
BAUS_TFF2_TARGETS_UP	1954	30	-1.07	-0.351	0.401	0.528
REACTOME_BINDING_AND_UPTAKE_OF_LIGANDS_BY_SCAVENGER_RECEPTORS	1955	46	-1.071	-0.367	0.400	0.527
LEIN_MIDBRAIN_MARKERS	1956	67	-1.072	-0.244	0.399	0.526
BONOME_OVARIAN_CANCER_SURVIVAL_SUBOPTIMAL_DEBULKING	1957	419	-1.072	-0.25	0.399	0.526
MATZUK_SPERMATID_DIFFERENTIATION	1958	33	-1.072	-0.308	0.398	0.526
WP_PROSURVIVAL_SIGNALING_OF_NEUROPROTECTIN_D1	1959	15	-1.072	-0.392	0.398	0.526
MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3	1960	182	-1.072	-0.309	0.398	0.526
KEGG_VIBRIO_CHOLERAE_INFECTION	1961	50	-1.074	-0.351	0.397	0.525
REACTOME_REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF	1962	51	-1.074	-0.404	0.397	0.524
WP_FATTY_ACID_BIOSYNTHESIS	1963	22	-1.074	-0.367	0.396	0.524
REACTOME_NR1H3_NR1H2_REGULATE_GENE_EXPRESSION_LINKED_TO_CHOLESTEROL_TRANSPORT_AND_EFFLUX	1964	28	-1.075	-0.333	0.396	0.524
KANG_DOXORUBICIN_RESISTANCE_DN	1965	16	-1.075	-0.523	0.396	0.524
WNT_SIGNALING	1966	85	-1.075	-0.286	0.395	0.523
BREDEMEYER_RAG_SIGNALING_NOT_VIA_ATM_UP	1967	47	-1.075	-0.289	0.395	0.523
REACTOME_ER_TO_GOLGI_ANTEROGRADE_TRANSPORT	1968	132	-1.076	-0.365	0.395	0.523
BIOCARTA_NO1_PATHWAY	1969	27	-1.077	-0.354	0.393	0.521
NEMETH_INFLAMMATORY_RESPONSE_LPS_DN	1970	28	-1.078	-0.339	0.393	0.521
WANG_TUMOR_INVASIVENESS_DN	1971	180	-1.078	-0.357	0.392	0.521
DESERT_PERIPORTAL_HEPATOCELLULAR_CARCINOMA_SUBCLASS_UP	1972	145	-1.078	-0.284	0.392	0.521
REACTOME_GABA_B_RECEPTOR_ACTIVATION	1973	43	-1.078	-0.309	0.392	0.521
MIKKELSEN_IPS_LCP_WITH_H3K4ME3	1974	130	-1.079	-0.36	0.391	0.519
VANASSE_BCL2_TARGETS_UP	1975	27	-1.079	-0.317	0.391	0.519
SEMENZA_HIF1_TARGETS	1976	33	-1.079	-0.335	0.391	0.519
ABE_VEGFA_TARGETS_30MIN	1977	25	-1.079	-0.346	0.391	0.519
YAGI_AML_WITH_INV_16_TRANSLOCATION	1978	361	-1.079	-0.261	0.391	0.519
ENGELMANN_CANCER_PROGENITORS_UP	1979	42	-1.08	-0.301	0.391	0.519
REACTOME_REGULATION_OF_NF_KAPPA_B_SIGNALING	1980	15	-1.08	-0.41	0.390	0.519
FIGUEROA_AML_METHYLATION_CLUSTER_3_UP	1981	127	-1.08	-0.256	0.390	0.519
SMID_BREAST_CANCER_RELAPSE_IN_LUNG_UP	1982	21	-1.08	-0.375	0.390	0.519
YANG_BREAST_CANCER_ESR1_BULK_UP	1983	19	-1.081	-0.42	0.389	0.519
MOOTHA_GLYCOGEN_METABOLISM	1984	19	-1.081	-0.411	0.389	0.518
KEGG_GLYCEROLIPID_METABOLISM	1985	39	-1.082	-0.29	0.388	0.518
BIOCARTA_NDKDYNAMIN_PATHWAY	1986	16	-1.082	-0.435	0.388	0.517
SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP	1987	122	-1.082	-0.29	0.388	0.517
GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP	1988	436	-1.082	-0.283	0.388	0.517
PID_CMYB_PATHWAY	1989	78	-1.083	-0.319	0.387	0.516
BILANGES_RAPAMYCIN_SENSITIVE_GENES	1990	31	-1.084	-0.386	0.386	0.516
STEARMAN_LUNG_CANCER_EARLY_VS_LATE_UP	1991	105	-1.084	-0.4	0.386	0.516
CHICAS_RB1_TARGETS_GROWING	1992	211	-1.085	-0.325	0.384	0.514
LEIN_ASTROCYTE_MARKERS	1993	37	-1.085	-0.341	0.384	0.514
REACTOME_SIGNALING_BY_HEDGEHOG	1994	132	-1.085	-0.313	0.384	0.514
REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING	1995	40	-1.085	-0.37	0.384	0.514
GAUSSMANN_MLL_AF4_FUSION_TARGETS_B_UP	1996	23	-1.085	-0.363	0.384	0.514
REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION	1997	62	-1.085	-0.308	0.384	0.514
ADDYA_ERYTHROID_DIFFERENTIATION_BY_HEMIN	1998	69	-1.086	-0.312	0.384	0.514
WANG_PROSTATE_CANCER_ANDROGEN_INDEPENDENT	1999	55	-1.086	-0.333	0.384	0.514
LIN_NPAS4_TARGETS_DN	2000	55	-1.086	-0.279	0.384	0.514
BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_48HR_DN	2001	150	-1.086	-0.296	0.384	0.514
MEBARKI_HCC_PROGENITOR_WNT_DN	2002	64	-1.086	-0.349	0.383	0.514
COATES_MACROPHAGE_M1_VS_M2_UP	2003	69	-1.086	-0.259	0.383	0.514
VALK_AML_CLUSTER_16	2004	21	-1.087	-0.331	0.382	0.513
WP_PROXIMAL_TUBULE_TRANSPORT	2005	52	-1.088	-0.301	0.382	0.513
BROWNE_HCMV_INFECTION_6HR_UP	2006	58	-1.088	-0.287	0.381	0.513
WP_ONECARBON_METABOLISM_AND_RELATED_PATHWAYS	2007	49	-1.088	-0.271	0.381	0.512
ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_UP	2008	68	-1.089	-0.297	0.381	0.512
REACTOME_DEFECTS_OF_CONTACT_ACTIVATION_SYSTEM_CAS_AND_KALLIKREIN_KININ_SYSTEM_KKS	2009	16	-1.089	-0.411	0.380	0.512
BURTON_ADIPOGENESIS_PEAK_AT_2HR	2010	41	-1.089	-0.38	0.380	0.512
PID_AURORA_B_PATHWAY	2011	36	-1.089	-0.423	0.380	0.512
NIKOLSKY_MUTATED_AND_AMPLIFIED_IN_BREAST_CANCER	2012	74	-1.09	-0.266	0.380	0.512
GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP	2013	460	-1.091	-0.235	0.379	0.510
BIOCARTA_MPR_PATHWAY	2014	20	-1.092	-0.375	0.377	0.509
WAKABAYASHI_ADIPOGENESIS_PPARG_BOUND_36HR	2015	26	-1.092	-0.339	0.377	0.508
ACEVEDO_LIVER_CANCER_WITH_H3K9ME3_UP	2016	92	-1.093	-0.316	0.376	0.507
XU_HGF_TARGETS_INDUCED_BY_AKT1_48HR_DN	2017	17	-1.093	-0.444	0.376	0.507
REACTOME_ONCOGENE_INDUCED_SENESCENCE	2018	30	-1.094	-0.412	0.375	0.507
XIE_ST_HSC_S1PR3_OE_DN	2019	20	-1.094	-0.39	0.375	0.507
REACTOME_MATURATION_OF_SARSCOV2_NUCLEOPROTEIN	2020	15	-1.094	-0.454	0.375	0.507
KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION	2021	83	-1.094	-0.294	0.375	0.506
REACTOME_ORGANELLE_BIOGENESIS_AND_MAINTENANCE	2022	207	-1.095	-0.31	0.374	0.506
DARWICHE_PAPILLOMA_RISK_LOW_UP	2023	132	-1.095	-0.297	0.374	0.506
REACTOME_SIGNALING_BY_WNT	2024	253	-1.095	-0.312	0.374	0.506
HALLMARK_ANDROGEN_RESPONSE	2025	90	-1.095	-0.375	0.374	0.506
REACTOME_TRANSCRIPTIONAL_ACTIVATION_OF_MITOCHONDRIAL_BIOGENESIS	2026	46	-1.096	-0.326	0.373	0.506
LAIHO_COLORECTAL_CANCER_SERRATED_UP	2027	99	-1.096	-0.43	0.373	0.505
LEE_DOUBLE_POLAR_THYMOCYTE	2028	25	-1.096	-0.34	0.373	0.505
WP_ALZHEIMERS_DISEASE	2029	234	-1.097	-0.295	0.372	0.504
WP_ALZHEIMERS_DISEASE_AND_MIRNA_EFFECTS	2030	234	-1.097	-0.295	0.372	0.504
WP_PKCGAMMA_CALCIUM_SIGNALING_PATHWAY_IN_ATAXIA	2031	22	-1.098	-0.367	0.370	0.503
GRADE_COLON_AND_RECTAL_CANCER_DN	2032	84	-1.1	-0.256	0.369	0.501
PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN	2033	19	-1.1	-0.368	0.369	0.501
REACTOME_VISUAL_PHOTOTRANSDUCTION	2034	90	-1.101	-0.296	0.368	0.500
SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_DN	2035	47	-1.101	-0.301	0.368	0.500
DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP	2036	250	-1.101	-0.356	0.368	0.500
SESTO_RESPONSE_TO_UV_C6	2037	35	-1.101	-0.465	0.368	0.500
ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_DN	2038	39	-1.101	-0.34	0.367	0.500
REACTOME_SELECTIVE_AUTOPHAGY	2039	63	-1.101	-0.393	0.367	0.500
PLASARI_TGFB1_SIGNALING_VIA_NFIC_1HR_UP	2040	25	-1.102	-0.318	0.367	0.499
SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_DN	2041	29	-1.103	-0.412	0.366	0.498
KEGG_GRAFT_VERSUS_HOST_DISEASE	2042	38	-1.103	-0.398	0.366	0.498
WP_INTRAFLAGELLAR_TRANSPORT_PROTEINS_BINDING_TO_DYNEIN	2043	19	-1.103	-0.427	0.366	0.498
TOMLINS_METASTASIS_DN	2044	17	-1.103	-0.464	0.366	0.498
LI_CISPLATIN_RESISTANCE_DN	2045	25	-1.103	-0.324	0.366	0.498
WP_NOTCH_SIGNALING_PATHWAY	2046	58	-1.103	-0.345	0.365	0.498
REACTOME_ACTIVATION_OF_IRF3_IRF7_MEDIATED_BY_TBK1_IKK_EPSILON	2047	17	-1.104	-0.411	0.365	0.498
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN	2048	88	-1.104	-0.278	0.364	0.497
DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_UP	2049	22	-1.104	-0.404	0.364	0.497
KEGG_ACUTE_MYELOID_LEUKEMIA	2050	56	-1.105	-0.343	0.364	0.497
BROWNE_HCMV_INFECTION_10HR_UP	2051	89	-1.105	-0.272	0.364	0.497
DALESSIO_TSA_RESPONSE	2052	22	-1.106	-0.339	0.363	0.496
MARTIN_NFKB_TARGETS_UP	2053	40	-1.106	-0.301	0.363	0.496
FIGUEROA_AML_METHYLATION_CLUSTER_4_UP	2054	86	-1.106	-0.262	0.362	0.496
MCBRYAN_PUBERTAL_BREAST_5_6WK_DN	2055	110	-1.106	-0.335	0.362	0.496
HOLLEMAN_VINCRISTINE_RESISTANCE_ALL_UP	2056	21	-1.106	-0.388	0.362	0.496
KEGG_CALCIUM_SIGNALING_PATHWAY	2057	171	-1.107	-0.299	0.361	0.495
BILBAN_B_CLL_LPL_UP	2058	57	-1.107	-0.268	0.361	0.495
KEGG_NITROGEN_METABOLISM	2059	23	-1.107	-0.347	0.361	0.495
WP_PROGERIAASSOCIATED_LIPODYSTROPHY	2060	20	-1.108	-0.398	0.360	0.494
YAUCH_HEDGEHOG_SIGNALING_PARACRINE_DN	2061	192	-1.108	-0.277	0.360	0.494
GAVIN_FOXP3_TARGETS_CLUSTER_P2	2062	66	-1.109	-0.264	0.360	0.494
REACTOME_SIGNALING_BY_NODAL	2063	21	-1.109	-0.359	0.359	0.493
LIU_IL13_MEMORY_MODEL_UP	2064	17	-1.109	-0.43	0.359	0.493
REACTOME_ACYL_CHAIN_REMODELLING_OF_PE	2065	21	-1.109	-0.399	0.359	0.493
WONG_ENDMETRIUM_CANCER_DN	2066	68	-1.109	-0.316	0.359	0.493
REACTOME_GENE_AND_PROTEIN_EXPRESSION_BY_JAK_STAT_SIGNALING_AFTER_INTERLEUKIN_12_STIMULATION	2067	33	-1.109	-0.408	0.359	0.493
PID_IL2_PI3K_PATHWAY	2068	30	-1.11	-0.362	0.358	0.493
BURTON_ADIPOGENESIS_1	2069	28	-1.11	-0.458	0.358	0.492
DOUGLAS_BMI1_TARGETS_UP	2070	467	-1.111	-0.289	0.357	0.492
RAO_BOUND_BY_SALL4_ISOFORM_A	2071	137	-1.111	-0.241	0.357	0.492
BREDEMEYER_RAG_SIGNALING_VIA_ATM_NOT_VIA_NFKB_UP	2072	36	-1.111	-0.327	0.357	0.492
WP_CHOLESTASIS	2073	19	-1.112	-0.372	0.356	0.491
FARMER_BREAST_CANCER_APOCRINE_VS_BASAL	2074	281	-1.112	-0.319	0.356	0.491
KEGG_DRUG_METABOLISM_CYTOCHROME_P450	2075	62	-1.113	-0.35	0.355	0.490
PID_P38_ALPHA_BETA_DOWNSTREAM_PATHWAY	2076	37	-1.113	-0.396	0.355	0.490
REACTOME_RAS_PROCESSING	2077	20	-1.114	-0.422	0.354	0.489
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP	2078	243	-1.114	-0.325	0.354	0.489
BROWNE_HCMV_INFECTION_30MIN_UP	2079	45	-1.114	-0.305	0.353	0.488
GRYDER_PAX3FOXO1_ENHANCERS_KO_DOWN	2080	354	-1.115	-0.317	0.353	0.488
DARWICHE_SKIN_TUMOR_PROMOTER_DN	2081	145	-1.115	-0.268	0.353	0.488
PURBEY_TARGETS_OF_CTBP1_AND_SATB1_UP	2082	61	-1.115	-0.344	0.353	0.488
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREY_DN	2083	55	-1.115	-0.312	0.353	0.488
REACTOME_RHOD_GTPASE_CYCLE	2084	44	-1.115	-0.427	0.353	0.488
PID_P38_MK2_PATHWAY	2085	21	-1.116	-0.466	0.352	0.487
DAZARD_UV_RESPONSE_CLUSTER_G6	2086	114	-1.116	-0.44	0.351	0.487
BACOLOD_RESISTANCE_TO_ALKYLATING_AGENTS_UP	2087	20	-1.116	-0.406	0.351	0.487
SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_UP	2088	38	-1.117	-0.31	0.351	0.487
REACTOME_ADRENALINE_NORADRENALINE_INHIBITS_INSULIN_SECRETION	2089	28	-1.117	-0.339	0.351	0.486
ROZANOV_MMP14_TARGETS_DN	2090	26	-1.117	-0.356	0.351	0.486
CHEN_LUNG_CANCER_SURVIVAL	2091	26	-1.117	-0.427	0.350	0.486
KEGG_PPAR_SIGNALING_PATHWAY	2092	67	-1.117	-0.276	0.350	0.486
WP_PATHOGENESIS_OF_SARSCOV2_MEDIATED_BY_NSP9NSP10_COMPLEX	2093	19	-1.118	-0.448	0.350	0.486
LEE_METASTASIS_AND_ALTERNATIVE_SPLICING_DN	2094	42	-1.118	-0.308	0.349	0.486
SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_UP	2095	136	-1.119	-0.336	0.349	0.485
BLANCO_MELO_COVID19_SARS_COV_2_POS_PATIENT_LUNG_TISSUE_DN	2096	143	-1.12	-0.33	0.348	0.484
WP_2Q13_COPY_NUMBER_VARIATION_SYNDROME	2097	50	-1.12	-0.313	0.347	0.483
WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_36HR	2098	120	-1.12	-0.315	0.347	0.483
KANG_CISPLATIN_RESISTANCE_UP	2099	17	-1.12	-0.442	0.347	0.483
REACTOME_MEIOTIC_SYNAPSIS	2100	29	-1.12	-0.371	0.347	0.483
NADERI_BREAST_CANCER_PROGNOSIS_DN	2101	18	-1.121	-0.343	0.347	0.483
REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES	2102	252	-1.121	-0.288	0.347	0.483
EGUCHI_CELL_CYCLE_RB1_TARGETS	2103	21	-1.121	-0.452	0.346	0.483
REACTOME_IRS_MEDIATED_SIGNALLING	2104	48	-1.121	-0.292	0.346	0.483
REACTOME_DISASSEMBLY_OF_THE_DESTRUCTION_COMPLEX_AND_RECRUITMENT_OF_AXIN_TO_THE_MEMBRANE	2105	29	-1.121	-0.406	0.346	0.483
REACTOME_DISEASES_ASSOCIATED_WITH_O_GLYCOSYLATION_OF_PROTEINS	2106	57	-1.121	-0.347	0.346	0.483
ONO_AML1_TARGETS_UP	2107	24	-1.121	-0.407	0.346	0.483
BERNARD_PPAPDC1B_TARGETS_UP	2108	28	-1.122	-0.409	0.346	0.483
NOJIMA_SFRP2_TARGETS_DN	2109	24	-1.122	-0.41	0.346	0.483
GARY_CD5_TARGETS_UP	2110	397	-1.122	-0.327	0.346	0.483
CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_UP	2111	107	-1.123	-0.336	0.345	0.482
PODAR_RESPONSE_TO_ADAPHOSTIN_UP	2112	124	-1.123	-0.398	0.345	0.482
FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_UP	2113	80	-1.123	-0.314	0.345	0.482
LIAO_HAVE_SOX4_BINDING_SITES	2114	40	-1.123	-0.312	0.344	0.482
KIM_LIVER_CANCER_POOR_SURVIVAL_UP	2115	20	-1.124	-0.467	0.344	0.482
SMID_BREAST_CANCER_LUMINAL_A_DN	2116	16	-1.124	-0.416	0.343	0.482
HEIDENBLAD_AMPLICON_8Q24_DN	2117	34	-1.124	-0.35	0.343	0.482
BIOCARTA_CTLA4_PATHWAY	2118	20	-1.124	-0.401	0.343	0.481
GILDEA_METASTASIS	2119	24	-1.124	-0.402	0.343	0.481
MANNE_COVID19_COMBINED_COHORT_VS_HEALTHY_DONOR_PLATELETS_DN	2120	172	-1.125	-0.285	0.343	0.481
REACTOME_VLDLR_INTERNALISATION_AND_DEGRADATION	2121	16	-1.125	-0.471	0.342	0.481
PID_ILK_PATHWAY	2122	44	-1.125	-0.449	0.342	0.481
DELYS_THYROID_CANCER_DN	2123	214	-1.125	-0.255	0.342	0.481
KEGG_VIRAL_MYOCARDITIS	2124	67	-1.125	-0.307	0.342	0.481
KUMAR_PATHOGEN_LOAD_BY_MACROPHAGES	2125	193	-1.126	-0.253	0.341	0.480
COWLING_MYCN_TARGETS	2126	36	-1.127	-0.352	0.341	0.480
ZHONG_SECRETOME_OF_LUNG_CANCER_AND_ENDOTHELIUM	2127	63	-1.127	-0.373	0.341	0.480
REACTOME_NOTCH2_ACTIVATION_AND_TRANSMISSION_OF_SIGNAL_TO_THE_NUCLEUS	2128	20	-1.127	-0.456	0.340	0.479
WEINMANN_ADAPTATION_TO_HYPOXIA_DN	2129	36	-1.127	-0.414	0.340	0.479
STAMBOLSKY_TARGETS_OF_MUTATED_TP53_UP	2130	42	-1.128	-0.336	0.339	0.478
ALONSO_METASTASIS_DN	2131	20	-1.128	-0.339	0.339	0.478
YANG_BREAST_CANCER_ESR1_LASER_DN	2132	42	-1.128	-0.45	0.339	0.478
WP_FATTY_ACID_BETAOXIDATION	2133	33	-1.128	-0.317	0.339	0.478
JOHANSSON_GLIOMAGENESIS_BY_PDGFB_UP	2134	49	-1.129	-0.429	0.339	0.478
LOPEZ_MBD_TARGETS_IMPRINTED_AND_X_LINKED	2135	16	-1.129	-0.352	0.338	0.478
FARMER_BREAST_CANCER_CLUSTER_2	2136	30	-1.129	-0.519	0.338	0.478
MORI_LARGE_PRE_BII_LYMPHOCYTE_UP	2137	75	-1.129	-0.415	0.338	0.478
ONDER_CDH1_TARGETS_1_DN	2138	141	-1.13	-0.376	0.337	0.477
GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_UP	2139	17	-1.13	-0.423	0.337	0.477
SESTO_RESPONSE_TO_UV_C7	2140	66	-1.13	-0.421	0.337	0.477
BIOCARTA_CERAMIDE_PATHWAY	2141	20	-1.131	-0.447	0.336	0.476
PID_PS1_PATHWAY	2142	41	-1.131	-0.37	0.336	0.476
WANG_IMMORTALIZED_BY_HOXA9_AND_MEIS1_UP	2143	29	-1.132	-0.311	0.335	0.475
WANG_THOC1_TARGETS_DN	2144	19	-1.132	-0.421	0.335	0.475
SCHAEFFER_SOX9_TARGETS_IN_PROSTATE_DEVELOPMENT_DN	2145	42	-1.132	-0.32	0.335	0.475
HOWLIN_CITED1_TARGETS_1_UP	2146	30	-1.132	-0.299	0.335	0.475
REACTOME_ROS_AND_RNS_PRODUCTION_IN_PHAGOCYTES	2147	33	-1.133	-0.322	0.335	0.475
HUMMERICH_BENIGN_SKIN_TUMOR_DN	2148	20	-1.133	-0.409	0.334	0.474
RYAN_MANTLE_CELL_LYMPHOMA_NOTCH_DIRECT_UP	2149	125	-1.133	-0.272	0.334	0.474
ZHANG_PROLIFERATING_VS_QUIESCENT	2150	45	-1.134	-0.441	0.333	0.473
REACTOME_SPHINGOLIPID_METABOLISM	2151	61	-1.135	-0.359	0.332	0.473
HOFMANN_MYELODYSPLASTIC_SYNDROM_HIGH_RISK_DN	2152	19	-1.135	-0.395	0.332	0.473
WP_FAMILIAL_HYPERLIPIDEMIA_TYPE_1	2153	15	-1.135	-0.424	0.332	0.472
REACTOME_INITIATION_OF_NUCLEAR_ENVELOPE_NE_REFORMATION	2154	17	-1.136	-0.508	0.331	0.472
REACTOME_TRANSLATION_OF_SARSCOV1_STRUCTURAL_PROTEINS	2155	28	-1.137	-0.418	0.330	0.470
REACTOME_TNF_RECEPTOR_SUPERFAMILY_TNFSF_MEMBERS_MEDIATING_NON_CANONICAL_NF_KB_PATHWAY	2156	17	-1.137	-0.444	0.330	0.470
MIKKELSEN_ES_LCP_WITH_H3K4ME3	2157	103	-1.137	-0.389	0.330	0.470
GROSS_HYPOXIA_VIA_ELK3_UP	2158	174	-1.138	-0.35	0.329	0.470
WENDT_COHESIN_TARGETS_UP	2159	25	-1.138	-0.498	0.329	0.470
PARK_APL_PATHOGENESIS_DN	2160	44	-1.138	-0.349	0.329	0.469
WP_EICOSANOID_METABOLISM_VIA_CYCLOOXYGENASES_COX	2161	26	-1.138	-0.361	0.329	0.469
NIKOLSKY_BREAST_CANCER_15Q26_AMPLICON	2162	15	-1.138	-0.401	0.329	0.469
MEISSNER_ES_ICP_WITH_H3K4ME3	2163	22	-1.139	-0.347	0.328	0.468
BERENJENO_TRANSFORMED_BY_RHOA_FOREVER_UP	2164	19	-1.14	-0.357	0.327	0.468
DAZARD_RESPONSE_TO_UV_SCC_DN	2165	98	-1.14	-0.429	0.327	0.468
DITTMER_PTHLH_TARGETS_UP	2166	95	-1.141	-0.475	0.326	0.467
ONO_FOXP3_TARGETS_UP	2167	21	-1.141	-0.339	0.326	0.466
BOYAULT_LIVER_CANCER_SUBCLASS_G123_DN	2168	48	-1.141	-0.289	0.326	0.466
COLINA_TARGETS_OF_4EBP1_AND_4EBP2	2169	324	-1.142	-0.302	0.325	0.466
MANNE_COVID19_NONICU_VS_HEALTHY_DONOR_PLATELETS_UP	2170	104	-1.142	-0.312	0.325	0.465
REACTOME_INTRACELLULAR_SIGNALING_BY_SECOND_MESSENGERS	2171	275	-1.142	-0.315	0.325	0.465
ZHAN_MULTIPLE_MYELOMA_MS_UP	2172	40	-1.143	-0.309	0.324	0.464
KEGG_TYPE_II_DIABETES_MELLITUS	2173	43	-1.143	-0.319	0.324	0.464
WP_PREGNANE_X_RECEPTOR_PATHWAY	2174	29	-1.144	-0.353	0.323	0.463
REACTOME_VXPX_CARGO_TARGETING_TO_CILIUM	2175	19	-1.144	-0.408	0.323	0.463
IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR	2176	381	-1.144	-0.284	0.323	0.463
HOOI_ST7_TARGETS_UP	2177	70	-1.144	-0.338	0.323	0.463
NAGASHIMA_EGF_SIGNALING_UP	2178	48	-1.144	-0.395	0.322	0.463
WANG_TARGETS_OF_MLL_CBP_FUSION_UP	2179	38	-1.144	-0.325	0.322	0.463
KEGG_BLADDER_CANCER	2180	38	-1.144	-0.403	0.322	0.463
KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION	2181	44	-1.145	-0.374	0.322	0.463
REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS	2182	34	-1.145	-0.345	0.322	0.463
REACTOME_ION_HOMEOSTASIS	2183	52	-1.146	-0.333	0.321	0.462
MATZUK_MALE_REPRODUCTION_SERTOLI	2184	28	-1.146	-0.336	0.321	0.462
REACTOME_CILIUM_ASSEMBLY	2185	144	-1.146	-0.333	0.321	0.462
WEBER_METHYLATED_HCP_IN_SPERM_UP	2186	15	-1.147	-0.371	0.320	0.462
WP_IL2_SIGNALING_PATHWAY	2187	41	-1.147	-0.353	0.320	0.462
VALK_AML_WITH_EVI1	2188	22	-1.147	-0.356	0.320	0.462
DAZARD_UV_RESPONSE_CLUSTER_G4	2189	16	-1.147	-0.468	0.320	0.462
KASLER_HDAC7_TARGETS_2_DN	2190	29	-1.147	-0.386	0.320	0.462
FARDIN_HYPOXIA_11	2191	26	-1.147	-0.418	0.319	0.461
CROMER_METASTASIS_UP	2192	62	-1.148	-0.416	0.318	0.460
REACTOME_COPI_MEDIATED_ANTEROGRADE_TRANSPORT	2193	87	-1.148	-0.397	0.318	0.460
HALLMARK_PI3K_AKT_MTOR_SIGNALING	2194	98	-1.148	-0.33	0.318	0.460
VANTVEER_BREAST_CANCER_METASTASIS_DN	2195	89	-1.149	-0.395	0.318	0.460
BRUNO_HEMATOPOIESIS	2196	56	-1.149	-0.351	0.318	0.460
VANTVEER_BREAST_CANCER_ESR1_DN	2197	193	-1.149	-0.359	0.318	0.460
WANG_CLIM2_TARGETS_UP	2198	189	-1.149	-0.301	0.318	0.460
HOSHIDA_LIVER_CANCER_SUBCLASS_S3	2199	251	-1.149	-0.265	0.318	0.460
INGRAM_SHH_TARGETS_UP	2200	108	-1.149	-0.283	0.318	0.460
MCBRYAN_PUBERTAL_BREAST_3_4WK_DN	2201	33	-1.149	-0.374	0.318	0.460
LIAO_METASTASIS	2202	438	-1.149	-0.311	0.317	0.460
KASLER_HDAC7_TARGETS_1_UP	2203	156	-1.15	-0.295	0.317	0.460
JOHNSTONE_PARVB_TARGETS_1_DN	2204	41	-1.15	-0.389	0.317	0.460
BURTON_ADIPOGENESIS_2	2205	70	-1.15	-0.338	0.317	0.460
REACTOME_MAP3K8_TPL2_DEPENDENT_MAPK1_3_ACTIVATION	2206	15	-1.15	-0.486	0.317	0.460
BIOCARTA_RACCYCD_PATHWAY	2207	26	-1.15	-0.5	0.316	0.460
SESTO_RESPONSE_TO_UV_C1	2208	59	-1.151	-0.475	0.316	0.460
WELCSH_BRCA1_TARGETS_UP	2209	174	-1.151	-0.431	0.316	0.460
YANG_BREAST_CANCER_ESR1_DN	2210	23	-1.151	-0.479	0.316	0.460
REACTOME_FGFR1_MUTANT_RECEPTOR_ACTIVATION	2211	26	-1.151	-0.356	0.316	0.460
KOBAYASHI_EGFR_SIGNALING_24HR_DN	2212	220	-1.152	-0.38	0.315	0.458
HOQUE_METHYLATED_IN_CANCER	2213	54	-1.154	-0.299	0.313	0.456
CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_UP	2214	18	-1.154	-0.389	0.312	0.456
KAMIKUBO_MYELOID_MN1_NETWORK	2215	18	-1.154	-0.508	0.312	0.456
LIU_BREAST_CANCER	2216	22	-1.155	-0.402	0.312	0.456
ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP	2217	206	-1.155	-0.277	0.312	0.456
NEWMAN_ERCC6_TARGETS_UP	2218	20	-1.155	-0.355	0.312	0.456
BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_UP	2219	39	-1.156	-0.368	0.311	0.454
DOANE_BREAST_CANCER_CLASSES_DN	2220	27	-1.156	-0.484	0.311	0.454
BAE_BRCA1_TARGETS_UP	2221	62	-1.156	-0.45	0.311	0.454
KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_DN	2222	61	-1.156	-0.358	0.311	0.454
SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12	2223	245	-1.156	-0.295	0.310	0.454
WP_APOPTOSIS_MODULATION_AND_SIGNALING	2224	82	-1.157	-0.329	0.310	0.454
REACTOME_RHOG_GTPASE_CYCLE	2225	63	-1.157	-0.375	0.310	0.454
PID_HNF3B_PATHWAY	2226	40	-1.157	-0.326	0.309	0.453
WP_IL9_SIGNALING_PATHWAY	2227	17	-1.158	-0.412	0.309	0.453
PID_BETA_CATENIN_NUC_PATHWAY	2228	71	-1.158	-0.324	0.309	0.453
WOOD_EBV_EBNA1_TARGETS_DN	2229	45	-1.159	-0.436	0.308	0.452
YAMAZAKI_TCEB3_TARGETS_DN	2230	166	-1.159	-0.332	0.308	0.452
PID_FOXM1_PATHWAY	2231	38	-1.159	-0.436	0.307	0.451
VANDESLUIS_COMMD1_TARGETS_GROUP_3_DN	2232	33	-1.16	-0.356	0.307	0.451
REACTOME_PRESYNAPTIC_FUNCTION_OF_KAINATE_RECEPTORS	2233	21	-1.16	-0.392	0.307	0.451
NAKAYAMA_FRA2_TARGETS	2234	39	-1.161	-0.421	0.306	0.450
BROWNE_HCMV_INFECTION_8HR_DN	2235	38	-1.161	-0.351	0.306	0.449
MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN	2236	40	-1.161	-0.408	0.305	0.449
FOURNIER_ACINAR_DEVELOPMENT_EARLY_UP	2237	15	-1.162	-0.489	0.305	0.449
BIOCARTA_COMP_PATHWAY	2238	18	-1.162	-0.474	0.304	0.448
GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_DN	2239	21	-1.162	-0.385	0.304	0.448
REACTOME_BETA_CATENIN_PHOSPHORYLATION_CASCADE	2240	16	-1.163	-0.512	0.303	0.447
WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP	2241	58	-1.164	-0.34	0.303	0.446
WP_ENERGY_METABOLISM	2242	44	-1.165	-0.33	0.302	0.445
BARRIER_CANCER_RELAPSE_NORMAL_SAMPLE_UP	2243	29	-1.166	-0.353	0.301	0.444
MENSE_HYPOXIA_UP	2244	76	-1.166	-0.404	0.300	0.443
SMITH_TERT_TARGETS_DN	2245	81	-1.167	-0.379	0.299	0.442
VANDESLUIS_COMMD1_TARGETS_GROUP_3_UP	2246	74	-1.168	-0.342	0.299	0.442
REACTOME_ACTIVATION_OF_GENE_EXPRESSION_BY_SREBF_SREBP	2247	38	-1.168	-0.447	0.299	0.442
BLANCO_MELO_BRONCHIAL_EPITHELIAL_CELLS_INFLUENZA_A_INFECTION_DN	2248	58	-1.169	-0.364	0.298	0.441
REACTOME_PHOSPHOLIPID_METABOLISM	2249	168	-1.169	-0.298	0.298	0.441
YU_MYC_TARGETS_UP	2250	36	-1.169	-0.523	0.298	0.441
REACTOME_SIGNALING_BY_NUCLEAR_RECEPTORS	2251	216	-1.171	-0.322	0.296	0.438
HILLION_HMGA1B_TARGETS	2252	80	-1.171	-0.352	0.296	0.438
DAZARD_RESPONSE_TO_UV_NHEK_DN	2253	247	-1.172	-0.455	0.295	0.437
REACTOME_REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS	2254	114	-1.172	-0.338	0.295	0.437
PLASARI_TGFB1_SIGNALING_VIA_NFIC_10HR_DN	2255	25	-1.172	-0.37	0.295	0.437
PID_PI3KCI_AKT_PATHWAY	2256	30	-1.172	-0.465	0.295	0.437
WP_GASTRIC_CANCER_NETWORK_1	2257	21	-1.173	-0.414	0.294	0.437
MULLIGHAN_MLL_SIGNATURE_2_UP	2258	350	-1.173	-0.293	0.294	0.437
DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN	2259	379	-1.173	-0.463	0.294	0.437
MEISSNER_NPC_HCP_WITH_H3_UNMETHYLATED	2260	410	-1.173	-0.3	0.294	0.437
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP	2261	72	-1.173	-0.315	0.294	0.437
WP_FOLLICLE_STIMULATING_HORMONE_FSH_SIGNALING_PATHWAY	2262	22	-1.173	-0.389	0.294	0.437
WP_HEMATOPOIETIC_STEM_CELL_GENE_REGULATION_BY_GABP_ALPHABETA_COMPLEX	2263	18	-1.174	-0.406	0.293	0.436
DAZARD_UV_RESPONSE_CLUSTER_G2	2264	22	-1.174	-0.52	0.293	0.435
REACTOME_ESR_MEDIATED_SIGNALING	2265	148	-1.174	-0.365	0.292	0.435
KIM_WT1_TARGETS_8HR_UP	2266	154	-1.175	-0.377	0.292	0.435
WEST_ADRENOCORTICAL_CARCINOMA_VS_ADENOMA_DN	2267	24	-1.175	-0.375	0.292	0.435
REACTOME_SIGNALING_BY_NOTCH1	2268	66	-1.176	-0.361	0.291	0.433
LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN	2269	110	-1.177	-0.404	0.290	0.433
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_OLD	2270	28	-1.177	-0.407	0.290	0.433
MURAKAMI_UV_RESPONSE_6HR_DN	2271	20	-1.177	-0.429	0.290	0.432
WANG_LSD1_TARGETS_UP	2272	21	-1.177	-0.405	0.290	0.432
VERHAAK_GLIOBLASTOMA_PRONEURAL	2273	142	-1.177	-0.26	0.290	0.432
KUNINGER_IGF1_VS_PDGFB_TARGETS_UP	2274	65	-1.178	-0.363	0.289	0.432
BIOCARTA_GSK3_PATHWAY	2275	20	-1.178	-0.452	0.289	0.431
WP_SPHINGOLIPID_PATHWAY	2276	17	-1.179	-0.483	0.288	0.431
WP_STEROL_REGULATORY_ELEMENTBINDING_PROTEINS_SREBP_SIGNALING	2277	66	-1.18	-0.412	0.287	0.429
REACTOME_THE_ROLE_OF_NEF_IN_HIV_1_REPLICATION_AND_DISEASE_PATHOGENESIS	2278	28	-1.18	-0.382	0.287	0.429
BIOCARTA_NUCLEARRS_PATHWAY	2279	33	-1.18	-0.387	0.287	0.429
CASORELLI_APL_SECONDARY_VS_DE_NOVO_UP	2280	30	-1.18	-0.337	0.286	0.429
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4	2281	227	-1.181	-0.297	0.286	0.429
SMIRNOV_RESPONSE_TO_IR_6HR_UP	2282	136	-1.181	-0.386	0.286	0.429
REACTOME_PYROPTOSIS	2283	22	-1.181	-0.473	0.286	0.429
REACTOME_DEFECTIVE_B4GALT7_CAUSES_EDS_PROGEROID_TYPE	2284	17	-1.181	-0.425	0.286	0.429
WINNEPENNINCKX_MELANOMA_METASTASIS_DN	2285	39	-1.181	-0.378	0.286	0.429
MIKKELSEN_MEF_ICP_WITH_H3K4ME3_AND_H3K27ME3	2286	32	-1.181	-0.385	0.286	0.429
KANNAN_TP53_TARGETS_UP	2287	50	-1.181	-0.437	0.286	0.429
REACTOME_CYCLIN_A_B1_B2_ASSOCIATED_EVENTS_DURING_G2_M_TRANSITION	2288	24	-1.181	-0.469	0.285	0.429
TAVAZOIE_METASTASIS	2289	91	-1.182	-0.318	0.285	0.429
ZHANG_TARGETS_OF_EWSR1_FLI1_FUSION	2290	78	-1.182	-0.333	0.285	0.429
WP_APOPTOSIS	2291	81	-1.183	-0.354	0.284	0.428
BIOCARTA_PTDINS_PATHWAY	2292	23	-1.183	-0.443	0.284	0.428
SHAFFER_IRF4_TARGETS_IN_ACTIVATED_DENDRITIC_CELL	2293	58	-1.183	-0.383	0.284	0.428
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP	2294	59	-1.183	-0.321	0.284	0.428
KIM_ALL_DISORDERS_OLIGODENDROCYTE_NUMBER_CORR_DN	2295	28	-1.184	-0.342	0.283	0.426
HAHTOLA_SEZARY_SYNDROM_UP	2296	84	-1.184	-0.341	0.283	0.426
MARKEY_RB1_CHRONIC_LOF_DN	2297	96	-1.184	-0.297	0.282	0.426
HUTTMANN_B_CLL_POOR_SURVIVAL_DN	2298	54	-1.185	-0.333	0.282	0.426
CHOW_RASSF1_TARGETS_UP	2299	22	-1.185	-0.507	0.282	0.426
SCHLINGEMANN_SKIN_CARCINOGENESIS_TPA_DN	2300	23	-1.185	-0.447	0.282	0.426
SASAKI_ADULT_T_CELL_LEUKEMIA	2301	147	-1.185	-0.373	0.282	0.426
KORKOLA_EMBRYONIC_CARCINOMA_VS_SEMINOMA_DN	2302	22	-1.185	-0.349	0.282	0.426
BIOCARTA_PGC1A_PATHWAY	2303	15	-1.185	-0.412	0.282	0.426
MCCABE_HOXC6_TARGETS_CANCER_UP	2304	25	-1.186	-0.383	0.281	0.425
LASTOWSKA_COAMPLIFIED_WITH_MYCN	2305	32	-1.186	-0.35	0.281	0.425
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5	2306	87	-1.186	-0.284	0.280	0.425
PID_HDAC_CLASSII_PATHWAY	2307	31	-1.187	-0.407	0.280	0.425
REACTOME_ROLE_OF_LAT2_NTAL_LAB_ON_CALCIUM_MOBILIZATION	2308	21	-1.187	-0.399	0.280	0.425
REACTOME_GENERATION_OF_SECOND_MESSENGER_MOLECULES	2309	29	-1.187	-0.388	0.280	0.425
REACTOME_ACTIVATED_TAK1_MEDIATES_P38_MAPK_ACTIVATION	2310	18	-1.187	-0.469	0.280	0.425
DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_UP	2311	52	-1.187	-0.379	0.280	0.425
IKEDA_MIR1_TARGETS_UP	2312	50	-1.187	-0.503	0.280	0.425
YIH_RESPONSE_TO_ARSENITE_C1	2313	21	-1.187	-0.524	0.280	0.425
REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK	2314	18	-1.188	-0.482	0.280	0.425
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_DN	2315	221	-1.188	-0.324	0.279	0.425
WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_UP	2316	31	-1.188	-0.373	0.279	0.424
DAZARD_RESPONSE_TO_UV_SCC_UP	2317	88	-1.188	-0.436	0.279	0.424
GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_DN	2318	361	-1.189	-0.285	0.278	0.423
VERNELL_RETINOBLASTOMA_PATHWAY_DN	2319	16	-1.19	-0.568	0.277	0.423
GERHOLD_ADIPOGENESIS_DN	2320	57	-1.19	-0.378	0.277	0.422
NATSUME_RESPONSE_TO_INTERFERON_BETA_UP	2321	66	-1.19	-0.29	0.277	0.422
PID_P73PATHWAY	2322	68	-1.191	-0.386	0.277	0.422
REACTOME_ADP_SIGNALLING_THROUGH_P2Y_PURINOCEPTOR_12	2323	22	-1.191	-0.386	0.276	0.421
KEGG_TERPENOID_BACKBONE_BIOSYNTHESIS	2324	15	-1.191	-0.401	0.276	0.421
BAE_BRCA1_TARGETS_DN	2325	29	-1.191	-0.385	0.276	0.421
REACTOME_FRS_MEDIATED_FGFR4_SIGNALING	2326	22	-1.192	-0.366	0.275	0.420
STEIN_ESRRA_TARGETS_DN	2327	84	-1.193	-0.401	0.274	0.419
SANA_TNF_SIGNALING_DN	2328	72	-1.193	-0.331	0.274	0.419
BILANGES_SERUM_SENSITIVE_VIA_TSC2	2329	22	-1.194	-0.416	0.273	0.418
IGARASHI_ATF4_TARGETS_DN	2330	85	-1.194	-0.356	0.273	0.418
AMUNDSON_DNA_DAMAGE_RESPONSE_TP53	2331	15	-1.195	-0.535	0.272	0.416
WP_TAMOXIFEN_METABOLISM	2332	19	-1.196	-0.462	0.272	0.416
REACTOME_NR1H2_AND_NR1H3_MEDIATED_SIGNALING	2333	36	-1.196	-0.351	0.271	0.416
WIKMAN_ASBESTOS_LUNG_CANCER_UP	2334	16	-1.196	-0.448	0.271	0.416
BOYLAN_MULTIPLE_MYELOMA_PCA3_UP	2335	63	-1.196	-0.301	0.271	0.416
GENTILE_UV_HIGH_DOSE_DN	2336	248	-1.197	-0.454	0.271	0.415
KYNG_DNA_DAMAGE_DN	2337	167	-1.197	-0.373	0.271	0.415
MARTIN_VIRAL_GPCR_SIGNALING_UP	2338	78	-1.197	-0.3	0.270	0.415
IKEDA_MIR133_TARGETS_UP	2339	42	-1.198	-0.53	0.270	0.414
BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_48HR_DN	2340	28	-1.198	-0.412	0.269	0.414
WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP	2341	213	-1.198	-0.38	0.269	0.414
JACKSON_DNMT1_TARGETS_UP	2342	76	-1.199	-0.384	0.269	0.414
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_9	2343	64	-1.199	-0.39	0.269	0.413
HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_UP	2344	127	-1.199	-0.389	0.269	0.413
BURTON_ADIPOGENESIS_12	2345	21	-1.199	-0.53	0.268	0.413
CLIMENT_BREAST_CANCER_COPY_NUMBER_UP	2346	23	-1.2	-0.344	0.268	0.413
KEGG_CELL_ADHESION_MOLECULES_CAMS	2347	123	-1.201	-0.377	0.267	0.412
REACTOME_INFECTION_WITH_MYCOBACTERIUM_TUBERCULOSIS	2348	24	-1.201	-0.446	0.267	0.412
REACTOME_PHASE_II_CONJUGATION_OF_COMPOUNDS	2349	82	-1.201	-0.302	0.267	0.412
WP_NOTCH_SIGNALING	2350	40	-1.201	-0.422	0.267	0.412
CHIN_BREAST_CANCER_COPY_NUMBER_UP	2351	26	-1.201	-0.455	0.267	0.412
REACTOME_NEGATIVE_REGULATORS_OF_DDX58_IFIH1_SIGNALING	2352	29	-1.201	-0.458	0.266	0.411
LIEN_BREAST_CARCINOMA_METAPLASTIC	2353	30	-1.201	-0.366	0.266	0.411
FARMER_BREAST_CANCER_BASAL_VS_LULMINAL	2354	282	-1.201	-0.344	0.266	0.411
REACTOME_TBC_RABGAPS	2355	42	-1.202	-0.436	0.266	0.411
YU_MYC_TARGETS_DN	2356	50	-1.202	-0.344	0.265	0.411
DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN	2357	142	-1.203	-0.289	0.265	0.410
WP_NRF2_PATHWAY	2358	130	-1.203	-0.298	0.264	0.409
CROMER_TUMORIGENESIS_DN	2359	46	-1.203	-0.36	0.264	0.409
REACTOME_NEUTROPHIL_DEGRANULATION	2360	425	-1.204	-0.312	0.264	0.409
BENPORATH_NOS_TARGETS	2361	144	-1.204	-0.323	0.263	0.409
CUI_GLUCOSE_DEPRIVATION	2362	56	-1.204	-0.397	0.263	0.409
WP_ACE_INHIBITOR_PATHWAY	2363	17	-1.204	-0.502	0.263	0.409
GOUYER_TATI_TARGETS_DN	2364	16	-1.205	-0.503	0.263	0.408
REACTOME_ACETYLCHOLINE_NEUROTRANSMITTER_RELEASE_CYCLE	2365	16	-1.205	-0.435	0.263	0.408
MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_UP	2366	48	-1.205	-0.328	0.262	0.408
BIOCARTA_BAD_PATHWAY	2367	25	-1.206	-0.389	0.262	0.407
KEGG_COLORECTAL_CANCER	2368	61	-1.206	-0.38	0.262	0.407
PID_IL2_STAT5_PATHWAY	2369	30	-1.206	-0.365	0.262	0.407
PID_PDGFRA_PATHWAY	2370	22	-1.206	-0.425	0.262	0.407
DELACROIX_RAR_TARGETS_DN	2371	24	-1.207	-0.431	0.261	0.407
REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS	2372	194	-1.207	-0.334	0.261	0.407
STARK_PREFRONTAL_CORTEX_22Q11_DELETION_UP	2373	162	-1.207	-0.309	0.260	0.406
ZHU_CMV_8_HR_UP	2374	37	-1.208	-0.33	0.260	0.406
WP_NEPHROTIC_SYNDROME	2375	42	-1.208	-0.337	0.260	0.406
WATANABE_ULCERATIVE_COLITIS_WITH_CANCER_UP	2376	15	-1.208	-0.429	0.260	0.406
BARRIER_CANCER_RELAPSE_NORMAL_SAMPLE_DN	2377	24	-1.208	-0.521	0.260	0.406
BECKER_TAMOXIFEN_RESISTANCE_DN	2378	48	-1.208	-0.416	0.260	0.406
ZHOU_INFLAMMATORY_RESPONSE_FIMA_DN	2379	206	-1.208	-0.252	0.260	0.406
COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_DN	2380	26	-1.209	-0.374	0.259	0.406
JIANG_HYPOXIA_NORMAL	2381	174	-1.21	-0.404	0.258	0.404
KYNG_WERNER_SYNDROM_AND_NORMAL_AGING_UP	2382	65	-1.21	-0.354	0.258	0.404
WEINMANN_ADAPTATION_TO_HYPOXIA_UP	2383	24	-1.211	-0.431	0.257	0.403
ROSS_ACUTE_MYELOID_LEUKEMIA_CBF	2384	70	-1.211	-0.311	0.257	0.403
NABA_SECRETED_FACTORS	2385	304	-1.211	-0.373	0.257	0.403
BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_UP	2386	88	-1.212	-0.375	0.257	0.402
CERIBELLI_PROMOTERS_INACTIVE_AND_BOUND_BY_NFY	2387	26	-1.212	-0.412	0.257	0.402
KUMAR_TARGETS_OF_MLL_AF9_FUSION	2388	347	-1.212	-0.263	0.256	0.402
TERAMOTO_OPN_TARGETS_CLUSTER_6	2389	23	-1.212	-0.404	0.256	0.402
NIKOLSKY_BREAST_CANCER_17Q11_Q21_AMPLICON	2390	95	-1.213	-0.271	0.256	0.402
ZWANG_DOWN_BY_2ND_EGF_PULSE	2391	162	-1.213	-0.275	0.255	0.401
CHEN_HOXA5_TARGETS_9HR_UP	2392	176	-1.214	-0.437	0.255	0.400
BONOME_OVARIAN_CANCER_SURVIVAL_OPTIMAL_DEBULKING	2393	188	-1.214	-0.292	0.255	0.400
ROSS_AML_WITH_MLL_FUSIONS	2394	74	-1.214	-0.317	0.254	0.400
REACTOME_INTERLEUKIN_12_FAMILY_SIGNALING	2395	51	-1.214	-0.38	0.254	0.400
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREEN_DN	2396	19	-1.214	-0.401	0.254	0.400
AIYAR_COBRA1_TARGETS_UP	2397	35	-1.215	-0.405	0.254	0.399
FIGUEROA_AML_METHYLATION_CLUSTER_6_UP	2398	108	-1.215	-0.295	0.253	0.399
PID_NFKAPPAB_ATYPICAL_PATHWAY	2399	16	-1.215	-0.482	0.253	0.399
VANASSE_BCL2_TARGETS_DN	2400	50	-1.215	-0.287	0.253	0.399
GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP	2401	146	-1.216	-0.32	0.253	0.399
VETTER_TARGETS_OF_PRKCA_AND_ETS1_DN	2402	16	-1.216	-0.409	0.253	0.399
KEGG_NOTCH_SIGNALING_PATHWAY	2403	42	-1.216	-0.43	0.253	0.399
KEGG_RENIN_ANGIOTENSIN_SYSTEM	2404	16	-1.216	-0.456	0.252	0.399
DELLA_RESPONSE_TO_TSA_AND_BUTYRATE	2405	21	-1.217	-0.473	0.252	0.398
REACTOME_MUSCLE_CONTRACTION	2406	190	-1.217	-0.334	0.251	0.398
KIM_GERMINAL_CENTER_T_HELPER_UP	2407	51	-1.217	-0.406	0.251	0.398
REACTOME_IRE1ALPHA_ACTIVATES_CHAPERONES	2408	48	-1.217	-0.438	0.251	0.398
REACTOME_NEGATIVE_REGULATION_OF_FLT3	2409	15	-1.218	-0.418	0.251	0.397
OHGUCHI_LIVER_HNF4A_TARGETS_UP	2410	45	-1.218	-0.335	0.250	0.397
WP_NUCLEAR_RECEPTORS_IN_LIPID_METABOLISM_AND_TOXICITY	2411	33	-1.219	-0.396	0.250	0.396
MATZUK_SPERMATOZOA	2412	101	-1.219	-0.272	0.250	0.396
REACTOME_TAK1_DEPENDENT_IKK_AND_NF_KAPPA_B_ACTIVATION	2413	36	-1.219	-0.438	0.250	0.396
PID_P53_DOWNSTREAM_PATHWAY	2414	124	-1.22	-0.377	0.249	0.395
REACTOME_DIGESTION_AND_ABSORPTION	2415	25	-1.22	-0.431	0.249	0.395
REACTOME_ANCHORING_OF_THE_BASAL_BODY_TO_THE_PLASMA_MEMBRANE	2416	64	-1.22	-0.393	0.249	0.395
REACTOME_G_BETA_GAMMA_SIGNALLING_THROUGH_PI3KGAMMA	2417	24	-1.221	-0.401	0.248	0.394
BIOCARTA_FAS_PATHWAY	2418	30	-1.221	-0.444	0.248	0.394
BIOCARTA_EFP_PATHWAY	2419	15	-1.221	-0.527	0.247	0.394
REACTOME_PLASMA_LIPOPROTEIN_CLEARANCE	2420	34	-1.222	-0.404	0.247	0.393
WP_THYROID_STIMULATING_HORMONE_TSH_SIGNALING_PATHWAY	2421	64	-1.223	-0.375	0.246	0.392
SCIBETTA_KDM5B_TARGETS_UP	2422	15	-1.223	-0.516	0.246	0.392
FURUKAWA_DUSP6_TARGETS_PCI35_UP	2423	62	-1.223	-0.354	0.246	0.392
WP_TYROBP_CAUSAL_NETWORK_IN_MICROGLIA	2424	52	-1.223	-0.343	0.246	0.392
MORI_IMMATURE_B_LYMPHOCYTE_DN	2425	76	-1.223	-0.45	0.246	0.392
WP_CILIOPATHIES	2426	119	-1.224	-0.276	0.245	0.391
RIZ_ERYTHROID_DIFFERENTIATION_APOBEC2	2427	21	-1.224	-0.443	0.245	0.391
REACTOME_RAB_REGULATION_OF_TRAFFICKING	2428	102	-1.225	-0.393	0.244	0.390
GERY_CEBP_TARGETS	2429	112	-1.225	-0.334	0.244	0.390
DAZARD_UV_RESPONSE_CLUSTER_G1	2430	57	-1.226	-0.435	0.244	0.390
FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL	2431	273	-1.227	-0.332	0.243	0.388
SCIBETTA_KDM5B_TARGETS_DN	2432	70	-1.227	-0.421	0.242	0.388
WP_VASOPRESSINREGULATED_WATER_REABSORPTION	2433	44	-1.227	-0.4	0.242	0.388
DEBOSSCHER_NFKB_TARGETS_REPRESSED_BY_GLUCOCORTICOIDS	2434	18	-1.227	-0.512	0.242	0.388
KIM_PTEN_TARGETS_UP	2435	15	-1.228	-0.422	0.242	0.388
BLANCO_MELO_COVID19_BRONCHIAL_EPITHELIAL_CELLS_SARS_COV_2_INFECTION_DN	2436	49	-1.228	-0.393	0.241	0.387
REACTOME_GOLGI_TO_ER_RETROGRADE_TRANSPORT	2437	113	-1.229	-0.409	0.241	0.386
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP	2438	124	-1.229	-0.428	0.241	0.386
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN	2439	172	-1.229	-0.306	0.240	0.386
WP_SUDDEN_INFANT_DEATH_SYNDROME_SIDS_SUSCEPTIBILITY_PATHWAYS	2440	150	-1.23	-0.292	0.240	0.385
HASLINGER_B_CLL_WITH_13Q14_DELETION	2441	21	-1.23	-0.425	0.239	0.385
AFFAR_YY1_TARGETS_DN	2442	241	-1.23	-0.27	0.239	0.385
WP_4HYDROXYTAMOXIFEN_DEXAMETHASONE_AND_RETINOIC_ACIDS_REGULATION_OF_P27_EXPRESSION	2443	17	-1.231	-0.534	0.239	0.384
REACTOME_METABOLISM_OF_NITRIC_OXIDE_NOS3_ACTIVATION_AND_REGULATION	2444	15	-1.232	-0.453	0.238	0.383
KEGG_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS	2445	19	-1.233	-0.405	0.237	0.381
REACTOME_INTRAFLAGELLAR_TRANSPORT	2446	36	-1.233	-0.393	0.237	0.381
REACTOME_INTERFERON_SIGNALING	2447	185	-1.233	-0.286	0.236	0.381
NIKOLSKY_BREAST_CANCER_6P24_P22_AMPLICON	2448	17	-1.234	-0.451	0.236	0.380
QUINTENS_EMBRYONIC_BRAIN_RESPONSE_TO_IR	2449	61	-1.234	-0.373	0.236	0.380
HALLMARK_ESTROGEN_RESPONSE_EARLY	2450	180	-1.234	-0.331	0.236	0.380
NADLER_OBESITY_UP	2451	55	-1.236	-0.369	0.234	0.378
FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_UP	2452	463	-1.236	-0.33	0.234	0.378
RASHI_RESPONSE_TO_IONIZING_RADIATION_3	2453	42	-1.237	-0.364	0.234	0.377
REACTOME_PRE_NOTCH_PROCESSING_IN_GOLGI	2454	18	-1.237	-0.479	0.233	0.377
REACTOME_GLYCOGEN_METABOLISM	2455	24	-1.237	-0.46	0.233	0.377
WP_ANDROGEN_RECEPTOR_SIGNALING_PATHWAY	2456	78	-1.237	-0.44	0.233	0.377
MULLIGHAN_MLL_SIGNATURE_1_UP	2457	322	-1.237	-0.308	0.233	0.377
FOSTER_KDM1A_TARGETS_DN	2458	154	-1.238	-0.349	0.232	0.376
REACTOME_CYTOSOLIC_SULFONATION_OF_SMALL_MOLECULES	2459	20	-1.238	-0.406	0.232	0.376
REACTOME_PROTEIN_PROTEIN_INTERACTIONS_AT_SYNAPSES	2460	83	-1.239	-0.346	0.232	0.376
WP_CANCER_IMMUNOTHERAPY_BY_PD1_BLOCKADE	2461	23	-1.239	-0.424	0.232	0.376
VANTVEER_BREAST_CANCER_POOR_PROGNOSIS	2462	38	-1.239	-0.348	0.232	0.376
UEDA_PERIFERAL_CLOCK	2463	135	-1.239	-0.387	0.231	0.375
SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_DN	2464	66	-1.239	-0.313	0.231	0.375
HALLMARK_P53_PATHWAY	2465	177	-1.24	-0.431	0.231	0.375
REACTOME_G_PROTEIN_ACTIVATION	2466	24	-1.24	-0.39	0.231	0.375
PARENT_MTOR_SIGNALING_DN	2467	36	-1.24	-0.414	0.231	0.375
DELASERNA_MYOD_TARGETS_UP	2468	78	-1.24	-0.327	0.231	0.375
REACTOME_RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS	2469	71	-1.241	-0.393	0.230	0.374
WP_MITOCHONDRIAL_IMMUNE_RESPONSE_TO_SARSCOV2	2470	27	-1.241	-0.377	0.230	0.374
FONTAINE_FOLLICULAR_THYROID_ADENOMA_UP	2471	62	-1.241	-0.333	0.230	0.374
REACTOME_P75NTR_SIGNALS_VIA_NF_KB	2472	15	-1.241	-0.602	0.229	0.374
NADERI_BREAST_CANCER_PROGNOSIS_UP	2473	39	-1.241	-0.364	0.229	0.374
WHITFIELD_CELL_CYCLE_LITERATURE	2474	42	-1.242	-0.459	0.229	0.374
REACTOME_RHOJ_GTPASE_CYCLE	2475	49	-1.242	-0.393	0.229	0.373
REACTOME_NGF_STIMULATED_TRANSCRIPTION	2476	38	-1.242	-0.369	0.229	0.373
OKUMURA_INFLAMMATORY_RESPONSE_LPS	2477	149	-1.242	-0.322	0.228	0.373
BORCZUK_MALIGNANT_MESOTHELIOMA_DN	2478	89	-1.243	-0.388	0.228	0.373
REACTOME_INTERLEUKIN_12_SIGNALING	2479	41	-1.244	-0.409	0.227	0.371
THUM_SYSTOLIC_HEART_FAILURE_DN	2480	166	-1.244	-0.355	0.227	0.371
ROSS_AML_WITH_AML1_ETO_FUSION	2481	64	-1.244	-0.304	0.227	0.371
MA_MYELOID_DIFFERENTIATION_DN	2482	40	-1.244	-0.346	0.227	0.371
PETRETTO_CARDIAC_HYPERTROPHY	2483	31	-1.244	-0.432	0.226	0.371
GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_UP	2484	52	-1.245	-0.466	0.226	0.371
REACTOME_ACTIVATION_OF_KAINATE_RECEPTORS_UPON_GLUTAMATE_BINDING	2485	30	-1.245	-0.411	0.226	0.371
WANG_HCP_PROSTATE_CANCER	2486	92	-1.246	-0.398	0.225	0.368
AKL_HTLV1_INFECTION_UP	2487	22	-1.247	-0.539	0.225	0.368
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION	2488	244	-1.247	-0.364	0.225	0.368
POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_DN	2489	56	-1.247	-0.37	0.224	0.368
ONO_AML1_TARGETS_DN	2490	35	-1.247	-0.37	0.224	0.367
MCCLUNG_DELTA_FOSB_TARGETS_2WK	2491	35	-1.247	-0.328	0.224	0.367
REACTOME_PKA_MEDIATED_PHOSPHORYLATION_OF_CREB	2492	20	-1.248	-0.358	0.224	0.367
WP_REGUCALCIN_IN_PROXIMAL_TUBULE_EPITHELIAL_KIDNEY_CELLS	2493	27	-1.248	-0.408	0.223	0.367
FURUKAWA_DUSP6_TARGETS_PCI35_DN	2494	61	-1.249	-0.418	0.223	0.367
BIOCARTA_CREB_PATHWAY	2495	21	-1.249	-0.482	0.223	0.367
REACTOME_INSULIN_PROCESSING	2496	24	-1.249	-0.383	0.222	0.366
GENTILE_UV_RESPONSE_CLUSTER_D6	2497	29	-1.249	-0.502	0.222	0.366
FIGUEROA_AML_METHYLATION_CLUSTER_3_DN	2498	28	-1.249	-0.405	0.222	0.366
REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_BCR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS	2499	35	-1.249	-0.391	0.222	0.366
WP_1Q211_COPY_NUMBER_VARIATION_SYNDROME	2500	24	-1.25	-0.424	0.222	0.366
CAVARD_LIVER_CANCER_MALIGNANT_VS_BENIGN	2501	28	-1.25	-0.383	0.221	0.365
SA_CASPASE_CASCADE	2502	18	-1.25	-0.387	0.221	0.365
REACTOME_NOTCH3_ACTIVATION_AND_TRANSMISSION_OF_SIGNAL_TO_THE_NUCLEUS	2503	23	-1.25	-0.496	0.221	0.365
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_DN	2504	262	-1.251	-0.301	0.221	0.365
WILLIAMS_ESR2_TARGETS_UP	2505	23	-1.251	-0.419	0.220	0.365
BROWNE_HCMV_INFECTION_4HR_UP	2506	47	-1.252	-0.307	0.220	0.364
SUNG_METASTASIS_STROMA_DN	2507	42	-1.252	-0.436	0.220	0.364
KYNG_DNA_DAMAGE_BY_4NQO_OR_UV	2508	55	-1.252	-0.355	0.220	0.364
YAGI_AML_WITH_11Q23_REARRANGED	2509	299	-1.252	-0.302	0.220	0.364
SCHLESINGER_H3K27ME3_IN_NORMAL_AND_METHYLATED_IN_CANCER	2510	26	-1.253	-0.486	0.219	0.363
WP_SYNAPTIC_VESICLE_PATHWAY	2511	50	-1.253	-0.337	0.219	0.363
PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_UP	2512	29	-1.253	-0.388	0.219	0.363
LU_AGING_BRAIN_DN	2513	135	-1.253	-0.298	0.219	0.363
WP_47_HEDGEHOG_SIGNALING_PATHWAY	2514	15	-1.253	-0.484	0.219	0.363
HORTON_SREBF_TARGETS	2515	23	-1.253	-0.55	0.219	0.363
FALVELLA_SMOKERS_WITH_LUNG_CANCER	2516	67	-1.253	-0.374	0.218	0.363
MARTINEZ_RESPONSE_TO_TRABECTEDIN	2517	42	-1.254	-0.43	0.218	0.363
VALK_AML_WITH_11Q23_REARRANGED	2518	16	-1.254	-0.478	0.218	0.363
VANHARANTA_UTERINE_FIBROID_DN	2519	57	-1.254	-0.349	0.218	0.363
WP_EICOSANOID_SYNTHESIS	2520	23	-1.254	-0.418	0.218	0.362
REACTOME_FCGR3A_MEDIATED_IL10_SYNTHESIS	2521	44	-1.255	-0.332	0.217	0.362
CHEN_LVAD_SUPPORT_OF_FAILING_HEART_DN	2522	41	-1.255	-0.361	0.217	0.362
NABA_ECM_AFFILIATED	2523	140	-1.255	-0.381	0.217	0.362
WP_OVERVIEW_OF_PROINFLAMMATORY_AND_PROFIBROTIC_MEDIATORS	2524	111	-1.255	-0.409	0.217	0.362
SHIPP_DLBCL_CURED_VS_FATAL_UP	2525	38	-1.255	-0.461	0.217	0.362
HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_DN	2526	27	-1.255	-0.479	0.217	0.362
GENTILE_UV_RESPONSE_CLUSTER_D8	2527	32	-1.256	-0.556	0.217	0.362
WP_ZINC_HOMEOSTASIS	2528	34	-1.256	-0.433	0.217	0.362
PID_NOTCH_PATHWAY	2529	54	-1.256	-0.404	0.216	0.362
REACTOME_SUMOYLATION_OF_INTRACELLULAR_RECEPTORS	2530	30	-1.256	-0.371	0.216	0.362
WIKMAN_ASBESTOS_LUNG_CANCER_DN	2531	25	-1.256	-0.381	0.216	0.362
WP_LEPTININSULIN_SIGNALING_OVERLAP	2532	17	-1.256	-0.41	0.216	0.362
JI_RESPONSE_TO_FSH_UP	2533	58	-1.256	-0.443	0.216	0.362
WANG_BARRETTS_ESOPHAGUS_AND_ESOPHAGUS_CANCER_UP	2534	26	-1.258	-0.381	0.215	0.360
REACTOME_THE_NLRP3_INFLAMMASOME	2535	15	-1.258	-0.516	0.214	0.360
KORKOLA_EMBRYONAL_CARCINOMA_UP	2536	35	-1.259	-0.386	0.214	0.359
KEGG_BASAL_CELL_CARCINOMA	2537	54	-1.259	-0.365	0.214	0.359
BRACHAT_RESPONSE_TO_CISPLATIN	2538	19	-1.259	-0.54	0.214	0.359
REACTOME_RIPK1_MEDIATED_REGULATED_NECROSIS	2539	28	-1.259	-0.484	0.213	0.359
REACTOME_CD28_CO_STIMULATION	2540	31	-1.259	-0.401	0.213	0.359
STOSSI_RESPONSE_TO_ESTRADIOL	2541	42	-1.26	-0.339	0.213	0.358
SHAFFER_IRF4_TARGETS_IN_PLASMA_CELL_VS_MATURE_B_LYMPHOCYTE	2542	64	-1.26	-0.42	0.212	0.357
AMIT_SERUM_RESPONSE_480_MCF10A	2543	29	-1.26	-0.502	0.212	0.357
LENAOUR_DENDRITIC_CELL_MATURATION_UP	2544	111	-1.261	-0.277	0.212	0.357
REACTOME_SYNAPTIC_ADHESION_LIKE_MOLECULES	2545	21	-1.261	-0.458	0.212	0.357
SUNG_METASTASIS_STROMA_UP	2546	94	-1.261	-0.424	0.212	0.357
WP_EICOSANOID_METABOLISM_VIA_LIPOOXYGENASES_LOX	2547	24	-1.261	-0.453	0.212	0.357
LIU_VMYB_TARGETS_UP	2548	106	-1.261	-0.408	0.212	0.357
LINDVALL_IMMORTALIZED_BY_TERT_UP	2549	59	-1.262	-0.398	0.211	0.356
SUZUKI_AMPLIFIED_IN_ORAL_CANCER	2550	17	-1.262	-0.435	0.211	0.356
LEI_MYB_TARGETS	2551	291	-1.262	-0.428	0.211	0.356
BIOCARTA_IGF1R_PATHWAY	2552	23	-1.262	-0.512	0.211	0.356
REACTOME_INTERLEUKIN_2_FAMILY_SIGNALING	2553	44	-1.263	-0.361	0.210	0.356
YAMASHITA_METHYLATED_IN_PROSTATE_CANCER	2554	56	-1.263	-0.375	0.210	0.356
REACTOME_SIGNALING_BY_ACTIVIN	2555	15	-1.263	-0.54	0.210	0.355
MARTENS_BOUND_BY_PML_RARA_FUSION	2556	364	-1.263	-0.325	0.210	0.355
LIAN_LIPA_TARGETS_3M	2557	59	-1.263	-0.412	0.210	0.355
DORSAM_HOXA9_TARGETS_DN	2558	31	-1.264	-0.387	0.210	0.355
PID_WNT_CANONICAL_PATHWAY	2559	18	-1.264	-0.487	0.209	0.355
GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_UP	2560	76	-1.264	-0.402	0.209	0.355
RUAN_RESPONSE_TO_TNF_TROGLITAZONE_DN	2561	37	-1.265	-0.351	0.208	0.353
REACTOME_INACTIVATION_OF_CSF3_G_CSF_SIGNALING	2562	23	-1.266	-0.432	0.208	0.353
JAATINEN_HEMATOPOIETIC_STEM_CELL_DN	2563	207	-1.266	-0.343	0.208	0.353
REACTOME_NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION	2564	190	-1.266	-0.322	0.207	0.352
MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_DN	2565	102	-1.267	-0.342	0.207	0.352
WP_FAS_LIGAND_PATHWAY_AND_STRESS_INDUCTION_OF_HEAT_SHOCK_PROTEINS	2566	42	-1.267	-0.43	0.207	0.352
TERAMOTO_OPN_TARGETS_CLUSTER_7	2567	16	-1.267	-0.439	0.207	0.352
MORI_IMMATURE_B_LYMPHOCYTE_UP	2568	41	-1.268	-0.353	0.206	0.351
REACTOME_NUCLEOTIDE_CATABOLISM	2569	29	-1.268	-0.363	0.206	0.351
WP_BLADDER_CANCER	2570	37	-1.268	-0.444	0.206	0.351
DIRMEIER_LMP1_RESPONSE_EARLY	2571	59	-1.268	-0.401	0.206	0.351
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_UP	2572	31	-1.268	-0.506	0.206	0.351
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_16	2573	69	-1.268	-0.348	0.206	0.351
WU_APOPTOSIS_BY_CDKN1A_VIA_TP53	2574	42	-1.268	-0.496	0.205	0.351
MEBARKI_HCC_PROGENITOR_WNT_UP_CTNNB1_DEPENDENT_BLOCKED_BY_FZD8CRD	2575	39	-1.269	-0.338	0.205	0.351
HOFFMANN_PRE_BI_TO_LARGE_PRE_BII_LYMPHOCYTE_UP	2576	25	-1.269	-0.39	0.205	0.351
KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY	2577	51	-1.27	-0.307	0.204	0.349
LU_EZH2_TARGETS_DN	2578	307	-1.27	-0.404	0.204	0.349
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_AND_COMPLEXES	2579	56	-1.27	-0.434	0.204	0.349
SIMBULAN_UV_RESPONSE_IMMORTALIZED_DN	2580	30	-1.271	-0.543	0.203	0.349
HALLMARK_ESTROGEN_RESPONSE_LATE	2581	193	-1.271	-0.354	0.203	0.349
PID_FOXO_PATHWAY	2582	43	-1.271	-0.528	0.203	0.348
REACTOME_ZBP1_DAI_MEDIATED_INDUCTION_OF_TYPE_I_IFNS	2583	20	-1.272	-0.456	0.203	0.348
MCCLUNG_CREB1_TARGETS_UP	2584	84	-1.272	-0.308	0.202	0.348
DIAZ_CHRONIC_MYELOGENOUS_LEUKEMIA_DN	2585	107	-1.272	-0.315	0.202	0.348
PIEPOLI_LGI1_TARGETS_DN	2586	16	-1.272	-0.434	0.202	0.348
WP_HOSTPATHOGEN_INTERACTION_OF_HUMAN_CORONAVIRUSES_AUTOPHAGY	2587	17	-1.273	-0.515	0.201	0.346
ZHAN_MULTIPLE_MYELOMA_PR_UP	2588	35	-1.273	-0.478	0.201	0.346
REACTOME_EFFECTS_OF_PIP2_HYDROLYSIS	2589	24	-1.274	-0.383	0.201	0.346
GENTILE_UV_RESPONSE_CLUSTER_D4	2590	47	-1.274	-0.597	0.201	0.346
REACTOME_PLASMA_LIPOPROTEIN_ASSEMBLY_REMODELING_AND_CLEARANCE	2591	67	-1.274	-0.358	0.201	0.346
MCCABE_BOUND_BY_HOXC6	2592	307	-1.274	-0.249	0.201	0.346
REACTOME_ADP_SIGNALLING_THROUGH_P2Y_PURINOCEPTOR_1	2593	25	-1.274	-0.391	0.201	0.346
BASAKI_YBX1_TARGETS_UP	2594	231	-1.274	-0.43	0.200	0.346
HU_GENOTOXIC_DAMAGE_4HR	2595	32	-1.275	-0.497	0.200	0.345
TIEN_INTESTINE_PROBIOTICS_2HR_DN	2596	75	-1.275	-0.514	0.200	0.345
KEGG_PRION_DISEASES	2597	35	-1.275	-0.357	0.200	0.345
IKEDA_MIR30_TARGETS_UP	2598	106	-1.275	-0.464	0.200	0.345
STEIN_ESR1_TARGETS	2599	76	-1.276	-0.355	0.199	0.344
WP_ETHANOL_EFFECTS_ON_HISTONE_MODIFICATIONS	2600	29	-1.276	-0.37	0.199	0.344
BIOCARTA_HIVNEF_PATHWAY	2601	53	-1.276	-0.41	0.199	0.344
RAO_BOUND_BY_SALL4_ISOFORM_B	2602	418	-1.276	-0.307	0.198	0.344
PHONG_TNF_RESPONSE_VIA_P38_COMPLETE	2603	191	-1.276	-0.435	0.198	0.344
LIM_MAMMARY_LUMINAL_MATURE_DN	2604	83	-1.277	-0.366	0.198	0.343
REACTOME_RHOF_GTPASE_CYCLE	2605	35	-1.277	-0.489	0.198	0.343
MILI_PSEUDOPODIA_CHEMOTAXIS_DN	2606	352	-1.278	-0.433	0.197	0.342
RATTENBACHER_BOUND_BY_CELF1	2607	306	-1.278	-0.274	0.197	0.342
SUBTIL_PROGESTIN_TARGETS	2608	32	-1.278	-0.476	0.197	0.342
RAMALHO_STEMNESS_DN	2609	64	-1.278	-0.363	0.197	0.342
DORMOY_ELAVL1_TARGETS	2610	17	-1.279	-0.446	0.197	0.342
TURASHVILI_BREAST_NORMAL_DUCTAL_VS_LOBULAR_UP	2611	48	-1.279	-0.469	0.197	0.342
BRIDEAU_IMPRINTED_GENES	2612	61	-1.279	-0.306	0.196	0.342
SMID_BREAST_CANCER_RELAPSE_IN_BONE_UP	2613	86	-1.279	-0.369	0.196	0.342
LEE_AGING_MUSCLE_DN	2614	36	-1.28	-0.375	0.196	0.341
LEE_CALORIE_RESTRICTION_NEOCORTEX_UP	2615	59	-1.28	-0.336	0.195	0.340
WP_WNT_SIGNALING_IN_KIDNEY_DISEASE	2616	35	-1.28	-0.39	0.195	0.340
JI_RESPONSE_TO_FSH_DN	2617	50	-1.281	-0.535	0.195	0.340
ZHAN_VARIABLE_EARLY_DIFFERENTIATION_GENES_UP	2618	17	-1.281	-0.442	0.195	0.340
WESTON_VEGFA_TARGETS_3HR	2619	61	-1.281	-0.372	0.195	0.340
HALLMARK_BILE_ACID_METABOLISM	2620	110	-1.281	-0.31	0.195	0.340
WP_FAMILIAL_PARTIAL_LIPODYSTROPHY	2621	29	-1.281	-0.371	0.195	0.340
WP_REGULATION_OF_SISTER_CHROMATID_SEPARATION_AT_THE_METAPHASEANAPHASE_TRANSITION	2622	15	-1.281	-0.575	0.194	0.340
FUKUSHIMA_TNFSF11_TARGETS	2623	15	-1.282	-0.437	0.194	0.340
WP_MALE_INFERTILITY	2624	126	-1.282	-0.272	0.194	0.340
SU_TESTIS	2625	71	-1.282	-0.357	0.194	0.339
REACTOME_G_PROTEIN_MEDIATED_EVENTS	2626	53	-1.282	-0.334	0.194	0.339
NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON	2627	111	-1.282	-0.33	0.194	0.339
WP_GPR143_IN_MELANOCYTES_AND_RETINAL_PIGMENT_EPITHELIUM_CELLS	2628	27	-1.282	-0.396	0.193	0.339
SIG_PIP3_SIGNALING_IN_CARDIAC_MYOCTES	2629	63	-1.283	-0.422	0.193	0.339
BROWNE_HCMV_INFECTION_1HR_UP	2630	49	-1.283	-0.336	0.193	0.339
ISHIDA_E2F_TARGETS	2631	47	-1.283	-0.468	0.193	0.339
WP_CHROMOSOMAL_AND_MICROSATELLITE_INSTABILITY_IN_COLORECTAL_CANCER	2632	71	-1.283	-0.41	0.193	0.339
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_WS	2633	28	-1.283	-0.458	0.193	0.339
DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN	2634	146	-1.284	-0.329	0.192	0.338
REACTOME_FRS_MEDIATED_FGFR1_SIGNALING	2635	23	-1.284	-0.397	0.192	0.338
MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_UP	2636	105	-1.284	-0.347	0.192	0.338
LIU_VAV3_PROSTATE_CARCINOGENESIS_DN	2637	15	-1.284	-0.475	0.192	0.338
WP_HEAD_AND_NECK_SQUAMOUS_CELL_CARCINOMA	2638	66	-1.284	-0.476	0.192	0.338
MULLIGHAN_NPM1_SIGNATURE_3_DN	2639	134	-1.285	-0.328	0.192	0.338
AMIT_DELAYED_EARLY_GENES	2640	17	-1.285	-0.625	0.191	0.337
MCDOWELL_ACUTE_LUNG_INJURY_DN	2641	44	-1.285	-0.319	0.191	0.337
NIKOLSKY_BREAST_CANCER_5P15_AMPLICON	2642	20	-1.286	-0.488	0.191	0.337
WP_FOLATE_METABOLISM	2643	65	-1.286	-0.315	0.191	0.337
WP_NEURAL_CREST_DIFFERENTIATION	2644	98	-1.286	-0.337	0.190	0.336
WP_CARDIAC_PROGENITOR_DIFFERENTIATION	2645	49	-1.286	-0.432	0.190	0.336
NABA_ECM_GLYCOPROTEINS	2646	162	-1.287	-0.373	0.190	0.336
REACTOME_INTERFERON_ALPHA_BETA_SIGNALING	2647	69	-1.288	-0.34	0.189	0.334
BALDWIN_PRKCI_TARGETS_UP	2648	33	-1.288	-0.476	0.189	0.334
SESTO_RESPONSE_TO_UV_C4	2649	16	-1.288	-0.53	0.189	0.334
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_4NQO_IN_WS	2650	33	-1.288	-0.434	0.189	0.334
GENTILE_UV_RESPONSE_CLUSTER_D1	2651	15	-1.288	-0.566	0.189	0.334
REICHERT_MITOSIS_LIN9_TARGETS	2652	25	-1.288	-0.591	0.188	0.334
KEGG_APOPTOSIS	2653	81	-1.289	-0.375	0.188	0.334
FINETTI_BREAST_CANCER_KINOME_RED	2654	15	-1.289	-0.619	0.188	0.334
AMIT_SERUM_RESPONSE_40_MCF10A	2655	27	-1.289	-0.454	0.188	0.333
YORDY_RECIPROCAL_REGULATION_BY_ETS1_AND_SP100_UP	2656	16	-1.29	-0.479	0.187	0.333
PID_BETA_CATENIN_DEG_PATHWAY	2657	15	-1.29	-0.523	0.187	0.333
CHO_NR4A1_TARGETS	2658	27	-1.29	-0.414	0.187	0.333
REACTOME_NEGATIVE_REGULATION_OF_MET_ACTIVITY	2659	21	-1.29	-0.494	0.187	0.333
WP_CALCIUM_REGULATION_IN_CARDIAC_CELLS	2660	146	-1.291	-0.317	0.187	0.333
REACTOME_THE_PHOTOTRANSDUCTION_CASCADE	2661	32	-1.291	-0.394	0.186	0.332
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450	2662	61	-1.291	-0.402	0.186	0.332
REACTOME_REGULATED_NECROSIS	2663	50	-1.291	-0.47	0.186	0.332
GUO_TARGETS_OF_IRS1_AND_IRS2	2664	83	-1.291	-0.351	0.186	0.332
CHIANG_LIVER_CANCER_SUBCLASS_POLYSOMY7_UP	2665	66	-1.291	-0.367	0.186	0.332
REACTOME_IKK_COMPLEX_RECRUITMENT_MEDIATED_BY_RIP1	2666	23	-1.291	-0.476	0.186	0.332
BREDEMEYER_RAG_SIGNALING_NOT_VIA_ATM_DN	2667	49	-1.291	-0.318	0.186	0.332
REACTOME_DAG_AND_IP3_SIGNALING	2668	40	-1.292	-0.336	0.186	0.332
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN	2669	33	-1.292	-0.455	0.185	0.332
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_TRANS	2670	134	-1.292	-0.363	0.185	0.332
ZHENG_GLIOBLASTOMA_PLASTICITY_DN	2671	55	-1.292	-0.337	0.185	0.332
REACTOME_HS_GAG_DEGRADATION	2672	21	-1.293	-0.477	0.184	0.331
GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_DN	2673	129	-1.294	-0.419	0.184	0.329
KIM_HYPOXIA	2674	15	-1.294	-0.523	0.183	0.329
FISCHER_G1_S_CELL_CYCLE	2675	166	-1.295	-0.365	0.183	0.329
KAAB_HEART_ATRIUM_VS_VENTRICLE_UP	2676	231	-1.295	-0.313	0.183	0.329
PID_HIF1_TFPATHWAY	2677	59	-1.295	-0.372	0.183	0.328
OHM_METHYLATED_IN_ADULT_CANCERS	2678	27	-1.296	-0.398	0.182	0.327
PECE_MAMMARY_STEM_CELL_DN	2679	109	-1.296	-0.441	0.182	0.327
CHESLER_BRAIN_HIGHEST_GENETIC_VARIANCE	2680	29	-1.296	-0.387	0.182	0.327
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_UV_IN_OLD	2681	22	-1.296	-0.481	0.182	0.327
WP_PHOTODYNAMIC_THERAPYINDUCED_NFE2L2_NRF2_SURVIVAL_SIGNALING	2682	23	-1.296	-0.391	0.182	0.327
HALLMARK_XENOBIOTIC_METABOLISM	2683	191	-1.298	-0.304	0.181	0.326
REACTOME_REGULATION_OF_IFNA_IFNB_SIGNALING	2684	26	-1.298	-0.438	0.181	0.326
LEIN_LOCALIZED_TO_PROXIMAL_DENDRITES	2685	30	-1.298	-0.4	0.181	0.326
MIKKELSEN_NPC_ICP_WITH_H3K4ME3	2686	348	-1.298	-0.248	0.180	0.325
WEIGEL_OXIDATIVE_STRESS_BY_TBH_AND_H2O2	2687	32	-1.299	-0.472	0.180	0.325
MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN	2688	129	-1.299	-0.316	0.180	0.325
PID_REG_GR_PATHWAY	2689	79	-1.3	-0.341	0.179	0.324
WP_THYMIC_STROMAL_LYMPHOPOIETIN_TSLP_SIGNALING_PATHWAY	2690	44	-1.301	-0.442	0.178	0.323
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_UP	2691	115	-1.301	-0.409	0.178	0.322
BOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIX	2692	17	-1.301	-0.514	0.178	0.322
WP_2586_ARYL_HYDROCARBON_RECEPTOR_PATHWAY	2693	43	-1.301	-0.474	0.178	0.322
PID_CD40_PATHWAY	2694	30	-1.301	-0.442	0.178	0.322
HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2	2695	17	-1.302	-0.537	0.177	0.322
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES	2696	68	-1.302	-0.403	0.177	0.322
GEORGES_CELL_CYCLE_MIR192_TARGETS	2697	57	-1.302	-0.471	0.177	0.322
REACTOME_RND2_GTPASE_CYCLE	2698	39	-1.302	-0.493	0.177	0.321
NATSUME_RESPONSE_TO_INTERFERON_BETA_DN	2699	46	-1.303	-0.494	0.177	0.321
CROMER_METASTASIS_DN	2700	66	-1.304	-0.495	0.176	0.320
MCBRYAN_PUBERTAL_BREAST_6_7WK_UP	2701	174	-1.304	-0.374	0.176	0.320
MOREAUX_MULTIPLE_MYELOMA_BY_TACI_UP	2702	313	-1.304	-0.372	0.176	0.320
BASAKI_YBX1_TARGETS_DN	2703	321	-1.304	-0.344	0.176	0.320
WP_NAD_METABOLISM_IN_ONCOGENEINDUCED_SENESCENCE_AND_MITOCHONDRIAL_DYSFUNCTIONASSOCIATED_SENESCENCE	2704	22	-1.304	-0.503	0.175	0.320
CROONQUIST_NRAS_SIGNALING_DN	2705	64	-1.305	-0.494	0.175	0.319
SANA_RESPONSE_TO_IFNG_UP	2706	64	-1.305	-0.383	0.175	0.318
APRELIKOVA_BRCA1_TARGETS	2707	43	-1.306	-0.498	0.174	0.318
WP_REGULATION_OF_WNT_BCATENIN_SIGNALING_BY_SMALL_MOLECULE_COMPOUNDS	2708	17	-1.307	-0.45	0.174	0.317
WP_HEART_DEVELOPMENT	2709	42	-1.307	-0.373	0.173	0.317
REACTOME_SHC_MEDIATED_CASCADE_FGFR4	2710	20	-1.307	-0.419	0.173	0.317
KEGG_NON_SMALL_CELL_LUNG_CANCER	2711	52	-1.308	-0.409	0.173	0.316
REACTOME_DISEASES_OF_SIGNAL_TRANSDUCTION_BY_GROWTH_FACTOR_RECEPTORS_AND_SECOND_MESSENGERS	2712	392	-1.308	-0.392	0.173	0.316
REACTOME_TICAM1_RIP1_MEDIATED_IKK_COMPLEX_RECRUITMENT	2713	19	-1.31	-0.556	0.171	0.313
KYNG_DNA_DAMAGE_BY_GAMMA_RADIATION	2714	73	-1.31	-0.358	0.171	0.313
SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_DN	2715	40	-1.31	-0.334	0.171	0.313
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP	2716	153	-1.31	-0.299	0.171	0.313
HOWLIN_CITED1_TARGETS_1_DN	2717	32	-1.311	-0.491	0.170	0.312
CAIRO_HEPATOBLASTOMA_DN	2718	238	-1.311	-0.299	0.170	0.312
MORI_PRE_BI_LYMPHOCYTE_UP	2719	68	-1.312	-0.447	0.170	0.311
HALLMARK_NOTCH_SIGNALING	2720	30	-1.312	-0.472	0.170	0.311
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_MAGENTA_UP	2721	22	-1.312	-0.559	0.169	0.311
PID_LIS1_PATHWAY	2722	27	-1.312	-0.502	0.169	0.311
WU_SILENCED_BY_METHYLATION_IN_BLADDER_CANCER	2723	44	-1.313	-0.371	0.169	0.311
WP_FAMILIAL_HYPERLIPIDEMIA_TYPE_2	2724	15	-1.313	-0.485	0.168	0.310
PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_DN	2725	143	-1.313	-0.334	0.168	0.310
REACTOME_SIGNALING_BY_FGFR2	2726	64	-1.313	-0.426	0.168	0.310
LE_EGR2_TARGETS_DN	2727	99	-1.313	-0.387	0.168	0.310
BIOCARTA_TH1TH2_PATHWAY	2728	21	-1.313	-0.517	0.168	0.310
KEGG_HEDGEHOG_SIGNALING_PATHWAY	2729	54	-1.314	-0.387	0.168	0.310
PID_HDAC_CLASSI_PATHWAY	2730	63	-1.314	-0.443	0.168	0.310
MELLMAN_TUT1_TARGETS_DN	2731	45	-1.314	-0.403	0.167	0.309
FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_DN	2732	83	-1.314	-0.35	0.167	0.309
REACTOME_CA2_PATHWAY	2733	58	-1.315	-0.365	0.167	0.309
REACTOME_REGULATION_OF_PLK1_ACTIVITY_AT_G2_M_TRANSITION	2734	65	-1.315	-0.48	0.167	0.309
JOHNSTONE_PARVB_TARGETS_2_UP	2735	126	-1.316	-0.433	0.166	0.308
ONDER_CDH1_TARGETS_3_UP	2736	18	-1.316	-0.479	0.166	0.307
MCCLUNG_COCAIN_REWARD_4WK	2737	69	-1.316	-0.349	0.166	0.307
ZHU_CMV_8_HR_DN	2738	48	-1.317	-0.457	0.166	0.307
KORKOLA_SEMINOMA_UP	2739	34	-1.317	-0.414	0.165	0.307
REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1	2740	17	-1.318	-0.518	0.164	0.305
ZHAN_EARLY_DIFFERENTIATION_GENES_DN	2741	41	-1.319	-0.391	0.164	0.305
NOUZOVA_METHYLATED_IN_APL	2742	46	-1.319	-0.342	0.164	0.305
WP_BREAST_CANCER_PATHWAY	2743	148	-1.319	-0.323	0.164	0.304
SHIN_B_CELL_LYMPHOMA_CLUSTER_9	2744	17	-1.32	-0.517	0.163	0.304
ZHANG_GATA6_TARGETS_DN	2745	54	-1.32	-0.372	0.163	0.303
REACTOME_SIGNALING_BY_INSULIN_RECEPTOR	2746	76	-1.32	-0.336	0.163	0.303
RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_DN	2747	417	-1.32	-0.314	0.163	0.303
LEIN_NEURON_MARKERS	2748	59	-1.32	-0.35	0.163	0.303
REACTOME_TRAFFICKING_OF_GLUR2_CONTAINING_AMPA_RECEPTORS	2749	16	-1.321	-0.432	0.163	0.303
WANG_RESPONSE_TO_BEXAROTENE_DN	2750	28	-1.321	-0.404	0.163	0.303
MURAKAMI_UV_RESPONSE_6HR_UP	2751	31	-1.321	-0.478	0.163	0.303
REACTOME_G_BETA_GAMMA_SIGNALLING_THROUGH_CDC42	2752	20	-1.321	-0.459	0.163	0.303
WP_CIRCADIAN_RHYTHM_GENES	2753	178	-1.321	-0.305	0.163	0.303
ENK_UV_RESPONSE_EPIDERMIS_UP	2754	256	-1.321	-0.412	0.162	0.303
LEE_LIVER_CANCER_E2F1_DN	2755	57	-1.321	-0.326	0.162	0.303
WP_GPR40_PATHWAY	2756	15	-1.322	-0.493	0.162	0.303
REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX	2757	90	-1.323	-0.51	0.161	0.302
PROVENZANI_METASTASIS_DN	2758	128	-1.323	-0.458	0.161	0.302
REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY	2759	64	-1.323	-0.357	0.161	0.302
REACTOME_TNF_SIGNALING	2760	37	-1.323	-0.462	0.161	0.302
LEE_AGING_CEREBELLUM_UP	2761	79	-1.323	-0.331	0.161	0.302
KEGG_ENDOMETRIAL_CANCER	2762	51	-1.323	-0.438	0.161	0.302
WP_APOPTOSISRELATED_NETWORK_DUE_TO_ALTERED_NOTCH3_IN_OVARIAN_CANCER	2763	51	-1.324	-0.506	0.160	0.301
ABBUD_LIF_SIGNALING_1_DN	2764	24	-1.324	-0.396	0.160	0.300
REACTOME_SIGNALING_BY_NOTCH2	2765	29	-1.325	-0.473	0.159	0.300
MITSIADES_RESPONSE_TO_APLIDIN_UP	2766	345	-1.325	-0.386	0.159	0.299
REACTOME_AURKA_ACTIVATION_BY_TPX2	2767	53	-1.326	-0.473	0.159	0.299
SU_PLACENTA	2768	26	-1.326	-0.442	0.158	0.298
PID_INTEGRIN2_PATHWAY	2769	28	-1.327	-0.501	0.158	0.298
HENDRICKS_SMARCA4_TARGETS_DN	2770	43	-1.327	-0.345	0.158	0.298
SEAVEY_EPITHELIOID_HEMANGIOENDOTHELIOMA	2771	78	-1.327	-0.334	0.158	0.298
HOWLIN_CITED1_TARGETS_2_UP	2772	17	-1.327	-0.487	0.158	0.298
BIOCARTA_TNFR1_PATHWAY	2773	29	-1.327	-0.479	0.157	0.297
REACTOME_THROMBOXANE_SIGNALLING_THROUGH_TP_RECEPTOR	2774	24	-1.328	-0.431	0.157	0.297
WP_PHOTODYNAMIC_THERAPYINDUCED_HIF1_SURVIVAL_SIGNALING	2775	34	-1.328	-0.435	0.157	0.297
KOBAYASHI_RESPONSE_TO_ROMIDEPSIN	2776	16	-1.328	-0.434	0.157	0.297
SENESE_HDAC3_TARGETS_DN	2777	396	-1.329	-0.372	0.156	0.296
REACTOME_INTERLEUKIN_7_SIGNALING	2778	23	-1.329	-0.424	0.156	0.296
GUILLAUMOND_KLF10_TARGETS_UP	2779	46	-1.329	-0.359	0.156	0.296
WP_COMPLEMENT_SYSTEM	2780	94	-1.329	-0.387	0.156	0.296
SENESE_HDAC2_TARGETS_UP	2781	99	-1.329	-0.447	0.156	0.296
ZHANG_BREAST_CANCER_PROGENITORS_DN	2782	119	-1.329	-0.374	0.156	0.296
SENESE_HDAC1_TARGETS_UP	2783	369	-1.33	-0.411	0.156	0.296
CAIRO_LIVER_DEVELOPMENT_DN	2784	213	-1.33	-0.335	0.156	0.296
VALK_AML_CLUSTER_2	2785	25	-1.33	-0.403	0.156	0.296
MOROSETTI_FACIOSCAPULOHUMERAL_MUSCULAR_DISTROPHY_UP	2786	17	-1.331	-0.421	0.155	0.295
RIGGINS_TAMOXIFEN_RESISTANCE_DN	2787	189	-1.331	-0.419	0.154	0.294
MURAKAMI_UV_RESPONSE_24HR	2788	20	-1.332	-0.482	0.154	0.293
MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3	2789	105	-1.332	-0.449	0.154	0.293
ZHU_CMV_ALL_DN	2790	113	-1.332	-0.415	0.154	0.293
JEON_SMAD6_TARGETS_UP	2791	19	-1.332	-0.584	0.154	0.293
BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_UP	2792	338	-1.333	-0.33	0.153	0.293
MCCABE_HOXC6_TARGETS_DN	2793	18	-1.333	-0.478	0.153	0.292
THUM_SYSTOLIC_HEART_FAILURE_UP	2794	362	-1.333	-0.312	0.153	0.292
REACTOME_SIGNALING_BY_ALK_IN_CANCER	2795	50	-1.333	-0.515	0.153	0.292
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_UP	2796	56	-1.333	-0.417	0.153	0.292
BIOCARTA_ETS_PATHWAY	2797	17	-1.334	-0.465	0.153	0.292
MOREIRA_RESPONSE_TO_TSA_DN	2798	18	-1.334	-0.486	0.152	0.292
FERRANDO_TAL1_NEIGHBORS	2799	17	-1.334	-0.493	0.152	0.291
KENNY_CTNNB1_TARGETS_UP	2800	42	-1.335	-0.4	0.151	0.290
REACTOME_MISCELLANEOUS_TRANSPORT_AND_BINDING_EVENTS	2801	17	-1.335	-0.438	0.151	0.290
WP_VEGFAVEGFR2_SIGNALING_PATHWAY	2802	389	-1.336	-0.405	0.151	0.290
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_23	2803	17	-1.336	-0.491	0.151	0.290
PID_ALK1_PATHWAY	2804	26	-1.336	-0.485	0.151	0.290
KEGG_ALDOSTERONE_REGULATED_SODIUM_REABSORPTION	2805	40	-1.337	-0.387	0.151	0.289
REACTOME_SIGNALING_BY_PDGFR_IN_DISEASE	2806	19	-1.337	-0.546	0.150	0.289
RIZ_ERYTHROID_DIFFERENTIATION_CCNE1	2807	38	-1.337	-0.423	0.150	0.288
NIKOLSKY_BREAST_CANCER_7Q21_Q22_AMPLICON	2808	55	-1.337	-0.346	0.150	0.288
REACTOME_RAB_GERANYLGERANYLATION	2809	57	-1.337	-0.417	0.150	0.288
JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_DN	2810	35	-1.338	-0.372	0.150	0.288
CHEN_PDGF_TARGETS	2811	16	-1.338	-0.574	0.149	0.287
REACTOME_CASPASE_ACTIVATION_VIA_EXTRINSIC_APOPTOTIC_SIGNALLING_PATHWAY	2812	25	-1.339	-0.412	0.149	0.287
ENK_UV_RESPONSE_EPIDERMIS_DN	2813	459	-1.339	-0.404	0.149	0.287
LIU_OVARIAN_CANCER_TUMORS_AND_XENOGRAFTS_KINASES_DN	2814	33	-1.339	-0.47	0.149	0.287
CHANDRAN_METASTASIS_TOP50_DN	2815	38	-1.339	-0.507	0.148	0.287
BRACHAT_RESPONSE_TO_CAMPTOTHECIN_UP	2816	21	-1.339	-0.582	0.148	0.287
MARKEY_RB1_ACUTE_LOF_DN	2817	203	-1.339	-0.323	0.148	0.287
RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_UP	2818	351	-1.341	-0.327	0.148	0.285
WP_ENDOMETRIAL_CANCER	2819	62	-1.341	-0.455	0.147	0.285
PLASARI_TGFB1_TARGETS_10HR_DN	2820	230	-1.341	-0.304	0.147	0.285
WIELAND_UP_BY_HBV_INFECTION	2821	93	-1.341	-0.341	0.147	0.285
LIAN_LIPA_TARGETS_6M	2822	74	-1.341	-0.42	0.147	0.285
WP_REGULATORY_CIRCUITS_OF_THE_STAT3_SIGNALING_PATHWAY	2823	70	-1.342	-0.359	0.147	0.285
NIKOLSKY_BREAST_CANCER_20Q11_AMPLICON	2824	24	-1.342	-0.497	0.147	0.285
SESTO_RESPONSE_TO_UV_C8	2825	67	-1.342	-0.55	0.146	0.284
BONCI_TARGETS_OF_MIR15A_AND_MIR16_1	2826	83	-1.342	-0.365	0.146	0.284
MORI_MATURE_B_LYMPHOCYTE_UP	2827	82	-1.343	-0.318	0.146	0.284
WP_INITIATION_OF_TRANSCRIPTION_AND_TRANSLATION_ELONGATION_AT_THE_HIV1_LTR	2828	27	-1.343	-0.463	0.146	0.284
JAZAG_TGFB1_SIGNALING_VIA_SMAD4_DN	2829	57	-1.343	-0.373	0.146	0.283
NAGASHIMA_NRG1_SIGNALING_UP	2830	151	-1.343	-0.449	0.145	0.283
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN	2831	105	-1.344	-0.502	0.145	0.282
REACTOME_METABOLISM_OF_STEROIDS	2832	140	-1.344	-0.344	0.145	0.282
RIGGI_EWING_SARCOMA_PROGENITOR_UP	2833	367	-1.344	-0.281	0.145	0.282
WP_MAMMARY_GLAND_DEVELOPMENT_PATHWAY_PREGNANCY_AND_LACTATION_STAGE_3_OF_4	2834	31	-1.344	-0.377	0.145	0.282
REACTOME_MITOTIC_PROMETAPHASE	2835	150	-1.344	-0.457	0.145	0.282
REACTOME_PHASE_0_RAPID_DEPOLARISATION	2836	30	-1.345	-0.492	0.144	0.282
KEGG_HEMATOPOIETIC_CELL_LINEAGE	2837	84	-1.345	-0.462	0.144	0.282
WP_BARDETBIEDL_SYNDROME	2838	70	-1.345	-0.355	0.144	0.282
REACTOME_SIGNALING_BY_KIT_IN_DISEASE	2839	20	-1.345	-0.548	0.144	0.282
RUTELLA_RESPONSE_TO_HGF_UP	2840	367	-1.346	-0.366	0.144	0.281
KYNG_DNA_DAMAGE_BY_4NQO	2841	34	-1.346	-0.406	0.144	0.281
LANDIS_ERBB2_BREAST_TUMORS_324_DN	2842	139	-1.347	-0.38	0.143	0.280
WP_SARS_CORONAVIRUS_AND_INNATE_IMMUNITY	2843	29	-1.348	-0.433	0.142	0.279
QI_HYPOXIA	2844	117	-1.348	-0.37	0.142	0.279
LIU_CMYB_TARGETS_UP	2845	143	-1.348	-0.402	0.142	0.279
MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_DN	2846	16	-1.348	-0.595	0.142	0.278
MAHAJAN_RESPONSE_TO_IL1A_DN	2847	62	-1.349	-0.445	0.141	0.278
IIZUKA_LIVER_CANCER_PROGRESSION_L1_G1_UP	2848	18	-1.349	-0.533	0.141	0.278
PID_PRL_SIGNALING_EVENTS_PATHWAY	2849	21	-1.349	-0.52	0.141	0.278
DITTMER_PTHLH_TARGETS_DN	2850	66	-1.35	-0.491	0.141	0.277
OUYANG_PROSTATE_CANCER_PROGRESSION_UP	2851	19	-1.35	-0.479	0.140	0.276
REACTOME_ION_TRANSPORT_BY_P_TYPE_ATPASES	2852	54	-1.351	-0.365	0.140	0.275
WP_OSTEOCLAST_SIGNALING	2853	15	-1.352	-0.507	0.139	0.275
WP_INTERACTOME_OF_POLYCOMB_REPRESSIVE_COMPLEX_2_PRC2	2854	16	-1.352	-0.632	0.139	0.275
WP_WNT_SIGNALING	2855	110	-1.352	-0.341	0.139	0.274
WP_THYROID_HORMONES_PRODUCTION_AND_PERIPHERAL_DOWNSTREAM_SIGNALING_EFFECTS	2856	84	-1.353	-0.327	0.139	0.274
SCHLOSSER_SERUM_RESPONSE_UP	2857	106	-1.353	-0.381	0.138	0.273
YAMAZAKI_TCEB3_TARGETS_UP	2858	151	-1.354	-0.415	0.138	0.272
RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_DN	2859	222	-1.354	-0.341	0.137	0.272
KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION	2860	107	-1.354	-0.335	0.137	0.272
WANG_RESPONSE_TO_BEXAROTENE_UP	2861	31	-1.355	-0.378	0.137	0.272
FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_DN	2862	24	-1.355	-0.435	0.137	0.271
WP_NEUROGENESIS_REGULATION_IN_THE_OLFACTORY_EPITHELIUM	2863	52	-1.356	-0.358	0.136	0.270
PEDRIOLI_MIR31_TARGETS_UP	2864	159	-1.356	-0.326	0.136	0.270
PID_TRAIL_PATHWAY	2865	28	-1.357	-0.461	0.136	0.269
NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN	2866	491	-1.357	-0.408	0.135	0.268
BIOCARTA_RAS_PATHWAY	2867	21	-1.357	-0.566	0.135	0.268
XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN	2868	78	-1.358	-0.419	0.135	0.268
ELVIDGE_HIF1A_TARGETS_DN	2869	77	-1.358	-0.414	0.135	0.268
CROONQUIST_IL6_DEPRIVATION_DN	2870	86	-1.358	-0.472	0.135	0.268
WP_COMPLEMENT_AND_COAGULATION_CASCADES	2871	57	-1.359	-0.419	0.134	0.268
REACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION	2872	36	-1.359	-0.409	0.134	0.267
NELSON_RESPONSE_TO_ANDROGEN_UP	2873	72	-1.359	-0.459	0.134	0.267
BIOCARTA_CYTOKINE_PATHWAY	2874	18	-1.359	-0.54	0.134	0.267
REACTOME_O_GLYCOSYLATION_OF_TSR_DOMAIN_CONTAINING_PROTEINS	2875	33	-1.36	-0.471	0.134	0.267
THEODOROU_MAMMARY_TUMORIGENESIS	2876	27	-1.36	-0.498	0.134	0.267
PID_IL6_7_PATHWAY	2877	46	-1.36	-0.445	0.133	0.267
PID_ALPHA_SYNUCLEIN_PATHWAY	2878	31	-1.361	-0.435	0.133	0.265
LOPES_METHYLATED_IN_COLON_CANCER_DN	2879	28	-1.361	-0.382	0.133	0.265
ZHAN_MULTIPLE_MYELOMA_MF_UP	2880	40	-1.361	-0.398	0.132	0.265
WP_T_CELL_RECEPTOR_AND_COSTIMULATORY_SIGNALING	2881	28	-1.361	-0.439	0.132	0.265
RADAEVA_RESPONSE_TO_IFNA1_UP	2882	45	-1.362	-0.437	0.132	0.265
REACTOME_REGULATION_OF_KIT_SIGNALING	2883	15	-1.362	-0.523	0.132	0.265
BOYAULT_LIVER_CANCER_SUBCLASS_G1_UP	2884	91	-1.362	-0.452	0.132	0.265
WP_INTERLEUKIN1_IL1_STRUCTURAL_PATHWAY	2885	46	-1.362	-0.483	0.132	0.265
WANG_CISPLATIN_RESPONSE_AND_XPC_DN	2886	185	-1.362	-0.431	0.132	0.265
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_UP	2887	124	-1.363	-0.373	0.131	0.264
BURTON_ADIPOGENESIS_7	2888	42	-1.363	-0.477	0.131	0.264
ZHU_CMV_24_HR_DN	2889	79	-1.363	-0.427	0.131	0.264
WP_PROSTAGLANDIN_SYNTHESIS_AND_REGULATION	2890	44	-1.364	-0.378	0.131	0.263
DORSAM_HOXA9_TARGETS_UP	2891	32	-1.364	-0.513	0.131	0.263
GRUETZMANN_PANCREATIC_CANCER_UP	2892	316	-1.364	-0.432	0.131	0.263
CHICAS_RB1_TARGETS_SENESCENT	2893	465	-1.364	-0.398	0.130	0.263
POMEROY_MEDULLOBLASTOMA_PROGNOSIS_UP	2894	40	-1.364	-0.435	0.130	0.263
BIOCARTA_IL12_PATHWAY	2895	19	-1.364	-0.508	0.130	0.263
KYNG_DNA_DAMAGE_UP	2896	193	-1.364	-0.324	0.130	0.263
HUANG_FOXA2_TARGETS_UP	2897	39	-1.365	-0.43	0.130	0.263
DAZARD_RESPONSE_TO_UV_NHEK_UP	2898	189	-1.365	-0.41	0.130	0.262
WP_WHITE_FAT_CELL_DIFFERENTIATION	2899	30	-1.366	-0.444	0.129	0.261
MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_UP	2900	216	-1.366	-0.343	0.129	0.261
WP_FRAGILE_X_SYNDROME	2901	111	-1.366	-0.35	0.129	0.261
JOSEPH_RESPONSE_TO_SODIUM_BUTYRATE_DN	2902	54	-1.366	-0.383	0.129	0.261
KIM_WT1_TARGETS_8HR_DN	2903	106	-1.367	-0.385	0.129	0.261
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY	2904	131	-1.367	-0.35	0.128	0.261
REACTOME_BASIGIN_INTERACTIONS	2905	25	-1.367	-0.529	0.128	0.260
ONO_FOXP3_TARGETS_DN	2906	38	-1.368	-0.416	0.128	0.260
REACTOME_CD209_DC_SIGN_SIGNALING	2907	21	-1.368	-0.499	0.128	0.260
REN_ALVEOLAR_RHABDOMYOSARCOMA_DN	2908	379	-1.368	-0.525	0.128	0.260
REACTOME_LONG_TERM_POTENTIATION	2909	23	-1.369	-0.494	0.127	0.259
RIZ_ERYTHROID_DIFFERENTIATION_12HR	2910	35	-1.369	-0.4	0.127	0.259
PID_NFAT_3PATHWAY	2911	49	-1.369	-0.448	0.127	0.258
YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP	2912	75	-1.369	-0.366	0.127	0.258
GENTILE_UV_LOW_DOSE_DN	2913	55	-1.369	-0.479	0.127	0.258
WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN	2914	93	-1.37	-0.456	0.127	0.258
NIKOLSKY_BREAST_CANCER_8P12_P11_AMPLICON	2915	42	-1.37	-0.356	0.126	0.258
KAN_RESPONSE_TO_ARSENIC_TRIOXIDE	2916	111	-1.37	-0.376	0.126	0.258
HALLMARK_ALLOGRAFT_REJECTION	2917	187	-1.37	-0.334	0.126	0.258
LIU_CDX2_TARGETS_UP	2918	35	-1.371	-0.42	0.126	0.257
DOANE_RESPONSE_TO_ANDROGEN_UP	2919	156	-1.371	-0.303	0.126	0.257
DAVICIONI_MOLECULAR_ARMS_VS_ERMS_UP	2920	270	-1.372	-0.349	0.125	0.256
REACTOME_SIGNALING_BY_FGFR1_IN_DISEASE	2921	33	-1.373	-0.437	0.124	0.255
KATSANOU_ELAVL1_TARGETS_DN	2922	120	-1.373	-0.315	0.124	0.254
MAGRANGEAS_MULTIPLE_MYELOMA_IGLL_VS_IGLK_UP	2923	39	-1.373	-0.406	0.124	0.254
REACTOME_TRANSLOCATION_OF_SLC2A4_GLUT4_TO_THE_PLASMA_MEMBRANE	2924	57	-1.374	-0.521	0.124	0.254
WP_ENVELOPE_PROTEINS_AND_THEIR_POTENTIAL_ROLES_IN_EDMD_PHYSIOPATHOLOGY	2925	39	-1.374	-0.472	0.124	0.254
PID_CASPASE_PATHWAY	2926	49	-1.374	-0.444	0.123	0.253
KIM_WT1_TARGETS_12HR_UP	2927	138	-1.375	-0.424	0.123	0.253
BIOCARTA_RELA_PATHWAY	2928	15	-1.375	-0.581	0.123	0.253
BAELDE_DIABETIC_NEPHROPATHY_DN	2929	382	-1.375	-0.452	0.123	0.253
WINTER_HYPOXIA_METAGENE	2930	213	-1.375	-0.414	0.123	0.253
REACTOME_VEGFR2_MEDIATED_VASCULAR_PERMEABILITY	2931	25	-1.375	-0.509	0.123	0.253
KONG_E2F3_TARGETS	2932	79	-1.375	-0.474	0.123	0.253
MULLIGHAN_NPM1_SIGNATURE_3_UP	2933	272	-1.375	-0.353	0.123	0.253
BOYAULT_LIVER_CANCER_SUBCLASS_G2	2934	25	-1.376	-0.566	0.122	0.253
FIGUEROA_AML_METHYLATION_CLUSTER_7_UP	2935	87	-1.376	-0.351	0.122	0.253
REACTOME_ATTACHMENT_AND_ENTRY	2936	18	-1.376	-0.47	0.122	0.252
MARTIN_INTERACT_WITH_HDAC	2937	40	-1.376	-0.505	0.122	0.252
REACTOME_INFLAMMASOMES	2938	18	-1.376	-0.506	0.122	0.252
GUO_HEX_TARGETS_UP	2939	68	-1.377	-0.395	0.122	0.252
BURTON_ADIPOGENESIS_PEAK_AT_0HR	2940	55	-1.377	-0.37	0.122	0.252
HUMMERICH_MALIGNANT_SKIN_TUMOR_DN	2941	19	-1.377	-0.513	0.122	0.252
REACTOME_LISTERIA_MONOCYTOGENES_ENTRY_INTO_HOST_CELLS	2942	20	-1.377	-0.559	0.122	0.252
STARK_HYPPOCAMPUS_22Q11_DELETION_UP	2943	41	-1.377	-0.367	0.122	0.252
CERVERA_SDHB_TARGETS_2	2944	97	-1.378	-0.322	0.121	0.252
BIOCARTA_IL2_PATHWAY	2945	22	-1.378	-0.414	0.121	0.252
PLASARI_NFIC_TARGETS_BASAL_UP	2946	25	-1.378	-0.45	0.121	0.252
BRACHAT_RESPONSE_TO_METHOTREXATE_UP	2947	18	-1.378	-0.564	0.121	0.252
REACTOME_FRS_MEDIATED_FGFR3_SIGNALING	2948	20	-1.378	-0.436	0.121	0.252
KEGG_OOCYTE_MEIOSIS	2949	105	-1.378	-0.391	0.121	0.252
BLANCO_MELO_BRONCHIAL_EPITHELIAL_CELLS_INFLUENZA_A_INFECTION_UP	2950	105	-1.378	-0.357	0.121	0.252
VARELA_ZMPSTE24_TARGETS_DN	2951	37	-1.378	-0.401	0.121	0.251
REACTOME_DOWNREGULATION_OF_SMAD2_3_SMAD4_TRANSCRIPTIONAL_ACTIVITY	2952	29	-1.378	-0.601	0.121	0.251
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM6	2953	45	-1.379	-0.378	0.120	0.251
REACTOME_DOWNREGULATION_OF_TGF_BETA_RECEPTOR_SIGNALING	2954	25	-1.379	-0.646	0.120	0.251
TANG_SENESCENCE_TP53_TARGETS_DN	2955	50	-1.379	-0.51	0.120	0.251
HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_UP	2956	22	-1.379	-0.488	0.120	0.251
KERLEY_RESPONSE_TO_CISPLATIN_UP	2957	41	-1.38	-0.497	0.120	0.250
PID_ARF_3PATHWAY	2958	16	-1.381	-0.541	0.119	0.249
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER	2959	121	-1.382	-0.505	0.118	0.248
JAEGER_METASTASIS_UP	2960	42	-1.382	-0.384	0.118	0.248
LEE_CALORIE_RESTRICTION_MUSCLE_DN	2961	44	-1.382	-0.425	0.118	0.248
WOTTON_RUNX_TARGETS_UP	2962	15	-1.382	-0.503	0.118	0.248
WP_PHOTODYNAMIC_THERAPYINDUCED_AP1_SURVIVAL_SIGNALING	2963	50	-1.382	-0.396	0.118	0.248
ZHAN_MULTIPLE_MYELOMA_LB_DN	2964	31	-1.383	-0.424	0.118	0.247
WP_DRAVET_SYNDROME	2965	21	-1.383	-0.41	0.117	0.247
YIH_RESPONSE_TO_ARSENITE_C3	2966	28	-1.383	-0.45	0.117	0.246
WP_PROLACTIN_SIGNALING_PATHWAY	2967	73	-1.384	-0.473	0.117	0.246
KEGG_GLIOMA	2968	63	-1.384	-0.432	0.117	0.246
SENGUPTA_EBNA1_ANTICORRELATED	2969	115	-1.384	-0.423	0.117	0.246
LEIN_CHOROID_PLEXUS_MARKERS	2970	87	-1.385	-0.363	0.116	0.245
KEGG_WNT_SIGNALING_PATHWAY	2971	144	-1.385	-0.361	0.116	0.245
WANG_NEOPLASTIC_TRANSFORMATION_BY_CCND1_MYC	2972	20	-1.385	-0.458	0.116	0.245
NAKAJIMA_MAST_CELL	2973	42	-1.386	-0.432	0.116	0.244
REACTOME_SIGNALING_BY_TGFB_FAMILY_MEMBERS	2974	119	-1.386	-0.472	0.116	0.244
WEIGEL_OXIDATIVE_STRESS_RESPONSE	2975	31	-1.386	-0.541	0.115	0.244
KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY	2976	65	-1.387	-0.369	0.115	0.243
VALK_AML_CLUSTER_8	2977	23	-1.387	-0.417	0.115	0.243
PID_VEGFR1_PATHWAY	2978	24	-1.387	-0.525	0.115	0.243
BASSO_CD40_SIGNALING_DN	2979	62	-1.387	-0.382	0.115	0.243
BIOCARTA_IL6_PATHWAY	2980	21	-1.387	-0.571	0.115	0.243
WENG_POR_TARGETS_LIVER_UP	2981	38	-1.388	-0.429	0.114	0.242
REACTOME_RIP_MEDIATED_NFKB_ACTIVATION_VIA_ZBP1	2982	17	-1.389	-0.497	0.114	0.241
SA_TRKA_RECEPTOR	2983	16	-1.389	-0.596	0.114	0.241
HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_DN	2984	20	-1.389	-0.443	0.113	0.241
PID_VEGFR1_2_PATHWAY	2985	66	-1.389	-0.456	0.113	0.241
MAHADEVAN_IMATINIB_RESISTANCE_UP	2986	21	-1.39	-0.453	0.113	0.241
WP_VITAMIN_DSENSITIVE_CALCIUM_SIGNALING_IN_DEPRESSION	2987	32	-1.39	-0.456	0.113	0.241
GROSS_HYPOXIA_VIA_HIF1A_DN	2988	90	-1.39	-0.424	0.113	0.241
WORSCHECH_TUMOR_REJECTION_UP	2989	54	-1.39	-0.426	0.113	0.241
GROSS_HYPOXIA_VIA_ELK3_ONLY_DN	2990	40	-1.39	-0.451	0.113	0.241
REACTOME_GLUCURONIDATION	2991	15	-1.39	-0.502	0.113	0.241
RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_UP	2992	100	-1.39	-0.402	0.113	0.241
PID_NEPHRIN_NEPH1_PATHWAY	2993	30	-1.391	-0.49	0.113	0.240
MCBRYAN_PUBERTAL_BREAST_6_7WK_DN	2994	66	-1.391	-0.447	0.112	0.240
LI_INDUCED_T_TO_NATURAL_KILLER_DN	2995	112	-1.391	-0.322	0.112	0.240
GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_UP	2996	34	-1.391	-0.429	0.112	0.240
WP_ATM_SIGNALING_PATHWAY	2997	36	-1.391	-0.484	0.112	0.240
ZWANG_CLASS_2_TRANSIENTLY_INDUCED_BY_EGF	2998	43	-1.391	-0.463	0.112	0.240
PLASARI_TGFB1_SIGNALING_VIA_NFIC_10HR_UP	2999	44	-1.392	-0.397	0.112	0.239
MARSHALL_VIRAL_INFECTION_RESPONSE_DN	3000	23	-1.392	-0.458	0.112	0.239
BIOCARTA_NOS1_PATHWAY	3001	20	-1.392	-0.481	0.111	0.239
WP_ENDODERM_DIFFERENTIATION	3002	126	-1.392	-0.329	0.111	0.239
EPPERT_HSC_R	3003	92	-1.392	-0.358	0.111	0.239
MONNIER_POSTRADIATION_TUMOR_ESCAPE_DN	3004	285	-1.393	-0.383	0.111	0.239
GRESHOCK_CANCER_COPY_NUMBER_UP	3005	296	-1.393	-0.336	0.111	0.239
REACTOME_SIGNALING_BY_CSF3_G_CSF	3006	28	-1.394	-0.483	0.111	0.238
GYORFFY_MITOXANTRONE_RESISTANCE	3007	31	-1.394	-0.469	0.110	0.238
ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN	3008	218	-1.394	-0.324	0.110	0.238
WP_OVERLAP_BETWEEN_SIGNAL_TRANSDUCTION_PATHWAYS_CONTRIBUTING_TO_LMNA_LAMINOPATHIES	3009	51	-1.394	-0.461	0.110	0.237
REACTOME_AMYLOID_FIBER_FORMATION	3010	51	-1.394	-0.396	0.110	0.237
GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN	3011	71	-1.395	-0.39	0.110	0.237
PID_INSULIN_GLUCOSE_PATHWAY	3012	26	-1.395	-0.516	0.110	0.237
WP_COMPLEMENT_SYSTEM_IN_NEURONAL_DEVELOPMENT_AND_PLASTICITY	3013	99	-1.395	-0.354	0.109	0.236
CHIBA_RESPONSE_TO_TSA_DN	3014	18	-1.396	-0.585	0.109	0.236
BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP	3015	55	-1.396	-0.363	0.109	0.236
VANTVEER_BREAST_CANCER_BRCA1_DN	3016	32	-1.396	-0.481	0.109	0.236
DANG_MYC_TARGETS_DN	3017	30	-1.396	-0.503	0.109	0.236
SAFFORD_T_LYMPHOCYTE_ANERGY	3018	83	-1.396	-0.36	0.109	0.236
KIM_ALL_DISORDERS_CALB1_CORR_DN	3019	34	-1.397	-0.483	0.109	0.236
KEGG_JAK_STAT_SIGNALING_PATHWAY	3020	148	-1.397	-0.358	0.109	0.236
PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_DN	3021	337	-1.397	-0.304	0.108	0.235
MCCLUNG_DELTA_FOSB_TARGETS_8WK	3022	45	-1.397	-0.394	0.108	0.235
PARENT_MTOR_SIGNALING_UP	3023	477	-1.397	-0.36	0.108	0.235
REACTOME_SIGNALING_BY_TYPE_1_INSULIN_LIKE_GROWTH_FACTOR_1_RECEPTOR_IGF1R	3024	54	-1.397	-0.353	0.108	0.235
TSAI_RESPONSE_TO_IONIZING_RADIATION	3025	141	-1.399	-0.376	0.107	0.234
WP_NANOPARTICLE_TRIGGERED_AUTOPHAGIC_CELL_DEATH	3026	20	-1.399	-0.458	0.107	0.234
REACTOME_SIGNAL_AMPLIFICATION	3027	33	-1.399	-0.411	0.107	0.233
FIGUEROA_AML_METHYLATION_CLUSTER_1_UP	3028	90	-1.4	-0.325	0.107	0.232
REACTOME_SIGNALING_BY_FGFR	3029	77	-1.4	-0.437	0.106	0.232
REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_27_HYDROXYCHOLESTEROL	3030	15	-1.4	-0.58	0.106	0.232
WP_THERMOGENESIS	3031	100	-1.4	-0.347	0.106	0.232
REACTOME_NRIF_SIGNALS_CELL_DEATH_FROM_THE_NUCLEUS	3032	15	-1.4	-0.572	0.106	0.232
CHEBOTAEV_GR_TARGETS_UP	3033	68	-1.4	-0.372	0.106	0.232
BURTON_ADIPOGENESIS_3	3034	92	-1.401	-0.482	0.106	0.232
WP_NUCLEOTIDEBINDING_OLIGOMERIZATION_DOMAIN_NOD_PATHWAY	3035	27	-1.401	-0.456	0.106	0.232
ALCALAY_AML_BY_NPM1_LOCALIZATION_DN	3036	169	-1.401	-0.339	0.106	0.232
AMIT_EGF_RESPONSE_40_HELA	3037	37	-1.401	-0.545	0.106	0.232
CHUANG_OXIDATIVE_STRESS_RESPONSE_UP	3038	27	-1.402	-0.494	0.105	0.230
STREICHER_LSM1_TARGETS_DN	3039	19	-1.403	-0.506	0.105	0.230
REACTOME_SHC_MEDIATED_CASCADE_FGFR1	3040	21	-1.403	-0.445	0.105	0.230
PID_ARF6_DOWNSTREAM_PATHWAY	3041	15	-1.404	-0.576	0.104	0.229
WP_HEPATITIS_C_AND_HEPATOCELLULAR_CARCINOMA	3042	43	-1.404	-0.5	0.104	0.229
HOEBEKE_LYMPHOID_STEM_CELL_UP	3043	79	-1.404	-0.431	0.104	0.229
BAKKER_FOXO3_TARGETS_UP	3044	43	-1.404	-0.413	0.104	0.229
WP_MEASLES_VIRUS_INFECTION	3045	128	-1.404	-0.32	0.104	0.229
REACTOME_CHOLESTEROL_BIOSYNTHESIS	3046	24	-1.404	-0.595	0.104	0.229
WP_INFLUENCE_OF_LAMINOPATHIES_ON_WNT_SIGNALING	3047	33	-1.404	-0.459	0.104	0.229
REACTOME_NOD1_2_SIGNALING_PATHWAY	3048	31	-1.404	-0.506	0.104	0.229
WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN	3049	155	-1.404	-0.437	0.104	0.229
OLSSON_E2F3_TARGETS_DN	3050	30	-1.405	-0.562	0.104	0.229
HUANG_DASATINIB_SENSITIVITY_UP	3051	73	-1.405	-0.561	0.103	0.229
WP_MELANOMA	3052	66	-1.405	-0.452	0.103	0.229
HOELZEL_NF1_TARGETS_DN	3053	92	-1.407	-0.319	0.102	0.227
SIMBULAN_UV_RESPONSE_NORMAL_DN	3054	28	-1.407	-0.565	0.102	0.227
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR2	3055	30	-1.407	-0.418	0.102	0.226
BYSTROEM_CORRELATED_WITH_IL5_UP	3056	40	-1.407	-0.433	0.102	0.226
LEE_AGING_CEREBELLUM_DN	3057	61	-1.407	-0.373	0.102	0.226
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_UP	3058	70	-1.407	-0.511	0.102	0.226
EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION	3059	47	-1.408	-0.406	0.102	0.226
DOUGLAS_BMI1_TARGETS_DN	3060	252	-1.408	-0.424	0.102	0.226
HALLMARK_ANGIOGENESIS	3061	34	-1.409	-0.428	0.101	0.225
WP_MYOMETRIAL_RELAXATION_AND_CONTRACTION_PATHWAYS	3062	147	-1.41	-0.357	0.100	0.224
PIONTEK_PKD1_TARGETS_UP	3063	36	-1.41	-0.395	0.100	0.224
BROWNE_HCMV_INFECTION_6HR_DN	3064	141	-1.41	-0.432	0.100	0.224
POS_HISTAMINE_RESPONSE_NETWORK	3065	25	-1.41	-0.554	0.100	0.224
REACTOME_BILE_ACID_AND_BILE_SALT_METABOLISM	3066	43	-1.41	-0.421	0.100	0.224
KEGG_ENDOCYTOSIS	3067	155	-1.412	-0.402	0.099	0.222
MOSERLE_IFNA_RESPONSE	3068	28	-1.412	-0.519	0.099	0.222
ABRAHAM_ALPC_VS_MULTIPLE_MYELOMA_UP	3069	26	-1.412	-0.457	0.099	0.221
BANG_VERTEPORFIN_ENDOMETRIAL_CANCER_CELLS_UP	3070	18	-1.413	-0.594	0.099	0.221
DE_YY1_TARGETS_DN	3071	84	-1.413	-0.53	0.099	0.221
STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN	3072	41	-1.413	-0.436	0.099	0.221
BROWNE_HCMV_INFECTION_2HR_DN	3073	45	-1.413	-0.445	0.098	0.220
BIOCARTA_FCER1_PATHWAY	3074	38	-1.414	-0.449	0.098	0.220
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_UP	3075	49	-1.414	-0.469	0.098	0.220
WANG_MLL_TARGETS	3076	261	-1.414	-0.346	0.098	0.220
KEGG_PANCREATIC_CANCER	3077	68	-1.414	-0.492	0.098	0.220
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_DN	3078	131	-1.415	-0.435	0.097	0.219
VANTVEER_BREAST_CANCER_ESR1_UP	3079	120	-1.415	-0.386	0.097	0.219
GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN	3080	201	-1.415	-0.339	0.097	0.219
WP_CAMKK2_PATHWAY	3081	31	-1.415	-0.491	0.097	0.219
PID_FAS_PATHWAY	3082	37	-1.415	-0.438	0.097	0.219
WP_PANCREATIC_ADENOCARCINOMA_PATHWAY	3083	85	-1.416	-0.492	0.097	0.218
GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_DN	3084	31	-1.417	-0.391	0.096	0.218
SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_DN	3085	33	-1.417	-0.477	0.096	0.218
URS_ADIPOCYTE_DIFFERENTIATION_UP	3086	61	-1.417	-0.362	0.096	0.218
ZHAN_MULTIPLE_MYELOMA_MF_DN	3087	32	-1.418	-0.412	0.096	0.216
ABE_VEGFA_TARGETS	3088	16	-1.419	-0.473	0.095	0.216
WP_FGF23_SIGNALING_IN_HYPOPHOSPHATEMIC_RICKETS_AND_RELATED_DISORDERS	3089	22	-1.419	-0.414	0.095	0.215
REACTOME_NICOTINATE_METABOLISM	3090	23	-1.419	-0.457	0.095	0.215
SIG_BCR_SIGNALING_PATHWAY	3091	46	-1.419	-0.435	0.095	0.215
GENTLES_LEUKEMIC_STEM_CELL_UP	3092	22	-1.419	-0.421	0.095	0.215
POOLA_INVASIVE_BREAST_CANCER_UP	3093	244	-1.419	-0.381	0.095	0.215
WP_MELATONIN_METABOLISM_AND_EFFECTS	3094	34	-1.42	-0.443	0.095	0.215
REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	3095	16	-1.42	-0.492	0.094	0.215
WP_KISSPEPTINKISSPEPTIN_RECEPTOR_SYSTEM_IN_THE_OVARY	3096	38	-1.42	-0.382	0.094	0.215
ODONNELL_TFRC_TARGETS_DN	3097	105	-1.42	-0.393	0.094	0.215
REACTOME_RESOLUTION_OF_SISTER_CHROMATID_COHESION	3098	91	-1.421	-0.513	0.094	0.214
SASSON_RESPONSE_TO_GONADOTROPHINS_UP	3099	72	-1.422	-0.47	0.093	0.213
WESTON_VEGFA_TARGETS	3100	87	-1.422	-0.391	0.093	0.213
WP_HEMATOPOIETIC_STEM_CELL_DIFFERENTIATION	3101	52	-1.422	-0.485	0.093	0.213
MARCHINI_TRABECTEDIN_RESISTANCE_UP	3102	20	-1.422	-0.539	0.093	0.213
ASTON_MAJOR_DEPRESSIVE_DISORDER_UP	3103	39	-1.422	-0.396	0.093	0.213
BEIER_GLIOMA_STEM_CELL_DN	3104	54	-1.423	-0.391	0.093	0.212
WHITFIELD_CELL_CYCLE_S	3105	103	-1.423	-0.449	0.093	0.212
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1	3106	223	-1.424	-0.37	0.092	0.211
KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_DN	3107	69	-1.424	-0.432	0.092	0.211
ZWANG_EGF_PERSISTENTLY_UP	3108	22	-1.424	-0.518	0.092	0.211
PID_PI3K_PLC_TRK_PATHWAY	3109	33	-1.424	-0.504	0.092	0.211
REACTOME_CELL_EXTRACELLULAR_MATRIX_INTERACTIONS	3110	17	-1.425	-0.61	0.092	0.210
SASSON_RESPONSE_TO_FORSKOLIN_UP	3111	74	-1.425	-0.47	0.091	0.210
PID_RETINOIC_ACID_PATHWAY	3112	28	-1.425	-0.512	0.091	0.210
REACTOME_OPIOID_SIGNALLING	3113	89	-1.425	-0.377	0.091	0.210
PID_IL8_CXCR1_PATHWAY	3114	23	-1.426	-0.442	0.091	0.209
ABE_VEGFA_TARGETS_2HR	3115	28	-1.426	-0.445	0.091	0.209
REACTOME_SIGNALING_BY_WNT_IN_CANCER	3116	32	-1.426	-0.52	0.091	0.209
MAGRANGEAS_MULTIPLE_MYELOMA_IGLL_VS_IGLK_DN	3117	22	-1.426	-0.464	0.091	0.209
MANNE_COVID19_NONICU_VS_HEALTHY_DONOR_PLATELETS_DN	3118	158	-1.427	-0.34	0.090	0.209
FISCHER_DIRECT_P53_TARGETS_META_ANALYSIS	3119	244	-1.428	-0.446	0.090	0.208
WILLIAMS_ESR1_TARGETS_UP	3120	25	-1.428	-0.462	0.090	0.207
VALK_AML_CLUSTER_1	3121	25	-1.43	-0.453	0.089	0.205
MIKKELSEN_NPC_LCP_WITH_H3K4ME3	3122	46	-1.43	-0.427	0.089	0.205
VALK_AML_WITH_CEBPA	3123	33	-1.43	-0.428	0.089	0.205
HOLLERN_SOLID_NODULAR_BREAST_TUMOR_DN	3124	28	-1.43	-0.44	0.089	0.205
PASINI_SUZ12_TARGETS_UP	3125	94	-1.43	-0.354	0.088	0.205
GAVIN_PDE3B_TARGETS	3126	22	-1.431	-0.462	0.088	0.204
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN	3127	86	-1.431	-0.443	0.088	0.204
KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_UP	3128	114	-1.432	-0.484	0.088	0.204
OUYANG_PROSTATE_CANCER_MARKERS	3129	21	-1.432	-0.498	0.087	0.203
LEONARD_HYPOXIA	3130	33	-1.432	-0.543	0.087	0.203
ROESSLER_LIVER_CANCER_METASTASIS_UP	3131	100	-1.432	-0.332	0.087	0.203
REACTOME_RUNX1_REGULATES_GENES_INVOLVED_IN_MEGAKARYOCYTE_DIFFERENTIATION_AND_PLATELET_FUNCTION	3132	27	-1.433	-0.414	0.087	0.203
FOURNIER_ACINAR_DEVELOPMENT_LATE_DN	3133	21	-1.433	-0.679	0.087	0.203
KEGG_MELANOMA	3134	71	-1.433	-0.381	0.087	0.203
HALLMARK_INTERFERON_ALPHA_RESPONSE	3135	86	-1.433	-0.41	0.087	0.202
DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN	3136	230	-1.433	-0.416	0.087	0.202
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP	3137	283	-1.434	-0.331	0.086	0.202
IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM	3138	173	-1.434	-0.316	0.086	0.202
MCDOWELL_ACUTE_LUNG_INJURY_UP	3139	44	-1.434	-0.472	0.086	0.202
SANSOM_APC_TARGETS_DN	3140	331	-1.434	-0.359	0.086	0.202
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_DN	3141	57	-1.434	-0.382	0.086	0.202
REACTOME_REGULATION_OF_TNFR1_SIGNALING	3142	31	-1.435	-0.511	0.086	0.202
HOLLERN_PAPILLARY_BREAST_TUMOR	3143	16	-1.435	-0.438	0.086	0.201
PID_INSULIN_PATHWAY	3144	41	-1.435	-0.513	0.086	0.201
BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN	3145	40	-1.435	-0.603	0.086	0.201
WP_CANNABINOID_RECEPTOR_SIGNALING	3146	26	-1.435	-0.435	0.086	0.201
LEIN_OLIGODENDROCYTE_MARKERS	3147	60	-1.436	-0.399	0.085	0.201
PID_P75_NTR_PATHWAY	3148	63	-1.436	-0.449	0.085	0.201
WP_OVERVIEW_OF_INTERFERONSMEDIATED_SIGNALING_PATHWAY	3149	30	-1.436	-0.452	0.085	0.201
WP_DISRUPTION_OF_POSTSYNAPTIC_SIGNALING_BY_CNV	3150	33	-1.436	-0.459	0.085	0.201
LEE_LIVER_CANCER_MYC_DN	3151	55	-1.436	-0.381	0.085	0.201
LIU_OVARIAN_CANCER_TUMORS_AND_XENOGRAFTS_XDGS_UP	3152	52	-1.437	-0.526	0.085	0.200
REACTOME_ION_CHANNEL_TRANSPORT	3153	153	-1.437	-0.327	0.085	0.200
DASU_IL6_SIGNALING_UP	3154	53	-1.437	-0.477	0.085	0.200
WP_PHYSICOCHEMICAL_FEATURES_AND_TOXICITYASSOCIATED_PATHWAYS	3155	64	-1.437	-0.434	0.085	0.200
SWEET_LUNG_CANCER_KRAS_DN	3156	370	-1.438	-0.3	0.084	0.199
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN	3157	229	-1.438	-0.369	0.084	0.199
PID_TAP63_PATHWAY	3158	51	-1.439	-0.492	0.084	0.198
REACTOME_RHO_GTPASES_ACTIVATE_FORMINS	3159	107	-1.439	-0.517	0.083	0.198
MEDINA_SMARCA4_TARGETS	3160	34	-1.439	-0.438	0.083	0.198
REACTOME_RECEPTOR_TYPE_TYROSINE_PROTEIN_PHOSPHATASES	3161	20	-1.439	-0.49	0.083	0.198
YANAGIHARA_ESX1_TARGETS	3162	27	-1.439	-0.557	0.083	0.198
BIOCARTA_MAPK_PATHWAY	3163	81	-1.439	-0.472	0.083	0.198
WP_WNT_SIGNALING_PATHWAY_AND_PLURIPOTENCY	3164	98	-1.439	-0.393	0.083	0.198
PID_HDAC_CLASSIII_PATHWAY	3165	19	-1.44	-0.507	0.083	0.198
HU_ANGIOGENESIS_UP	3166	19	-1.44	-0.566	0.083	0.198
WP_DEVELOPMENT_OF_URETERIC_COLLECTION_SYSTEM	3167	56	-1.44	-0.399	0.083	0.198
WP_SMALL_CELL_LUNG_CANCER	3168	93	-1.44	-0.429	0.083	0.198
ALONSO_METASTASIS_EMT_UP	3169	30	-1.441	-0.549	0.083	0.197
THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN	3170	201	-1.441	-0.47	0.082	0.197
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_UP	3171	48	-1.441	-0.533	0.082	0.197
REACTOME_NEGATIVE_REGULATION_OF_FGFR2_SIGNALING	3172	34	-1.441	-0.434	0.082	0.197
HALLMARK_CHOLESTEROL_HOMEOSTASIS	3173	71	-1.443	-0.51	0.081	0.195
WEST_ADRENOCORTICAL_TUMOR_DN	3174	471	-1.443	-0.325	0.081	0.195
BROWNE_HCMV_INFECTION_30MIN_DN	3175	118	-1.443	-0.312	0.081	0.195
RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP	3176	66	-1.443	-0.375	0.081	0.195
FONTAINE_THYROID_TUMOR_UNCERTAIN_MALIGNANCY_UP	3177	33	-1.443	-0.381	0.081	0.195
BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_DN	3178	44	-1.444	-0.48	0.081	0.195
IVANOVA_HEMATOPOIESIS_STEM_CELL	3179	150	-1.444	-0.336	0.081	0.194
DOANE_RESPONSE_TO_ANDROGEN_DN	3180	210	-1.444	-0.362	0.081	0.194
WP_RENINANGIOTENSINALDOSTERONE_SYSTEM_RAAS	3181	43	-1.445	-0.449	0.080	0.194
MCBRYAN_PUBERTAL_BREAST_5_6WK_UP	3182	109	-1.445	-0.417	0.080	0.194
MIKKELSEN_MCV6_LCP_WITH_H3K4ME3	3183	130	-1.445	-0.431	0.080	0.194
LUI_THYROID_CANCER_CLUSTER_5	3184	16	-1.445	-0.537	0.080	0.193
CROONQUIST_IL6_DEPRIVATION_UP	3185	16	-1.446	-0.544	0.080	0.193
REACTOME_PI_METABOLISM	3186	68	-1.447	-0.436	0.079	0.192
TRAYNOR_RETT_SYNDROM_UP	3187	36	-1.447	-0.431	0.079	0.192
PID_S1P_META_PATHWAY	3188	16	-1.447	-0.62	0.079	0.192
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP	3189	79	-1.447	-0.412	0.079	0.192
BURTON_ADIPOGENESIS_11	3190	41	-1.447	-0.628	0.079	0.191
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP	3191	207	-1.447	-0.431	0.079	0.191
KESHELAVA_MULTIPLE_DRUG_RESISTANCE	3192	62	-1.448	-0.448	0.079	0.191
FLECHNER_PBL_KIDNEY_TRANSPLANT_OK_VS_DONOR_DN	3193	36	-1.448	-0.572	0.079	0.191
REACTOME_SHC_MEDIATED_CASCADE_FGFR3	3194	18	-1.448	-0.483	0.079	0.191
WP_FOXP3_IN_COVID19	3195	15	-1.449	-0.551	0.078	0.190
WP_ESTROGEN_SIGNALING_PATHWAY	3196	22	-1.449	-0.556	0.078	0.190
FIRESTEIN_CTNNB1_PATHWAY	3197	29	-1.449	-0.488	0.078	0.190
SASSON_RESPONSE_TO_FORSKOLIN_DN	3198	80	-1.45	-0.507	0.078	0.189
CHANG_IMMORTALIZED_BY_HPV31_UP	3199	61	-1.45	-0.329	0.078	0.189
LEIN_PONS_MARKERS	3200	79	-1.45	-0.366	0.078	0.189
JINESH_BLEBBISHIELD_VS_LIVE_CONTROL_DN	3201	238	-1.45	-0.393	0.077	0.189
WP_GLIOBLASTOMA_SIGNALING_PATHWAYS	3202	78	-1.452	-0.483	0.077	0.187
REACTOME_CARBOXYTERMINAL_POST_TRANSLATIONAL_MODIFICATIONS_OF_TUBULIN	3203	28	-1.452	-0.482	0.077	0.187
NOUSHMEHR_GBM_SILENCED_BY_METHYLATION	3204	40	-1.452	-0.455	0.077	0.187
MCLACHLAN_DENTAL_CARIES_DN	3205	74	-1.452	-0.349	0.076	0.187
KEGG_LONG_TERM_DEPRESSION	3206	64	-1.452	-0.383	0.076	0.187
BYSTROEM_CORRELATED_WITH_IL5_DN	3207	58	-1.452	-0.447	0.076	0.187
REACTOME_MYD88_INDEPENDENT_TLR4_CASCADE	3208	99	-1.453	-0.467	0.076	0.187
REACTOME_SIGNALING_BY_NOTCH3	3209	42	-1.453	-0.467	0.076	0.187
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_UP	3210	27	-1.453	-0.435	0.076	0.187
RIZKI_TUMOR_INVASIVENESS_3D_UP	3211	179	-1.453	-0.318	0.076	0.187
IBRAHIM_NRF1_DOWN	3212	120	-1.453	-0.406	0.076	0.187
REACTOME_RECYCLING_OF_BILE_ACIDS_AND_SALTS	3213	16	-1.453	-0.583	0.076	0.187
REACTOME_INTERLEUKIN_3_INTERLEUKIN_5_AND_GM_CSF_SIGNALING	3214	48	-1.454	-0.417	0.076	0.186
WP_GPCRS_CLASS_C_METABOTROPIC_GLUTAMATE_PHEROMONE	3215	15	-1.454	-0.604	0.076	0.186
BLANCO_MELO_BETA_INTERFERON_TREATED_BRONCHIAL_EPITHELIAL_CELLS_DN	3216	154	-1.454	-0.42	0.075	0.186
REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY	3217	23	-1.454	-0.535	0.075	0.186
ELVIDGE_HYPOXIA_BY_DMOG_UP	3218	114	-1.455	-0.454	0.075	0.185
REACTOME_RHOQ_GTPASE_CYCLE	3219	54	-1.455	-0.518	0.075	0.185
WP_BDNFTRKB_SIGNALING	3220	32	-1.456	-0.445	0.075	0.185
GUTIERREZ_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN	3221	46	-1.456	-0.452	0.075	0.185
WP_ULCERATIVE_COLITIS_SIGNALING	3222	17	-1.456	-0.51	0.074	0.184
WP_COHESIN_COMPLEX_CORNELIA_DE_LANGE_SYNDROME	3223	25	-1.457	-0.597	0.074	0.184
MEISSNER_NPC_HCP_WITH_H3K4ME2	3224	396	-1.457	-0.379	0.074	0.184
REACTOME_DISEASES_OF_PROGRAMMED_CELL_DEATH	3225	40	-1.457	-0.432	0.074	0.184
WP_SYNAPTIC_SIGNALING_PATHWAYS_ASSOCIATED_WITH_AUTISM_SPECTRUM_DISORDER	3226	48	-1.457	-0.395	0.074	0.183
KORKOLA_YOLK_SAC_TUMOR	3227	53	-1.457	-0.39	0.074	0.183
REACTOME_SYNTHESIS_OF_PIPS_AT_THE_PLASMA_MEMBRANE	3228	45	-1.458	-0.488	0.074	0.183
RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP	3229	295	-1.458	-0.418	0.074	0.183
REACTOME_NUCLEOTIDE_BINDING_DOMAIN_LEUCINE_RICH_REPEAT_CONTAINING_RECEPTOR_NLR_SIGNALING_PATHWAYS	3230	48	-1.458	-0.487	0.073	0.183
BIOCARTA_GCR_PATHWAY	3231	17	-1.459	-0.597	0.073	0.182
REACTOME_DARPP_32_EVENTS	3232	24	-1.459	-0.537	0.073	0.182
MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_DN	3233	18	-1.459	-0.593	0.073	0.182
REACTOME_RECRUITMENT_OF_NUMA_TO_MITOTIC_CENTROSOMES	3234	64	-1.459	-0.479	0.073	0.182
WP_CHOLESTEROL_SYNTHESIS_DISORDERS	3235	16	-1.459	-0.636	0.073	0.182
WP_RAC1PAK1P38MMP2_PATHWAY	3236	66	-1.46	-0.47	0.073	0.181
SIG_REGULATION_OF_THE_ACTIN_CYTOSKELETON_BY_RHO_GTPASES	3237	34	-1.461	-0.537	0.072	0.181
WHITFIELD_CELL_CYCLE_G2_M	3238	156	-1.461	-0.453	0.072	0.180
WP_2Q112_COPY_NUMBER_VARIATION_SYNDROME	3239	24	-1.461	-0.493	0.072	0.180
STEGER_ADIPOGENESIS_DN	3240	24	-1.462	-0.496	0.072	0.180
BOWIE_RESPONSE_TO_TAMOXIFEN	3241	17	-1.462	-0.567	0.071	0.179
KAYO_AGING_MUSCLE_UP	3242	213	-1.462	-0.318	0.071	0.179
NABA_ECM_REGULATORS	3243	217	-1.462	-0.419	0.071	0.179
REACTOME_FLT3_SIGNALING	3244	37	-1.462	-0.46	0.071	0.179
REACTOME_FOXO_MEDIATED_TRANSCRIPTION	3245	57	-1.464	-0.519	0.071	0.178
PID_SMAD2_3PATHWAY	3246	16	-1.464	-0.686	0.071	0.178
NEWMAN_ERCC6_TARGETS_DN	3247	33	-1.464	-0.458	0.070	0.177
LE_EGR2_TARGETS_UP	3248	94	-1.464	-0.49	0.070	0.177
VALK_AML_CLUSTER_4	3249	21	-1.466	-0.516	0.069	0.175
BUCKANOVICH_T_LYMPHOCYTE_HOMING_ON_TUMOR_UP	3250	18	-1.466	-0.549	0.069	0.175
NICK_RESPONSE_TO_PROC_TREATMENT_DN	3251	19	-1.467	-0.583	0.069	0.175
PID_SMAD2_3NUCLEAR_PATHWAY	3252	73	-1.468	-0.439	0.069	0.173
REACTOME_INTERLEUKIN_RECEPTOR_SHC_SIGNALING	3253	27	-1.468	-0.443	0.069	0.173
REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	3254	20	-1.468	-0.479	0.069	0.173
REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE	3255	54	-1.468	-0.381	0.068	0.173
GAZDA_DIAMOND_BLACKFAN_ANEMIA_MYELOID_UP	3256	25	-1.468	-0.52	0.068	0.173
JI_CARCINOGENESIS_BY_KRAS_AND_STK11_DN	3257	17	-1.469	-0.518	0.068	0.173
HUTTMANN_B_CLL_POOR_SURVIVAL_UP	3258	234	-1.469	-0.378	0.068	0.173
WP_PLURIPOTENT_STEM_CELL_DIFFERENTIATION_PATHWAY	3259	44	-1.469	-0.51	0.068	0.173
REACTOME_EGR2_AND_SOX10_MEDIATED_INITIATION_OF_SCHWANN_CELL_MYELINATION	3260	27	-1.47	-0.511	0.068	0.172
REACTOME_ASSEMBLY_AND_CELL_SURFACE_PRESENTATION_OF_NMDA_RECEPTORS	3261	32	-1.47	-0.484	0.068	0.172
COATES_MACROPHAGE_M1_VS_M2_DN	3262	64	-1.47	-0.386	0.068	0.172
VALK_AML_CLUSTER_10	3263	31	-1.47	-0.407	0.067	0.172
REACTOME_SEMA3A_PAK_DEPENDENT_AXON_REPULSION	3264	15	-1.471	-0.581	0.067	0.172
SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A	3265	18	-1.471	-0.481	0.067	0.172
DELASERNA_MYOD_TARGETS_DN	3266	49	-1.471	-0.459	0.067	0.172
REACTOME_REGULATION_OF_MECP2_EXPRESSION_AND_ACTIVITY	3267	25	-1.471	-0.579	0.067	0.172
JISON_SICKLE_CELL_DISEASE_UP	3268	167	-1.472	-0.404	0.067	0.171
KEGG_DILATED_CARDIOMYOPATHY	3269	89	-1.472	-0.438	0.067	0.171
REACTOME_CIRCADIAN_CLOCK	3270	60	-1.472	-0.485	0.067	0.171
SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_UP	3271	143	-1.472	-0.408	0.066	0.170
REACTOME_TRAFFICKING_OF_AMPA_RECEPTORS	3272	30	-1.473	-0.427	0.066	0.170
CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP	3273	91	-1.473	-0.456	0.066	0.170
HALLMARK_HEME_METABOLISM	3274	178	-1.473	-0.406	0.066	0.170
HAHTOLA_MYCOSIS_FUNGOIDES_SKIN_DN	3275	26	-1.473	-0.565	0.066	0.170
LINDVALL_IMMORTALIZED_BY_TERT_DN	3276	62	-1.473	-0.446	0.066	0.170
ZHENG_FOXP3_TARGETS_IN_THYMUS_UP	3277	164	-1.474	-0.501	0.066	0.169
AMIT_SERUM_RESPONSE_120_MCF10A	3278	56	-1.474	-0.541	0.066	0.169
REACTOME_MYOGENESIS	3279	28	-1.475	-0.514	0.065	0.168
CHYLA_CBFA2T3_TARGETS_UP	3280	319	-1.475	-0.337	0.065	0.168
YAGI_AML_WITH_T_8_21_TRANSLOCATION	3281	317	-1.475	-0.364	0.065	0.168
REACTOME_TRAF6_MEDIATED_NF_KB_ACTIVATION	3282	24	-1.475	-0.548	0.065	0.168
PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_UP	3283	46	-1.475	-0.422	0.065	0.168
TSENG_ADIPOGENIC_POTENTIAL_DN	3284	41	-1.475	-0.427	0.065	0.168
REACTOME_ERK_MAPK_TARGETS	3285	22	-1.476	-0.596	0.065	0.168
BILD_CTNNB1_ONCOGENIC_SIGNATURE	3286	57	-1.476	-0.605	0.065	0.168
HASLINGER_B_CLL_WITH_MUTATED_VH_GENES	3287	17	-1.476	-0.444	0.065	0.168
REACTOME_TOLL_LIKE_RECEPTOR_9_TLR9_CASCADE	3288	96	-1.476	-0.463	0.065	0.168
HOUSTIS_ROS	3289	35	-1.476	-0.492	0.065	0.168
CAMPS_COLON_CANCER_COPY_NUMBER_DN	3290	37	-1.477	-0.426	0.064	0.168
VALK_AML_CLUSTER_3	3291	29	-1.477	-0.43	0.064	0.167
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_15	3292	30	-1.477	-0.444	0.064	0.167
SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN	3293	342	-1.477	-0.304	0.064	0.167
PID_PDGFRB_PATHWAY	3294	123	-1.477	-0.471	0.064	0.167
HALLMARK_APICAL_SURFACE	3295	41	-1.478	-0.437	0.064	0.166
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP	3296	135	-1.478	-0.356	0.064	0.166
WP_ACUTE_VIRAL_MYOCARDITIS	3297	83	-1.479	-0.405	0.064	0.166
GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP	3298	117	-1.479	-0.483	0.063	0.165
WP_LEPTIN_SIGNALING_PATHWAY	3299	74	-1.479	-0.497	0.063	0.165
WP_MIR5093P_ALTERATION_OF_YAP1ECM_AXIS	3300	17	-1.48	-0.534	0.063	0.164
WP_PHOSPHOINOSITIDES_METABOLISM	3301	43	-1.48	-0.456	0.063	0.164
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN	3302	78	-1.481	-0.428	0.063	0.164
REACTOME_STIMULI_SENSING_CHANNELS	3303	79	-1.481	-0.366	0.063	0.164
VANDESLUIS_COMMD1_TARGETS_GROUP_4_UP	3304	16	-1.481	-0.517	0.062	0.164
WP_TRANSCRIPTION_COFACTORS_SKI_AND_SKIL_PROTEIN_PARTNERS	3305	17	-1.481	-0.578	0.062	0.164
MIKKELSEN_IPS_ICP_WITH_H3K4ME3_AND_H327ME3	3306	97	-1.482	-0.501	0.062	0.163
GRABARCZYK_BCL11B_TARGETS_UP	3307	58	-1.482	-0.453	0.062	0.163
WP_TYPE_2_PAPILLARY_RENAL_CELL_CARCINOMA	3308	30	-1.483	-0.547	0.062	0.162
SMID_BREAST_CANCER_RELAPSE_IN_PLEURA_DN	3309	25	-1.483	-0.445	0.062	0.162
JACKSON_DNMT1_TARGETS_DN	3310	21	-1.483	-0.528	0.062	0.162
SENESE_HDAC3_TARGETS_UP	3311	422	-1.483	-0.428	0.061	0.162
REACTOME_OTHER_SEMAPHORIN_INTERACTIONS	3312	17	-1.483	-0.581	0.061	0.162
RIGGINS_TAMOXIFEN_RESISTANCE_UP	3313	62	-1.483	-0.363	0.061	0.162
BRUECKNER_TARGETS_OF_MIRLET7A3_UP	3314	97	-1.483	-0.462	0.061	0.162
TSENG_ADIPOGENIC_POTENTIAL_UP	3315	27	-1.484	-0.495	0.061	0.162
LEE_AGING_NEOCORTEX_UP	3316	72	-1.484	-0.428	0.061	0.162
VALK_AML_CLUSTER_7	3317	26	-1.484	-0.469	0.061	0.162
REACTOME_SPRY_REGULATION_OF_FGF_SIGNALING	3318	16	-1.484	-0.697	0.061	0.162
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP	3319	107	-1.484	-0.406	0.061	0.162
KAMMINGA_SENESCENCE	3320	33	-1.485	-0.432	0.061	0.161
KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION	3321	61	-1.485	-0.473	0.061	0.161
WP_DNA_DAMAGE_RESPONSE_ONLY_ATM_DEPENDENT	3322	107	-1.485	-0.446	0.061	0.161
BOSCO_INTERFERON_INDUCED_ANTIVIRAL_MODULE	3323	66	-1.485	-0.404	0.061	0.161
REACTOME_CTLA4_INHIBITORY_SIGNALING	3324	21	-1.485	-0.622	0.061	0.161
HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_UP	3325	211	-1.485	-0.506	0.061	0.161
BOYLAN_MULTIPLE_MYELOMA_C_DN	3326	46	-1.485	-0.45	0.061	0.161
REACTOME_COPI_DEPENDENT_GOLGI_TO_ER_RETROGRADE_TRAFFIC	3327	79	-1.485	-0.481	0.060	0.161
REACTOME_RND3_GTPASE_CYCLE	3328	39	-1.486	-0.601	0.060	0.161
GROSS_HYPOXIA_VIA_ELK3_ONLY_UP	3329	32	-1.486	-0.576	0.060	0.161
MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP	3330	158	-1.486	-0.5	0.060	0.161
PID_RXR_VDR_PATHWAY	3331	25	-1.486	-0.453	0.060	0.161
PID_NFKAPPAB_CANONICAL_PATHWAY	3332	21	-1.486	-0.647	0.060	0.161
GAZIN_EPIGENETIC_SILENCING_BY_KRAS	3333	22	-1.486	-0.499	0.060	0.161
BIOCARTA_IL3_PATHWAY	3334	15	-1.486	-0.515	0.060	0.161
WP_IMMUNE_RESPONSE_TO_TUBERCULOSIS	3335	21	-1.487	-0.585	0.060	0.160
FRIDMAN_SENESCENCE_UP	3336	74	-1.487	-0.547	0.060	0.160
BIOCARTA_DEATH_PATHWAY	3337	28	-1.488	-0.491	0.059	0.160
KEGG_TGF_BETA_SIGNALING_PATHWAY	3338	82	-1.488	-0.416	0.059	0.160
STEARMAN_TUMOR_FIELD_EFFECT_UP	3339	34	-1.488	-0.426	0.059	0.160
REACTOME_CARGO_RECOGNITION_FOR_CLATHRIN_MEDIATED_ENDOCYTOSIS	3340	99	-1.488	-0.406	0.059	0.160
REACTOME_UPTAKE_AND_ACTIONS_OF_BACTERIAL_TOXINS	3341	27	-1.488	-0.475	0.059	0.160
RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_DN	3342	272	-1.488	-0.353	0.059	0.160
PID_CDC42_REG_PATHWAY	3343	29	-1.488	-0.503	0.059	0.160
WP_GLYCOGEN_SYNTHESIS_AND_DEGRADATION	3344	39	-1.489	-0.54	0.059	0.160
LINDGREN_BLADDER_CANCER_CLUSTER_3_DN	3345	182	-1.489	-0.431	0.059	0.159
LEE_LIVER_CANCER_MYC_TGFA_UP	3346	57	-1.489	-0.468	0.059	0.159
SWEET_KRAS_TARGETS_DN	3347	60	-1.489	-0.404	0.059	0.159
REACTOME_G_PROTEIN_BETA_GAMMA_SIGNALLING	3348	31	-1.489	-0.489	0.059	0.159
KUROZUMI_RESPONSE_TO_ONCOCYTIC_VIRUS	3349	42	-1.489	-0.497	0.059	0.159
REACTOME_SIGNAL_REGULATORY_PROTEIN_FAMILY_INTERACTIONS	3350	15	-1.49	-0.494	0.058	0.159
REACTOME_SEALING_OF_THE_NUCLEAR_ENVELOPE_NE_BY_ESCRT_III	3351	18	-1.491	-0.497	0.058	0.157
BERENJENO_TRANSFORMED_BY_RHOA_DN	3352	343	-1.491	-0.444	0.058	0.157
WP_CORTICOTROPINRELEASING_HORMONE_SIGNALING_PATHWAY	3353	88	-1.492	-0.411	0.058	0.157
REACTOME_RAF_ACTIVATION	3354	33	-1.492	-0.606	0.057	0.156
GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP	3355	181	-1.492	-0.333	0.057	0.156
REACTOME_SPHINGOLIPID_DE_NOVO_BIOSYNTHESIS	3356	25	-1.493	-0.568	0.057	0.155
LIU_SOX4_TARGETS_UP	3357	114	-1.493	-0.493	0.057	0.155
LEE_NEURAL_CREST_STEM_CELL_UP	3358	131	-1.494	-0.341	0.057	0.155
BIOCARTA_AKT_PATHWAY	3359	19	-1.494	-0.534	0.057	0.155
FOSTER_TOLERANT_MACROPHAGE_UP	3360	133	-1.494	-0.359	0.057	0.155
WP_HYPERTROPHY_MODEL	3361	16	-1.494	-0.563	0.056	0.155
KORKOLA_TERATOMA_UP	3362	16	-1.494	-0.52	0.056	0.155
WP_GENES_CONTROLLING_NEPHROGENESIS	3363	41	-1.495	-0.479	0.056	0.155
REACTOME_NUCLEAR_SIGNALING_BY_ERBB4	3364	30	-1.495	-0.461	0.056	0.154
REACTOME_NEPHRIN_FAMILY_INTERACTIONS	3365	21	-1.496	-0.568	0.056	0.154
DOANE_BREAST_CANCER_ESR1_DN	3366	44	-1.496	-0.449	0.056	0.154
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP	3367	63	-1.496	-0.459	0.056	0.153
REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA	3368	96	-1.497	-0.43	0.055	0.152
FOROUTAN_PRODRANK_TGFB_EMT_DN	3369	69	-1.498	-0.478	0.055	0.152
RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_UP	3370	144	-1.498	-0.347	0.055	0.151
SCHAEFFER_SOX9_TARGETS_IN_PROSTATE_DEVELOPMENT_UP	3371	20	-1.498	-0.455	0.055	0.151
PID_PLK1_PATHWAY	3372	36	-1.498	-0.616	0.055	0.151
GAURNIER_PSMD4_TARGETS	3373	69	-1.499	-0.453	0.055	0.151
BIOCARTA_CALCINEURIN_PATHWAY	3374	17	-1.499	-0.608	0.055	0.151
WP_COPPER_HOMEOSTASIS	3375	45	-1.499	-0.551	0.055	0.151
VALK_AML_CLUSTER_9	3376	30	-1.499	-0.476	0.055	0.151
FINETTI_BREAST_CANCERS_KINOME_BLUE	3377	19	-1.499	-0.517	0.055	0.151
REACTOME_AGGREPHAGY	3378	31	-1.499	-0.551	0.055	0.151
DAZARD_UV_RESPONSE_CLUSTER_G28	3379	16	-1.499	-0.675	0.055	0.151
UROSEVIC_RESPONSE_TO_IMIQUIMOD	3380	17	-1.5	-0.546	0.054	0.151
SASSON_RESPONSE_TO_GONADOTROPHINS_DN	3381	81	-1.5	-0.527	0.054	0.151
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_DN	3382	17	-1.5	-0.581	0.054	0.151
PID_IL2_1PATHWAY	3383	54	-1.5	-0.444	0.054	0.151
WP_INTRACELLULAR_TRAFFICKING_PROTEINS_INVOLVED_IN_CMT_NEUROPATHY	3384	25	-1.5	-0.533	0.054	0.151
MCBRYAN_PUBERTAL_BREAST_3_4WK_UP	3385	184	-1.5	-0.399	0.054	0.151
HARRIS_HYPOXIA	3386	77	-1.501	-0.444	0.054	0.150
DASU_IL6_SIGNALING_SCAR_UP	3387	28	-1.501	-0.601	0.054	0.150
DELACROIX_RAR_TARGETS_UP	3388	42	-1.501	-0.455	0.054	0.150
XU_GH1_AUTOCRINE_TARGETS_DN	3389	109	-1.501	-0.416	0.054	0.150
PID_HIF2PATHWAY	3390	29	-1.502	-0.488	0.053	0.150
REACTOME_TIGHT_JUNCTION_INTERACTIONS	3391	27	-1.502	-0.503	0.053	0.150
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_0	3392	60	-1.502	-0.446	0.053	0.150
WP_MAP3K1_ROLE_IN_PROMOTING_AND_BLOCKING_GONADAL_DETERMINATION	3393	17	-1.502	-0.531	0.053	0.150
SA_MMP_CYTOKINE_CONNECTION	3394	15	-1.502	-0.602	0.053	0.150
ELVIDGE_HYPOXIA_UP	3395	141	-1.503	-0.461	0.053	0.148
BIOCARTA_ARENRF2_PATHWAY	3396	19	-1.503	-0.563	0.053	0.148
HUMMERICH_SKIN_CANCER_PROGRESSION_DN	3397	95	-1.504	-0.413	0.053	0.148
BIOCARTA_BCR_PATHWAY	3398	32	-1.504	-0.513	0.053	0.148
PEART_HDAC_PROLIFERATION_CLUSTER_UP	3399	49	-1.504	-0.537	0.052	0.148
PID_AURORA_A_PATHWAY	3400	29	-1.505	-0.615	0.052	0.148
PID_TNF_PATHWAY	3401	43	-1.505	-0.526	0.052	0.148
CORRE_MULTIPLE_MYELOMA_UP	3402	57	-1.505	-0.405	0.052	0.147
KYNG_DNA_DAMAGE_BY_UV	3403	51	-1.505	-0.403	0.052	0.147
REACTOME_APOPTOTIC_EXECUTION_PHASE	3404	44	-1.505	-0.555	0.052	0.147
BIOCARTA_MAL_PATHWAY	3405	18	-1.505	-0.607	0.052	0.147
CHEBOTAEV_GR_TARGETS_DN	3406	102	-1.505	-0.36	0.052	0.147
REACTOME_RND1_GTPASE_CYCLE	3407	38	-1.505	-0.537	0.052	0.147
LE_NEURONAL_DIFFERENTIATION_UP	3408	16	-1.506	-0.521	0.052	0.147
BURTON_ADIPOGENESIS_8	3409	72	-1.506	-0.538	0.052	0.147
BOQUEST_STEM_CELL_DN	3410	186	-1.506	-0.353	0.052	0.147
SHIN_B_CELL_LYMPHOMA_CLUSTER_7	3411	27	-1.506	-0.538	0.052	0.147
REACTOME_NEGATIVE_REGULATION_OF_MAPK_PATHWAY	3412	43	-1.506	-0.564	0.052	0.147
WP_PLATELETMEDIATED_INTERACTIONS_WITH_VASCULAR_AND_CIRCULATING_CELLS	3413	17	-1.507	-0.583	0.051	0.146
PETROVA_PROX1_TARGETS_UP	3414	21	-1.508	-0.515	0.051	0.146
MIKKELSEN_MEF_LCP_WITH_H3K4ME3	3415	99	-1.508	-0.438	0.051	0.146
WESTON_VEGFA_TARGETS_6HR	3416	48	-1.508	-0.434	0.051	0.146
KOBAYASHI_EGFR_SIGNALING_24HR_UP	3417	82	-1.508	-0.492	0.051	0.146
AMIT_EGF_RESPONSE_240_HELA	3418	51	-1.509	-0.478	0.051	0.145
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_SCP2_QTL_TRANS	3419	22	-1.509	-0.49	0.051	0.145
REACTOME_GPER1_SIGNALING	3420	44	-1.509	-0.444	0.050	0.144
LI_WILMS_TUMOR_ANAPLASTIC_UP	3421	16	-1.51	-0.691	0.050	0.143
REACTOME_RAF_INDEPENDENT_MAPK1_3_ACTIVATION	3422	22	-1.511	-0.631	0.050	0.143
BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_DN	3423	41	-1.511	-0.501	0.050	0.143
REACTOME_DEFECTIVE_INTRINSIC_PATHWAY_FOR_APOPTOSIS	3424	24	-1.512	-0.503	0.049	0.142
REACTOME_RAC2_GTPASE_CYCLE	3425	76	-1.512	-0.486	0.049	0.142
KARLSSON_TGFB1_TARGETS_DN	3426	161	-1.513	-0.493	0.049	0.141
DEMAGALHAES_AGING_UP	3427	47	-1.513	-0.464	0.049	0.141
DACOSTA_ERCC3_ALLELE_XPCS_VS_TTD_UP	3428	26	-1.513	-0.461	0.049	0.141
WP_MATRIX_METALLOPROTEINASES	3429	30	-1.513	-0.564	0.049	0.141
REACTOME_SIGNALING_BY_HIPPO	3430	18	-1.514	-0.678	0.049	0.141
WP_MIRNA_REGULATION_OF_PROSTATE_CANCER_SIGNALING_PATHWAYS	3431	29	-1.514	-0.576	0.049	0.141
SA_B_CELL_RECEPTOR_COMPLEXES	3432	24	-1.514	-0.601	0.048	0.140
PID_NFAT_TFPATHWAY	3433	43	-1.514	-0.392	0.048	0.140
REACTOME_RHO_GTPASES_ACTIVATE_WASPS_AND_WAVES	3434	32	-1.515	-0.634	0.048	0.140
MATTIOLI_MULTIPLE_MYELOMA_WITH_14Q32_TRANSLOCATIONS	3435	30	-1.515	-0.506	0.048	0.140
KEGG_PROSTATE_CANCER	3436	87	-1.515	-0.466	0.048	0.139
SESTO_RESPONSE_TO_UV_C2	3437	45	-1.516	-0.693	0.048	0.139
HORIUCHI_WTAP_TARGETS_UP	3438	250	-1.516	-0.403	0.048	0.139
CHIARETTI_ACUTE_LYMPHOBLASTIC_LEUKEMIA_ZAP70	3439	56	-1.517	-0.417	0.047	0.138
WP_IL17_SIGNALING_PATHWAY	3440	32	-1.517	-0.535	0.047	0.138
BIOCARTA_NGF_PATHWAY	3441	19	-1.517	-0.547	0.047	0.138
PID_IGF1_PATHWAY	3442	28	-1.518	-0.682	0.047	0.137
BIDUS_METASTASIS_DN	3443	117	-1.518	-0.379	0.047	0.137
NAKAMURA_ADIPOGENESIS_EARLY_UP	3444	50	-1.518	-0.522	0.047	0.137
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_DN	3445	51	-1.518	-0.387	0.047	0.137
KOHOUTEK_CCNT1_TARGETS	3446	45	-1.518	-0.52	0.047	0.137
KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY	3447	76	-1.519	-0.382	0.047	0.137
PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP	3448	116	-1.519	-0.385	0.047	0.137
MARZEC_IL2_SIGNALING_DN	3449	34	-1.519	-0.465	0.047	0.137
REACTOME_TGF_BETA_RECEPTOR_SIGNALING_IN_EMT_EPITHELIAL_TO_MESENCHYMAL_TRANSITION	3450	16	-1.52	-0.721	0.046	0.136
HAHTOLA_MYCOSIS_FUNGOIDES_CD4_UP	3451	57	-1.521	-0.511	0.046	0.135
KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP	3452	116	-1.521	-0.378	0.046	0.135
COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP	3453	88	-1.521	-0.55	0.046	0.135
MEBARKI_HCC_PROGENITOR_WNT_UP_BLOCKED_BY_FZD8CRD	3454	99	-1.522	-0.397	0.046	0.134
BIOCARTA_IGF1_PATHWAY	3455	21	-1.522	-0.582	0.046	0.134
KIM_MYCL1_AMPLIFICATION_TARGETS_DN	3456	17	-1.522	-0.659	0.046	0.134
LANDIS_BREAST_CANCER_PROGRESSION_UP	3457	42	-1.522	-0.633	0.045	0.134
WP_IL1_SIGNALING_PATHWAY	3458	52	-1.523	-0.566	0.045	0.134
TARTE_PLASMA_CELL_VS_PLASMABLAST_UP	3459	365	-1.523	-0.378	0.045	0.134
WONG_ENDMETRIUM_CANCER_UP	3460	20	-1.523	-0.562	0.045	0.134
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY	3461	63	-1.523	-0.384	0.045	0.133
BIOCARTA_MCALPAIN_PATHWAY	3462	18	-1.524	-0.592	0.045	0.133
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP	3463	167	-1.524	-0.484	0.045	0.133
WP_MECP2_AND_ASSOCIATED_RETT_SYNDROME	3464	62	-1.524	-0.417	0.045	0.133
WP_OXIDATIVE_DAMAGE_RESPONSE	3465	38	-1.524	-0.466	0.045	0.133
WP_ERBB_SIGNALING_PATHWAY	3466	86	-1.525	-0.477	0.045	0.133
WP_INSULIN_SIGNALING	3467	152	-1.525	-0.443	0.044	0.133
PAL_PRMT5_TARGETS_DN	3468	26	-1.525	-0.531	0.044	0.133
DAWSON_METHYLATED_IN_LYMPHOMA_TCL1	3469	40	-1.525	-0.397	0.044	0.133
REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION	3470	105	-1.525	-0.455	0.044	0.133
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN	3471	383	-1.525	-0.579	0.044	0.133
WP_SPINAL_CORD_INJURY	3472	107	-1.526	-0.399	0.044	0.132
WATANABE_COLON_CANCER_MSI_VS_MSS_UP	3473	25	-1.526	-0.47	0.044	0.132
BURTON_ADIPOGENESIS_10	3474	26	-1.526	-0.57	0.044	0.132
IWANAGA_CARCINOGENESIS_BY_KRAS_DN	3475	98	-1.526	-0.331	0.044	0.132
BOYLAN_MULTIPLE_MYELOMA_PCA1_UP	3476	98	-1.526	-0.402	0.044	0.132
PID_MYC_REPRESS_PATHWAY	3477	61	-1.527	-0.493	0.044	0.132
MATZUK_EMBRYONIC_GERM_CELL	3478	18	-1.527	-0.448	0.044	0.131
JINESH_BLEBBISHIELD_TO_IMMUNE_CELL_FUSION_PBSHMS_DN	3479	308	-1.527	-0.372	0.044	0.131
GHANDHI_DIRECT_IRRADIATION_DN	3480	26	-1.527	-0.5	0.044	0.131
HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_UP	3481	71	-1.527	-0.413	0.043	0.131
JINESH_BLEBBISHIELD_TO_IMMUNE_CELL_FUSION_PBSHMS_UP	3482	304	-1.528	-0.472	0.043	0.131
HAN_SATB1_TARGETS_UP	3483	364	-1.528	-0.432	0.043	0.131
WP_2Q37_COPY_NUMBER_VARIATION_SYNDROME	3484	104	-1.529	-0.415	0.043	0.130
BROWNE_INTERFERON_RESPONSIVE_GENES	3485	60	-1.53	-0.451	0.043	0.129
WU_HBX_TARGETS_2_UP	3486	20	-1.53	-0.608	0.043	0.129
ASGHARZADEH_NEUROBLASTOMA_POOR_SURVIVAL_DN	3487	34	-1.53	-0.452	0.043	0.129
VILIMAS_NOTCH1_TARGETS_UP	3488	51	-1.53	-0.473	0.043	0.129
KAPOSI_LIVER_CANCER_MET_UP	3489	17	-1.531	-0.702	0.042	0.129
NAKAMURA_CANCER_MICROENVIRONMENT_UP	3490	22	-1.531	-0.516	0.042	0.128
REACTOME_SIGNALLING_TO_RAS	3491	19	-1.531	-0.568	0.042	0.128
LEE_EARLY_T_LYMPHOCYTE_UP	3492	83	-1.531	-0.496	0.042	0.128
WENG_POR_DOSAGE	3493	21	-1.531	-0.471	0.042	0.128
KEGG_STEROID_BIOSYNTHESIS	3494	15	-1.532	-0.683	0.042	0.128
RAGHAVACHARI_PLATELET_SPECIFIC_GENES	3495	60	-1.532	-0.493	0.042	0.128
ZWANG_EGF_INTERVAL_DN	3496	166	-1.532	-0.455	0.042	0.128
WP_PDGF_PATHWAY	3497	39	-1.532	-0.589	0.042	0.128
ROVERSI_GLIOMA_COPY_NUMBER_DN	3498	48	-1.532	-0.37	0.042	0.128
REACTOME_DAP12_INTERACTIONS	3499	40	-1.533	-0.431	0.042	0.128
STEIN_ESTROGEN_RESPONSE_NOT_VIA_ESRRA	3500	17	-1.533	-0.527	0.042	0.127
URS_ADIPOCYTE_DIFFERENTIATION_DN	3501	28	-1.533	-0.487	0.042	0.127
PILON_KLF1_TARGETS_UP	3502	406	-1.533	-0.358	0.042	0.127
FONTAINE_PAPILLARY_THYROID_CARCINOMA_DN	3503	66	-1.533	-0.392	0.041	0.127
AKL_HTLV1_INFECTION_DN	3504	56	-1.533	-0.477	0.041	0.127
JIANG_TIP30_TARGETS_UP	3505	39	-1.534	-0.537	0.041	0.127
REACTOME_THROMBIN_SIGNALLING_THROUGH_PROTEINASE_ACTIVATED_RECEPTORS_PARS	3506	31	-1.535	-0.479	0.041	0.126
WP_RETT_SYNDROME_CAUSING_GENES	3507	43	-1.535	-0.393	0.041	0.126
BIOCARTA_HCMV_PATHWAY	3508	17	-1.536	-0.689	0.041	0.126
SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER	3509	39	-1.536	-0.436	0.040	0.125
KEGG_INOSITOL_PHOSPHATE_METABOLISM	3510	46	-1.537	-0.43	0.040	0.124
WILCOX_RESPONSE_TO_PROGESTERONE_UP	3511	124	-1.537	-0.464	0.040	0.124
REACTOME_ACTIVATED_NOTCH1_TRANSMITS_SIGNAL_TO_THE_NUCLEUS	3512	29	-1.538	-0.543	0.040	0.123
PARK_TRETINOIN_RESPONSE_AND_RARA_PLZF_FUSION	3513	22	-1.538	-0.515	0.040	0.123
LIANG_SILENCED_BY_METHYLATION_UP	3514	29	-1.538	-0.496	0.040	0.123
BIOCARTA_MEF2D_PATHWAY	3515	17	-1.538	-0.617	0.040	0.123
WP_MBDNF_AND_PROBDNF_REGULATION_OF_GABA_NEUROTRANSMISSION	3516	38	-1.539	-0.453	0.040	0.123
KANG_IMMORTALIZED_BY_TERT_DN	3517	98	-1.539	-0.402	0.039	0.123
REACTOME_NUCLEAR_EVENTS_KINASE_AND_TRANSCRIPTION_FACTOR_ACTIVATION	3518	60	-1.539	-0.47	0.039	0.123
INGRAM_SHH_TARGETS_DN	3519	51	-1.54	-0.436	0.039	0.122
ALONSO_METASTASIS_NEURAL_UP	3520	17	-1.54	-0.582	0.039	0.122
WP_ROLES_OF_CERAMIDES_IN_THE_DEVELOPMENT_OF_INSULIN_RESISTANCE	3521	21	-1.54	-0.48	0.039	0.122
WP_INTERLEUKIN11_SIGNALING_PATHWAY	3522	43	-1.54	-0.554	0.039	0.122
RAO_BOUND_BY_SALL4	3523	179	-1.541	-0.409	0.039	0.122
TSENG_IRS1_TARGETS_DN	3524	111	-1.541	-0.418	0.039	0.122
WP_ONCOSTATIN_M_SIGNALING_PATHWAY	3525	61	-1.541	-0.554	0.039	0.121
WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP	3526	111	-1.542	-0.406	0.039	0.121
REACTOME_INTERLEUKIN_37_SIGNALING	3527	19	-1.542	-0.593	0.039	0.121
REACTOME_NEGATIVE_REGULATION_OF_FGFR4_SIGNALING	3528	31	-1.542	-0.485	0.039	0.121
DING_LUNG_CANCER_MUTATED_SIGNIFICANTLY	3529	26	-1.542	-0.438	0.039	0.121
BIOCARTA_PTEN_PATHWAY	3530	17	-1.542	-0.673	0.038	0.121
KRASNOSELSKAYA_ILF3_TARGETS_DN	3531	42	-1.543	-0.412	0.038	0.120
REACTOME_REGULATION_OF_TLR_BY_ENDOGENOUS_LIGAND	3532	19	-1.543	-0.605	0.038	0.120
NABA_CORE_MATRISOME	3533	231	-1.543	-0.449	0.038	0.120
KUMAR_AUTOPHAGY_NETWORK	3534	56	-1.543	-0.38	0.038	0.120
REACTOME_PURINERGIC_SIGNALING_IN_LEISHMANIASIS_INFECTION	3535	24	-1.544	-0.547	0.038	0.120
BIOCARTA_NKCELLS_PATHWAY	3536	19	-1.544	-0.507	0.038	0.120
AMIT_EGF_RESPONSE_480_MCF10A	3537	36	-1.544	-0.571	0.038	0.120
BEIER_GLIOMA_STEM_CELL_UP	3538	30	-1.544	-0.468	0.038	0.120
CUI_TCF21_TARGETS_UP	3539	32	-1.544	-0.485	0.038	0.120
WP_OSTEOBLAST_DIFFERENTIATION_AND_RELATED_DISEASES	3540	113	-1.544	-0.386	0.038	0.120
SCIAN_INVERSED_TARGETS_OF_TP53_AND_TP73_DN	3541	27	-1.545	-0.674	0.038	0.120
REACTOME_CLATHRIN_MEDIATED_ENDOCYTOSIS	3542	138	-1.545	-0.448	0.038	0.119
RODWELL_AGING_KIDNEY_UP	3543	391	-1.545	-0.369	0.037	0.119
AMIT_EGF_RESPONSE_480_HELA	3544	139	-1.546	-0.584	0.037	0.119
AMIT_EGF_RESPONSE_60_MCF10A	3545	32	-1.546	-0.651	0.037	0.119
REACTOME_GAB1_SIGNALOSOME	3546	16	-1.547	-0.646	0.037	0.118
HUPER_BREAST_BASAL_VS_LUMINAL_DN	3547	55	-1.547	-0.587	0.037	0.118
ODONNELL_TFRC_TARGETS_UP	3548	307	-1.548	-0.33	0.037	0.117
VERHAAK_GLIOBLASTOMA_CLASSICAL	3549	142	-1.548	-0.374	0.037	0.117
IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_DN	3550	279	-1.548	-0.322	0.037	0.117
FISCHER_G2_M_CELL_CYCLE	3551	206	-1.548	-0.578	0.037	0.117
CARRILLOREIXACH_HEPATOBLASTOMA_VS_NORMAL_HYPOMETHYLATED_AND_UP	3552	150	-1.548	-0.364	0.036	0.117
REACTOME_TNFR1_INDUCED_NFKAPPAB_SIGNALING_PATHWAY	3553	25	-1.548	-0.564	0.036	0.117
WP_TRANSCRIPTION_FACTOR_REGULATION_IN_ADIPOGENESIS	3554	21	-1.549	-0.525	0.036	0.117
WP_INHIBITION_OF_EXOSOME_BIOGENESIS_AND_SECRETION_BY_MANUMYCIN_A_IN_CRPC_CELLS	3555	17	-1.549	-0.71	0.036	0.117
REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL	3556	139	-1.549	-0.375	0.036	0.117
BIOCARTA_TPO_PATHWAY	3557	23	-1.549	-0.612	0.036	0.117
KAMIKUBO_MYELOID_CEBPA_NETWORK	3558	28	-1.55	-0.473	0.036	0.116
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_UP	3559	36	-1.55	-0.519	0.036	0.116
WP_AIRWAY_SMOOTH_MUSCLE_CELL_CONTRACTION	3560	16	-1.551	-0.553	0.036	0.116
WP_TGFBETA_SIGNALING_PATHWAY	3561	123	-1.551	-0.534	0.036	0.116
PID_INTEGRIN_A4B1_PATHWAY	3562	32	-1.551	-0.522	0.036	0.116
MAYBURD_RESPONSE_TO_L663536_UP	3563	22	-1.552	-0.564	0.035	0.114
REACTOME_ACTIVATION_OF_MATRIX_METALLOPROTEINASES	3564	31	-1.552	-0.619	0.035	0.114
KOBAYASHI_EGFR_SIGNALING_6HR_DN	3565	16	-1.552	-0.773	0.035	0.114
WP_NRF2ARE_REGULATION	3566	22	-1.552	-0.626	0.035	0.114
SUH_COEXPRESSED_WITH_ID1_AND_ID2_UP	3567	17	-1.553	-0.582	0.035	0.114
HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_DN	3568	58	-1.553	-0.451	0.035	0.114
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_17	3569	19	-1.553	-0.525	0.035	0.114
PID_ERBB2_ERBB3_PATHWAY	3570	43	-1.554	-0.572	0.035	0.113
AZARE_STAT3_TARGETS	3571	19	-1.554	-0.665	0.035	0.113
PID_IL1_PATHWAY	3572	32	-1.554	-0.598	0.035	0.113
BIOCARTA_EPO_PATHWAY	3573	19	-1.555	-0.503	0.034	0.113
WP_4249_HEDGEHOG_SIGNALING_PATHWAY	3574	39	-1.555	-0.424	0.034	0.112
PID_AP1_PATHWAY	3575	67	-1.556	-0.423	0.034	0.112
GHO_ATF5_TARGETS_DN	3576	15	-1.556	-0.675	0.034	0.112
REACTOME_TIE2_SIGNALING	3577	18	-1.556	-0.542	0.034	0.112
RUIZ_TNC_TARGETS_UP	3578	134	-1.556	-0.467	0.034	0.112
JOSEPH_RESPONSE_TO_SODIUM_BUTYRATE_UP	3579	28	-1.556	-0.604	0.034	0.112
ZWANG_EGF_PERSISTENTLY_DN	3580	43	-1.556	-0.522	0.034	0.112
REACTOME_ACTIVATION_OF_SMO	3581	16	-1.557	-0.541	0.034	0.112
GROSS_HYPOXIA_VIA_ELK3_DN	3582	133	-1.557	-0.499	0.034	0.111
BIOCARTA_INSULIN_PATHWAY	3583	21	-1.557	-0.56	0.034	0.111
PID_ERBB1_DOWNSTREAM_PATHWAY	3584	102	-1.557	-0.537	0.034	0.111
DAZARD_UV_RESPONSE_CLUSTER_G24	3585	19	-1.557	-0.604	0.034	0.111
OLSSON_E2F3_TARGETS_UP	3586	23	-1.558	-0.565	0.034	0.111
BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_24HR_DN	3587	32	-1.558	-0.482	0.033	0.111
KRASNOSELSKAYA_ILF3_TARGETS_UP	3588	36	-1.558	-0.49	0.033	0.111
MUELLER_COMMON_TARGETS_OF_AML_FUSIONS_DN	3589	29	-1.56	-0.476	0.033	0.110
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_UP	3590	24	-1.56	-0.457	0.033	0.110
PEREZ_TP63_TARGETS	3591	291	-1.56	-0.387	0.033	0.109
BREUHAHN_GROWTH_FACTOR_SIGNALING_IN_LIVER_CANCER	3592	15	-1.56	-0.701	0.033	0.109
KOYAMA_SEMA3B_TARGETS_UP	3593	202	-1.561	-0.377	0.033	0.109
WP_INTERFERON_TYPE_I_SIGNALING_PATHWAYS	3594	49	-1.561	-0.5	0.033	0.109
REACTOME_WNT_LIGAND_BIOGENESIS_AND_TRAFFICKING	3595	24	-1.562	-0.504	0.032	0.108
DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP	3596	54	-1.562	-0.404	0.032	0.108
BIOCARTA_CXCR4_PATHWAY	3597	18	-1.562	-0.656	0.032	0.108
REACTOME_SIGNALING_BY_NTRK3_TRKC	3598	16	-1.562	-0.609	0.032	0.108
MATTHEWS_AP1_TARGETS	3599	17	-1.562	-0.557	0.032	0.108
DOANE_BREAST_CANCER_ESR1_UP	3600	98	-1.563	-0.4	0.032	0.108
ZHENG_GLIOBLASTOMA_PLASTICITY_UP	3601	214	-1.563	-0.383	0.032	0.108
PID_ATF2_PATHWAY	3602	54	-1.563	-0.485	0.032	0.108
DACOSTA_ERCC3_ALLELE_XPCS_VS_TTD_DN	3603	30	-1.563	-0.5	0.032	0.108
WP_AMPLIFICATION_AND_EXPANSION_OF_ONCOGENIC_PATHWAYS_AS_METASTATIC_TRAITS	3604	15	-1.564	-0.616	0.032	0.107
PID_IL8_CXCR2_PATHWAY	3605	29	-1.564	-0.509	0.032	0.107
LINDGREN_BLADDER_CANCER_HIGH_RECURRENCE	3606	43	-1.564	-0.475	0.032	0.107
PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_UP	3607	101	-1.565	-0.377	0.032	0.106
REACTOME_SIGNALING_BY_BMP	3608	27	-1.565	-0.457	0.031	0.106
WP_BLOOD_CLOTTING_CASCADE	3609	22	-1.565	-0.571	0.031	0.106
LY_AGING_MIDDLE_DN	3610	15	-1.566	-0.747	0.031	0.105
BIOCARTA_41BB_PATHWAY	3611	18	-1.566	-0.517	0.031	0.105
WP_GASTRIN_SIGNALING_PATHWAY	3612	105	-1.566	-0.513	0.031	0.105
WP_TCELL_ACTIVATION_SARSCOV2	3613	82	-1.566	-0.38	0.031	0.105
REACTOME_CELLULAR_HEXOSE_TRANSPORT	3614	17	-1.566	-0.587	0.031	0.105
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_DN	3615	41	-1.567	-0.544	0.031	0.105
DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_DN	3616	65	-1.567	-0.529	0.031	0.105
REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES	3617	31	-1.567	-0.599	0.031	0.105
BIOCARTA_TOB1_PATHWAY	3618	19	-1.567	-0.508	0.031	0.105
WP_IL3_SIGNALING_PATHWAY	3619	48	-1.568	-0.466	0.031	0.105
WP_TCELL_ANTIGEN_RECEPTOR_TCR_PATHWAY_DURING_STAPHYLOCOCCUS_AUREUS_INFECTION	3620	61	-1.568	-0.41	0.031	0.104
AFFAR_YY1_TARGETS_UP	3621	182	-1.568	-0.346	0.031	0.104
EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_UP	3622	174	-1.569	-0.421	0.030	0.104
WP_CELLS_AND_MOLECULES_INVOLVED_IN_LOCAL_ACUTE_INFLAMMATORY_RESPONSE	3623	16	-1.569	-0.592	0.030	0.104
BIOCARTA_LAIR_PATHWAY	3624	16	-1.569	-0.592	0.030	0.104
WP_HOSTPATHOGEN_INTERACTION_OF_HUMAN_CORONAVIRUSES_MAPK_SIGNALING	3625	36	-1.569	-0.512	0.030	0.104
REACTOME_DAP12_SIGNALING	3626	28	-1.569	-0.48	0.030	0.104
REACTOME_OVARIAN_TUMOR_DOMAIN_PROTEASES	3627	35	-1.57	-0.536	0.030	0.104
PID_KIT_PATHWAY	3628	49	-1.57	-0.505	0.030	0.104
BORLAK_LIVER_CANCER_EGF_UP	3629	49	-1.57	-0.542	0.030	0.103
REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2	3630	116	-1.57	-0.441	0.030	0.103
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_UP	3631	30	-1.571	-0.611	0.030	0.103
WP_TLR4_SIGNALING_AND_TOLERANCE	3632	25	-1.571	-0.535	0.030	0.103
BIOCARTA_GPCR_PATHWAY	3633	29	-1.571	-0.536	0.030	0.103
MCCLUNG_COCAINE_REWARD_5D	3634	67	-1.571	-0.421	0.030	0.103
KEGG_SMALL_CELL_LUNG_CANCER	3635	82	-1.571	-0.474	0.030	0.103
LUI_THYROID_CANCER_CLUSTER_1	3636	43	-1.572	-0.565	0.030	0.103
REACTOME_SIGNALING_BY_FLT3_FUSION_PROTEINS	3637	18	-1.572	-0.619	0.030	0.103
FIGUEROA_AML_METHYLATION_CLUSTER_1_DN	3638	34	-1.572	-0.461	0.029	0.102
PID_HEDGEHOG_GLI_PATHWAY	3639	47	-1.572	-0.547	0.029	0.102
IVANOVA_HEMATOPOIESIS_MATURE_CELL	3640	220	-1.573	-0.432	0.029	0.102
REACTOME_INTEGRATION_OF_ENERGY_METABOLISM	3641	108	-1.574	-0.387	0.029	0.102
WEIGEL_OXIDATIVE_STRESS_BY_HNE_AND_TBH	3642	55	-1.574	-0.544	0.029	0.102
REACTOME_INTERLEUKIN_20_FAMILY_SIGNALING	3643	21	-1.574	-0.558	0.029	0.101
RIEGE_DELTANP63_DIRECT_TARGETS_UP	3644	116	-1.574	-0.59	0.029	0.101
PID_ERBB1_RECEPTOR_PROXIMAL_PATHWAY	3645	35	-1.575	-0.673	0.029	0.101
PID_SYNDECAN_3_PATHWAY	3646	15	-1.575	-0.685	0.029	0.101
BOYAULT_LIVER_CANCER_SUBCLASS_G5_DN	3647	22	-1.575	-0.556	0.029	0.101
GENTILE_UV_RESPONSE_CLUSTER_D2	3648	34	-1.575	-0.639	0.029	0.101
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN	3649	167	-1.575	-0.443	0.029	0.101
WP_ALPHA_6_BETA_4_SIGNALING_PATHWAY	3650	32	-1.575	-0.67	0.029	0.101
HALLMARK_IL2_STAT5_SIGNALING	3651	180	-1.576	-0.394	0.029	0.101
IGLESIAS_E2F_TARGETS_UP	3652	135	-1.576	-0.449	0.029	0.101
MIKKELSEN_MCV6_ICP_WITH_H3K4ME3_AND_H3K27ME3	3653	26	-1.576	-0.55	0.029	0.101
BIOCARTA_EGF_PATHWAY	3654	26	-1.576	-0.647	0.028	0.101
WP_KIT_RECEPTOR_SIGNALING_PATHWAY	3655	56	-1.576	-0.52	0.028	0.101
FARMER_BREAST_CANCER_CLUSTER_7	3656	17	-1.576	-0.59	0.028	0.100
UDAYAKUMAR_MED1_TARGETS_DN	3657	204	-1.576	-0.487	0.028	0.100
BROWNE_HCMV_INFECTION_12HR_DN	3658	77	-1.577	-0.437	0.028	0.100
SIG_INSULIN_RECEPTOR_PATHWAY_IN_CARDIAC_MYOCYTES	3659	48	-1.577	-0.582	0.028	0.100
TENEDINI_MEGAKARYOCYTE_MARKERS	3660	58	-1.577	-0.467	0.028	0.100
STREICHER_LSM1_TARGETS_UP	3661	40	-1.577	-0.467	0.028	0.100
REACTOME_ORGANIC_CATION_ANION_ZWITTERION_TRANSPORT	3662	15	-1.578	-0.576	0.028	0.099
REACTOME_CONSTITUTIVE_SIGNALING_BY_LIGAND_RESPONSIVE_EGFR_CANCER_VARIANTS	3663	19	-1.578	-0.71	0.028	0.099
HANSON_HRAS_SIGNALING_VIA_NFKB	3664	21	-1.578	-0.499	0.028	0.099
LINDGREN_BLADDER_CANCER_CLUSTER_1_DN	3665	319	-1.578	-0.399	0.028	0.099
GREENBAUM_E2A_TARGETS_UP	3666	29	-1.579	-0.645	0.028	0.099
PID_TOLL_ENDOGENOUS_PATHWAY	3667	23	-1.579	-0.526	0.028	0.099
GAJATE_RESPONSE_TO_TRABECTEDIN_UP	3668	59	-1.579	-0.565	0.028	0.099
DUNNE_TARGETS_OF_AML1_MTG8_FUSION_DN	3669	18	-1.58	-0.618	0.028	0.099
HOSHIDA_LIVER_CANCER_SUBCLASS_S1	3670	221	-1.58	-0.435	0.027	0.098
WP_IL4_SIGNALING_PATHWAY	3671	54	-1.58	-0.507	0.027	0.098
IWANAGA_CARCINOGENESIS_BY_KRAS_UP	3672	141	-1.581	-0.42	0.027	0.098
MCLACHLAN_DENTAL_CARIES_UP	3673	225	-1.581	-0.435	0.027	0.098
REACTOME_RHOC_GTPASE_CYCLE	3674	64	-1.582	-0.572	0.027	0.097
REACTOME_CELL_CELL_JUNCTION_ORGANIZATION	3675	54	-1.582	-0.475	0.027	0.097
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_UP	3676	60	-1.583	-0.401	0.027	0.097
WP_INFLAMMATORY_BOWEL_DISEASE_SIGNALING	3677	42	-1.583	-0.494	0.027	0.096
AMIT_SERUM_RESPONSE_60_MCF10A	3678	49	-1.584	-0.644	0.026	0.095
WP_DEVELOPMENT_AND_HETEROGENEITY_OF_THE_ILC_FAMILY	3679	30	-1.585	-0.464	0.026	0.095
WESTON_VEGFA_TARGETS_12HR	3680	25	-1.585	-0.52	0.026	0.095
ZHENG_BOUND_BY_FOXP3	3681	397	-1.586	-0.385	0.026	0.094
KEGG_ERBB_SIGNALING_PATHWAY	3682	84	-1.586	-0.503	0.026	0.094
AMIT_EGF_RESPONSE_120_HELA	3683	58	-1.586	-0.543	0.026	0.094
WP_ECTODERM_DIFFERENTIATION	3684	126	-1.586	-0.387	0.026	0.094
BOQUEST_STEM_CELL_CULTURED_VS_FRESH_UP	3685	375	-1.586	-0.349	0.026	0.094
PID_EPHA2_FWD_PATHWAY	3686	18	-1.586	-0.707	0.026	0.094
GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_DN	3687	26	-1.587	-0.702	0.026	0.094
SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_DN	3688	130	-1.587	-0.531	0.026	0.094
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6	3689	64	-1.587	-0.453	0.026	0.094
REACTOME_SIGNALING_BY_FLT3_ITD_AND_TKD_MUTANTS	3690	16	-1.587	-0.583	0.026	0.094
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP	3691	145	-1.588	-0.537	0.026	0.094
BARIS_THYROID_CANCER_DN	3692	55	-1.588	-0.57	0.025	0.094
WP_NOVEL_INTRACELLULAR_COMPONENTS_OF_RIGILIKE_RECEPTOR_PATHWAY	3693	52	-1.588	-0.449	0.025	0.093
BLANCO_MELO_COVID19_SARS_COV_2_INFECTION_A594_CELLS_UP	3694	74	-1.588	-0.422	0.025	0.093
DUTTA_APOPTOSIS_VIA_NFKB	3695	31	-1.589	-0.538	0.025	0.093
PID_ECADHERIN_STABILIZATION_PATHWAY	3696	38	-1.589	-0.638	0.025	0.093
SCHRAETS_MLL_TARGETS_DN	3697	31	-1.589	-0.508	0.025	0.093
LIM_MAMMARY_STEM_CELL_DN	3698	345	-1.589	-0.437	0.025	0.093
KEGG_INSULIN_SIGNALING_PATHWAY	3699	130	-1.589	-0.446	0.025	0.093
WP_GENETIC_CAUSES_OF_PSVDINCPH	3700	29	-1.589	-0.487	0.025	0.093
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN	3701	169	-1.589	-0.399	0.025	0.093
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR4	3702	27	-1.589	-0.482	0.025	0.093
REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS	3703	30	-1.59	-0.506	0.025	0.093
BERENJENO_TRANSFORMED_BY_RHOA_FOREVER_DN	3704	26	-1.59	-0.665	0.025	0.093
ASTON_MAJOR_DEPRESSIVE_DISORDER_DN	3705	145	-1.59	-0.377	0.025	0.093
ZHU_SKIL_TARGETS_UP	3706	18	-1.591	-0.611	0.025	0.092
EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_DN	3707	37	-1.591	-0.441	0.025	0.092
REACTOME_DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA	3708	72	-1.592	-0.435	0.025	0.092
BIOCARTA_CCR5_PATHWAY	3709	16	-1.592	-0.629	0.025	0.092
REACTOME_ABC_TRANSPORTERS_IN_LIPID_HOMEOSTASIS	3710	18	-1.593	-0.533	0.024	0.091
REACTOME_DEACTIVATION_OF_THE_BETA_CATENIN_TRANSACTIVATING_COMPLEX	3711	39	-1.593	-0.511	0.024	0.091
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP	3712	86	-1.593	-0.432	0.024	0.091
WP_TOLLLIKE_RECEPTOR_SIGNALING_PATHWAY	3713	99	-1.594	-0.411	0.024	0.091
WILSON_PROTEASES_AT_TUMOR_BONE_INTERFACE_UP	3714	20	-1.594	-0.695	0.024	0.091
DANG_REGULATED_BY_MYC_DN	3715	227	-1.594	-0.496	0.024	0.091
MEBARKI_HCC_PROGENITOR_WNT_UP_CTNNB1_DEPENDENT	3716	71	-1.594	-0.42	0.024	0.091
REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION	3717	28	-1.594	-0.502	0.024	0.090
DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_DN	3718	57	-1.594	-0.41	0.024	0.090
AMIT_EGF_RESPONSE_240_MCF10A	3719	19	-1.594	-0.737	0.024	0.090
DORN_ADENOVIRUS_INFECTION_48HR_DN	3720	32	-1.594	-0.671	0.024	0.090
WP_VITAMIN_D_RECEPTOR_PATHWAY	3721	157	-1.595	-0.392	0.024	0.090
BIOCARTA_KERATINOCYTE_PATHWAY	3722	45	-1.596	-0.506	0.024	0.090
SNIJDERS_AMPLIFIED_IN_HEAD_AND_NECK_TUMORS	3723	34	-1.596	-0.587	0.024	0.090
COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_UP	3724	34	-1.596	-0.5	0.024	0.090
MARIADASON_RESPONSE_TO_BUTYRATE_SULINDAC_6	3725	36	-1.597	-0.478	0.023	0.089
VERRECCHIA_RESPONSE_TO_TGFB1_C1	3726	18	-1.597	-0.629	0.023	0.089
SCHEIDEREIT_IKK_TARGETS	3727	15	-1.598	-0.694	0.023	0.089
REACTOME_SIGNALING_BY_VEGF	3728	100	-1.598	-0.508	0.023	0.089
MCBRYAN_PUBERTAL_BREAST_4_5WK_UP	3729	233	-1.598	-0.451	0.023	0.088
WP_B_CELL_RECEPTOR_SIGNALING_PATHWAY	3730	95	-1.598	-0.424	0.023	0.088
BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_DN	3731	35	-1.598	-0.509	0.023	0.088
PRAMOONJAGO_SOX4_TARGETS_UP	3732	45	-1.599	-0.648	0.023	0.088
CHUNG_BLISTER_CYTOTOXICITY_DN	3733	37	-1.599	-0.486	0.023	0.088
WP_CONSTITUTIVE_ANDROSTANE_RECEPTOR_PATHWAY	3734	27	-1.599	-0.522	0.023	0.088
BROWNE_HCMV_INFECTION_48HR_DN	3735	421	-1.599	-0.363	0.023	0.088
BURTON_ADIPOGENESIS_9	3736	75	-1.6	-0.458	0.023	0.088
GOLDRATH_ANTIGEN_RESPONSE	3737	314	-1.6	-0.431	0.023	0.087
SENESE_HDAC1_AND_HDAC2_TARGETS_DN	3738	186	-1.6	-0.419	0.023	0.087
CHANDRAN_METASTASIS_DN	3739	252	-1.6	-0.377	0.023	0.087
REACTOME_ESTROGEN_DEPENDENT_NUCLEAR_EVENTS_DOWNSTREAM_OF_ESR_MEMBRANE_SIGNALING	3740	22	-1.6	-0.693	0.023	0.087
DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN	3741	258	-1.601	-0.425	0.022	0.087
REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION	3742	29	-1.602	-0.624	0.022	0.087
WOTTON_RUNX_TARGETS_DN	3743	26	-1.602	-0.561	0.022	0.087
PID_TCPTP_PATHWAY	3744	40	-1.603	-0.555	0.022	0.085
BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS	3745	25	-1.604	-0.583	0.022	0.085
PID_ECADHERIN_NASCENT_AJ_PATHWAY	3746	38	-1.604	-0.648	0.022	0.085
WP_PDGFRBETA_PATHWAY	3747	28	-1.604	-0.622	0.022	0.085
BRUECKNER_TARGETS_OF_MIRLET7A3_DN	3748	66	-1.604	-0.591	0.022	0.085
DORN_ADENOVIRUS_INFECTION_32HR_DN	3749	31	-1.604	-0.673	0.022	0.085
JEON_SMAD6_TARGETS_DN	3750	18	-1.604	-0.637	0.022	0.085
ZHAN_V1_LATE_DIFFERENTIATION_GENES_UP	3751	32	-1.604	-0.554	0.022	0.085
RODWELL_AGING_KIDNEY_NO_BLOOD_UP	3752	178	-1.604	-0.422	0.022	0.085
SAGIV_CD24_TARGETS_UP	3753	21	-1.605	-0.621	0.022	0.084
GOBERT_CORE_OLIGODENDROCYTE_DIFFERENTIATION	3754	41	-1.605	-0.456	0.022	0.084
DAVICIONI_PAX_FOXO1_SIGNATURE_IN_ARMS_DN	3755	17	-1.606	-0.532	0.021	0.084
DAVICIONI_PAX_FOXO1_SIGNATURE_IN_ARMS_UP	3756	50	-1.606	-0.446	0.021	0.084
HUANG_GATA2_TARGETS_UP	3757	129	-1.606	-0.429	0.021	0.084
WP_TNFALPHA_SIGNALING_PATHWAY	3758	88	-1.606	-0.489	0.021	0.084
ABBUD_LIF_SIGNALING_1_UP	3759	39	-1.606	-0.457	0.021	0.084
SWEET_KRAS_TARGETS_UP	3760	67	-1.607	-0.61	0.021	0.083
WIERENGA_STAT5A_TARGETS_DN	3761	158	-1.607	-0.378	0.021	0.083
WP_RAS_AND_BRADYKININ_PATHWAYS_IN_COVID19	3762	29	-1.607	-0.592	0.021	0.083
WP_EGFR_TYROSINE_KINASE_INHIBITOR_RESISTANCE	3763	80	-1.607	-0.515	0.021	0.083
NAGASHIMA_NRG1_SIGNALING_DN	3764	42	-1.608	-0.499	0.021	0.083
KANG_DOXORUBICIN_RESISTANCE_UP	3765	46	-1.608	-0.66	0.021	0.083
SHI_SPARC_TARGETS_UP	3766	21	-1.608	-0.635	0.021	0.083
GAVIN_FOXP3_TARGETS_CLUSTER_P3	3767	133	-1.608	-0.362	0.021	0.083
PID_LYMPH_ANGIOGENESIS_PATHWAY	3768	23	-1.608	-0.679	0.021	0.083
WP_GLUTATHIONE_METABOLISM	3769	17	-1.608	-0.651	0.021	0.083
REACTOME_NOREPINEPHRINE_NEUROTRANSMITTER_RELEASE_CYCLE	3770	17	-1.608	-0.547	0.021	0.083
PID_BMP_PATHWAY	3771	37	-1.609	-0.518	0.021	0.083
DURAND_STROMA_S_UP	3772	254	-1.609	-0.352	0.021	0.083
REACTOME_FLT3_SIGNALING_IN_DISEASE	3773	27	-1.61	-0.597	0.021	0.082
ONDER_CDH1_TARGETS_1_UP	3774	115	-1.61	-0.504	0.020	0.082
VERRECCHIA_DELAYED_RESPONSE_TO_TGFB1	3775	37	-1.61	-0.634	0.020	0.082
JOHNSTONE_PARVB_TARGETS_3_UP	3776	352	-1.611	-0.535	0.020	0.081
BOYAULT_LIVER_CANCER_SUBCLASS_G6_DN	3777	18	-1.612	-0.615	0.020	0.081
WP_NETWORK_MAP_OF_SARSCOV2_SIGNALING_PATHWAY	3778	201	-1.612	-0.384	0.020	0.081
IBRAHIM_NRF2_DOWN	3779	123	-1.612	-0.483	0.020	0.081
MAHAJAN_RESPONSE_TO_IL1A_UP	3780	73	-1.612	-0.446	0.020	0.081
HOEGERKORP_CD44_TARGETS_DIRECT_UP	3781	23	-1.612	-0.554	0.020	0.081
SHIN_B_CELL_LYMPHOMA_CLUSTER_3	3782	25	-1.612	-0.489	0.020	0.081
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_DN	3783	28	-1.612	-0.528	0.020	0.081
DE_YY1_TARGETS_UP	3784	17	-1.613	-0.642	0.020	0.081
MEBARKI_HCC_PROGENITOR_FZD8CRD_UP	3785	397	-1.613	-0.404	0.020	0.081
IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP	3786	104	-1.613	-0.466	0.020	0.081
AIGNER_ZEB1_TARGETS	3787	31	-1.614	-0.718	0.020	0.080
KENNY_CTNNB1_TARGETS_DN	3788	41	-1.614	-0.571	0.020	0.080
GARCIA_TARGETS_OF_FLI1_AND_DAX1_UP	3789	39	-1.614	-0.565	0.020	0.080
VERRECCHIA_RESPONSE_TO_TGFB1_C5	3790	21	-1.614	-0.649	0.020	0.080
RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN	3791	216	-1.615	-0.49	0.020	0.080
KARAKAS_TGFB1_SIGNALING	3792	18	-1.615	-0.602	0.019	0.079
LANDIS_ERBB2_BREAST_TUMORS_324_UP	3793	126	-1.615	-0.574	0.019	0.079
PETROVA_PROX1_TARGETS_DN	3794	52	-1.616	-0.492	0.019	0.079
ROZANOV_MMP14_TARGETS_UP	3795	221	-1.616	-0.387	0.019	0.079
WP_EPO_RECEPTOR_SIGNALING	3796	26	-1.616	-0.557	0.019	0.079
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN	3797	383	-1.616	-0.519	0.019	0.079
ROSS_AML_WITH_PML_RARA_FUSION	3798	67	-1.616	-0.475	0.019	0.079
HALLMARK_HEDGEHOG_SIGNALING	3799	34	-1.617	-0.455	0.019	0.079
WANG_BARRETTS_ESOPHAGUS_DN	3800	25	-1.617	-0.701	0.019	0.079
WP_SEROTONIN_RECEPTOR_2_AND_ELKSRFGATA4_SIGNALING	3801	20	-1.617	-0.523	0.019	0.079
HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_UP	3802	20	-1.618	-0.541	0.019	0.078
PID_S1P_S1P2_PATHWAY	3803	23	-1.619	-0.626	0.019	0.077
BIOCARTA_PDGF_PATHWAY	3804	27	-1.619	-0.617	0.019	0.077
WP_P53_TRANSCRIPTIONAL_GENE_NETWORK	3805	80	-1.619	-0.48	0.019	0.077
WP_PHYSIOLOGICAL_AND_PATHOLOGICAL_HYPERTROPHY_OF_THE_HEART	3806	23	-1.62	-0.601	0.018	0.077
WP_NUCLEAR_RECEPTORS_METAPATHWAY	3807	290	-1.621	-0.368	0.018	0.077
SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN	3808	286	-1.621	-0.402	0.018	0.076
RICKMAN_METASTASIS_DN	3809	218	-1.622	-0.522	0.018	0.076
KEGG_HYPERTROPHIC_CARDIOMYOPATHY_HCM	3810	82	-1.622	-0.502	0.018	0.076
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_UP	3811	218	-1.622	-0.367	0.018	0.076
WP_GLUCURONIDATION	3812	17	-1.622	-0.542	0.018	0.076
REACTOME_LDL_CLEARANCE	3813	17	-1.622	-0.669	0.018	0.076
WP_NAD_BIOSYNTHETIC_PATHWAYS	3814	19	-1.622	-0.504	0.018	0.076
WP_STING_PATHWAY_IN_KAWASAKILIKE_DISEASE_AND_COVID19	3815	16	-1.622	-0.62	0.018	0.076
BROWNE_HCMV_INFECTION_24HR_DN	3816	127	-1.623	-0.454	0.018	0.076
FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_DN	3817	352	-1.623	-0.377	0.018	0.076
HALLMARK_MYOGENESIS	3818	194	-1.623	-0.425	0.018	0.076
HARRIS_BRAIN_CANCER_PROGENITORS	3819	34	-1.623	-0.506	0.018	0.076
MORI_LARGE_PRE_BII_LYMPHOCYTE_DN	3820	50	-1.624	-0.488	0.018	0.075
WP_KALLMANN_SYNDROME	3821	22	-1.624	-0.507	0.018	0.075
KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_UP	3822	123	-1.624	-0.536	0.018	0.075
CROONQUIST_NRAS_VS_STROMAL_STIMULATION_DN	3823	82	-1.625	-0.495	0.018	0.074
RADMACHER_AML_PROGNOSIS	3824	65	-1.626	-0.508	0.017	0.074
DELACROIX_RARG_BOUND_MEF	3825	311	-1.626	-0.434	0.017	0.074
BROWNE_HCMV_INFECTION_10HR_DN	3826	49	-1.626	-0.484	0.017	0.074
GAVIN_FOXP3_TARGETS_CLUSTER_P4	3827	84	-1.626	-0.426	0.017	0.074
REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS	3828	25	-1.627	-0.55	0.017	0.074
WP_SEROTONIN_RECEPTOR_467_AND_NR3C_SIGNALING	3829	19	-1.627	-0.585	0.017	0.073
WP_G13_SIGNALING_PATHWAY	3830	37	-1.629	-0.573	0.017	0.072
HOELZEL_NF1_TARGETS_UP	3831	117	-1.629	-0.37	0.017	0.072
PHONG_TNF_RESPONSE_VIA_P38_PARTIAL	3832	149	-1.629	-0.591	0.017	0.072
PID_GMCSF_PATHWAY	3833	36	-1.629	-0.555	0.017	0.072
REACTOME_CONSTITUTIVE_SIGNALING_BY_EGFRVIII	3834	15	-1.63	-0.743	0.017	0.071
WP_HIPPOYAP_SIGNALING_PATHWAY	3835	22	-1.631	-0.616	0.017	0.071
HALLMARK_HYPOXIA	3836	180	-1.631	-0.475	0.017	0.071
CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_DN	3837	147	-1.631	-0.373	0.016	0.071
REACTOME_KERATINIZATION	3838	129	-1.632	-0.527	0.016	0.070
BIOCARTA_STRESS_PATHWAY	3839	24	-1.632	-0.587	0.016	0.070
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP	3840	147	-1.633	-0.391	0.016	0.070
BIOCARTA_INFLAM_PATHWAY	3841	26	-1.633	-0.598	0.016	0.070
BROCKE_APOPTOSIS_REVERSED_BY_IL6	3842	122	-1.633	-0.466	0.016	0.070
WP_SELENIUM_MICRONUTRIENT_NETWORK	3843	71	-1.634	-0.412	0.016	0.070
WHITFIELD_CELL_CYCLE_G2	3844	124	-1.634	-0.534	0.016	0.070
BROWNE_HCMV_INFECTION_18HR_DN	3845	157	-1.634	-0.425	0.016	0.070
WP_HEPATITIS_B_INFECTION	3846	145	-1.634	-0.435	0.016	0.070
MUELLER_METHYLATED_IN_GLIOBLASTOMA	3847	41	-1.634	-0.53	0.016	0.070
WANG_METHYLATED_IN_BREAST_CANCER	3848	34	-1.634	-0.668	0.016	0.070
WP_EMBRYONIC_STEM_CELL_PLURIPOTENCY_PATHWAYS	3849	111	-1.635	-0.416	0.016	0.070
YAMASHITA_LIVER_CANCER_STEM_CELL_UP	3850	44	-1.635	-0.491	0.016	0.070
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_YELLOW_UP	3851	23	-1.635	-0.693	0.016	0.070
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP	3852	152	-1.635	-0.407	0.016	0.069
ZHENG_FOXP3_TARGETS_IN_T_LYMPHOCYTE_DN	3853	30	-1.635	-0.526	0.016	0.069
REACTOME_TRANSCRIPTIONAL_REGULATION_OF_PLURIPOTENT_STEM_CELLS	3854	29	-1.635	-0.513	0.016	0.069
WP_CARDIAC_HYPERTROPHIC_RESPONSE	3855	52	-1.636	-0.541	0.016	0.069
MOREAUX_B_LYMPHOCYTE_MATURATION_BY_TACI_UP	3856	70	-1.636	-0.494	0.016	0.069
FARMER_BREAST_CANCER_CLUSTER_4	3857	18	-1.637	-0.662	0.016	0.069
BIOCARTA_PYK2_PATHWAY	3858	26	-1.637	-0.718	0.015	0.069
SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER	3859	81	-1.638	-0.453	0.015	0.068
BIOCARTA_FMLP_PATHWAY	3860	34	-1.638	-0.537	0.015	0.068
PID_MET_PATHWAY	3861	75	-1.638	-0.605	0.015	0.068
REACTOME_NEGATIVE_REGULATION_OF_FGFR3_SIGNALING	3862	29	-1.638	-0.534	0.015	0.068
BIOCARTA_PAR1_PATHWAY	3863	17	-1.638	-0.597	0.015	0.068
BIOCARTA_NFAT_PATHWAY	3864	51	-1.638	-0.469	0.015	0.068
FOSTER_TOLERANT_MACROPHAGE_DN	3865	340	-1.639	-0.459	0.015	0.068
BIOCARTA_TOLL_PATHWAY	3866	24	-1.639	-0.575	0.015	0.067
LOPEZ_EPITHELIOID_MESOTHELIOMA	3867	15	-1.639	-0.622	0.015	0.067
REACTOME_INTERLEUKIN_17_SIGNALING	3868	65	-1.64	-0.531	0.015	0.067
ROSS_LEUKEMIA_WITH_MLL_FUSIONS	3869	71	-1.64	-0.511	0.015	0.067
KANG_IMMORTALIZED_BY_TERT_UP	3870	86	-1.64	-0.435	0.015	0.067
SAGIV_CD24_TARGETS_DN	3871	43	-1.64	-0.558	0.015	0.067
WP_FGFR3_SIGNALING_IN_CHONDROCYTE_PROLIFERATION_AND_TERMINAL_DIFFERENTIATION	3872	26	-1.641	-0.568	0.015	0.067
BIOCARTA_ALK_PATHWAY	3873	36	-1.641	-0.504	0.015	0.067
LEE_DIFFERENTIATING_T_LYMPHOCYTE	3874	157	-1.641	-0.378	0.015	0.067
BILD_SRC_ONCOGENIC_SIGNATURE	3875	50	-1.641	-0.695	0.015	0.067
REACTOME_SIGNALING_BY_EGFR_IN_CANCER	3876	24	-1.641	-0.715	0.015	0.067
GRANDVAUX_IRF3_TARGETS_DN	3877	18	-1.642	-0.653	0.015	0.066
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY	3878	121	-1.642	-0.5	0.015	0.066
REACTOME_TGF_BETA_RECEPTOR_SIGNALING_ACTIVATES_SMADS	3879	45	-1.643	-0.673	0.015	0.066
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP	3880	160	-1.643	-0.399	0.014	0.066
BIOCARTA_INTRINSIC_PATHWAY	3881	23	-1.644	-0.566	0.014	0.065
REACTOME_TOLL_LIKE_RECEPTOR_TLR1_TLR2_CASCADE	3882	106	-1.644	-0.48	0.014	0.065
POOLA_INVASIVE_BREAST_CANCER_DN	3883	121	-1.645	-0.432	0.014	0.065
TSAI_RESPONSE_TO_RADIATION_THERAPY	3884	29	-1.645	-0.588	0.014	0.065
REACTOME_SIGNALING_BY_INTERLEUKINS	3885	418	-1.645	-0.405	0.014	0.065
KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY	3886	71	-1.645	-0.472	0.014	0.065
LINDSTEDT_DENDRITIC_CELL_MATURATION_C	3887	56	-1.645	-0.516	0.014	0.065
FERRARI_RESPONSE_TO_FENRETINIDE_UP	3888	19	-1.646	-0.749	0.014	0.065
PASINI_SUZ12_TARGETS_DN	3889	285	-1.646	-0.553	0.014	0.065
PID_WNT_NONCANONICAL_PATHWAY	3890	30	-1.646	-0.546	0.014	0.065
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7	3891	315	-1.646	-0.441	0.014	0.065
WP_ID_SIGNALING_PATHWAY	3892	16	-1.647	-0.575	0.014	0.065
WP_G_PROTEIN_SIGNALING_PATHWAYS	3893	90	-1.647	-0.446	0.014	0.064
KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS	3894	87	-1.647	-0.468	0.014	0.064
REACTOME_HEME_SIGNALING	3895	43	-1.648	-0.522	0.014	0.064
XIE_ST_HSC_S1PR3_OE_UP	3896	153	-1.648	-0.444	0.014	0.064
PID_CXCR3_PATHWAY	3897	41	-1.648	-0.485	0.014	0.064
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP	3898	347	-1.649	-0.441	0.014	0.064
BIOCARTA_HDAC_PATHWAY	3899	25	-1.649	-0.537	0.014	0.064
CHEOK_RESPONSE_TO_MERCAPTOPURINE_DN	3900	20	-1.649	-0.509	0.014	0.064
WEST_ADRENOCORTICAL_TUMOR_MARKERS_UP	3901	21	-1.649	-0.656	0.014	0.063
GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP	3902	186	-1.649	-0.367	0.014	0.063
REACTOME_RAC3_GTPASE_CYCLE	3903	80	-1.65	-0.509	0.013	0.063
PID_INTEGRIN_CS_PATHWAY	3904	25	-1.65	-0.638	0.013	0.063
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP	3905	191	-1.65	-0.432	0.013	0.063
BROWNE_HCMV_INFECTION_20HR_DN	3906	89	-1.65	-0.528	0.013	0.063
WP_MYD88_DISTINCT_INPUTOUTPUT_PATHWAY	3907	18	-1.651	-0.605	0.013	0.063
XU_CREBBP_TARGETS_DN	3908	34	-1.651	-0.517	0.013	0.063
WP_SPLICING_FACTOR_NOVA_REGULATED_SYNAPTIC_PROTEINS	3909	39	-1.651	-0.456	0.013	0.063
PID_ENDOTHELIN_PATHWAY	3910	62	-1.652	-0.466	0.013	0.063
WIERENGA_STAT5A_TARGETS_GROUP1	3911	103	-1.652	-0.447	0.013	0.063
TING_SILENCED_BY_DICER	3912	25	-1.652	-0.516	0.013	0.063
WP_COMMON_PATHWAYS_UNDERLYING_DRUG_ADDICTION	3913	40	-1.652	-0.514	0.013	0.063
PID_ERBB1_INTERNALIZATION_PATHWAY	3914	40	-1.652	-0.658	0.013	0.063
PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN	3915	148	-1.653	-0.522	0.013	0.062
BIOCARTA_ERYTH_PATHWAY	3916	15	-1.654	-0.651	0.013	0.061
WANG_BARRETTS_ESOPHAGUS_AND_ESOPHAGUS_CANCER_DN	3917	37	-1.655	-0.552	0.013	0.061
BROWNE_HCMV_INFECTION_2HR_UP	3918	32	-1.655	-0.477	0.013	0.061
PID_AR_NONGENOMIC_PATHWAY	3919	31	-1.655	-0.588	0.013	0.061
BIOCARTA_ECM_PATHWAY	3920	19	-1.656	-0.734	0.013	0.061
BIOCARTA_NTHI_PATHWAY	3921	22	-1.656	-0.703	0.013	0.061
CHIBA_RESPONSE_TO_TSA_UP	3922	47	-1.656	-0.522	0.013	0.061
REACTOME_SIGNALING_BY_ERBB2_ECD_MUTANTS	3923	15	-1.656	-0.75	0.013	0.061
REACTOME_RHO_GTPASES_ACTIVATE_ROCKS	3924	18	-1.657	-0.718	0.013	0.060
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY	3925	99	-1.657	-0.436	0.012	0.060
PHONG_TNF_RESPONSE_NOT_VIA_P38	3926	302	-1.657	-0.5	0.012	0.060
ZHAN_MULTIPLE_MYELOMA_CD1_DN	3927	40	-1.657	-0.538	0.012	0.060
GREGORY_SYNTHETIC_LETHAL_WITH_IMATINIB	3928	119	-1.657	-0.41	0.012	0.060
KORKOLA_EMBRYONIC_CARCINOMA_VS_SEMINOMA_UP	3929	21	-1.658	-0.504	0.012	0.060
WP_CANONICAL_AND_NONCANONICAL_TGFB_SIGNALING	3930	17	-1.658	-0.73	0.012	0.060
REACTOME_RUNX2_REGULATES_OSTEOBLAST_DIFFERENTIATION	3931	23	-1.659	-0.58	0.012	0.060
SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES	3932	34	-1.659	-0.516	0.012	0.060
DELPUECH_FOXO3_TARGETS_UP	3933	62	-1.659	-0.629	0.012	0.060
REACTOME_RUNX2_REGULATES_BONE_DEVELOPMENT	3934	30	-1.659	-0.523	0.012	0.060
MASSARWEH_TAMOXIFEN_RESISTANCE_UP	3935	437	-1.66	-0.455	0.012	0.059
CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_DN	3936	294	-1.66	-0.412	0.012	0.059
SA_PTEN_PATHWAY	3937	16	-1.66	-0.717	0.012	0.059
SCHMIDT_POR_TARGETS_IN_LIMB_BUD_UP	3938	25	-1.66	-0.663	0.012	0.059
REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING	3939	24	-1.66	-0.559	0.012	0.059
REACTOME_EGFR_DOWNREGULATION	3940	30	-1.661	-0.627	0.012	0.059
PID_EPHA_FWDPATHWAY	3941	33	-1.661	-0.549	0.012	0.059
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN	3942	101	-1.661	-0.401	0.012	0.059
SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP	3943	352	-1.662	-0.384	0.012	0.059
WP_CHOLESTEROL_METABOLISM_WITH_BLOCH_AND_KANDUTSCHRUSSELL_PATHWAYS	3944	45	-1.662	-0.565	0.012	0.059
WP_IL6_SIGNALING_PATHWAY	3945	43	-1.662	-0.609	0.012	0.059
REACTOME_RHO_GTPASES_ACTIVATE_NADPH_OXIDASES	3946	23	-1.662	-0.515	0.012	0.058
ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_DN	3947	103	-1.663	-0.448	0.012	0.058
SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP	3948	67	-1.663	-0.523	0.012	0.058
WP_TYPE_II_INTERFERON_SIGNALING	3949	34	-1.663	-0.522	0.012	0.058
LU_IL4_SIGNALING	3950	79	-1.663	-0.423	0.012	0.058
LIU_VAV3_PROSTATE_CARCINOGENESIS_UP	3951	85	-1.664	-0.474	0.012	0.058
WP_METABOLIC_PATHWAY_OF_LDL_HDL_AND_TG_INCLUDING_DISEASES	3952	16	-1.664	-0.571	0.012	0.058
BIOCARTA_TGFB_PATHWAY	3953	18	-1.664	-0.756	0.012	0.058
DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN	3954	61	-1.665	-0.549	0.011	0.057
ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN	3955	127	-1.665	-0.402	0.011	0.057
PID_DELTA_NP63_PATHWAY	3956	43	-1.665	-0.604	0.011	0.057
REACTOME_RAS_ACTIVATION_UPON_CA2_INFLUX_THROUGH_NMDA_RECEPTOR	3957	20	-1.666	-0.525	0.011	0.057
BIOCARTA_CCR3_PATHWAY	3958	18	-1.666	-0.594	0.011	0.057
WU_HBX_TARGETS_2_DN	3959	15	-1.666	-0.685	0.011	0.057
JOHANSSON_GLIOMAGENESIS_BY_PDGFB_DN	3960	17	-1.667	-0.522	0.011	0.056
STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_DN	3961	20	-1.667	-0.534	0.011	0.056
LUI_THYROID_CANCER_PAX8_PPARG_UP	3962	37	-1.667	-0.649	0.011	0.056
YAO_HOXA10_TARGETS_VIA_PROGESTERONE_DN	3963	17	-1.667	-0.548	0.011	0.056
ZHAN_MULTIPLE_MYELOMA_CD2_UP	3964	38	-1.668	-0.493	0.011	0.056
PID_IFNG_PATHWAY	3965	38	-1.668	-0.652	0.011	0.056
REACTOME_NETRIN_1_SIGNALING	3966	47	-1.668	-0.476	0.011	0.056
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_TOP20_DN	3967	17	-1.668	-0.637	0.011	0.056
RIGGI_EWING_SARCOMA_PROGENITOR_DN	3968	157	-1.668	-0.428	0.011	0.056
SAKAI_TUMOR_INFILTRATING_MONOCYTES_UP	3969	26	-1.669	-0.566	0.011	0.056
UZONYI_RESPONSE_TO_LEUKOTRIENE_AND_THROMBIN	3970	31	-1.67	-0.531	0.011	0.056
YAGI_AML_FAB_MARKERS	3971	175	-1.67	-0.438	0.011	0.056
CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_UP	3972	67	-1.67	-0.428	0.011	0.056
KEGG_LEISHMANIA_INFECTION	3973	65	-1.67	-0.449	0.011	0.056
ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF	3974	405	-1.67	-0.51	0.011	0.056
DURAND_STROMA_NS_UP	3975	132	-1.671	-0.359	0.011	0.055
AMIT_EGF_RESPONSE_120_MCF10A	3976	37	-1.671	-0.62	0.011	0.055
KEGG_VEGF_SIGNALING_PATHWAY	3977	70	-1.671	-0.481	0.011	0.055
XU_HGF_SIGNALING_NOT_VIA_AKT1_6HR	3978	23	-1.671	-0.748	0.011	0.055
REACTOME_SMOOTH_MUSCLE_CONTRACTION	3979	37	-1.671	-0.557	0.011	0.055
LIM_MAMMARY_LUMINAL_PROGENITOR_UP	3980	50	-1.671	-0.55	0.011	0.055
WP_HAIR_FOLLICLE_DEVELOPMENT_CYTODIFFERENTIATION_PART_3_OF_3	3981	79	-1.672	-0.453	0.011	0.055
QI_PLASMACYTOMA_UP	3982	245	-1.672	-0.433	0.011	0.055
PID_GLYPICAN_1PATHWAY	3983	26	-1.673	-0.599	0.010	0.055
CHYLA_CBFA2T3_TARGETS_DN	3984	174	-1.673	-0.391	0.010	0.055
BIOCARTA_NFKB_PATHWAY	3985	20	-1.673	-0.693	0.010	0.055
PID_BCR_5PATHWAY	3986	63	-1.673	-0.508	0.010	0.055
REACTOME_LEISHMANIA_INFECTION	3987	244	-1.673	-0.425	0.010	0.055
LI_INDUCED_T_TO_NATURAL_KILLER_UP	3988	255	-1.673	-0.418	0.010	0.055
REACTOME_RHO_GTPASES_ACTIVATE_PAKS	3989	20	-1.673	-0.711	0.010	0.055
HALLMARK_INTERFERON_GAMMA_RESPONSE	3990	185	-1.673	-0.417	0.010	0.055
LINDSTEDT_DENDRITIC_CELL_MATURATION_D	3991	60	-1.674	-0.485	0.010	0.055
LANDIS_ERBB2_BREAST_TUMORS_65_UP	3992	20	-1.674	-0.639	0.010	0.055
XU_AKT1_TARGETS_6HR	3993	23	-1.674	-0.587	0.010	0.055
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR3	3994	25	-1.674	-0.535	0.010	0.055
REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION	3995	131	-1.674	-0.474	0.010	0.055
WIERENGA_STAT5A_TARGETS_UP	3996	166	-1.675	-0.417	0.010	0.054
HUMMERICH_SKIN_CANCER_PROGRESSION_UP	3997	84	-1.675	-0.476	0.010	0.054
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_DN	3998	125	-1.675	-0.476	0.010	0.054
BIOCARTA_INTEGRIN_PATHWAY	3999	34	-1.676	-0.661	0.010	0.054
LIU_SMARCA4_TARGETS	4000	42	-1.676	-0.562	0.010	0.054
BIOCARTA_SPRY_PATHWAY	4001	17	-1.677	-0.711	0.010	0.054
PID_IL12_STAT4_PATHWAY	4002	32	-1.677	-0.547	0.010	0.053
MEBARKI_HCC_PROGENITOR_WNT_UP_CTNNB1_INDEPENDENT	4003	20	-1.677	-0.624	0.010	0.053
REACTOME_MAPK_FAMILY_SIGNALING_CASCADES	4004	304	-1.678	-0.435	0.010	0.053
WP_VITAMIN_D_IN_INFLAMMATORY_DISEASES	4005	21	-1.679	-0.677	0.010	0.053
PID_HES_HEY_PATHWAY	4006	44	-1.68	-0.532	0.010	0.052
SHIN_B_CELL_LYMPHOMA_CLUSTER_8	4007	35	-1.68	-0.568	0.010	0.052
RUTELLA_RESPONSE_TO_HGF_DN	4008	200	-1.68	-0.432	0.010	0.052
REACTOME_TRANSCRIPTIONAL_REGULATION_BY_MECP2	4009	53	-1.681	-0.457	0.010	0.052
WP_AGERAGE_PATHWAY	4010	61	-1.681	-0.605	0.009	0.052
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY	4011	105	-1.681	-0.454	0.009	0.052
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_6	4012	25	-1.682	-0.525	0.009	0.051
KEGG_TIGHT_JUNCTION	4013	121	-1.682	-0.463	0.009	0.051
WP_BMP_SIGNALING_IN_EYELID_DEVELOPMENT	4014	20	-1.683	-0.613	0.009	0.051
REACTOME_SIGNALING_BY_SCF_KIT	4015	42	-1.683	-0.564	0.009	0.051
WP_INTERACTIONS_BETWEEN_IMMUNE_CELLS_AND_MICRORNAS_IN_TUMOR_MICROENVIRONMENT	4016	28	-1.683	-0.611	0.009	0.051
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM2	4017	146	-1.684	-0.445	0.009	0.051
VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_DN	4018	120	-1.684	-0.461	0.009	0.051
MAGRANGEAS_MULTIPLE_MYELOMA_IGG_VS_IGA_DN	4019	26	-1.684	-0.526	0.009	0.051
HALMOS_CEBPA_TARGETS_UP	4020	45	-1.684	-0.535	0.009	0.051
WU_CELL_MIGRATION	4021	164	-1.684	-0.622	0.009	0.051
LINDGREN_BLADDER_CANCER_CLUSTER_2B	4022	346	-1.684	-0.391	0.009	0.051
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_2	4023	49	-1.684	-0.51	0.009	0.051
OUELLET_CULTURED_OVARIAN_CANCER_INVASIVE_VS_LMP_DN	4024	28	-1.684	-0.551	0.009	0.051
REACTOME_TOLL_LIKE_RECEPTOR_CASCADES	4025	152	-1.684	-0.454	0.009	0.051
KATSANOU_ELAVL1_TARGETS_UP	4026	143	-1.684	-0.384	0.009	0.051
SHEPARD_BMYB_MORPHOLINO_DN	4027	176	-1.684	-0.422	0.009	0.051
REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS	4028	86	-1.684	-0.513	0.009	0.051
KRIEG_HYPOXIA_VIA_KDM3A	4029	46	-1.684	-0.574	0.009	0.051
MASSARWEH_TAMOXIFEN_RESISTANCE_DN	4030	195	-1.684	-0.411	0.009	0.051
HALLMARK_APOPTOSIS	4031	156	-1.686	-0.54	0.009	0.050
REACTOME_RHO_GTPASES_ACTIVATE_CIT	4032	18	-1.687	-0.741	0.009	0.050
ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_DN	4033	41	-1.687	-0.578	0.009	0.050
FRASOR_TAMOXIFEN_RESPONSE_UP	4034	41	-1.688	-0.568	0.009	0.050
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP	4035	99	-1.688	-0.599	0.009	0.049
WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2	4036	54	-1.688	-0.573	0.009	0.049
REACTOME_NEGATIVE_REGULATION_OF_FGFR1_SIGNALING	4037	32	-1.688	-0.508	0.009	0.049
STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_UP	4038	70	-1.689	-0.463	0.009	0.049
CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_DN	4039	32	-1.689	-0.622	0.009	0.049
KASLER_HDAC7_TARGETS_1_DN	4040	17	-1.689	-0.673	0.009	0.049
BLANCO_MELO_BRONCHIAL_EPITHELIAL_CELLS_INFLUENZA_A_DEL_NS1_INFECTION_DN	4041	138	-1.689	-0.469	0.009	0.049
DORN_ADENOVIRUS_INFECTION_24HR_DN	4042	34	-1.689	-0.69	0.009	0.049
GAL_LEUKEMIC_STEM_CELL_DN	4043	209	-1.689	-0.421	0.009	0.049
CHEOK_RESPONSE_TO_HD_MTX_UP	4044	22	-1.689	-0.559	0.009	0.049
AMIT_EGF_RESPONSE_60_HELA	4045	38	-1.69	-0.647	0.008	0.049
REACTOME_SENSORY_PROCESSING_OF_SOUND	4046	63	-1.691	-0.514	0.008	0.049
PID_MAPK_TRK_PATHWAY	4047	34	-1.691	-0.539	0.008	0.049
WP_TYPE_II_DIABETES_MELLITUS	4048	18	-1.691	-0.562	0.008	0.048
WP_BRAINDERIVED_NEUROTROPHIC_FACTOR_BDNF_SIGNALING_PATHWAY	4049	138	-1.692	-0.428	0.008	0.048
LEE_EARLY_T_LYMPHOCYTE_DN	4050	47	-1.692	-0.466	0.008	0.048
THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP	4051	69	-1.692	-0.58	0.008	0.048
FOROUTAN_TGFB_EMT_DN	4052	94	-1.693	-0.515	0.008	0.048
ANASTASSIOU_MULTICANCER_INVASIVENESS_SIGNATURE	4053	60	-1.693	-0.489	0.008	0.048
LEIN_CEREBELLUM_MARKERS	4054	69	-1.693	-0.431	0.008	0.048
SARTIPY_NORMAL_AT_INSULIN_RESISTANCE_UP	4055	22	-1.693	-0.614	0.008	0.048
WP_MECHANOREGULATION_AND_PATHOLOGY_OF_YAPTAZ_VIA_HIPPO_AND_NONHIPPO_MECHANISMS	4056	43	-1.694	-0.621	0.008	0.048
NAKAMURA_METASTASIS	4057	38	-1.694	-0.432	0.008	0.048
SENESE_HDAC1_TARGETS_DN	4058	193	-1.694	-0.445	0.008	0.048
GEISS_RESPONSE_TO_DSRNA_UP	4059	37	-1.694	-0.625	0.008	0.048
HALLMARK_UV_RESPONSE_DN	4060	131	-1.694	-0.541	0.008	0.048
PID_THROMBIN_PAR1_PATHWAY	4061	41	-1.696	-0.517	0.008	0.047
HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_UP	4062	52	-1.696	-0.487	0.008	0.047
LEE_LIVER_CANCER_ACOX1_UP	4063	60	-1.696	-0.51	0.008	0.047
MCBRYAN_PUBERTAL_TGFB1_TARGETS_DN	4064	60	-1.697	-0.525	0.008	0.046
LEE_METASTASIS_AND_ALTERNATIVE_SPLICING_UP	4065	67	-1.698	-0.552	0.008	0.046
GROSS_ELK3_TARGETS_DN	4066	27	-1.698	-0.513	0.008	0.046
PID_IL12_2PATHWAY	4067	58	-1.698	-0.497	0.008	0.046
REACTOME_RAP1_SIGNALLING	4068	15	-1.698	-0.654	0.008	0.046
VERRECCHIA_EARLY_RESPONSE_TO_TGFB1	4069	52	-1.698	-0.591	0.008	0.046
WOO_LIVER_CANCER_RECURRENCE_UP	4070	94	-1.699	-0.507	0.008	0.046
REACTOME_INOSITOL_PHOSPHATE_METABOLISM	4071	42	-1.699	-0.447	0.008	0.046
KIM_WT1_TARGETS_UP	4072	186	-1.699	-0.554	0.008	0.046
WP_EBSTEINBARR_VIRUS_LMP1_SIGNALING	4073	22	-1.699	-0.622	0.008	0.046
PLASARI_NFIC_TARGETS_BASAL_DN	4074	19	-1.7	-0.591	0.008	0.046
REACTOME_IRAK4_DEFICIENCY_TLR2_4	4075	18	-1.7	-0.644	0.008	0.046
VERHAAK_AML_WITH_NPM1_MUTATED_DN	4076	214	-1.7	-0.414	0.008	0.046
REACTOME_PI3K_AKT_SIGNALING_IN_CANCER	4077	98	-1.7	-0.433	0.008	0.046
WP_MAPK_CASCADE	4078	32	-1.702	-0.602	0.007	0.045
WP_HOSTPATHOGEN_INTERACTION_OF_HUMAN_CORONAVIRUSES_INTERFERON_INDUCTION	4079	31	-1.703	-0.635	0.007	0.045
DURCHDEWALD_SKIN_CARCINOGENESIS_DN	4080	223	-1.703	-0.561	0.007	0.044
BILD_HRAS_ONCOGENIC_SIGNATURE	4081	214	-1.704	-0.651	0.007	0.044
WU_HBX_TARGETS_1_DN	4082	21	-1.704	-0.67	0.007	0.044
HAN_JNK_SINGALING_UP	4083	29	-1.704	-0.566	0.007	0.044
RODRIGUES_THYROID_CARCINOMA_DN	4084	58	-1.705	-0.603	0.007	0.044
PLASARI_TGFB1_SIGNALING_VIA_NFIC_1HR_DN	4085	91	-1.705	-0.469	0.007	0.044
GENTILE_UV_HIGH_DOSE_UP	4086	18	-1.706	-0.67	0.007	0.044
CROONQUIST_NRAS_VS_STROMAL_STIMULATION_UP	4087	34	-1.706	-0.544	0.007	0.044
BIOCARTA_TCR_PATHWAY	4088	43	-1.706	-0.549	0.007	0.044
WP_CANONICAL_AND_NONCANONICAL_NOTCH_SIGNALING	4089	25	-1.707	-0.556	0.007	0.043
HUMMERICH_MALIGNANT_SKIN_TUMOR_UP	4090	16	-1.707	-0.666	0.007	0.043
PID_A6B1_A6B4_INTEGRIN_PATHWAY	4091	46	-1.708	-0.712	0.007	0.043
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_1	4092	61	-1.708	-0.473	0.007	0.043
WP_TGFBETA_SIGNALING_IN_THYROID_CELLS_FOR_EPITHELIALMESENCHYMAL_TRANSITION	4093	17	-1.709	-0.682	0.007	0.042
ZHAN_MULTIPLE_MYELOMA_LB_UP	4094	39	-1.709	-0.473	0.007	0.042
WP_PRION_DISEASE_PATHWAY	4095	32	-1.71	-0.57	0.007	0.042
WP_MICRORNAS_IN_CARDIOMYOCYTE_HYPERTROPHY	4096	76	-1.711	-0.539	0.007	0.041
REACTOME_RHO_GTPASE_EFFECTORS	4097	222	-1.711	-0.557	0.007	0.041
THUM_MIR21_TARGETS_HEART_DISEASE_UP	4098	15	-1.712	-0.565	0.007	0.041
BIOCARTA_BIOPEPTIDES_PATHWAY	4099	28	-1.712	-0.638	0.007	0.041
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN	4100	130	-1.712	-0.535	0.007	0.041
BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B	4101	447	-1.712	-0.404	0.007	0.041
PID_TGFBR_PATHWAY	4102	50	-1.713	-0.644	0.006	0.041
ZIRN_TRETINOIN_RESPONSE_WT1_UP	4103	20	-1.714	-0.562	0.006	0.041
BASSO_HAIRY_CELL_LEUKEMIA_UP	4104	75	-1.714	-0.536	0.006	0.041
ZHENG_FOXP3_TARGETS_UP	4105	23	-1.714	-0.556	0.006	0.041
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5	4106	372	-1.715	-0.507	0.006	0.040
KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION	4107	44	-1.715	-0.653	0.006	0.040
WP_PATHOGENIC_ESCHERICHIA_COLI_INFECTION	4108	44	-1.715	-0.653	0.006	0.040
NUMATA_CSF3_SIGNALING_VIA_STAT3	4109	20	-1.716	-0.526	0.006	0.040
KEGG_DORSO_VENTRAL_AXIS_FORMATION	4110	23	-1.716	-0.643	0.006	0.040
WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_UP	4111	268	-1.716	-0.412	0.006	0.040
WP_IL18_SIGNALING_PATHWAY	4112	248	-1.716	-0.426	0.006	0.040
KEGG_MAPK_SIGNALING_PATHWAY	4113	255	-1.717	-0.414	0.006	0.040
REACTOME_SIGNALING_BY_PTK6	4114	52	-1.717	-0.58	0.006	0.040
REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK	4115	18	-1.718	-0.704	0.006	0.039
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_DN	4116	92	-1.718	-0.576	0.006	0.039
REACTOME_ECM_PROTEOGLYCANS	4117	70	-1.718	-0.604	0.006	0.039
WANG_METASTASIS_OF_BREAST_CANCER_ESR1_DN	4118	26	-1.718	-0.532	0.006	0.039
LE_SKI_TARGETS_UP	4119	17	-1.719	-0.736	0.006	0.039
REACTOME_SIGNAL_TRANSDUCTION_BY_L1	4120	21	-1.719	-0.643	0.006	0.039
HOLLERN_SQUAMOUS_BREAST_TUMOR	4121	142	-1.719	-0.456	0.006	0.039
REACTOME_SIGNALING_BY_EGFR	4122	49	-1.72	-0.623	0.006	0.039
WP_NANOPARTICLEMEDIATED_ACTIVATION_OF_RECEPTOR_SIGNALING	4123	27	-1.72	-0.67	0.006	0.039
WP_VITAMIN_B12_METABOLISM	4124	48	-1.72	-0.485	0.006	0.039
REACTOME_DEATH_RECEPTOR_SIGNALLING	4125	124	-1.721	-0.521	0.006	0.039
LU_AGING_BRAIN_UP	4126	228	-1.721	-0.517	0.006	0.039
WP_MAPK_SIGNALING_PATHWAY	4127	239	-1.721	-0.421	0.006	0.039
REACTOME_SIGNALING_BY_NTRKS	4128	130	-1.721	-0.504	0.006	0.039
SU_THYMUS	4129	19	-1.722	-0.614	0.006	0.038
WP_MET_IN_TYPE_1_PAPILLARY_RENAL_CELL_CARCINOMA	4130	55	-1.722	-0.64	0.006	0.038
REACTOME_GLUCAGON_LIKE_PEPTIDE_1_GLP1_REGULATES_INSULIN_SECRETION	4131	42	-1.723	-0.534	0.006	0.038
WP_TNFRELATED_WEAK_INDUCER_OF_APOPTOSIS_TWEAK_SIGNALING_PATHWAY	4132	42	-1.723	-0.593	0.006	0.038
BOYLAN_MULTIPLE_MYELOMA_D_DN	4133	58	-1.723	-0.491	0.006	0.038
WIERENGA_STAT5A_TARGETS_GROUP2	4134	45	-1.723	-0.487	0.006	0.038
WENG_POR_TARGETS_GLOBAL_UP	4135	18	-1.724	-0.633	0.006	0.038
WP_GALANIN_RECEPTOR_PATHWAY	4136	20	-1.724	-0.583	0.006	0.038
BIOCARTA_GH_PATHWAY	4137	25	-1.724	-0.555	0.006	0.038
VALK_AML_CLUSTER_15	4138	28	-1.725	-0.561	0.006	0.038
BIOCARTA_AGR_PATHWAY	4139	31	-1.725	-0.608	0.006	0.037
REACTOME_RHOB_GTPASE_CYCLE	4140	62	-1.725	-0.622	0.006	0.037
WP_OLIGODENDROCYTE_SPECIFICATION_AND_DIFFERENTIATION_LEADING_TO_MYELIN_COMPONENTS_FOR_CNS	4141	29	-1.725	-0.584	0.006	0.037
SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_1	4142	372	-1.726	-0.423	0.005	0.037
SIG_CHEMOTAXIS	4143	44	-1.726	-0.589	0.005	0.037
REACTOME_EPHA_MEDIATED_GROWTH_CONE_COLLAPSE	4144	28	-1.726	-0.6	0.005	0.037
HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN	4145	79	-1.727	-0.449	0.005	0.037
KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY	4146	49	-1.727	-0.504	0.005	0.037
REACTOME_RHO_GTPASE_CYCLE	4147	384	-1.727	-0.505	0.005	0.037
WP_MICROTUBULE_CYTOSKELETON_REGULATION	4148	43	-1.727	-0.64	0.005	0.037
REACTOME_SENSORY_PROCESSING_OF_SOUND_BY_OUTER_HAIR_CELLS_OF_THE_COCHLEA	4149	41	-1.728	-0.561	0.005	0.037
REACTOME_COLLAGEN_BIOSYNTHESIS_AND_MODIFYING_ENZYMES	4150	57	-1.728	-0.569	0.005	0.037
WANG_BARRETTS_ESOPHAGUS_UP	4151	48	-1.728	-0.554	0.005	0.037
HOFFMANN_PRE_BI_TO_LARGE_PRE_BII_LYMPHOCYTE_DN	4152	67	-1.728	-0.471	0.005	0.037
MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN	4153	183	-1.728	-0.5	0.005	0.037
WP_2873_ARYL_HYDROCARBON_RECEPTOR_PATHWAY	4154	39	-1.728	-0.531	0.005	0.037
BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN	4155	79	-1.729	-0.555	0.005	0.037
VALK_AML_WITH_FLT3_ITD	4156	36	-1.729	-0.489	0.005	0.037
ULE_SPLICING_VIA_NOVA2	4157	40	-1.729	-0.527	0.005	0.037
CROONQUIST_NRAS_SIGNALING_UP	4158	35	-1.729	-0.573	0.005	0.037
PID_INTEGRIN5_PATHWAY	4159	16	-1.73	-0.689	0.005	0.037
HOLLERN_EMT_BREAST_TUMOR_UP	4160	118	-1.73	-0.427	0.005	0.037
BIOCARTA_AMI_PATHWAY	4161	19	-1.731	-0.617	0.005	0.036
CAIRO_HEPATOBLASTOMA_CLASSES_DN	4162	184	-1.731	-0.39	0.005	0.036
KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM	4163	67	-1.731	-0.465	0.005	0.036
WP_MESODERMAL_COMMITMENT_PATHWAY	4164	131	-1.731	-0.421	0.005	0.036
CHANG_IMMORTALIZED_BY_HPV31_DN	4165	57	-1.731	-0.526	0.005	0.036
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_DN	4166	80	-1.732	-0.457	0.005	0.036
REACTOME_ACTIVATION_OF_AMPK_DOWNSTREAM_OF_NMDARS	4167	17	-1.733	-0.614	0.005	0.036
PID_P38_MKK3_6PATHWAY	4168	24	-1.733	-0.643	0.005	0.036
WP_ANGIOPOIETINLIKE_PROTEIN_8_REGULATORY_PATHWAY	4169	125	-1.733	-0.509	0.005	0.036
DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP	4170	221	-1.734	-0.513	0.005	0.036
WP_PROSTAGLANDIN_SIGNALING	4171	30	-1.735	-0.604	0.005	0.036
REACTOME_RECYCLING_PATHWAY_OF_L1	4172	34	-1.735	-0.648	0.005	0.036
DORN_ADENOVIRUS_INFECTION_12HR_UP	4173	23	-1.735	-0.67	0.005	0.035
HALMOS_CEBPA_TARGETS_DN	4174	39	-1.736	-0.577	0.005	0.035
SABATES_COLORECTAL_ADENOMA_UP	4175	123	-1.736	-0.462	0.005	0.035
REACTOME_SIGNALING_BY_ERBB2	4176	48	-1.736	-0.625	0.005	0.035
REACTOME_SYNTHESIS_OF_IP3_AND_IP4_IN_THE_CYTOSOL	4177	25	-1.737	-0.56	0.005	0.035
WP_CELL_MIGRATION_AND_INVASION_THROUGH_P75NTR	4178	30	-1.739	-0.654	0.005	0.034
HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP	4179	372	-1.739	-0.411	0.005	0.034
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_DN	4180	45	-1.74	-0.536	0.005	0.034
BIOCARTA_IL7_PATHWAY	4181	16	-1.74	-0.663	0.005	0.034
LANDIS_BREAST_CANCER_PROGRESSION_DN	4182	68	-1.74	-0.522	0.005	0.034
WP_ANGIOGENESIS	4183	23	-1.741	-0.683	0.005	0.034
REACTOME_GPVI_MEDIATED_ACTIVATION_CASCADE	4184	33	-1.741	-0.553	0.005	0.034
LINDSTEDT_DENDRITIC_CELL_MATURATION_A	4185	59	-1.741	-0.489	0.005	0.034
XIE_LT_HSC_S1PR3_OE_UP	4186	24	-1.741	-0.559	0.005	0.034
MEBARKI_HCC_PROGENITOR_WNT_UP	4187	160	-1.741	-0.455	0.005	0.034
REACTOME_SYNDECAN_INTERACTIONS	4188	27	-1.741	-0.778	0.005	0.034
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_UP	4189	51	-1.742	-0.494	0.004	0.034
BIOCARTA_RHO_PATHWAY	4190	21	-1.742	-0.733	0.004	0.034
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP	4191	66	-1.742	-0.536	0.004	0.034
YAN_ESCAPE_FROM_ANOIKIS	4192	22	-1.742	-0.687	0.004	0.034
BIOCARTA_AT1R_PATHWAY	4193	26	-1.743	-0.705	0.004	0.033
ONDER_CDH1_TARGETS_2_UP	4194	210	-1.743	-0.409	0.004	0.033
REACTOME_APOPTOTIC_CLEAVAGE_OF_CELLULAR_PROTEINS	4195	36	-1.743	-0.645	0.004	0.033
REACTOME_IL_6_TYPE_CYTOKINE_RECEPTOR_LIGAND_INTERACTIONS	4196	16	-1.743	-0.667	0.004	0.033
CARRILLOREIXACH_MRS3_VS_LOWER_RISK_HEPATOBLASTOMA_DN	4197	139	-1.744	-0.46	0.004	0.033
PID_NCADHERIN_PATHWAY	4198	31	-1.744	-0.693	0.004	0.033
LIM_MAMMARY_STEM_CELL_UP	4199	403	-1.744	-0.45	0.004	0.033
AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_DN	4200	15	-1.745	-0.682	0.004	0.033
REACTOME_RHOA_GTPASE_CYCLE	4201	124	-1.745	-0.545	0.004	0.033
KEGG_GNRH_SIGNALING_PATHWAY	4202	98	-1.745	-0.479	0.004	0.033
MISSIAGLIA_REGULATED_BY_METHYLATION_UP	4203	107	-1.747	-0.567	0.004	0.033
GAVIN_FOXP3_TARGETS_CLUSTER_P7	4204	76	-1.747	-0.475	0.004	0.033
REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING	4205	87	-1.747	-0.56	0.004	0.033
SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP	4206	99	-1.747	-0.448	0.004	0.033
REACTOME_VEGFR2_MEDIATED_CELL_PROLIFERATION	4207	17	-1.748	-0.755	0.004	0.032
WP_CLOCKCONTROLLED_AUTOPHAGY_IN_BONE_METABOLISM	4208	72	-1.748	-0.452	0.004	0.032
REACTOME_RHO_GTPASES_ACTIVATE_PKNS	4209	31	-1.748	-0.63	0.004	0.032
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_DN	4210	62	-1.748	-0.584	0.004	0.032
PID_IL27_PATHWAY	4211	26	-1.748	-0.577	0.004	0.032
SHEPARD_CRASH_AND_BURN_MUTANT_DN	4212	162	-1.748	-0.456	0.004	0.032
WP_HEPATOCYTE_GROWTH_FACTOR_RECEPTOR_SIGNALING	4213	33	-1.748	-0.708	0.004	0.032
REACTOME_SCAVENGING_BY_CLASS_A_RECEPTORS	4214	19	-1.748	-0.662	0.004	0.032
PID_ARF6_PATHWAY	4215	28	-1.749	-0.565	0.004	0.032
HUPER_BREAST_BASAL_VS_LUMINAL_UP	4216	50	-1.749	-0.729	0.004	0.032
FONTAINE_PAPILLARY_THYROID_CARCINOMA_UP	4217	59	-1.749	-0.5	0.004	0.032
BIOCARTA_TNFR2_PATHWAY	4218	16	-1.749	-0.723	0.004	0.032
PID_IL4_2PATHWAY	4219	61	-1.75	-0.474	0.004	0.032
SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION	4220	45	-1.75	-0.626	0.004	0.032
DIRMEIER_LMP1_RESPONSE_LATE_UP	4221	48	-1.75	-0.553	0.004	0.032
IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN	4222	91	-1.75	-0.495	0.004	0.032
LINDSTEDT_DENDRITIC_CELL_MATURATION_B	4223	46	-1.751	-0.58	0.004	0.032
WP_SIGNAL_TRANSDUCTION_THROUGH_IL1R	4224	32	-1.751	-0.586	0.004	0.032
TAVOR_CEBPA_TARGETS_UP	4225	47	-1.751	-0.577	0.004	0.032
WP_OXIDATIVE_STRESS_RESPONSE	4226	33	-1.751	-0.519	0.004	0.032
LEE_NAIVE_T_LYMPHOCYTE	4227	16	-1.751	-0.664	0.004	0.032
WP_S1P_RECEPTOR_SIGNAL_TRANSDUCTION	4228	21	-1.752	-0.693	0.004	0.032
ROY_WOUND_BLOOD_VESSEL_UP	4229	44	-1.752	-0.527	0.004	0.032
ROY_WOUND_BLOOD_VESSEL_DN	4230	21	-1.752	-0.736	0.004	0.032
REACTOME_SEMA4D_INDUCED_CELL_MIGRATION_AND_GROWTH_CONE_COLLAPSE	4231	19	-1.753	-0.708	0.004	0.032
WP_EGFEGFR_SIGNALING_PATHWAY	4232	156	-1.753	-0.563	0.004	0.032
HAN_SATB1_TARGETS_DN	4233	309	-1.754	-0.451	0.004	0.032
PID_FCER1_PATHWAY	4234	55	-1.755	-0.56	0.004	0.031
FLORIO_NEOCORTEX_BASAL_RADIAL_GLIA_DN	4235	151	-1.757	-0.577	0.004	0.031
HALLMARK_TNFA_SIGNALING_VIA_NFKB	4236	184	-1.757	-0.56	0.004	0.031
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREY_UP	4237	15	-1.757	-0.719	0.004	0.031
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP	4238	186	-1.757	-0.429	0.004	0.031
REACTOME_NCAM1_INTERACTIONS	4239	38	-1.757	-0.632	0.004	0.030
REACTOME_DOWNREGULATION_OF_ERBB2_SIGNALING	4240	28	-1.758	-0.64	0.004	0.030
MANALO_HYPOXIA_UP	4241	180	-1.758	-0.498	0.004	0.030
HELLEBREKERS_SILENCED_DURING_TUMOR_ANGIOGENESIS	4242	67	-1.759	-0.497	0.004	0.030
GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_UP	4243	83	-1.759	-0.529	0.004	0.030
PEREZ_TP53_AND_TP63_TARGETS	4244	175	-1.759	-0.442	0.004	0.030
SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_2	4245	44	-1.759	-0.522	0.004	0.030
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_1	4246	38	-1.759	-0.628	0.004	0.030
PID_AJDISS_2PATHWAY	4247	47	-1.759	-0.614	0.004	0.030
PID_IL3_PATHWAY	4248	26	-1.759	-0.641	0.004	0.030
PID_ANTHRAX_PATHWAY	4249	17	-1.759	-0.681	0.004	0.030
WP_INFLAMMATORY_RESPONSE_PATHWAY	4250	30	-1.76	-0.678	0.004	0.030
ZWANG_CLASS_3_TRANSIENTLY_INDUCED_BY_EGF	4251	182	-1.76	-0.604	0.004	0.030
REACTOME_CRMPS_IN_SEMA3A_SIGNALING	4252	15	-1.76	-0.723	0.004	0.030
REACTOME_SIGNALING_BY_ERYTHROPOIETIN	4253	25	-1.76	-0.592	0.004	0.030
WP_ADIPOGENESIS	4254	123	-1.76	-0.471	0.004	0.030
ROZANOV_MMP14_TARGETS_SUBSET	4255	31	-1.76	-0.621	0.003	0.030
WILCOX_RESPONSE_TO_PROGESTERONE_DN	4256	53	-1.761	-0.554	0.003	0.030
YANG_BCL3_TARGETS_UP	4257	286	-1.761	-0.407	0.003	0.030
GAVIN_FOXP3_TARGETS_CLUSTER_P6	4258	80	-1.762	-0.517	0.003	0.030
PARK_TRETINOIN_RESPONSE_AND_PML_RARA_FUSION	4259	29	-1.762	-0.615	0.003	0.030
REACTOME_RHOV_GTPASE_CYCLE	4260	33	-1.762	-0.714	0.003	0.030
VALK_AML_CLUSTER_11	4261	35	-1.762	-0.552	0.003	0.030
WP_MODULATORS_OF_TCR_SIGNALING_AND_T_CELL_ACTIVATION	4262	57	-1.762	-0.481	0.003	0.030
HALLMARK_INFLAMMATORY_RESPONSE	4263	187	-1.762	-0.472	0.003	0.030
REACTOME_PARASITE_INFECTION	4264	61	-1.762	-0.581	0.003	0.030
BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN	4265	135	-1.763	-0.483	0.003	0.030
KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN	4266	262	-1.763	-0.489	0.003	0.030
REACTOME_INTERLEUKIN_4_AND_INTERLEUKIN_13_SIGNALING	4267	102	-1.764	-0.48	0.003	0.030
HUANG_FOXA2_TARGETS_DN	4268	37	-1.764	-0.599	0.003	0.030
LIU_PROSTATE_CANCER_DN	4269	406	-1.764	-0.433	0.003	0.030
BOQUEST_STEM_CELL_UP	4270	237	-1.764	-0.414	0.003	0.030
SCHEIDEREIT_IKK_INTERACTING_PROTEINS	4271	48	-1.765	-0.578	0.003	0.030
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR1	4272	31	-1.766	-0.512	0.003	0.029
BOSCO_ALLERGEN_INDUCED_TH2_ASSOCIATED_MODULE	4273	124	-1.767	-0.411	0.003	0.029
REACTOME_INTERLEUKIN_10_SIGNALING	4274	43	-1.768	-0.645	0.003	0.029
RASHI_NFKB1_TARGETS	4275	17	-1.768	-0.78	0.003	0.029
SIG_CD40PATHWAYMAP	4276	33	-1.769	-0.597	0.003	0.029
MORI_PRE_BI_LYMPHOCYTE_DN	4277	67	-1.769	-0.486	0.003	0.029
REACTOME_EPHB_MEDIATED_FORWARD_SIGNALING	4278	41	-1.77	-0.714	0.003	0.028
BROWNE_HCMV_INFECTION_14HR_DN	4279	249	-1.77	-0.465	0.003	0.028
PID_TXA2PATHWAY	4280	52	-1.77	-0.536	0.003	0.028
HOOI_ST7_TARGETS_DN	4281	88	-1.771	-0.458	0.003	0.028
MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_UP	4282	228	-1.771	-0.437	0.003	0.028
WP_EBOLA_VIRUS_INFECTION_IN_HOST	4283	123	-1.771	-0.532	0.003	0.028
KEGG_MELANOGENESIS	4284	99	-1.772	-0.472	0.003	0.028
ENGELMANN_CANCER_PROGENITORS_DN	4285	58	-1.772	-0.565	0.003	0.028
KANG_AR_TARGETS_UP	4286	17	-1.773	-0.721	0.003	0.028
DORSEY_GAB2_TARGETS	4287	30	-1.773	-0.6	0.003	0.028
WP_MFAP5_EFFECT_ON_PERMEABILITY_AND_MOTILITY_OF_ENDOTHELIAL_CELLS_VIA_CYTOSKELETON_REARRANGEMENT	4288	18	-1.774	-0.767	0.003	0.028
HALLMARK_MITOTIC_SPINDLE	4289	182	-1.774	-0.623	0.003	0.028
VANHARANTA_UTERINE_FIBROID_UP	4290	41	-1.774	-0.568	0.003	0.028
BIOCARTA_MET_PATHWAY	4291	33	-1.775	-0.682	0.003	0.027
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_DN	4292	64	-1.775	-0.495	0.003	0.027
LUI_THYROID_CANCER_CLUSTER_2	4293	36	-1.776	-0.534	0.003	0.027
RODRIGUES_DCC_TARGETS_DN	4294	106	-1.776	-0.554	0.003	0.027
PID_S1P_S1P3_PATHWAY	4295	25	-1.776	-0.715	0.003	0.027
KEGG_RENAL_CELL_CARCINOMA	4296	65	-1.776	-0.64	0.003	0.027
HALLMARK_TGF_BETA_SIGNALING	4297	50	-1.777	-0.702	0.003	0.027
SMID_BREAST_CANCER_ERBB2_UP	4298	120	-1.777	-0.447	0.003	0.027
SERVITJA_ISLET_HNF1A_TARGETS_UP	4299	157	-1.777	-0.44	0.003	0.027
OSADA_ASCL1_TARGETS_DN	4300	23	-1.777	-0.723	0.003	0.027
CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP	4301	142	-1.778	-0.547	0.003	0.027
REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING	4302	22	-1.778	-0.722	0.003	0.027
MARIADASON_REGULATED_BY_HISTONE_ACETYLATION_UP	4303	47	-1.778	-0.597	0.003	0.027
PID_ERBB4_PATHWAY	4304	37	-1.78	-0.546	0.003	0.027
KORKOLA_TERATOMA	4305	35	-1.78	-0.578	0.003	0.027
REACTOME_BMAL1_CLOCK_NPAS2_ACTIVATES_CIRCADIAN_GENE_EXPRESSION	4306	20	-1.781	-0.605	0.003	0.026
PID_PI3KCI_PATHWAY	4307	40	-1.781	-0.581	0.003	0.026
REACTOME_REGULATION_OF_INSULIN_SECRETION	4308	78	-1.781	-0.489	0.003	0.026
WP_HIPPOMERLIN_SIGNALING_DYSREGULATION	4309	113	-1.782	-0.486	0.003	0.026
REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION	4310	39	-1.782	-0.565	0.003	0.026
WP_MONOAMINE_TRANSPORT	4311	31	-1.782	-0.574	0.003	0.026
REACTOME_ONCOGENIC_MAPK_SIGNALING	4312	73	-1.782	-0.572	0.003	0.026
HADDAD_B_LYMPHOCYTE_PROGENITOR	4313	219	-1.783	-0.447	0.003	0.026
WP_ANGIOTENSIN_II_RECEPTOR_TYPE_1_PATHWAY	4314	26	-1.784	-0.629	0.003	0.026
WP_NETRINUNC5B_SIGNALING_PATHWAY	4315	46	-1.786	-0.635	0.002	0.025
CHICAS_RB1_TARGETS_CONFLUENT	4316	465	-1.786	-0.465	0.002	0.025
REACTOME_MET_ACTIVATES_PTK2_SIGNALING	4317	30	-1.786	-0.742	0.002	0.025
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN	4318	300	-1.786	-0.621	0.002	0.025
GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP	4319	156	-1.788	-0.474	0.002	0.025
WP_MIRNA_TARGETS_IN_ECM_AND_MEMBRANE_RECEPTORS	4320	21	-1.788	-0.799	0.002	0.025
WP_ENDOCHONDRAL_OSSIFICATION_WITH_SKELETAL_DYSPLASIAS	4321	58	-1.788	-0.523	0.002	0.025
WP_ENDOCHONDRAL_OSSIFICATION	4322	58	-1.788	-0.523	0.002	0.025
ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP	4323	372	-1.788	-0.42	0.002	0.025
MURATA_VIRULENCE_OF_H_PILORI	4324	21	-1.789	-0.709	0.002	0.025
PID_PTP1B_PATHWAY	4325	52	-1.789	-0.505	0.002	0.025
BROWN_MYELOID_CELL_DEVELOPMENT_UP	4326	143	-1.789	-0.436	0.002	0.025
REACTOME_FCERI_MEDIATED_MAPK_ACTIVATION	4327	37	-1.789	-0.528	0.002	0.025
LEE_LIVER_CANCER_CIPROFIBRATE_UP	4328	56	-1.79	-0.484	0.002	0.025
REACTOME_RET_SIGNALING	4329	40	-1.79	-0.565	0.002	0.025
KONDO_EZH2_TARGETS	4330	184	-1.791	-0.441	0.002	0.025
WP_HYPOTHESIZED_PATHWAYS_IN_PATHOGENESIS_OF_CARDIOVASCULAR_DISEASE	4331	24	-1.791	-0.663	0.002	0.025
LEE_LIVER_CANCER_E2F1_UP	4332	61	-1.793	-0.538	0.002	0.024
REACTOME_EXTRA_NUCLEAR_ESTROGEN_SIGNALING	4333	72	-1.793	-0.576	0.002	0.024
BROWNE_HCMV_INFECTION_16HR_DN	4334	74	-1.794	-0.514	0.002	0.024
HALLMARK_COMPLEMENT	4335	193	-1.794	-0.464	0.002	0.024
REACTOME_ACTIVATION_OF_NMDA_RECEPTORS_AND_POSTSYNAPTIC_EVENTS	4336	82	-1.795	-0.473	0.002	0.024
WP_MALIGNANT_PLEURAL_MESOTHELIOMA	4337	409	-1.795	-0.456	0.002	0.024
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	4338	187	-1.795	-0.555	0.002	0.024
PID_FAK_PATHWAY	4339	56	-1.795	-0.724	0.002	0.024
SCHOEN_NFKB_SIGNALING	4340	29	-1.796	-0.643	0.002	0.024
BIOCARTA_HER2_PATHWAY	4341	23	-1.796	-0.703	0.002	0.024
DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN	4342	424	-1.797	-0.573	0.002	0.023
WANG_SMARCE1_TARGETS_UP	4343	249	-1.798	-0.469	0.002	0.023
REACTOME_OTHER_INTERLEUKIN_SIGNALING	4344	21	-1.798	-0.676	0.002	0.023
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_UP	4345	98	-1.798	-0.471	0.002	0.023
HELLER_HDAC_TARGETS_UP	4346	252	-1.799	-0.487	0.002	0.023
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP	4347	143	-1.799	-0.474	0.002	0.023
SENESE_HDAC2_TARGETS_DN	4348	103	-1.799	-0.483	0.002	0.023
PHONG_TNF_TARGETS_UP	4349	59	-1.8	-0.703	0.002	0.023
BIOCARTA_IL1R_PATHWAY	4350	30	-1.8	-0.639	0.002	0.023
RASHI_RESPONSE_TO_IONIZING_RADIATION_2	4351	106	-1.8	-0.674	0.002	0.023
PID_SYNDECAN_4_PATHWAY	4352	32	-1.8	-0.676	0.002	0.023
REACTOME_GERM_LAYER_FORMATION_AT_GASTRULATION	4353	15	-1.801	-0.711	0.002	0.023
LEE_LIVER_CANCER_HEPATOBLAST	4354	15	-1.802	-0.812	0.002	0.023
COULOUARN_TEMPORAL_TGFB1_SIGNATURE_DN	4355	120	-1.802	-0.509	0.002	0.023
KUNINGER_IGF1_VS_PDGFB_TARGETS_DN	4356	37	-1.802	-0.62	0.002	0.023
KEGG_PATHWAYS_IN_CANCER	4357	312	-1.802	-0.461	0.002	0.023
PID_ECADHERIN_KERATINOCYTE_PATHWAY	4358	20	-1.803	-0.793	0.002	0.023
REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION	4359	239	-1.803	-0.446	0.002	0.023
REACTOME_GAP_JUNCTION_ASSEMBLY	4360	20	-1.804	-0.639	0.002	0.023
LUCAS_HNF4A_TARGETS_UP	4361	50	-1.804	-0.513	0.002	0.023
FIRESTEIN_PROLIFERATION	4362	148	-1.804	-0.423	0.002	0.023
REACTOME_ANCHORING_FIBRIL_FORMATION	4363	15	-1.804	-0.885	0.002	0.023
MARSON_FOXP3_TARGETS_UP	4364	59	-1.804	-0.562	0.002	0.023
PID_P38_ALPHA_BETA_PATHWAY	4365	29	-1.804	-0.674	0.002	0.023
REACTOME_CELL_JUNCTION_ORGANIZATION	4366	79	-1.804	-0.553	0.002	0.023
NEMETH_INFLAMMATORY_RESPONSE_LPS_UP	4367	80	-1.805	-0.553	0.002	0.023
REACTOME_FORMATION_OF_THE_CORNIFIED_ENVELOPE	4368	96	-1.805	-0.58	0.002	0.023
BHAT_ESR1_TARGETS_VIA_AKT1_DN	4369	71	-1.806	-0.561	0.002	0.023
PID_EPHRINB_REV_PATHWAY	4370	30	-1.806	-0.57	0.002	0.023
BLANCO_MELO_HUMAN_PARAINFLUENZA_VIRUS_3_INFECTION_A594_CELLS_UP	4371	164	-1.807	-0.441	0.002	0.022
PID_ARF6_TRAFFICKING_PATHWAY	4372	45	-1.808	-0.549	0.002	0.022
FUJII_YBX1_TARGETS_UP	4373	36	-1.808	-0.529	0.002	0.022
KEGG_ADHERENS_JUNCTION	4374	68	-1.809	-0.674	0.002	0.022
AMIT_SERUM_RESPONSE_240_MCF10A	4375	51	-1.809	-0.746	0.002	0.022
REACTOME_SIGNALING_BY_FGFR4	4376	41	-1.809	-0.587	0.002	0.022
REACTOME_SIGNALLING_TO_ERKS	4377	33	-1.81	-0.64	0.002	0.022
KHETCHOUMIAN_TRIM24_TARGETS_UP	4378	46	-1.81	-0.581	0.002	0.022
KANG_AR_TARGETS_DN	4379	17	-1.811	-0.595	0.002	0.022
PEDRIOLI_MIR31_TARGETS_DN	4380	329	-1.811	-0.422	0.002	0.022
ZHENG_IL22_SIGNALING_UP	4381	50	-1.811	-0.511	0.002	0.022
BOYLAN_MULTIPLE_MYELOMA_C_CLUSTER_DN	4382	28	-1.812	-0.549	0.002	0.022
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN	4383	59	-1.812	-0.59	0.002	0.022
REACTOME_LAMININ_INTERACTIONS	4384	29	-1.812	-0.815	0.002	0.022
ZIRN_TRETINOIN_RESPONSE_UP	4385	15	-1.812	-0.742	0.002	0.022
KAYO_CALORIE_RESTRICTION_MUSCLE_UP	4386	88	-1.812	-0.495	0.002	0.022
REACTOME_CONSTITUTIVE_SIGNALING_BY_ABERRANT_PI3K_IN_CANCER	4387	77	-1.813	-0.474	0.002	0.022
LANDEMAINE_LUNG_METASTASIS	4388	16	-1.813	-0.667	0.002	0.022
BLANCO_MELO_RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_A594_CELLS_UP	4389	244	-1.814	-0.487	0.002	0.021
REACTOME_CROSSLINKING_OF_COLLAGEN_FIBRILS	4390	18	-1.814	-0.77	0.002	0.021
TOMLINS_PROSTATE_CANCER_DN	4391	36	-1.814	-0.692	0.002	0.021
GEISS_RESPONSE_TO_DSRNA_DN	4392	15	-1.814	-0.687	0.002	0.021
WP_EXTRACELLULAR_VESICLEMEDIATED_SIGNALING_IN_RECIPIENT_CELLS	4393	28	-1.814	-0.701	0.002	0.021
GAL_LEUKEMIC_STEM_CELL_UP	4394	104	-1.815	-0.466	0.002	0.021
SIG_IL4RECEPTOR_IN_B_LYPHOCYTES	4395	27	-1.815	-0.706	0.002	0.021
WANG_TNF_TARGETS	4396	24	-1.815	-0.584	0.002	0.021
REACTOME_CELL_CELL_COMMUNICATION	4397	114	-1.815	-0.527	0.002	0.021
DAVIES_MULTIPLE_MYELOMA_VS_MGUS_DN	4398	23	-1.815	-0.705	0.002	0.021
PID_INTEGRIN_A9B1_PATHWAY	4399	22	-1.815	-0.703	0.002	0.021
WP_FIBRIN_COMPLEMENT_RECEPTOR_3_SIGNALING_PATHWAY	4400	42	-1.816	-0.548	0.002	0.021
BILBAN_B_CLL_LPL_DN	4401	34	-1.816	-0.602	0.002	0.021
DUTERTRE_ESTRADIOL_RESPONSE_6HR_DN	4402	77	-1.816	-0.507	0.002	0.021
BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_DN	4403	32	-1.816	-0.559	0.002	0.021
REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION	4404	279	-1.816	-0.535	0.002	0.021
WP_DEREGULATION_OF_RAB_AND_RAB_EFFECTOR_GENES_IN_BLADDER_CANCER	4405	16	-1.817	-0.644	0.002	0.021
LIM_MAMMARY_LUMINAL_MATURE_UP	4406	92	-1.817	-0.538	0.002	0.021
WP_NEUROINFLAMMATION_AND_GLUTAMATERGIC_SIGNALING	4407	137	-1.817	-0.441	0.002	0.021
WP_LDL_INFLUENCE_ON_CD14_AND_TLR4	4408	24	-1.817	-0.632	0.002	0.021
PID_SYNDECAN_2_PATHWAY	4409	30	-1.818	-0.704	0.002	0.021
WP_LEUKOCYTEINTRINSIC_HIPPO_PATHWAY_FUNCTIONS	4410	25	-1.819	-0.66	0.002	0.021
WP_RANKLRANK_SIGNALING_PATHWAY	4411	52	-1.819	-0.567	0.002	0.021
RODRIGUES_NTN1_TARGETS_DN	4412	141	-1.819	-0.52	0.002	0.021
VALK_AML_CLUSTER_12	4413	29	-1.819	-0.614	0.002	0.021
REACTOME_MOLECULES_ASSOCIATED_WITH_ELASTIC_FIBRES	4414	37	-1.82	-0.683	0.002	0.021
PID_ERBB_NETWORK_PATHWAY	4415	15	-1.82	-0.707	0.002	0.021
DAUER_STAT3_TARGETS_UP	4416	44	-1.821	-0.625	0.001	0.021
BOYLAN_MULTIPLE_MYELOMA_C_D_DN	4417	231	-1.822	-0.434	0.001	0.021
REACTOME_INTERLEUKIN_6_FAMILY_SIGNALING	4418	23	-1.823	-0.673	0.001	0.021
PID_ANGIOPOIETIN_RECEPTOR_PATHWAY	4419	48	-1.823	-0.618	0.001	0.021
PID_IL23_PATHWAY	4420	36	-1.823	-0.607	0.001	0.021
REACTOME_SIGNALING_BY_FGFR3	4421	40	-1.823	-0.612	0.001	0.021
WP_TYPE_I_INTERFERON_INDUCTION_AND_SIGNALING_DURING_SARSCOV2_INFECTION	4422	29	-1.823	-0.65	0.001	0.021
REACTOME_INTERFERON_GAMMA_SIGNALING	4423	87	-1.823	-0.474	0.001	0.021
WP_THYROXINE_THYROID_HORMONE_PRODUCTION	4424	24	-1.825	-0.605	0.001	0.021
PID_NETRIN_PATHWAY	4425	31	-1.826	-0.722	0.001	0.020
PLASARI_TGFB1_TARGETS_10HR_UP	4426	175	-1.826	-0.505	0.001	0.020
PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2	4427	65	-1.828	-0.647	0.001	0.020
WP_PI3KAKT_SIGNALING_PATHWAY	4428	313	-1.83	-0.428	0.001	0.020
REACTOME_SIGNALING_BY_NTRK2_TRKB	4429	24	-1.831	-0.635	0.001	0.020
BIOCARTA_PDZS_PATHWAY	4430	17	-1.831	-0.666	0.001	0.020
REACTOME_RHO_GTPASES_ACTIVATE_IQGAPS	4431	19	-1.831	-0.774	0.001	0.020
HOLLERN_EMT_BREAST_TUMOR_DN	4432	107	-1.832	-0.618	0.001	0.020
FOROUTAN_INTEGRATED_TGFB_EMT_DN	4433	64	-1.832	-0.589	0.001	0.019
LEE_LIVER_CANCER_MYC_E2F1_UP	4434	54	-1.832	-0.498	0.001	0.019
PID_SHP2_PATHWAY	4435	52	-1.833	-0.55	0.001	0.019
WP_SARSCOV2_INNATE_IMMUNITY_EVASION_AND_CELLSPECIFIC_IMMUNE_RESPONSE	4436	61	-1.833	-0.508	0.001	0.019
GESERICK_TERT_TARGETS_DN	4437	20	-1.833	-0.671	0.001	0.019
REACTOME_EPH_EPHRIN_MEDIATED_REPULSION_OF_CELLS	4438	51	-1.834	-0.627	0.001	0.019
PID_FRA_PATHWAY	4439	35	-1.834	-0.659	0.001	0.019
WP_OVERVIEW_OF_NANOPARTICLE_EFFECTS	4440	18	-1.835	-0.728	0.001	0.019
BOSCO_EPITHELIAL_DIFFERENTIATION_MODULE	4441	61	-1.835	-0.609	0.001	0.019
REACTOME_GRB2_EVENTS_IN_ERBB2_SIGNALING	4442	16	-1.835	-0.686	0.001	0.019
PID_RAC1_PATHWAY	4443	53	-1.835	-0.647	0.001	0.019
VERRECCHIA_RESPONSE_TO_TGFB1_C2	4444	20	-1.836	-0.737	0.001	0.019
MOHANKUMAR_HOXA1_TARGETS_DN	4445	138	-1.836	-0.472	0.001	0.019
PID_UPA_UPAR_PATHWAY	4446	39	-1.837	-0.66	0.001	0.019
ZHOU_INFLAMMATORY_RESPONSE_LPS_UP	4447	306	-1.837	-0.449	0.001	0.019
GU_PDEF_TARGETS_UP	4448	67	-1.837	-0.666	0.001	0.019
KEGG_CHEMOKINE_SIGNALING_PATHWAY	4449	175	-1.838	-0.476	0.001	0.019
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM3	4450	69	-1.838	-0.552	0.001	0.019
REACTOME_DISEASES_OF_IMMUNE_SYSTEM	4451	31	-1.838	-0.607	0.001	0.019
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_DN	4452	50	-1.839	-0.549	0.001	0.019
REACTOME_SIGNALING_BY_RECEPTOR_TYROSINE_KINASES	4453	489	-1.84	-0.474	0.001	0.019
LU_TUMOR_ANGIOGENESIS_UP	4454	22	-1.84	-0.602	0.001	0.019
REACTOME_SIGNALING_BY_BRAF_AND_RAF1_FUSIONS	4455	58	-1.84	-0.567	0.001	0.019
NGUYEN_NOTCH1_TARGETS_UP	4456	26	-1.842	-0.691	0.001	0.019
ONDER_CDH1_TARGETS_2_DN	4457	412	-1.842	-0.621	0.001	0.019
REACTOME_NON_INTEGRIN_MEMBRANE_ECM_INTERACTIONS	4458	58	-1.843	-0.713	0.001	0.018
WP_CHEMOKINE_SIGNALING_PATHWAY	4459	159	-1.844	-0.481	0.001	0.018
HENDRICKS_SMARCA4_TARGETS_UP	4460	49	-1.844	-0.676	0.001	0.018
REACTOME_CDC42_GTPASE_CYCLE	4461	128	-1.844	-0.548	0.001	0.018
REACTOME_FOXO_MEDIATED_TRANSCRIPTION_OF_OXIDATIVE_STRESS_METABOLIC_AND_NEURONAL_GENES	4462	24	-1.845	-0.622	0.001	0.018
PID_RAC1_REG_PATHWAY	4463	36	-1.845	-0.598	0.001	0.018
HALLMARK_IL6_JAK_STAT3_SIGNALING	4464	86	-1.846	-0.501	0.001	0.018
REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK	4465	51	-1.847	-0.65	0.001	0.018
REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING	4466	16	-1.847	-0.68	9.965E-04	1.781E-02
SOGA_COLORECTAL_CANCER_MYC_DN	4467	64	-1.848	-0.566	9.905E-04	1.779E-02
TUOMISTO_TUMOR_SUPPRESSION_BY_COL13A1_UP	4468	17	-1.848	-0.61	9.870E-04	1.779E-02
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_DN	4469	146	-1.849	-0.479	9.707E-04	1.761E-02
KANG_FLUOROURACIL_RESISTANCE_DN	4470	16	-1.849	-0.79	9.689E-04	1.761E-02
PID_CDC42_PATHWAY	4471	68	-1.85	-0.652	9.582E-04	1.757E-02
KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC	4472	73	-1.851	-0.562	9.496E-04	1.750E-02
WP_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY	4473	73	-1.851	-0.562	9.496E-04	1.750E-02
HELLER_SILENCED_BY_METHYLATION_UP	4474	254	-1.853	-0.465	9.272E-04	1.726E-02
AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_UP	4475	109	-1.853	-0.551	9.237E-04	1.726E-02
BIOCARTA_RAC1_PATHWAY	4476	21	-1.853	-0.659	9.237E-04	1.726E-02
WP_TOLLLIKE_RECEPTOR_SIGNALING_RELATED_TO_MYD88	4477	31	-1.853	-0.621	9.237E-04	1.726E-02
PID_CD8_TCR_PATHWAY	4478	51	-1.854	-0.528	9.173E-04	1.726E-02
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINDED_IN_ERYTHROCYTE_UP	4479	43	-1.854	-0.632	9.164E-04	1.726E-02
PID_CXCR4_PATHWAY	4480	93	-1.855	-0.553	9.009E-04	1.726E-02
REACTOME_SEMAPHORIN_INTERACTIONS	4481	60	-1.856	-0.61	8.811E-04	1.703E-02
WINZEN_DEGRADED_VIA_KHSRP	4482	93	-1.858	-0.595	8.548E-04	1.661E-02
PID_AVB3_OPN_PATHWAY	4483	31	-1.859	-0.736	8.527E-04	1.661E-02
VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP	4484	154	-1.859	-0.533	8.488E-04	1.661E-02
REACTOME_ELASTIC_FIBRE_FORMATION	4485	44	-1.86	-0.68	8.333E-04	1.646E-02
WP_RELATIONSHIP_BETWEEN_INFLAMMATION_COX2_AND_EGFR	4486	25	-1.861	-0.639	8.178E-04	1.624E-02
ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_UP	4487	164	-1.861	-0.464	8.135E-04	1.624E-02
PID_EPHB_FWD_PATHWAY	4488	40	-1.862	-0.757	8.040E-04	1.615E-02
WP_REGULATION_OF_ACTIN_CYTOSKELETON	4489	140	-1.864	-0.531	7.782E-04	1.572E-02
REACTOME_SIGNALING_BY_FGFR1	4490	49	-1.864	-0.583	7.700E-04	1.564E-02
FRASOR_RESPONSE_TO_ESTRADIOL_DN	4491	71	-1.864	-0.62	7.700E-04	1.564E-02
MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_UP	4492	23	-1.866	-0.618	7.566E-04	1.555E-02
PID_LYSOPHOSPHOLIPID_PATHWAY	4493	60	-1.866	-0.632	7.558E-04	1.555E-02
PID_RHOA_PATHWAY	4494	41	-1.866	-0.651	7.558E-04	1.555E-02
JI_METASTASIS_REPRESSED_BY_STK11	4495	24	-1.867	-0.658	7.403E-04	1.548E-02
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_DN	4496	40	-1.868	-0.596	7.355E-04	1.547E-02
XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP	4497	32	-1.868	-0.71	7.351E-04	1.547E-02
WP_CYTOKINES_AND_INFLAMMATORY_RESPONSE	4498	26	-1.868	-0.691	7.286E-04	1.547E-02
RICKMAN_HEAD_AND_NECK_CANCER_C	4499	91	-1.87	-0.555	7.119E-04	1.524E-02
REACTOME_MECP2_REGULATES_NEURONAL_RECEPTORS_AND_CHANNELS	4500	18	-1.87	-0.573	7.011E-04	1.510E-02
REACTOME_GAP_JUNCTION_TRAFFICKING_AND_REGULATION	4501	33	-1.871	-0.643	6.985E-04	1.510E-02
REACTOME_EPH_EPHRIN_SIGNALING	4502	89	-1.872	-0.645	6.955E-04	1.510E-02
REACTOME_KINESINS	4503	44	-1.872	-0.613	6.908E-04	1.510E-02
SALVADOR_MARTIN_PEDIATRIC_TBD_ANTI_TNF_THERAPY_NONRESPONDER_POST_TREATMENT_UP	4504	18	-1.873	-0.656	6.783E-04	1.497E-02
REACTOME_COLLAGEN_FORMATION	4505	78	-1.873	-0.617	6.714E-04	1.491E-02
GHANDHI_BYSTANDER_IRRADIATION_UP	4506	68	-1.873	-0.614	6.714E-04	1.491E-02
PID_TCR_PATHWAY	4507	61	-1.873	-0.55	6.701E-04	1.491E-02
REACTOME_INTEGRIN_SIGNALING	4508	27	-1.874	-0.612	6.615E-04	1.491E-02
PID_EPO_PATHWAY	4509	33	-1.874	-0.604	6.593E-04	1.491E-02
REACTOME_SIGNALING_BY_MODERATE_KINASE_ACTIVITY_BRAF_MUTANTS	4510	44	-1.876	-0.6	6.447E-04	1.477E-02
YANG_BREAST_CANCER_ESR1_UP	4511	33	-1.877	-0.64	6.339E-04	1.462E-02
REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE	4512	67	-1.877	-0.613	6.322E-04	1.462E-02
PID_NECTIN_PATHWAY	4513	26	-1.879	-0.795	6.051E-04	1.414E-02
REACTOME_GRB2_SOS_PROVIDES_LINKAGE_TO_MAPK_SIGNALING_FOR_INTEGRINS	4514	15	-1.88	-0.701	6.029E-04	1.414E-02
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP	4515	312	-1.88	-0.455	6.003E-04	1.414E-02
PID_ER_NONGENOMIC_PATHWAY	4516	40	-1.88	-0.654	5.986E-04	1.414E-02
WP_RESISTIN_AS_A_REGULATOR_OF_INFLAMMATION	4517	32	-1.882	-0.607	5.848E-04	1.403E-02
HALLMARK_COAGULATION	4518	134	-1.882	-0.558	5.784E-04	1.397E-02
BIOCARTA_TFF_PATHWAY	4519	24	-1.883	-0.668	5.766E-04	1.397E-02
CERVERA_SDHB_TARGETS_1_UP	4520	94	-1.883	-0.509	5.697E-04	1.395E-02
WP_TH17_CELL_DIFFERENTIATION_PATHWAY	4521	67	-1.883	-0.522	5.693E-04	1.395E-02
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN	4522	44	-1.884	-0.523	5.654E-04	1.395E-02
WP_ANTIVIRAL_AND_ANTIINFLAMMATORY_EFFECTS_OF_NRF2_ON_SARSCOV2_PATHWAY	4523	29	-1.886	-0.625	5.469E-04	1.367E-02
GRAHAM_CML_QUIESCENT_VS_CML_DIVIDING_UP	4524	21	-1.887	-0.735	5.405E-04	1.361E-02
PID_TRKR_PATHWAY	4525	59	-1.887	-0.614	5.400E-04	1.361E-02
DING_LUNG_CANCER_BY_MUTATION_RATE	4526	20	-1.887	-0.582	5.379E-04	1.361E-02
LENAOUR_DENDRITIC_CELL_MATURATION_DN	4527	119	-1.887	-0.523	5.366E-04	1.361E-02
FOROUTAN_INTEGRATED_TGFB_EMT_UP	4528	109	-1.888	-0.58	5.353E-04	1.361E-02
REACTOME_RHOU_GTPASE_CYCLE	4529	38	-1.888	-0.678	5.301E-04	1.361E-02
REACTOME_SIGNALING_BY_ERBB2_IN_CANCER	4530	25	-1.889	-0.712	5.206E-04	1.361E-02
PID_INTEGRIN3_PATHWAY	4531	41	-1.889	-0.67	5.168E-04	1.361E-02
VERHAAK_AML_WITH_NPM1_MUTATED_UP	4532	167	-1.89	-0.479	5.146E-04	1.361E-02
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4	4533	91	-1.891	-0.565	5.013E-04	1.347E-02
AMBROSINI_FLAVOPIRIDOL_TREATMENT_TP53	4534	93	-1.891	-0.577	4.991E-04	1.347E-02
HINATA_NFKB_TARGETS_FIBROBLAST_UP	4535	78	-1.891	-0.651	4.978E-04	1.347E-02
WP_NRP1TRIGGERED_SIGNALING_PATHWAYS_IN_PANCREATIC_CANCER	4536	50	-1.892	-0.663	4.952E-04	1.347E-02
RODRIGUES_NTN1_AND_DCC_TARGETS	4537	29	-1.892	-0.611	4.948E-04	1.347E-02
BLANCO_MELO_COVID19_SARS_COV_2_INFECTION_CALU3_CELLS_UP	4538	268	-1.892	-0.498	4.918E-04	1.347E-02
LEE_NEURAL_CREST_STEM_CELL_DN	4539	105	-1.894	-0.485	4.797E-04	1.347E-02
TIAN_TNF_SIGNALING_VIA_NFKB	4540	24	-1.895	-0.853	4.703E-04	1.334E-02
MARSON_FOXP3_TARGETS_STIMULATED_UP	4541	26	-1.898	-0.592	4.470E-04	1.278E-02
NAKAMURA_METASTASIS_MODEL_DN	4542	37	-1.899	-0.669	4.453E-04	1.278E-02
KEGG_REGULATION_OF_ACTIN_CYTOSKELETON	4543	198	-1.899	-0.539	4.449E-04	1.278E-02
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREEN_UP	4544	22	-1.903	-0.679	4.160E-04	1.219E-02
JINESH_BLEBBISHIELD_TRANSFORMED_STEM_CELL_SPHERES_UP	4545	145	-1.904	-0.517	4.160E-04	1.219E-02
WP_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_IN_COLORECTAL_CANCER	4546	153	-1.905	-0.532	4.039E-04	1.203E-02
ZHAN_MULTIPLE_MYELOMA_PR_DN	4547	39	-1.907	-0.642	3.927E-04	1.180E-02
PID_FGF_PATHWAY	4548	55	-1.907	-0.601	3.867E-04	1.172E-02
PLASARI_TGFB1_TARGETS_1HR_UP	4549	29	-1.908	-0.629	3.794E-04	1.159E-02
GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_DN	4550	39	-1.909	-0.595	3.777E-04	1.159E-02
REACTOME_SIGNALING_BY_MET	4551	79	-1.909	-0.67	3.760E-04	1.159E-02
BIOCARTA_EDG1_PATHWAY	4552	19	-1.909	-0.705	3.751E-04	1.159E-02
REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK	4553	106	-1.91	-0.5	3.721E-04	1.159E-02
SHEPARD_BMYB_TARGETS	4554	64	-1.911	-0.59	3.622E-04	1.156E-02
OISHI_CHOLANGIOMA_STEM_CELL_LIKE_DN	4555	251	-1.912	-0.465	3.579E-04	1.153E-02
REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX	4556	131	-1.912	-0.638	3.579E-04	1.153E-02
WP_PRIMARY_FOCAL_SEGMENTAL_GLOMERULOSCLEROSIS_FSGS	4557	68	-1.913	-0.581	3.510E-04	1.151E-02
REACTOME_G_ALPHA_12_13_SIGNALLING_EVENTS	4558	73	-1.913	-0.647	3.488E-04	1.151E-02
ONDER_CDH1_SIGNALING_VIA_CTNNB1	4559	69	-1.915	-0.628	3.411E-04	1.140E-02
LIANG_SILENCED_BY_METHYLATION_2	4560	54	-1.916	-0.63	3.342E-04	1.127E-02
WP_NONGENOMIC_ACTIONS_OF_125_DIHYDROXYVITAMIN_D3	4561	68	-1.917	-0.612	3.316E-04	1.127E-02
KIM_GLIS2_TARGETS_UP	4562	82	-1.917	-0.576	3.307E-04	1.127E-02
KEGG_LONG_TERM_POTENTIATION	4563	67	-1.919	-0.566	3.238E-04	1.124E-02
NAKAMURA_METASTASIS_MODEL_UP	4564	36	-1.919	-0.533	3.238E-04	1.124E-02
MORI_PLASMA_CELL_DN	4565	32	-1.919	-0.563	3.204E-04	1.124E-02
HOSHIDA_LIVER_CANCER_SURVIVAL_UP	4566	68	-1.92	-0.586	3.182E-04	1.124E-02
ROSS_AML_WITH_CBFB_MYH11_FUSION	4567	47	-1.92	-0.592	3.174E-04	1.124E-02
REACTOME_SHC1_EVENTS_IN_ERBB2_SIGNALING	4568	22	-1.921	-0.698	3.122E-04	1.124E-02
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP	4569	82	-1.922	-0.557	3.101E-04	1.124E-02
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION	4570	108	-1.922	-0.54	3.088E-04	1.124E-02
ONDER_CDH1_TARGETS_3_DN	4571	48	-1.923	-0.753	3.023E-04	1.124E-02
REACTOME_EPHRIN_SIGNALING	4572	18	-1.923	-0.764	3.019E-04	1.124E-02
REACTOME_P130CAS_LINKAGE_TO_MAPK_SIGNALING_FOR_INTEGRINS	4573	15	-1.925	-0.747	2.984E-04	1.124E-02
KIM_MYC_AMPLIFICATION_TARGETS_DN	4574	74	-1.925	-0.571	2.980E-04	1.124E-02
TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_DN	4575	34	-1.927	-0.64	2.898E-04	1.124E-02
WP_EXTRACELLULAR_VESICLES_IN_THE_CROSSTALK_OF_CARDIAC_CELLS	4576	19	-1.927	-0.715	2.859E-04	1.124E-02
WP_GLUCOCORTICOID_RECEPTOR_PATHWAY	4577	64	-1.928	-0.633	2.842E-04	1.124E-02
ALCALAY_AML_BY_NPM1_LOCALIZATION_UP	4578	115	-1.929	-0.502	2.808E-04	1.124E-02
WP_HIPPO_SIGNALING_REGULATION_PATHWAYS	4579	95	-1.93	-0.529	2.722E-04	1.118E-02
ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP	4580	347	-1.932	-0.471	2.644E-04	1.099E-02
REACTOME_SIGNALING_BY_ERBB4	4581	56	-1.933	-0.574	2.580E-04	1.085E-02
KEGG_AXON_GUIDANCE	4582	125	-1.934	-0.614	2.571E-04	1.085E-02
PID_RET_PATHWAY	4583	39	-1.934	-0.71	2.554E-04	1.085E-02
WP_FOCAL_ADHESION_PI3KAKTMTORSIGNALING_PATHWAY	4584	279	-1.935	-0.488	2.498E-04	1.085E-02
HALLMARK_APICAL_JUNCTION	4585	186	-1.936	-0.586	2.476E-04	1.085E-02
REACTOME_RAC1_GTPASE_CYCLE	4586	157	-1.937	-0.576	2.450E-04	1.085E-02
HALLMARK_KRAS_SIGNALING_UP	4587	187	-1.938	-0.494	2.429E-04	1.085E-02
REACTOME_MAP2K_AND_MAPK_ACTIVATION	4588	37	-1.938	-0.625	2.416E-04	1.085E-02
KEGG_ECM_RECEPTOR_INTERACTION	4589	81	-1.939	-0.664	2.381E-04	1.085E-02
SANA_TNF_SIGNALING_UP	4590	73	-1.941	-0.623	2.325E-04	1.085E-02
BLANCO_MELO_BETA_INTERFERON_TREATED_BRONCHIAL_EPITHELIAL_CELLS_UP	4591	299	-1.942	-0.519	2.295E-04	1.085E-02
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS	4592	81	-1.942	-0.657	2.291E-04	1.085E-02
LIU_TARGETS_OF_VMYB_VS_CMYB_DN	4593	35	-1.942	-0.592	2.261E-04	1.085E-02
BASSO_CD40_SIGNALING_UP	4594	93	-1.943	-0.576	2.235E-04	1.085E-02
WP_TCELL_RECEPTOR_SIGNALING_PATHWAY	4595	89	-1.943	-0.527	2.226E-04	1.085E-02
BLANCO_MELO_COVID19_SARS_COV_2_INFECTION_A594_ACE2_EXPRESSING_CELLS_RUXOLITINIB_UP	4596	324	-1.944	-0.439	2.170E-04	1.085E-02
WP_LTF_DANGER_SIGNAL_RESPONSE_PATHWAY	4597	18	-1.944	-0.695	2.166E-04	1.085E-02
FOROUTAN_PRODRANK_TGFB_EMT_UP	4598	162	-1.945	-0.628	2.127E-04	1.085E-02
GALINDO_IMMUNE_RESPONSE_TO_ENTEROTOXIN	4599	71	-1.95	-0.642	1.985E-04	1.059E-02
SERVITJA_LIVER_HNF1A_TARGETS_UP	4600	131	-1.95	-0.473	1.951E-04	1.057E-02
WP_NEURAL_CREST_CELL_MIGRATION_IN_CANCER	4601	40	-1.951	-0.612	1.934E-04	1.057E-02
PID_S1P_S1P1_PATHWAY	4602	19	-1.952	-0.8	1.925E-04	1.057E-02
GRAHAM_CML_QUIESCENT_VS_NORMAL_DIVIDING_UP	4603	50	-1.952	-0.63	1.916E-04	1.057E-02
VERHAAK_GLIOBLASTOMA_MESENCHYMAL	4604	194	-1.953	-0.59	1.886E-04	1.057E-02
WP_RAS_SIGNALING	4605	174	-1.954	-0.51	1.852E-04	1.057E-02
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_UP	4606	52	-1.956	-0.632	1.822E-04	1.057E-02
GU_PDEF_TARGETS_DN	4607	33	-1.958	-0.694	1.779E-04	1.057E-02
KIM_MYCN_AMPLIFICATION_TARGETS_DN	4608	87	-1.96	-0.635	1.710E-04	1.054E-02
PID_RHOA_REG_PATHWAY	4609	41	-1.96	-0.721	1.705E-04	1.054E-02
GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_DN	4610	79	-1.961	-0.571	1.680E-04	1.054E-02
FOROUTAN_TGFB_EMT_UP	4611	169	-1.961	-0.623	1.680E-04	1.054E-02
REACTOME_CREB1_PHOSPHORYLATION_THROUGH_NMDA_RECEPTOR_MEDIATED_ACTIVATION_OF_RAS_SIGNALING	4612	28	-1.964	-0.592	1.611E-04	1.054E-02
HINATA_NFKB_TARGETS_KERATINOCYTE_UP	4613	82	-1.964	-0.676	1.585E-04	1.054E-02
REACTOME_MET_PROMOTES_CELL_MOTILITY	4614	41	-1.966	-0.739	1.550E-04	1.054E-02
KEGG_GAP_JUNCTION	4615	73	-1.968	-0.522	1.529E-04	1.054E-02
REACTOME_COLLAGEN_DEGRADATION	4616	59	-1.968	-0.722	1.524E-04	1.054E-02
GOZGIT_ESR1_TARGETS_UP	4617	121	-1.969	-0.509	1.524E-04	1.054E-02
WP_NEOVASCULARISATION_PROCESSES	4618	37	-1.97	-0.653	1.477E-04	1.054E-02
CROONQUIST_STROMAL_STIMULATION_UP	4619	50	-1.97	-0.601	1.477E-04	1.054E-02
NABA_BASEMENT_MEMBRANES	4620	35	-1.972	-0.779	1.434E-04	1.054E-02
GHANDHI_DIRECT_IRRADIATION_UP	4621	86	-1.975	-0.593	1.374E-04	1.054E-02
ISSAEVA_MLL2_TARGETS	4622	53	-1.976	-0.61	1.344E-04	1.054E-02
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_UP	4623	160	-1.976	-0.585	1.339E-04	1.054E-02
JAEGER_METASTASIS_DN	4624	233	-1.978	-0.64	1.288E-04	1.054E-02
REACTOME_COLLAGEN_CHAIN_TRIMERIZATION	4625	40	-1.979	-0.741	1.257E-04	1.054E-02
NABA_COLLAGENS	4626	40	-1.979	-0.741	1.257E-04	1.054E-02
DELYS_THYROID_CANCER_UP	4627	414	-1.983	-0.531	1.201E-04	1.054E-02
ALTEMEIER_RESPONSE_TO_LPS_WITH_MECHANICAL_VENTILATION	4628	112	-1.985	-0.586	1.137E-04	1.054E-02
SEKI_INFLAMMATORY_RESPONSE_LPS_UP	4629	70	-1.987	-0.655	1.107E-04	1.054E-02
WP_LUNG_FIBROSIS	4630	59	-1.992	-0.581	9.948E-05	9.879E-03
BLANCO_MELO_COVID19_BRONCHIAL_EPITHELIAL_CELLS_SARS_COV_2_INFECTION_UP	4631	123	-1.993	-0.707	9.603E-05	9.809E-03
WP_INTEGRINMEDIATED_CELL_ADHESION	4632	98	-1.998	-0.618	9.259E-05	9.735E-03
PID_SYNDECAN_1_PATHWAY	4633	46	-1.998	-0.726	9.130E-05	9.735E-03
WP_TGFBETA_RECEPTOR_SIGNALING	4634	51	-1.998	-0.642	9.130E-05	9.735E-03
PID_AMB2_NEUTROPHILS_PATHWAY	4635	40	-2.0	-0.703	8.656E-05	9.735E-03
WP_IL1_AND_MEGAKARYOCYTES_IN_OBESITY	4636	23	-2.002	-0.715	8.311E-05	9.735E-03
REACTOME_ASSEMBLY_OF_COLLAGEN_FIBRILS_AND_OTHER_MULTIMERIC_STRUCTURES	4637	57	-2.002	-0.754	8.268E-05	9.735E-03
SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4	4638	166	-2.004	-0.52	8.053E-05	9.735E-03
WP_SEROTONIN_HTR1_GROUP_AND_FOS_PATHWAY	4639	33	-2.005	-0.57	8.010E-05	9.735E-03
PID_INTEGRIN1_PATHWAY	4640	64	-2.006	-0.722	7.838E-05	9.735E-03
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP	4641	186	-2.006	-0.642	7.795E-05	9.735E-03
WP_TGFBETA_RECEPTOR_SIGNALING_IN_SKELETAL_DYSPLASIAS	4642	55	-2.011	-0.647	7.321E-05	9.735E-03
REACTOME_SIGNALING_BY_PDGF	4643	56	-2.013	-0.649	7.106E-05	9.735E-03
SENESE_HDAC1_AND_HDAC2_TARGETS_UP	4644	200	-2.013	-0.535	7.063E-05	9.735E-03
WP_NEURAL_CREST_CELL_MIGRATION_DURING_DEVELOPMENT	4645	37	-2.016	-0.635	6.675E-05	9.735E-03
BLANCO_MELO_COVID19_SARS_COV_2_INFECTION_A594_ACE2_EXPRESSING_CELLS_UP	4646	375	-2.017	-0.454	6.632E-05	9.735E-03
COLDREN_GEFITINIB_RESISTANCE_DN	4647	174	-2.022	-0.6	6.072E-05	9.735E-03
WP_BURN_WOUND_HEALING	4648	94	-2.024	-0.627	5.900E-05	9.735E-03
HINATA_NFKB_TARGETS_KERATINOCYTE_DN	4649	20	-2.024	-0.787	5.900E-05	9.735E-03
CROMER_TUMORIGENESIS_UP	4650	55	-2.033	-0.674	4.995E-05	9.735E-03
ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP	4651	72	-2.035	-0.532	4.694E-05	9.735E-03
WP_MIRNAS_INVOLVEMENT_IN_THE_IMMUNE_RESPONSE_IN_SEPSIS	4652	33	-2.037	-0.698	4.608E-05	9.735E-03
WP_FOCAL_ADHESION	4653	186	-2.055	-0.621	3.402E-05	9.356E-03
REACTOME_L1CAM_INTERACTIONS	4654	103	-2.056	-0.572	3.402E-05	9.356E-03
LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT	4655	90	-2.057	-0.719	3.230E-05	9.356E-03
PID_RAS_PATHWAY	4656	29	-2.06	-0.67	3.015E-05	9.356E-03
PID_AVB3_INTEGRIN_PATHWAY	4657	70	-2.06	-0.712	3.015E-05	9.356E-03
KEGG_FOCAL_ADHESION	4658	187	-2.063	-0.627	2.885E-05	9.356E-03
WP_PHOTODYNAMIC_THERAPYINDUCED_NFKB_SURVIVAL_SIGNALING	4659	33	-2.069	-0.782	2.627E-05	9.356E-03
LEE_LIVER_CANCER_DENA_UP	4660	58	-2.076	-0.618	2.153E-05	9.356E-03
BLANCO_MELO_COVID19_SARS_COV_2_LOW_MOI_INFECTION_A594_ACE2_EXPRESSING_CELLS_UP	4661	113	-2.085	-0.556	2.067E-05	9.356E-03
PID_REELIN_PATHWAY	4662	28	-2.098	-0.686	1.636E-05	9.356E-03
ANDERSEN_CHOLANGIOCARCINOMA_CLASS2	4663	154	-2.126	-0.602	1.034E-05	9.356E-03
LI_PROSTATE_CANCER_EPIGENETIC	4664	32	-2.174	-0.659	2.584E-06	4.619E-03
REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH	4665	59	-2.207	-0.69	1.723E-06	4.619E-03
